# EDGAR Filing Document

**Accession Number:** 0000320335
**File Stem:** 0000320335-26-000090
**Filing Date:** 2026-2
**Character Count:** 764021
**Document Hash:** 2200ff3be767aae85bb34ca59e69d408
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000320335-26-000090.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0000320335-26-000090

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 221

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GLOBE LIFE INC.
- **CENTRAL INDEX KEY:** 0000320335
- **STANDARD INDUSTRIAL CLASSIFICATION:** LIFE INSURANCE [6311]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 630780404
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-08052
- **FILM NUMBER:** 26680229

**BUSINESS ADDRESS:**
- **STREET 1:** 7677 HENNEMAN WAY
- **CITY:** MCKINNEY
- **STATE:** TX
- **ZIP:** 75070
- **BUSINESS PHONE:** 972-569-4000

**MAIL ADDRESS:**
- **STREET 1:** 7677 HENNEMAN WAY
- **CITY:** MCKINNEY
- **STATE:** TX
- **ZIP:** 75070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TORCHMARK CORP
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TORCHMARK CORP SAVINGS & INVESTMENT PLAN
- **DATE OF NAME CHANGE:** 19820825

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIBERTY NATIONAL INSURANCE HOLDING CO
- **DATE OF NAME CHANGE:** 19820701

?xml version='1.0' encoding='ASCII'? gl-20251231

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

(Mark one)

**[ ☒ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2025

or

**[ ☐ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the transition period from <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> to <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

Commission file number: 001-08052

**GLOBE LIFE INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| Delaware | 63-0780404 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 7677 Henneman Way, McKinney, TX | 75070 |
| (Address of principal executive offices) | (Zip Code) |

---

972-569-4000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $1.00 par value per share | GL | New York Stock Exchange |
| Common Stock, $1.00 par value per share | GL | NYSE Texas, Inc. |
| 4.250% Junior Subordinated Debentures | GL PRD | New York Stock Exchange |

---

Securities registered pursuant to Section 12(g) of the Act: &nbsp;&nbsp;&nbsp;&nbsp;None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &nbsp;&nbsp;&nbsp;&nbsp;

Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp; No ◻&nbsp;&nbsp;&nbsp;&nbsp;

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ◻ No ⌧

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &nbsp;&nbsp;&nbsp;&nbsp;

Yes ⌧ &nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp; No ◻

GL 2025 FORM 10-K

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
| | | Emerging growth company | ◻ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ◻ |

---

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ⌧

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐

Indicate by checkmark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ⌧

As of June 30, 2025, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $10 billion based on the closing sale price as reported on the New York Stock Exchange.

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date.

---

| | |
|:---|:---|
| **Class** | **Outstanding as of January 30, 2026** |
| Common Stock, $1.00 par value per share | 78,637,130 shares |

---

**DOCUMENTS INCORPORATED BY REFERENCE**

---

| | |
|:---|:---|
| **Document** | **Parts Into Which Incorporated** |
| Proxy Statement for the Annual Meeting of Stockholders to be held on April 30, 2026 (Proxy Statement) | Part III |

---

GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Table of Contents**

---

| | | | |
|:---|:---|:---|:---|
| | | | **Page** |
| **[PART I.](#ia1583f94e55d42afa319983b2df261d2_13)** | | | |
|  | Item 1. | [Business](#ia1583f94e55d42afa319983b2df261d2_13) | [1](#ia1583f94e55d42afa319983b2df261d2_13) |
|  | Item 1A. | [Risk Factors](#ia1583f94e55d42afa319983b2df261d2_73) | [8](#ia1583f94e55d42afa319983b2df261d2_73) |
|  | Item 1B. | [Unresolved Staff Comments](#ia1583f94e55d42afa319983b2df261d2_103) | [16](#ia1583f94e55d42afa319983b2df261d2_103) |
|  | Item 1C. | [Cybersecurity](#ia1583f94e55d42afa319983b2df261d2_106) | [16](#ia1583f94e55d42afa319983b2df261d2_106) |
|  | Item 2. | [Properties](#ia1583f94e55d42afa319983b2df261d2_109) | [18](#ia1583f94e55d42afa319983b2df261d2_109) |
|  | Item 3. | [Legal Proceedings](#ia1583f94e55d42afa319983b2df261d2_112) | [18](#ia1583f94e55d42afa319983b2df261d2_112) |
|  | Item 4. | [Mine Safety Disclosures](#ia1583f94e55d42afa319983b2df261d2_115) | [18](#ia1583f94e55d42afa319983b2df261d2_115) |
| **[PART II.](#ia1583f94e55d42afa319983b2df261d2_118)** |  |  |  |
|  | Item 5. | [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#ia1583f94e55d42afa319983b2df261d2_118) | [19](#ia1583f94e55d42afa319983b2df261d2_118) |
|  | Item 6. | [\[Reserved\]](#ia1583f94e55d42afa319983b2df261d2_130) | [19](#ia1583f94e55d42afa319983b2df261d2_130) |
|  |  | [Cautionary Statements](#ia1583f94e55d42afa319983b2df261d2_133) | [20](#ia1583f94e55d42afa319983b2df261d2_133) |
|  | Item 7. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#ia1583f94e55d42afa319983b2df261d2_139) | [21](#ia1583f94e55d42afa319983b2df261d2_139) |
|  | Item 7A. | [Quantitative and Qualitative Disclosures about Market Risk](#ia1583f94e55d42afa319983b2df261d2_412) | [54](#ia1583f94e55d42afa319983b2df261d2_412) |
|  | Item 8. | [Financial Statements and Supplementary Data](#ia1583f94e55d42afa319983b2df261d2_421) | [54](#ia1583f94e55d42afa319983b2df261d2_421) |
|  |  | [Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433) | [57](#ia1583f94e55d42afa319983b2df261d2_433) |
|  |  | [Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436) | [58](#ia1583f94e55d42afa319983b2df261d2_436) |
|  |  | [Consolidated Statements of Comprehensive Income](#ia1583f94e55d42afa319983b2df261d2_439) | [59](#ia1583f94e55d42afa319983b2df261d2_439) |
|  |  | [Consolidated Statements of Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_442) | [60](#ia1583f94e55d42afa319983b2df261d2_442) |
|  |  | [Consolidated Statements of Cash Flows](#ia1583f94e55d42afa319983b2df261d2_445) | [61](#ia1583f94e55d42afa319983b2df261d2_445) |
|  |  | [Notes to Consolidated Financial Statements](#ia1583f94e55d42afa319983b2df261d2_448) | [62](#ia1583f94e55d42afa319983b2df261d2_448) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_451) | [62](#ia1583f94e55d42afa319983b2df261d2_451) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 2—Statutory Accounting](#ia1583f94e55d42afa319983b2df261d2_508) | [75](#ia1583f94e55d42afa319983b2df261d2_508) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 3—Supplemental Information about Changes to Accumulated Other Comprehensive Income](#ia1583f94e55d42afa319983b2df261d2_511) | [76](#ia1583f94e55d42afa319983b2df261d2_511) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_529) | [78](#ia1583f94e55d42afa319983b2df261d2_529) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_589) | [91](#ia1583f94e55d42afa319983b2df261d2_589) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613) | [95](#ia1583f94e55d42afa319983b2df261d2_613) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 7—Deferred Acquisition Costs](#ia1583f94e55d42afa319983b2df261d2_745) | [111](#ia1583f94e55d42afa319983b2df261d2_745) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 8—Liability for Unpaid Claims](#ia1583f94e55d42afa319983b2df261d2_769) | [113](#ia1583f94e55d42afa319983b2df261d2_769) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 9—Income Taxes](#ia1583f94e55d42afa319983b2df261d2_787) | [114](#ia1583f94e55d42afa319983b2df261d2_787) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_814) | [117](#ia1583f94e55d42afa319983b2df261d2_814) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 11—Supplemental Disclosures of Cash Flow Information](#ia1583f94e55d42afa319983b2df261d2_862) | [123](#ia1583f94e55d42afa319983b2df261d2_862) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_865) | [124](#ia1583f94e55d42afa319983b2df261d2_865) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 13—Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_886) | [127](#ia1583f94e55d42afa319983b2df261d2_886) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 14—Stock-Based Compensation](#ia1583f94e55d42afa319983b2df261d2_901) | [129](#ia1583f94e55d42afa319983b2df261d2_901) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916) | [134](#ia1583f94e55d42afa319983b2df261d2_916) |
|  | Item 9. | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#ia1583f94e55d42afa319983b2df261d2_958) | [141](#ia1583f94e55d42afa319983b2df261d2_958) |
|  | Item 9A. | [Controls and Procedures](#ia1583f94e55d42afa319983b2df261d2_961) | [141](#ia1583f94e55d42afa319983b2df261d2_961) |
|  | Item 9B. | [Other Information](#ia1583f94e55d42afa319983b2df261d2_982) | [144](#ia1583f94e55d42afa319983b2df261d2_982) |
|  | Item 9C. | [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#ia1583f94e55d42afa319983b2df261d2_985) | [144](#ia1583f94e55d42afa319983b2df261d2_985) |
| **[PART III.](#ia1583f94e55d42afa319983b2df261d2_988)** |  |  |  |
|  | Item 10. | [Directors, Executive Officers, and Corporate Governance](#ia1583f94e55d42afa319983b2df261d2_988) | [144](#ia1583f94e55d42afa319983b2df261d2_988) |
|  | Item 11. | [Executive Compensation](#ia1583f94e55d42afa319983b2df261d2_994) | [144](#ia1583f94e55d42afa319983b2df261d2_994) |
|  | Item 12. | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#ia1583f94e55d42afa319983b2df261d2_997) | [144](#ia1583f94e55d42afa319983b2df261d2_997) |
|  | Item 13. | [Certain Relationships and Related Transactions and Director Independence](#ia1583f94e55d42afa319983b2df261d2_1000) | [145](#ia1583f94e55d42afa319983b2df261d2_1000) |
|  | Item 14. | [Principal Accountant Fees and Services](#ia1583f94e55d42afa319983b2df261d2_1003) | [145](#ia1583f94e55d42afa319983b2df261d2_1003) |
| **[PART IV.](#ia1583f94e55d42afa319983b2df261d2_1006)** |  |  |  |
|  | Item 15. | [Exhibits and Financial Statement Schedules](#ia1583f94e55d42afa319983b2df261d2_1009) | [145](#ia1583f94e55d42afa319983b2df261d2_1009) |
|  |  | [Signatures](#ia1583f94e55d42afa319983b2df261d2_1024) | [154](#ia1583f94e55d42afa319983b2df261d2_1024) |

---

GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Part I** 

**Item 1. Business** 

Globe Life and the Company refer to Globe Life Inc., an insurance holding company incorporated in Delaware in 1979, and its subsidiaries and affiliates. Its primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company.

Globe Life's website is: www.globelifeinsurance.com. Globe Life makes available free of charge through its website, its annual report on Form 10-K, its quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports as soon as reasonably practicable after they have been electronically filed with or furnished to the Securities and Exchange Commission. Other information included in Globe Life's website is not incorporated into this filing.

GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

The following table presents Globe Life's business by primary marketing distribution channel. Additional information concerning industry segments may be found in *[Management's Discussion and Analysis](#ia1583f94e55d42afa319983b2df261d2_139)* and in *[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916)* within the *[Notes to the Consolidated Financial Statements](#ia1583f94e55d42afa319983b2df261d2_448).* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Primary Distribution Method** | **Underwriting Company** | **Products and Target Markets** | **Distribution** |
| ![RGB_Logos_Globe Life.jpg](gl-20251231_g1.jpg) | **Direct to Consumer Division** | Globe Life And Accident Insurance Company<br>McKinney, Texas | Individual life and supplemental health limited-benefit insurance including juvenile and senior life coverage and Medicare Supplement to lower middle-income to middle-income Americans. | Nationwide distribution through direct to consumer channels: including direct mail, electronic media, and insert media. |
| ![RGB_Logos_American Income Life.jpg](gl-20251231_g2.jpg) | **American Income Life Division** | American Income Life Insurance Company<br>Waco, Texas | Individual life and supplemental health limited-benefit insurance marketed to working families. | 11,920 average producing agents in the U.S., Canada, and New Zealand. |
| ![RGB_Logos_Globe Life Liberty National Division.jpg](gl-20251231_g3.jpg) | **Liberty National Division** | Liberty National Life Insurance Company<br>McKinney, Texas | Life and supplemental health limited-benefit insurance distributed through in-home and worksite channels. | 3,846 average producing agents in the U.S. |
| ![RGB_Logos_Globe Life Family Heritage Division.jpg](gl-20251231_g4.jpg) | **Family Heritage Division** | Family Heritage Life Insurance Company of America<br>Cleveland, Ohio | Supplemental limited-benefit health insurance to lower middle-income to middle-income families. | 1,527 average producing agents in the U.S. |
| ![RGB_Logos_United American.jpg](gl-20251231_g5.jpg) | **United American Division** | United American Insurance Company<br>McKinney, Texas | Supplemental health Medicare coverage to beneficiaries and, to a lesser extent, supplemental limited-benefit coverage to people under age 65. | 4,396 independent producing agents in the U.S. |
| Agents of American Income Life, Liberty National and Family Heritage are independent contractors that exclusively sell for Globe Life.  | Agents of American Income Life, Liberty National and Family Heritage are independent contractors that exclusively sell for Globe Life.  | Agents of American Income Life, Liberty National and Family Heritage are independent contractors that exclusively sell for Globe Life.  | Agents of American Income Life, Liberty National and Family Heritage are independent contractors that exclusively sell for Globe Life.  | Agents of American Income Life, Liberty National and Family Heritage are independent contractors that exclusively sell for Globe Life.  |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Insurance**

**Life Insurance**—The distribution channels for life insurance products include direct to consumer, exclusive independent agents, and general agency independent agents. These methods are described in greater detail within the primary marketing distribution channel chart as shown above. The following table presents annualized premium in force for the three years ended December 31, 2025 by distribution method:

---

| | | | |
|:---|:---|:---|:---|
| | **Annualized Premium in Force**<sup>(1)</sup><br>(Dollar amounts in thousands) | **Annualized Premium in Force**<sup>(1)</sup><br>(Dollar amounts in thousands) | **Annualized Premium in Force**<sup>(1)</sup><br>(Dollar amounts in thousands) |
| | **2025** | **2024** | **2023** |
| **Direct to Consumer**  | $924242 | $922508 | $933057 |
| **Exclusive agents:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 1869082 | 1761713 | 1654197 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 428124 | 410912 | 390693 |
| **Independent agents:** |  |  |  |
| &nbsp;&nbsp;&nbsp;United American | 6010 | 6499 | 6958 |
| &nbsp;&nbsp;&nbsp;Other | 193685 | 197629 | 200840 |
|  | $3421143 | $3299261 | $3185745 |

---

(1)See definition of annualized premium in force under *[Results of Operations](#ia1583f94e55d42afa319983b2df261d2_142)* [in](#ia1583f94e55d42afa319983b2df261d2_139)*[Management's Discussion & Analysis](#ia1583f94e55d42afa319983b2df261d2_139).*

Globe Life's insurance subsidiaries write a variety of nonparticipating ordinary life insurance products. These include traditional whole life, term life, and other life insurance. The Company does not currently sell interest-sensitive whole life products. The following tables present selected information about Globe Life's life insurance products.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| **Whole life:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Traditional | $2422449 | 71 | $2321947 | 70 | $2213816 | 69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest-sensitive | 26291 | 1 | 28105 | 1 | 29929 | 1 |
| **Term**  | 753774 | 22 | 745231 | 23 | 753261 | 24 |
| **Other**  | 218629 | 6 | 203978 | 6 | 188739 | 6 |
|  | $3421143 | 100 | $3299261 | 100 | $3185745 | 100 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) | **Policy Count and Average Face Amount Per Policy**<br>(Dollar amounts in thousands) |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Policy Count** | **Average Face Amount per Policy** | **Policy Count** | **Average Face Amount per Policy** | **Policy Count** | **Average Face Amount per Policy** |
| **Whole life:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Traditional | 9085450 | $16.5 | 9092122 | $16.2 | 9050091 | $16.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest-sensitive | 161883 | 20.4 | 169054 | 20.4 | 176339 | 20.4 |
| **Term**  | 4531580 | 15.1 | 4600839 | 15.2 | 4680364 | 15.1 |
| **Other**  | 505876 | 18.9 | 495894 | 18.1 | 479664 | 17.3 |
|  | 14284789 | $16.2 | 14357909 | $16.0 | 14386458 | $15.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Health Insurance**—The following table presents Globe Life's health insurance annualized premium in force for the three years ended December 31, 2025 by distribution channel.

---

| | | | |
|:---|:---|:---|:---|
| | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) |
| | **2025** | **2024** | **2023** |
| **Direct to Consumer**  | $81040 | $74815 | $70249 |
| **Exclusive agents:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Liberty National | 200815 | 201874 | 200160 |
| &nbsp;&nbsp;&nbsp;American Income | 121903 | 119986 | 116962 |
| &nbsp;&nbsp;&nbsp;Family Heritage | 495750 | 454725 | 418693 |
| **Independent agents and brokers:** |  |  |  |
| &nbsp;&nbsp;&nbsp;United American | 750162 | 624446 | 579237 |
|  | $1649670 | $1475846 | $1385301 |

---

Globe Life offers Medicare Supplement and limited-benefit supplemental health insurance products that include accident, cancer, critical illness, heart, intensive care, and other health products. These products are designed to supplement health coverage that applicants already own. Medicare Supplement plans are offered to enrollees in the traditional fee-for-service Medicare program. Medicare Supplement plans are standardized by federal regulation and are designed to pay certain costs, such as deductibles and co-payments not paid by Medicare.

The following table presents supplemental health annualized premium in force information for the three years ended December 31, 2025 by product category.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) | **Annualized Premium in Force**<br>(Dollar amounts in thousands) |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| Limited-benefit plans | $896994 | 54 | $824844 | 56 | $782424 | 56 |
| Medicare Supplement | 752676 | 46 | 651002 | 44 | 602877 | 44 |
|  | $1649670 | 100 | $1475846 | 100 | $1385301 | 100 |

---

**Pricing**—Premium rates for life and health insurance products are established using assumptions as to future mortality, morbidity, persistency, investment income, expenses, and target profit margins. These assumptions are based on Company experience and projected investment earnings rates. Revenues for individual life and health insurance products are primarily derived from premium income and, to a lesser extent, through policy charges to the policyholder account values on annuity products and certain individual life products. Profitability is affected by actual experience deviations from the established assumptions and to the extent investment income varies from that required for policy reserves.

Collections for certain life products are not recognized as revenues, but are added to policyholder account values. Revenues from these products are derived from charges to the account balances for insurance risk and administrative costs. Profits are earned to the extent these revenues exceed actual costs. Profits are also earned from investment income in excess of the amounts required for policy reserves.

**Underwriting**—The underwriting standards of Globe Life's insurance subsidiaries are established by management. Each subsidiary uses information obtained from the application, and in some cases additional information such as, telephone interviews with applicants, inspection reports, pharmacy data, motor vehicle records, responses to both medical and non-medical questions, doctors' statements and/or medical records and examinations. This information is used to determine whether a policy should be issued in accordance with the application, with a different rating, with a rider, with reduced coverage, or rejected.

**Reserves**—The life insurance policy reserves reflected in Globe Life's consolidated financial statements as future policy benefits are calculated based on accounting principles generally accepted in the United States of America ("GAAP"). These reserves, with future premiums and the associated interest compounded at assumed rates, are expected to be sufficient to cover policy and contract obligations as they mature. Generally, the mortality and lapse

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

assumptions used in the calculations of reserves are based on Company experience. Similar reserves are held on most of the health insurance policies written by Globe Life's insurance subsidiaries, since these policies generally are issued on a guaranteed-renewable basis. The assumptions used in the calculation of Globe Life's reserves are reported in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_451).* Reserves for certain life products consist of the policyholders' account values and are increased by policyholder deposits and interest credited and are decreased by policy charges and benefit payments.

**Reinsurance**—We participate in reinsurance activities in order to minimize exposure to significant risks, limit losses and provide additional capacity for future growth. Globe Life has historically participated in third-party reinsurance whereby we enter into various agreements with reinsurers that cover individual risks, group risks or defined blocks of business. Under the terms of the reinsurance agreements, the reinsurer agrees to reimburse us for the ceded amount in the event a claim is paid. Cessions under reinsurance agreements do not discharge our obligations as the primary insurer. In the event that reinsurers do not meet their obligations under the terms of the reinsurance agreements, reinsurance recoverable balances could become uncollectible. We focus on obtaining reinsurance from a diverse group of highly rated reinsurers. We regularly evaluate the financial condition of our reinsurers and monitor concentration risk with our reinsurers at least annually. Globe Life also utilizes wholly-owned subsidiaries domiciled in Bermuda to execute reinsurance agreements between affiliates to provide for an efficient capital structure. These intercompany agreements do not have an effect on our consolidated U.S. generally accepted accounting principles ("U.S. GAAP") financial statements as they eliminate in consolidation.

In the latter part of 2025 we received license approval and established an affiliated Bermuda reinsurance company, Globe Life Re Ltd.

See *[Schedule IV](#ia1583f94e55d42afa319983b2df261d2_1021), [Note 1—](#ia1583f94e55d42afa319983b2df261d2_451)[Significant](#ia1583f94e55d42afa319983b2df261d2_451)[Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_451), [Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_589), [Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613),* and *[Note 8—Liability for Unpaid Claims](#ia1583f94e55d42afa319983b2df261d2_769)* for more information.

**Investments**— Our primary investment objective is to meet our obligations to policyholders while increasing value to our stockholders by investing in a diversified, high-quality portfolio, comprised primarily of income producing securities and other assets. The nature, quality, and percentage mix of insurance company investments are regulated by state laws. The investments of Globe Life insurance subsidiaries consist predominantly of high-quality, investment-grade securities. Approximately 86% of our invested assets, at fair value, are fixed maturities at December 31, 2025. We also hold commercial mortgage loans, limited partnerships, equity securities and other invested assets, which include short-term investments (see *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_529)* and *[Management's Discussion and Analysis](#ia1583f94e55d42afa319983b2df261d2_139)*).

**Competition**—Globe Life competes with other life and health insurance carriers through policyholder service, price, product design, and sales efforts. While there are insurance companies competing with Globe Life, no individual company dominates any of Globe Life's life or health insurance markets.

Globe Life's health insurance products compete with, in addition to the products of other health insurance carriers, health maintenance organizations, preferred provider organizations, and other health care-related institutions which provide medical benefits based on contractual agreements.

The Company effectively competes with other carriers, in part, due to its ability to operate at lower policy acquisition and administrative expense levels than peer companies. This allows Globe Life to have competitive rates while maintaining higher underwriting margins.

**Regulation**

*U.S. Regulation* 

***Insurance***—Insurance companies are subject to regulation and supervision in the states in which they do business. The laws of the various states establish agencies with broad administrative and supervisory powers which include, among other things, granting and revoking licenses to transact business, regulating trade practices, licensing agents, approving policy forms, approving certain premium rates, setting minimum reserve and loss ratio requirements, subsidiary dividend declaration approval, determining the form and content of required financial statements, and prescribing the type and amount of investments permitted. Insurance companies are also required to file detailed annual reports with supervisory agencies, and records of their business are subject to examination at

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

any time. Under the rules of the National Association of Insurance Commissioners ("NAIC"), insurance companies are examined periodically by one or more of the supervisory agencies.

***Risk-Based Capital (RBC)***—The NAIC requires that a risk-based capital formula be applied to all life and health insurers. The risk-based capital formula is a threshold formula rather than a target capital formula. It is designed only to identify companies that require regulatory attention and is not to be used to rate or rank companies that are adequately capitalized. All Globe Life's insurance subsidiaries are more than adequately capitalized under the risk-based capital formula. See further discussion of RBC in *[Capital Resources](#ia1583f94e55d42afa319983b2df261d2_364).*

***Holding Company***—States have enacted legislation requiring registration and periodic reporting by insurance companies domiciled within their respective jurisdictions that control or are controlled by other corporations so as to constitute a holding company system. Globe Life Inc. and its subsidiaries have registered as a holding company system pursuant to such legislation in Indiana, Nebraska, Ohio, Texas, and New York.

Insurance holding company system statutes and regulations impose various limitations on investments in subsidiaries, and may require prior regulatory approval for material transactions between insurers and affiliates and for the payment of certain dividends and other distributions.

*Non-U.S. Insurance Regulation*

We operate in and have certain branches and subsidiaries in countries outside the United States, including Canada, New Zealand and Bermuda. Generally, our subsidiaries conducting business in these countries and territory must obtain licenses from local regulatory authorities and satisfy local regulatory requirements, including those relating to rates, forms, capital, reserves and financial reporting, as well as certain restrictions on their ability to pay dividends and distributions.

In 2025, we formed a second Bermuda company, Globe Life Re Ltd. ("GL Re"), which is an indirect wholly-owned subsidiary of Globe Life Inc. GL Re is registered by and subject to the supervision of the Bermuda Monetary Authority ("BMA") as a Class C insurer under the Bermuda Insurance Act of 1978 and its related rules and regulations, as amended (the "Insurance Act").

The Insurance Act imposes solvency and capital requirements as well as auditing and reporting requirements. There are minimum solvency margins that must be maintained in accordance with the licensing standards.

**Sustainable Business Practices**

Globe Life's sustainable business practices are a driver of the success and longevity that our Company has delivered since its origin. Environmental responsibility and sustainability are key components of our overall corporate responsibility efforts. We strive to reduce our impact on the environment by placing a company-wide emphasis on recycling and reducing waste at our corporate facilities. With respect to social matters, our focus continues to be on supporting a culture that is inclusive and attractive for all of our employees and independent sales agents. We are committed to maintaining a diverse workforce that reflects the communities in which we work. In addition, to enable the Company to appropriately respond to related challenges and opportunities, the Company has in place a Sustainability Committee, and the Board and its committees regularly engage with senior management on relevant and related issues.

**Human Capital Management**

Globe Life's talent base encompasses a broad range of experience that possesses the depth of critical skills to efficiently and effectively accomplish our business purpose and mission, serve our policyholders, and protect our shareholders' interests. Maintaining superior human capital is a key driver to the success and longevity that our Company has experienced since its origins dating back to the early 1900s. As of December 31, 2025, the Company had 3,695 full-time, part-time, and temporary employees, a 1% decrease over the prior year. The Company engages over 17,000 independently-contracted insurance agents. Refer to Management's Discussion & Analysis for exclusive agent counts.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

*People, Culture, and Community*

At Globe Life, we are united by our mission to Make Tomorrow Better<sup>(1)</sup> and this starts with our employees and agents. Beyond providing insurance protection for millions of individuals, serving our policyholders and generating financial results for our shareholders, we focus on cultivating a healthy, positive culture and a thriving community within and among our campuses that is inclusive of and attractive for all while serving together to Make Tomorrow Better for the communities where we live and work.

We conduct a confidential survey biennially to give our employees the opportunity to provide candid feedback about their experiences at the Company, including but not limited to, confidence in the Company and leadership, competitiveness of our compensation and benefit package, and departmental relationships. The results are shared with our employees, reviewed by senior leadership, and used to identify areas for improvement and create action plans based on the employee feedback received.

We strive to *Make Tomorrow Bette*r, in part by giving financial and service contributions to programs that provide hands-on assistance in the communities where we live, work, and visit. We focus our charitable giving on organizations that support children, families, veterans, and seniors, as well as those that work to support and encourage health and well-being. We also provide paid volunteer time for our employees and provide opportunities for employees to give back individually. These intentional areas of giving align with our mission to help families Make Tomorrow Better by working to protect their financial future. In 2025, we provided financial support of more than $8 million to organizations within that focus, including charities that support underserved communities, and provide scholarships to youth.

*Talent Development*

At Globe Life, we believe investing in our employees through training and development is paramount to their success. We have developed a learning ecosystem that includes a multitude of professional development opportunities, including online, self-directed, and instructor-led courses on a variety of topics. An education assistance program is also offered to facilitate growth in an area related to one's current position with the Company.

*Health, Safety, and Wellness* 

We strive to provide a safe and healthy work environment for every employee. We furnish employees with numerous tools and trainings throughout the year to help ensure they have the best information to safely engage with coworkers, customers, and third parties. In furtherance of our commitment to our employees, we offer a comprehensive employee benefits package that includes competitive monetary benefits, retirement benefits through a Section 401(k) plan and a qualified pension to eligible employees, fitness center reimbursement, paid-time-off (based on years of service), health insurance, dental and vision insurance, employee resource program, health savings and flexible spending accounts, family leave, and tuition assistance.

The Company remains committed to the well-being and safety of its employees, agents, customers, guests, vendors, and shareholders in our resolve to maintain a stable and secure business environment.

<sup>(1)&nbsp;&nbsp;&nbsp;&nbsp;</sup>Per the Globe Life Employee Handbook, the Globe Life mission statement is "We help families *Make Tomorrow Better* by working to protect their financial future."

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Item 1A. Risk Factors** 

**Risks Related to Our Business**

The following is a summary of the material risks and uncertainties that could adversely affect our business, financial condition, and results of operations.

**Business and Operational Risks**

***The development and maintenance of our various distribution channels are critical to growth in product sales and profits.***

Our future success depends, in substantial part, on our ability to recruit, hire, and motivate highly-skilled insurance personnel. Further, the development and retention of producing agents are critical to supporting sales growth in our agency operations because our insurance sales are primarily made by these individuals.

If we do not provide an attractive career opportunity with competitive compensation as well as motivation for producing agents to increase sales of our products, our growth could be impeded. Providing such opportunity may be difficult due to many factors, including but not limited to, fluctuations in economic and industry conditions and the effectiveness of our compensation programs and competition among other companies.

In addition, a failure to effectively develop new methods of reaching consumers, realize cost efficiencies or generate an attractive value proposition in our Direct to Consumer Division business could result in reduced sales and profits.

***Our life insurance products are sold in niche markets. We are at risk should any of these markets diminish.*** 

We have several life distribution channels that focus on distinct market niches, three of which are labor unions, affinity groups, and sales via direct to consumer solicitations. Deterioration of our relationships with either organized labor union groups or affinity groups, or adverse changes in the public's receptivity to Direct to Consumer marketing initiatives could negatively affect our life insurance business.

***Actual or alleged misclassification of independent contractors at our insurance subsidiaries could result in adverse legal, tax or financial consequences.*** 

A significant portion of our sales agents are independent contractors. Although we believe we have properly classified such individuals, a risk nevertheless exists that a court, the Internal Revenue Service or other authority will take the position that our sales agents are employees. From time to time, we are subject to civil litigation, including class and collective action litigation, alleging that we have improperly classified certain of our sales agents as independent contractors. In September 2024, the Equal Employment Opportunity Commission ("EEOC") notified us that it had determined that all sales agents affiliated with State General Agent Simon Arias were employees, not independent contractors, of Globe Life Inc. and/or AIL. Such determination is not binding but any potential civil action brought by the EEOC would likely include such an allegation. A future adverse judgment in connection with any such civil litigation described above could result in substantial damages. Future changes in rules, regulations or interpretations of existing rules and regulations, or significant adverse judgments in litigation, could require us to reclassify all or a portion of our agents as employees and the impact could significantly increase our operating costs and negatively impact our insurance business.

***The use of third-party vendors, including independent sales agents, to support the Company's operations makes the Company susceptible to the operational risk of those third parties, which could lower revenues, increase costs, reduce profits, disrupt business, or damage the Company's reputation.***

The Company utilizes third-party vendors, including independent sales agents, to provide certain business services and functions, which exposes the Company to risks outside of its control. The reliance on these third-party vendors creates a number of business risks, such as the risk that the Company may not maintain service quality, control or effective management of the outsourced business operations and that the Company cannot control the data, facilities, networks, emerging technology or information systems used by third-party vendors. We employ controls and procedures designed to facilitate service quality of our third-party vendors and mitigate risks resulting from the use of third-party vendors; however, such controls and procedures cannot be 100% effective in all cases. The

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

Company may be adversely affected by a third-party vendor who operates in a poorly controlled manner or fails to deliver contracted services, which could lower revenues, increase costs, reduce profits, disrupt business, or damage the Company's reputation.

Extensive federal and state laws regulate our business, imposing certain requirements that independent sales agents must follow in dealing with clients. Misconduct of our independent sales agents could result in violations of law by, or claims against, us or our subsidiaries. From time to time, we are subject to private litigation as a result of alleged misconduct by independent agents. We employ controls and procedures designed to prevent and detect agent misconduct; however, such controls and procedures cannot be 100% effective in all cases. Instances of misconduct or non-compliance or violations of laws or regulations by our independent sales agents could result in adverse findings in either examinations or litigation and subject us to sanctions, monetary liabilities, restrictions on or loss of the operation of our business or reputational harm, any of which could have a material adverse effect on our business, financial condition or results of operations.

Additionally, the Company is at risk of being unable to meet legal, regulatory, financial or customer obligations if the data, information systems, facilities or networks of a third-party vendor are disrupted, damaged or fail, whether due to physical disruptions, such as fire, natural disaster, pandemic or power outage, or due to cybersecurity incidents, ransomware or other impacts to vendors, including labor strikes, political unrest and terrorist attacks.

**Financial and Strategic Risks**

***Our investments are subject to market and credit risks. Significant downgrades, delinquencies and defaults in our investment portfolio could potentially result in lower net investment income and increased realized and unrealized investment losses.***

Our invested assets are subject to the customary risks of defaults, downgrades, and changes in market values. Our investment portfolio consists predominately of fixed income investments, where we are exposed to the risk that individual issuers will not have the ability to make required interest or principal payments. A concentration of these investments in any particular issuer, industry, group of related industries or geographic areas could increase this risk. Factors that may affect both market and credit risks include interest rate levels (consisting of both treasury rate and credit spread), financial market performance, disruptions in credit markets, general economic conditions, legislative changes, particular circumstances affecting the businesses or industries of each issuer and other factors beyond our control.

Additionally, as the majority of our investments are long-term fixed maturities that we typically hold until maturity, a significant increase in interest rates and/or credit spreads could cause a material temporary decline in the fair value of our fixed investment portfolio, even with regard to performing assets. These declines could cause a material increase in unrealized losses in our investment portfolio. Significant unrealized losses could substantially reduce our capital position and shareholders' equity. It is possible our investment in certain of these securities with unrealized losses could experience a credit event where an allowance for credit loss is recorded, reducing net income.

We cannot be assured that any particular issuer, regardless of industry, will be able to make required interest and principal payments on a timely basis or at all. Significant downgrades or defaults of issuers could negatively impact our risk-based capital and solvency ratios, leading to potential downgrades of the Company by rating agencies, potential reduction in future dividend capacity from our insurance subsidiaries, and/or higher financing costs at Globe Life Inc. (Parent Company) should additional statutory capital be required.

***Our investment portfolio contains certain alternative investments that may be illiquid and volatile, which could negatively affect our investment income and liquidity.***

Over the past several years, we have increased our investment in alternative investments, such as limited partnerships. These and other similar investments may have different, more significant risk characteristics than investments in fixed maturity securities, may be more volatile and may be illiquid due to restrictions on sales, transfers and redemption terms, all of which could negatively affect our investment income and overall portfolio liquidity.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

These alternative investments may not meet regulatory admissibility requirements or may result in increased regulatory capital charges to the insurance subsidiaries that hold these investments, which could limit those subsidiaries' ability to pay dividends and negatively impact our liquidity.

***Changes in interest rates could negatively affect income*.** 

Declines in interest rates expose insurance companies to the risk that they will fail to earn the level of interest on investments assumed in pricing products and in setting discount rates used to calculate policy liabilities, which could have a negative impact on income. Significant decreases in interest rates could result in calls by issuers of investments, where such features are available to issuers. Any such calls could result in a decline in our investment income, as reinvestment of the proceeds would likely be at lower interest rates.

An increase in interest rates could result in certain policyholders surrendering their life or annuity policies for cash, thereby potentially requiring our insurance subsidiaries to liquidate invested assets if other sources of liquidity are not available to meet their obligations. In such a case, realized losses could result from the sale of the invested assets and could adversely affect our statutory income, required capital levels, and results of operations.

***Our ability to fund operations is substantially dependent on available funds from our insurance subsidiaries.***

As a holding company with no direct operations, our principal asset is the capital stock of our insurance subsidiaries, which periodically declare and distribute dividends on their capital stock. Moreover, our liquidity, including our ability to pay our operating expenses and to make principal and interest payments on debt securities or other indebtedness owed by us, as well as our ability to pay dividends on our common stock or any preferred stock, depends significantly upon the surplus and earnings of our insurance subsidiaries and the ability of these subsidiaries to pay dividends or to advance or repay funds to us.

The principal sources of our insurance subsidiaries' liquidity are insurance premiums, as well as investment income, maturities, repayments, and other cash flow from our investment portfolio. Our insurance subsidiaries are subject to various state statutory and regulatory restrictions applicable to insurance companies that limit the amount of cash dividends, loans, and advances that those subsidiaries may pay to us, including laws establishing minimum solvency and liquidity thresholds. in addition, our Bermuda reinsurance subsidiaries are subject to regulation established by the Bermuda Monetary Authority ("BMA"). For example, in the states where our companies are domiciled, an insurance company generally may pay dividends only out of its unassigned surplus as reflected in its statutory financial statements filed in that state. Additionally, dividends paid by insurance subsidiaries are restricted based on regulations by their states of domicile. Accordingly, impairments in assets or disruptions in our insurance subsidiaries' operations that reduce their capital or cash flow could limit or disallow the payment of dividends, a principal source of our cash flow, to us.

Under an intercompany reinsurance agreement initiated in 2025, we have ceded approximately $1.2 billion of our life statutory reserves from Liberty National Life Insurance Company, Globe Life And Accident Insurance Company, and American Income Life Insurance Company to GL Re, as of December 31, 2025. Future regulatory changes made by the BMA or other events may impact the capital efficiency of the reinsurance structure and could require the holding company to contribute additional capital to GL Re or our U.S. insurance subsidiaries to recapture ceded business.

Other sources of liquidity include a variety of short-term and long-term instruments, including our credit facility, Pre-Capitalized Trust Securities ("P-CAPS") facility, commercial paper, long-term debt, Federal Home Loan Bank ("FHLB"), intercompany financing and reinsurance.

Changes in laws or regulations in the states in which our companies are domiciled could constrain the ability of our insurance subsidiaries to pay dividends or to advance or repay funds to us in sufficient amounts and at times necessary to pay our debt obligations, corporate expenses, or dividends on our capital stock.

***We are subject to liquidity risks associated with sourcing a concentration of our funding from the FHLB.***

We use institutional funding agreements originating from FHLB, which from time to time serve as a significant source of our liquidity. Additionally, we use agreements with the FHLB to meet near-term liquidity needs. If the FHLB

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

were to change its definition of eligible collateral, we could be required to post additional amounts of collateral in the form of cash or other assets. Additionally, if our creditworthiness falls below the FHLB's requirements or if legislative or other political actions cause changes to the FHLB's mandate or to the eligibility of life insurance companies to be members of the FHLB system, we could be required to find other sources to replace this funding, which may prove difficult and increase our liquidity risk.

***Adverse capital and credit market conditions may significantly affect our ability to meet liquidity needs or access capital, as well as affect our cost of capital.***

Should interest rates increase in the future, the higher interest expense on any newly issued debt may reduce net income. In addition, if the credit and capital markets were to experience significant disruption, uncertainty and instability, these conditions could adversely affect our access to capital. Such market conditions could limit our ability to replace maturing debt obligations in a timely manner, or at all, and/or access the capital necessary to grow our business and maintain required capital levels and credit ratings.

In the event that current sources of liquidity do not satisfy our needs, we may have to seek additional financing or raise capital. The availability and cost of additional financing or capital depend on a variety of factors such as market conditions, the general availability of credit or capital, the volume of trading activities, the overall availability of credit to the insurance industry, our credit ratings and credit capacity. Additionally, customers, lenders or investors could develop a negative perception of our financial prospects if we were to incur large investment losses or if the level of our business activity decreased due to a market downturn. Our access to funds may also be impaired if regulatory authorities or rating agencies take negative actions against us. If our internal sources of liquidity prove to be insufficient, we may not be able to successfully obtain additional financing on favorable terms or at all. As such, we may be forced to delay raising capital, issue shorter term securities than we would prefer or bear an unattractive cost of capital which could decrease our profitability and significantly reduce our financial flexibility. If so, our results of operations, financial condition, consolidated RBC, and cash flows could be materially negatively affected.

***We have become subject to, and may in the future be subject to, short selling strategies driving down the market price of our common stock.***

Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. A short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. Because it is in the short seller's best interests for the price of the securities to decline, some short sellers publish, or arrange for the publication of, opinions or characterizations regarding the relevant issuer, its business prospects and similar matters calculated to or which may create negative market momentum, which may permit them to obtain profits for themselves as a result of selling the stock short. Companies, like us, that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including in connection with securityholder litigation against Globe Life Inc. or investigations by regulators related to or prompted by such allegations.

We have been the target of several short sellers who have published reports making allegations about the Company, which resulted in a significant decline in the price of our common stock. In addition, these reports resulted in significant negative publicity against us, damaged our reputation, and resulted in a putative securities class action litigation and derivative shareholder litigation. See *[Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_589) f*or a discussion of such litigation. We have already expended significant resources to defend and repair our reputation. We will continue to defend against any unfounded and unsubstantiated claims about our business, our disclosures, and the integrity of our financial statements, which may require us to expend significant resources.

We may be subject to additional short seller reports and activity in the future. The publication of any such commentary regarding us may bring about a temporary, or long term, decline in the market price of our common stock. No assurances can be made that similar declines in the market price of our common stock or negative publicity will not occur in the future, in connection with such commentary by short sellers or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Industry Risks**

***Variations in actual-to-expected rates of mortality, morbidity and policyholder behavior could materially negatively affect our results of operations and financial condition.***

We establish policy reserves to pay future policyholder benefits. These reserves do not represent an exact calculation of liability, but rather are actuarial estimates based on models and accounting requirements that include many assumptions and projections which are inherently uncertain. The reserve assumptions involve the exercise of significant judgment with respect to levels or trends of mortality, morbidity, lapses, and discount rates. Changes in assumptions could materially impact our financial condition and results of operations. Further, actual results may differ significantly from the levels assumed, which could result in increased policy obligations and expenses and thus negatively affect our profit margins and income.

***A ratings downgrade or other negative action by a rating agency could materially affect our business, financial condition, and results of operations.***

Various rating agencies review the financial performance and condition of insurers, including our insurance subsidiaries, and publish their financial strength ratings as indicators of an insurer's ability to fulfill its contractual obligations. These ratings are important to maintaining public confidence in our insurance products. A downgrade or other negative action by a rating agency with respect to the financial strength ratings of our insurance subsidiaries could negatively affect us by limiting or restricting the ability of our insurance subsidiaries to pay dividends to us and reducing our sales by adversely affecting our ability to sell insurance products through independent insurance agencies.

***Obtaining timely and appropriate premium rate increases for certain supplemental health insurance policies is critical.*** 

A significant percentage of the supplemental health insurance premiums that our insurance subsidiaries earn is from Medicare Supplement insurance. Medicare Supplement insurance, including conditions under which the premiums for such policies may be increased, is highly regulated at both the state and federal level. As a result, Medicare Supplement business is characterized by lower profit margins than life insurance and requires strict administrative discipline and economies of scale for success. Since Medicare Supplement policies are coordinated with the federal Medicare program, which commonly experiences health care inflation every year, annual premium rate increases for the Medicare Supplement policies are typically necessary. Accordingly, the inability to obtain approval of appropriate premium rate increases for supplemental health insurance plans in a timely manner from state insurance regulatory authorities could adversely impact their profitability and thus our business, financial condition, and results of operations.

***Our business is subject to the risk of the occurrence of catastrophic events that could adversely affect our financial condition or operations.*** 

Our insurance policies are issued to and held by a large number of policyholders throughout the United States in relatively low-face amounts. Accordingly, it is unlikely that a large portion of our policyholder base would be affected by a single natural disaster. However, our insurance operations could be exposed to the risk of catastrophic mortality or morbidity caused by events such as a pandemic or other public health issues, hurricane, earthquake, or man-made catastrophes, including acts of terrorism or war, which may produce significant claims in larger areas, especially those that are heavily populated. Claims resulting from natural or man-made catastrophic events could cause substantial volatility in our financial results for any fiscal quarter or year and could materially reduce our profitability or harm our financial condition. In addition, government, business, and consumer reactions to public health events could result in material negative impacts to our business and operations.

Our life and health insurance products are particularly exposed to risks of catastrophic mortality, such as a pandemic or other events that result in a large number of deaths. In addition, the occurrence of such an event in a concentrated geographic area could have a severe disruptive effect on our workforce and business operations. The likelihood and severity of such events cannot be predicted and are difficult to estimate. In such an event, the impact to our operations could have a material adverse impact on our ability to conduct business and on our results of operations and financial condition, particularly if those problems affect our producing agents or our employees performing operational tasks and supporting computer-based data processing, or impair or destroy our capability to

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

transmit, store, and retrieve valuable data. In addition, in the event that a significant number of our management were unavailable following a disaster, the achievement of our strategic objectives could be negatively impacted.

***We are exposed to model risk, which is the risk of financial loss or reputational damage or adverse regulatory impacts caused by model errors or limitations, incorrect implementation of models, or misuse of or overreliance upon models.***

Models are utilized by our businesses and corporate areas primarily to project future cash flows associated with pricing products, calculating reserves and valuing assets, as well as in evaluating risk and determining capital requirements, among other uses. These models may not operate properly and may rely on assumptions and projections that are inherently uncertain. As our businesses continue to grow and evolve, the number and complexity of models we utilize expands, increasing our exposure to error in the design, implementation or use of models, including the associated input data and assumptions.

***Our business is subject to the risk of direct or indirect effects of climate change.***

Climate change may increase the frequency and severity of weather-related events and natural disasters, which may adversely impact our mortality and morbidity rates and disrupt our business operations. In addition, climate change and climate change regulation may affect the prospects of companies and other entities whose securities we hold or our willingness to continue to hold their securities. Climate change may also influence investor sentiment with respect to the Company and investments in our portfolio.

**Legal, Regulatory, and Compliance Risks**

***Recent volatility in the trading price of our common stock has and can be expected to result in securities class action litigation.***

In April 2024, the trading price of our common stock dropped following the publication of certain short seller reports. As of the date of this Report, one putative securities class action and five shareholder derivative lawsuits have been filed against Globe Life Inc. related to this event. While we intend to defend such actions vigorously, any judgment against us or any future stockholder litigation could have a material adverse effect on our business, financial condition or results of operations.

***Our businesses are heavily regulated and changes in regulation or regulatory scrutiny may have a material adverse impact on our business, financial condition or results of operation.***

Insurance companies, including our insurance subsidiaries, are subject to extensive supervision and regulation in the states in which they conduct business. The primary purpose of this supervision and regulation is the protection of policyholders, not investors. Regulatory agencies have broad administrative power over numerous aspects of our business, including premium rates for our life, Medicare Supplement and other supplemental health products, as well as other terms and conditions included in the insurance policies offered by our insurance subsidiaries, marketing practices, advertising, use of emerging technologies, agent licensing, independent agent practices, policy forms, capital adequacy, solvency, reserves and permitted investments.

Regulatory authorities also have the power to conduct investigations, and to bring administrative or judicial proceedings against us, which could result in suspension or revocation of our licenses, cease and desist orders, fines, civil penalties, disgorgement, criminal penalties or other disciplinary action that could have a material adverse impact on our business, financial condition or results of operation. Press coverage and other public statements that allege wrongdoing, even if untrue, can lead to increased regulatory inquiries or investigations.

The insurance laws, regulations and policies currently affecting our companies may change at any time, possibly having an adverse effect on our business. Should regulatory changes occur, we may be unable to maintain all required licenses and approvals, or fully comply with the wide variety of applicable laws and regulations or the relevant authority's interpretation of such laws and regulations. If we do not have the requisite licenses and approvals or do not comply with applicable regulatory requirements, the insurance regulatory authorities could preclude or temporarily suspend some or all of our business activities and/or impose substantial fines. Additionally, any violation or alleged violation of law or regulations could result in significant legal costs or in legal proceedings

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

that may result in monetary and legal remedies being imposed against the Company, which could have a material adverse effect on our business, financial condition or results of operations.

***Changes in accounting standards issued by accounting standard-setting bodies may affect our financial statements, reduce our reported profitability and change the timing of profit recognition.***

Our financial statements are subject to the application of GAAP and accounting practices as promulgated by the National Association of Insurance Commissioners' statutory accounting practices ("NAIC SAP"), which principles are periodically revised and/or expanded. Accordingly, from time to time we are required to adopt new or revised accounting standards or guidance issued by recognized authoritative bodies. Future accounting standards that we are required to adopt could change the current accounting treatment that we apply to our consolidated financial statements. These changes, including underlying assumptions, projections, estimates or judgments/interpretations by management, could have a material adverse effect on our business, financial condition, and results of operations. Refer to *[Note 1—Significant Accounting Policie](#ia1583f94e55d42afa319983b2df261d2_451)s* under the caption *[Accounting Pronouncements Yet to be Adopted](#ia1583f94e55d42afa319983b2df261d2_502)*.

***Non-compliance with laws or regulations related to customer and consumer privacy and information security, including a failure to ensure that third parties with access to sensitive customer and consumer information maintain its confidentiality, could materially adversely affect our reputation and business operations.***

The collection, maintenance, use, disclosure, and disposal of personally identifiable information by our insurance subsidiaries are regulated at the international, federal, and state levels. Applicable laws and rules are subject to change by legislation or administrative or judicial interpretation. We are subject to the privacy and security provisions of federal laws including, but not limited to, the Gramm-Leach-Biley Act of 1999 ("GLBA"), the Health Information Technology for Economic and Clinical Health Act ("HITECH"), and the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). HIPAA additionally requires that we impose privacy and security requirements on our third-party business associates. Various state laws also address the use and disclosure of personally identifiable information, to the extent they are more restrictive than these and other federal laws. Further, approximately half of the states have adopted a form of the National Association of Insurance Commissioners' data security model law, which imposes security requirements. Noncompliance with these laws, whether by us or by one of our business associates, could have a material adverse effect on our business, reputation, and results of operations and could result in material fines and penalties, various forms of damages, consent orders regarding our privacy and security practices, adverse actions against our licenses to do business, and injunctive relief.

**General Risk Factors**

***The failure to maintain effective information systems or manage responsible use of emerging technologies, including artificial intelligence, could adversely affect our financial condition and results of operations at the Company.***

Our business is highly dependent upon the internet, third-party service providers, and information systems to operate in an efficient and resilient manner. We gather and maintain data for the purpose of conducting marketing, actuarial analysis, sales, and policy administration functions. Our ability to modernize and maintain our information technology systems and infrastructure requires us to commit significant resources and effective planning and execution. This modernization includes the innovative, responsible, and secure use of artificial intelligence ("AI").

Malicious third parties, employee or agent errors or disasters affecting our information systems could impair our business operations, regulatory compliance, and financial condition. Employee or agent malfeasance or errors in the handling of our information systems may result in unauthorized access to customer or proprietary information, or an inability to use our information systems to efficiently support business operations. As a result of increasingly complex AI risks, more frequent and sophisticated cyberattacks and the highly regulated nature of the insurance industry, we must continually implement new, and maintain existing, technology or adapt existing technology to protect against security and privacy incidents and to meet compliance requirements of new and proposed regulations.

Any incident affecting confidential information systems resulting from the above factors could damage our reputation in the marketplace, deter potential customers from purchasing our products, result in the loss of existing customers,

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

subject us to significant civil and criminal liability, constrain cash flows, or require us to incur significant technical, legal, or other expenses. In addition, should we be unable to implement or maintain our technology effectively, efficiently, or in a timely manner, it could result in poor customer experience, poor agent experience, additional expenses, reputational harm, legal and regulatory actions, and other adverse consequences. This could also result in the inability to effectively support business operations.

***Changes in U.S. federal income tax law could increase our tax costs or negatively impact our insurance subsidiaries' capital.*** 

Changes to the Internal Revenue Code, administrative rulings, or court decisions affecting the insurance industry, including the products insurers offer, could increase our effective tax rate and lower our net income, adversely impact our insurance subsidiaries' capital, or limit the ability of our insurance subsidiaries to sell certain of their products.

***Damage to the brand and reputation of Globe Life or its subsidiaries could affect our ability to conduct business.***

Negative publicity through traditional media, internet, social media, and other public forums, including short seller reports and allegations of independent agent misconduct could damage our brand or reputation, which could adversely impact our ability to recruit and retain agents, our ability to market our products, and the persistency of in force policies. A reduction in the number of agents selling our products, or the rate of growth of the number of agents selling our products may have an adverse impact on product sales and profit, and such impact may be material.

***We may not meet expectations relating to corporate responsibility and sustainability standards and practices***.

Certain existing or potential investors, customers and regulators evaluate our business or other practices according to a variety of corporate responsibility and sustainability standards and expectations. Certain of our regulators have proposed or adopted, or may propose or adopt, certain corporate responsibility and sustainability rules or standards that would apply to our business. Our practices may be judged by these standards that are continually evolving and not always clear. Our decisions or priorities are made with the considerations of all stakeholders. Prevailing corporate responsibility and sustainability standards and expectations may also reflect contrasting or conflicting values or agendas.

We may not meet these corporate responsibility and sustainability expectations. Failure to meet, or achieve progress on, these expectations, on a timely basis, or at all, could adversely affect our reputation, business, financial performance, and growth. We may face adverse regulatory, investor, customer, media, or public scrutiny leading to business, reputational, or legal challenges. In addition, our policies, and processes to evaluate and manage these standards in coordination with other business priorities may not prove completely effective or satisfy investors, customers, regulators, or others.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Item 1B. Unresolved Staff Comments** 

As of December 31, 2025, Globe Life had no unresolved SEC staff comments.

**Item 1C. Cybersecurity** 

**Risk Management and Strategy**

We have implemented a comprehensive Enterprise Risk Management ("ERM") process to identify, assess and manage risks related to our overall organization, including material risks from cybersecurity threats. Our ERM process takes a holistic view of our specific risks and our strategy to anticipate and manage possible risks. Our Executive Vice President, General Counsel and Chief Risk Officer ("CRO") oversees our ERM program and execution of our risk strategy, including as it relates to cyber risk. The Chief Information Security Officer ("CISO"), who reports to the General Counsel and CRO, leads our cyber risk management and strategy and the Information Security Department.

Our cyber risk management and information security strategy includes elements to identify threats, assess risks, implement protective controls, detect attempts from threat actors to compromise the confidentiality, integrity, and availability of information and information systems, respond to those events and ultimately recover from incidents. We use a threat-based approach to identify and assess cyber risks. This approach includes membership in threat intelligence organizations such as the FS-ISAC (Financial Services Information Sharing and Analysis Center) to identify standard and emerging cyber-threats to financial services organizations and specifically to insurance companies. We also monitor for threats through vendor alerts, manufacturer bulletins, and government advisories.

Identified threats are analyzed using a recognized risk assessment model to consistently assess the likelihood and impact of these threats. We then map these threats to a well-established industry model called MITRE ATT&CK to identify areas of vulnerability. This analysis produces a likelihood score that is used in conjunction with an impact analysis to calculate the preliminary level of risk. The impact analysis includes factors such as disruption to business operations, employee and customer data, legal issues, reputational harm, and regulatory compliance. Based on the preliminary level of risk, we also analyze compensating controls and other factors to arrive at a residual risk level. If appropriate, additional mitigations may be planned based on this risk level.

We manage identified cyber risks by designing and implementing information security policies and controls addressing a wide range of current cyber threats. These policies and associated standards are designed to comply with current applicable legal and regulatory requirements and align with recognized frameworks for cybersecurity risk management. We review and update these policies and controls regularly in order to confirm ongoing alignment with the constantly changing threat landscape and evolving compliance requirements.

We assess the effectiveness of our corporate policies and controls internally, as well as through the engagement of external advisors to conduct regular reviews, penetration tests, and vulnerability scans of Company information systems and applications. Results from these assessments help inform updates to risk assessments, changes to security controls and processes, and updates to policies and standards as appropriate. We employ a variety of internal measures to detect, prevent, and reduce the frequency and severity of cybersecurity incidents on the Company's infrastructure, which may include, but are not limited to, the use of encryption, intrusion prevention, endpoint security, password protection, multi-factor authentication, internal phishing testing, security awareness training, and vulnerability scanning and penetration testing.

In addition, cybersecurity is incorporated into our third-party risk management program. We assess the ability of our vendors as appropriate to adequately protect information, which includes requiring agreements that address cybersecurity. We periodically review and assess vendors' adherence to these agreements and review for information security (including cybersecurity) incidents experienced by our third-party vendors. With respect to our independent sales agents, we require each agent to execute an agent agreement containing terms governing the ownership, use and confidentiality of policyholder and proprietary information. We also engage with agency offices to support their use of measures and safeguards to protect information.

Due to the type and volume of information that we collect and store to support our business, including to provide insurance coverage to prospective, current and former policyholders, we are an attractive target for cyber threat actors seeking financial gain. Our failure to maintain the safety of our policyholders' information could have a

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

material adverse effect on our reputation, financial condition and results of operations. To date, we have not experienced a cybersecurity incident that resulted in a material adverse effect on our business strategy, results of operations, or financial condition; however, we anticipate that our systems and data will continue to face attacks or other cybersecurity risks and there can be no guarantee that we will not experience such an incident in the future. Although we maintain cybersecurity insurance, the costs and expenses related to cybersecurity incidents may not be fully insured. We describe whether and how risks from identified cybersecurity threats, including as a result of previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition under *[Item 1A. Risk Factors](#ia1583f94e55d42afa319983b2df261d2_73)*, General Risk Factors, "The failure to maintain effective and efficient information systems at the Company could adversely affect our financial condition and results of operations."

**Governance**

Our Board of Directors considers information security to be an enterprise-wide risk management issue and oversees material cybersecurity risks through the Audit Committee. The Audit Committee is designated with the responsibility to monitor and periodically report to the full Board regarding management's risk management and information security processes. The ERM Committee and the Operational Risk Committee ("ORC") are the senior management-level groups designated with the responsibility to oversee the execution of our risk strategy, including as it relates to cyber risk. These Committees are composed of an enterprise-wide representative group of the Company's Executive and Senior Vice Presidents, as well as other essential directors and personnel. The ERM Committee is chaired by our CRO, and the ORC is chaired by our Divisional Senior Vice President, Risk Insurance Regulation and Chief Compliance Officer ("CCO"). The Chief Information Officer ("CIO") and CISO serve on both Committees. Our CRO has over a decade of experience managing risks at the Company, including those related to cybersecurity. Our CIO has over 15 years of experience in risk management, with a focus on cybersecurity threats. Our CCO has over 26 years of insurance industry expertise, including experience in risk management, cybersecurity, and incident response. The CISO serves on both Committees and leads cyber governance and strategy, as well as cyber risk and incident management. The CISO holds a master's degree in cybersecurity, has a Certified Information Systems Security Professional certification, and has over a decade of experience in cybersecurity.

The CISO assesses cyber risk and provides recommendations for management decision(s) by the ORC on a routine basis. The CISO briefs the Audit Committee on a quarterly basis. These updates include compliance measures designed to meet applicable regulations as well as current or planned changes to the regulations, an overview of the current cyber threats, risk management activities, and discussions of cyber incident investigations that warrant the attention of the Board. The CISO also provides an annual update to the entire Board of Directors on topics such as changes in cybersecurity, top threats facing the Company, key risks and mitigation efforts, and any potential material cybersecurity incidents. The Chair of the Audit Committee also provides a quarterly report to the Board on any information security topics presented to the Audit Committee by management.

**Incident Management**

The Company maintains and tests a cybersecurity incident response plan that outlines steps for the containment, investigation of, response to and recovery from cyber events. The plan also includes information pertaining to roles and responsibilities, escalation, third-party support, documentation, reporting, and law enforcement engagement. Escalation is designed to raise awareness of events that may require disclosure to help ensure assessments are performed without unreasonable delay. In alignment with our plan, we maintain playbooks that outline processes for responding to certain incidents commonly observed in the insurance industry. In addition, we have implemented a formal crisis management process, which outlines an incident response communication plan with executive leadership as well as criteria for communication with the chair of the Audit Committee and the Lead Director of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Item 2. Properties** 

Globe Life Inc., through its subsidiaries, owns or leases buildings across the U.S. that are used in the normal course of business. Globe Life Inc. occupies approximately 812,000 combined square feet in McKinney, Texas (headquarters) and at the Waco, Texas and Oklahoma City, Oklahoma campuses.

**Item 3. Legal Proceedings** 

Discussion regarding litigation is provided in *[Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_589)*.

**Item 4. Mine Safety Disclosures** 

Not Applicable.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Part II** 

**Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

**Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters**

The principal market in which Globe Life's common stock is traded is the New York Stock Exchange (NYSE: GL). There were 1,728 shareholders of record on December 31, 2025, excluding shareholder accounts held in nominee form.

The line graph shown below compares Globe Life's cumulative total return on its common stock with the cumulative total returns of the Standard & Poor's 500 Stock Index (S&P 500) and a Life and Health Insurance Index. Globe Life's stock is included within the S&P 500 Index.

![4](gl-20251231_g6.jpg)

\*$100 invested on 12/31/2020 in stock or index, including reinvestment of dividends. Fiscal year ended December 31.

Copyright© 2026 Standard & Poor's, a division of S&P Global. All rights reserved.

**Purchases of Certain Equity Securities by the Issuer and affiliated purchasers for the Fourth Quarter 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(a)** | **(b)** | **(c)** | **(d)** |
|<br>**Period** | **Total Number<br>of Shares<br>Purchased** | **Average<br>Price Paid<br>Per Share** | **Total Number of <br>Shares Purchased <br>as Part of <br>Publicly Announced <br>Plans or Programs** | **Maximum Number of <br>Shares (or Approximate Dollar<br>Amount) that May Yet Be<br>Purchased Under the <br>Plans or Programs** |
| October 1-31, 2025 | 801407 | $135.13 | 801407 |  |
| November 1-30, 2025 | 462070 | 132.58 | 462070 |  |
| December 1-31, 2025 | 152969 | 137.97 | 152969 |  |

---

**Item 6. [Reserved]** 

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**CAUTIONARY STATEMENTS**

We caution readers regarding certain forward-looking statements contained in the foregoing discussion and elsewhere in this document, and in any other statements made by, or on behalf of Globe Life whether or not in future filings with the Securities and Exchange Commission. Any statement that is not a historical fact, or that might otherwise be considered an opinion or projection concerning the Company or its business, whether express or implied, is meant as and should be considered a forward-looking statement. Such statements represent management's opinions concerning future operations, strategies, financial results or other developments. We specifically disclaim any obligation to update or revise any forward-looking statement because of new information, future developments, or otherwise.

Forward-looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control. If these estimates or assumptions prove to be incorrect, the actual results of Globe Life may differ materially from the forward-looking statements made on the basis of such estimates or assumptions. Whether or not actual results differ materially from forward-looking statements may depend on numerous foreseeable and unforeseeable events or developments, which may be national in scope, related to the insurance industry generally, or applicable to the Company specifically. Such events or developments could include, but are not necessarily limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Economic and other conditions, including the impact of inflation, immigration, geopolitical events, escalating tariff and non-tariff trade measures imposed by the U.S. and other countries, a prolonged government shutdown, and other governmental actions which affect the U.S. economy and/or U.S. consumer confidence, leading to unexpected changes in lapse rates and/or sales of our policies, as well as levels of mortality, morbidity, and/or utilization of health care services that differ from Globe Life's assumptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Regulatory developments, including changes in accounting standards or governmental regulations (particularly those impacting taxes and changes to the Federal Medicare program that affect Medicare Supplement insurance sales, claims utilization or use);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Market trends in the senior-aged health care industry that provide alternatives to traditional Medicare (such as Health Maintenance Organizations and other managed care or private plans) and that affect the sales of traditional Medicare Supplement insurance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Interest rate changes that affect product sales, financing costs, and/or investment yields;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.General economic, industry sector or individual debt issuers' financial conditions (including developments and volatility arising from geopolitical events, particularly in certain industries that may comprise part of our investment portfolio) that affect the current market value of securities we own, or that may impair an issuer's ability to make principal and/or interest payments due on those securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.Changes in the competitiveness of the Company's products and pricing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.Litigation or regulatory actions against the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.Levels of administrative and operational efficiencies that differ from our assumptions (including any reduction in efficiencies resulting from increased costs arising from the impact of higher than anticipated inflation);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.The ability to obtain timely and appropriate premium rate increases for health insurance policies from our regulators;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.The ability of our subsidiaries to pay dividends to the Parent Company and to receive required regulatory approvals on such amounts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.The customer response to new products and marketing initiatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.Reported amounts in the consolidated financial statements which are based on management estimates and judgments which may differ from the actual amounts ultimately realized;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.Compromise by a malicious actor or other event that causes a loss of secure data from, or inaccessibility to, our computer and other information technology systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.The Company's ability to attract and retain agents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.The severity, magnitude, and impact of natural or man-made catastrophic events, including but not limited to pandemics, tornadoes, hurricanes, earthquakes, war and terrorism, on our operations and personnel, commercial activity, level of claims, and demand for our products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.Globe Life's ability to access the commercial paper and debt markets, particularly if such markets become unpredictable or unstable for a certain period.

Readers are also directed to consider other risks and uncertainties described in other documents on file with the Securities and Exchange Commission, including those described under *[Item 1A. Risk Factors](#ia1583f94e55d42afa319983b2df261d2_73)*.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis**

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

The following discussion should be read in conjunction with Globe Life's *[Consolidated Financial Statements](#ia1583f94e55d42afa319983b2df261d2_1042)* and *[Notes](#ia1583f94e55d42afa319983b2df261d2_448)* thereto appearing elsewhere in this report. The following management discussion will only include comparison to prior year. For discussion regarding activity from 2023, please refer to the prior filed Form 10-Ks at www.sec.gov.

"Globe Life" and the "Company" refer to Globe Life Inc. and its subsidiaries and affiliates.

**Results of Operations**

---

| |
|:---|
| ***How Globe Life Views Its Operations.*** Globe Life Inc. is the holding company for a group of insurance companies that market through exclusive, direct-to-consumer and independent distribution channels primarily individual life and supplemental health insurance to lower middle to middle-income households throughout the United States. We view our operations by segments, which are the insurance product lines of life and supplemental health, and the investment segment that supports the product lines.  |
| ***Insurance Product Line Segments.*** The insurance product line segments involve the marketing, underwriting, and administration of policies. Each product line is further subdivided by the various distribution channels that market the insurance policies. Each distribution channel operates in a niche market offering insurance products designed for that particular market. Whether analyzing profitability of a segment as a whole, or the individual distribution channels within the segment, the measure of profitability used by management is the underwriting margin, as seen below: |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premium revenue<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Policy obligations)<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>(Policy acquisition costs and commissions)</u> <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Underwriting margin** |
| ***Investment Segment.*** The investment segment involves the management of our capital resources, including investments and the management of liquidity. Our measure of profitability for the investment segment is excess investment income, as seen below: |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net investment income<br><u>(Required interest on policy liabilities)</u> <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Excess investment income** |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

Globe Life serves the lower-middle to middle-income market. We believe this market is underserved, has significant growth potential, and provides us with a distinct competitive advantage. This advantage is protected due not only to our ability to efficiently reach this market through both exclusive and direct to consumer distribution channels, but also due to the amount of data and experience we possess, as we have been in this same market for over 60 years with essentially the same products. The basic protection life and health insurance products we offer are specifically designed to help provide financial security to consumers in this market.

***Current Highlights.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income as a return on equity (ROE) for the year ended December 31, 2025 was 20.9% and net operating income as an ROE, excluding accumulated other comprehensive income<sup>(1)</sup> was 16.0%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total premium increased 5% over the same period in the prior year. Life premium increased 3% for the period from $3.3 billion in 2024 to $3.4 billion in 2025. Health premium increased 9% to $1.5 billion over the prior-year period of $1.4 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net sales increased 13% over the same period in the prior year from $840 million in 2024 to $948 million in 2025. The average producing agent count across all of the exclusive agencies increased 3% over the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Book value per share increased 19% over the same period in the prior year from $62.50 to $74.17. Book value per share, excluding accumulated other comprehensive income<sup>(1)</sup>, increased 11% over the prior year from $86.40 in 2024 to $96.16 in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For the year ended December 31, 2025, the Company repurchased 5.4 million shares of Globe Life Inc. common stock at a total cost of $685 million for an average share price of $126.41.

The following graphs represent net income and net operating income<sup>(1)</sup> for the twelve month periods ended December 31, 2025 and 2024.

![965](gl-20251231_g7.jpg)![967](gl-20251231_g8.jpg)

(1)As shown in the charts above, net operating income is primarily comprised of insurance underwriting margin plus excess investment income and annuity and other income, offset by operating expenses after tax and, as such, is considered a non-GAAP measure. It has been used consistently by Globe Life's management for many years to evaluate the operating performance of the Company. It differs from net income primarily because it excludes certain non-operating items such as realized gains and losses and certain significant and unusual items included in net income. Net income is the most directly comparable GAAP measure.

Net operating income as an ROE, excluding accumulated other comprehensive income ("AOCI"), is considered a non-GAAP measure. Management utilizes this measure to view the business without the effect of changes in AOCI, which are primarily attributable to fluctuation in interest rates. The impact of the adjustment to exclude AOCI is $(1.8) billion and $(2.0) billion for the year ended December 31, 2025 and 2024, respectively.

Book value per share, excluding AOCI, is also considered a non-GAAP measure. Management utilizes this measure to view the book value of the business without the effect of changes in AOCI, which are primarily attributable to fluctuation in interest rates. The impact of the adjustment to exclude AOCI is $(21.99) and $(23.90) per share for the year ended December 31, 2025 and 2024, respectively.

Refer to *[Analysis of Profitability by Segment](#ia1583f94e55d42afa319983b2df261d2_169)* for non-GAAP reconciliation to GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Summary of Operations.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Net income totaled $1.16 billion in 2025, compared with $1.07 billion in 2024 and $971 million in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On a diluted per common share basis, net income per common share for 2025 increased 18% to $14.07. Net income per common share, on a diluted per common share basis was $11.94 in 2024 and $10.07 in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Net operating income was $1.20 billion in 2025, compared with $1.11 billion in 2024 and $1.03 billion in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On a diluted per common share basis, net operating income per common share for 2025 increased 17% to $14.52. Net operating income per common share, on a diluted per common share basis, was $12.37 in 2024 and $10.65 in 2023.

Net remeasurement gains of $134.3 million in 2025, $46.3 million in 2024, and $3.2 million in 2023 were attributable to the Company's annual third-quarter review and unlocking of life and health long-term assumptions, including lapses, mortality and morbidity. See the remeasurement gain/loss table in *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613)* for additional information.

Overall, the Company continues to see positive signs in its core operations, including sales and premium growth, and continues to achieve an operating ROE (excluding accumulated other comprehensive income) generally in the mid-teens.

Net operating income is primarily comprised of insurance underwriting margin plus excess investment income and annuity and other income, offset by operating expenses, after tax and, as such, is considered a non-GAAP measure. Net income is the most directly comparable GAAP measure. We do not consider realized gains and losses to be a component of our core insurance operations or operating segments. Additionally, net income is affected by certain non-operating items. We do not view these items as components of core operating results because they are not indicative of past performance or future prospects of the insurance operations. We remove items such as these that relate to prior periods or are non-operating items when evaluating the results of current operations, and therefore exclude such items from our segment analysis for current periods.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

Globe Life's operations on a segment-by-segment basis are discussed in depth below. Net operating income has been used consistently by management for many years to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company's business.

**Analysis of Profitability by Segment**

(Dollar amounts in thousands)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** | **2025 Change** | **%** | **2024 Change** | **%** |
| Life insurance underwriting margin | $1509361 | $1352597 | $1192972 | $156764 | 12 | $159625 | 13 |
| Health insurance underwriting margin | 390128 | 372423 | 377937 | 17705 | 5 | (5514) | (1) |
| Excess investment income | 138393 | 164404 | 130382 | (26011) | (16) | 34022 | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment profit or (loss) | 2037882 | 1889424 | 1701291 | 148458 | 8 | 188133 | 11 |
| Annuity and other income | 9470 | 7636 | 8800 | 1834 | 24 | (1164) | (13) |
| Administrative expense | (355595) | (342430) | (301161) | (13165) | 4 | (41269) | 14 |
| Other corporate expense | (208758) | (179610) | (143918) | (29148) | 16 | (35692) | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-tax total | 1482999 | 1375020 | 1265012 | 107979 | 8 | 110008 | 9 |
| Applicable taxes | (284612) | (266036) | (238368) | (18576) | 7 | (27668) | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net operating income**  | 1198387 | 1108984 | 1026644 | 89403 | 8 | 82340 | 8 |
| Reconciling items, net of tax: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Realized gains (losses) | (21952) | (19108) | (51884) | (2844) |  | 32776 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expenses | (1725) | (2070) | (3294) | 345 |  | 1224 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal proceedings | (13472) | (17044) | (711) | 3572 |  | (16333) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income**  | $1161238 | $1070762 | $970755 | $90476 | 8 | $100007 | 10 |

---

The life insurance segment is our primary segment and is the largest contributor to earnings in each year presented. In 2025, the life insurance segment underwriting margin increased $157 million, compared with 2024. This was primarily a result of increased premiums and favorable policy obligations as a percent of premium due to a remeasurement gain resulting from the assumption updates in 2025. In 2024, the life insurance segment underwriting margin increased $160 million when compared with 2023. This was primarily a result of increased premiums and favorable policy obligations as a percent of premium in addition to a remeasurement gain as a result of assumption changes in 2024. Excess investment income decreased $26 million in 2025 compared with 2024, resulting from lower average invested asset growth and lower average earned yields on our short-term, direct commercial mortgage loan and limited partnership investments. In 2025, underwriting margin in the health segment increased to $390 million due to increased sales and rate increases in our Medicare supplement business, compared with $372 million in 2024 and $378 million in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

In 2025, the largest contributor of total underwriting margin was the life insurance segment and the primary distribution channel was the American Income Life Division (American Income). The following charts represent the breakdown of total underwriting margin by operating segment and distribution channel for the year ended December 31, 2025.

![325](gl-20251231_g9.jpg)![326](gl-20251231_g10.jpg)

Total premium income rose 5% for the year ended December 31, 2025 to $4.9 billion. Total net sales increased 13% to $948 million when compared with 2024. Total first-year collected premium (defined in the following section) increased 5% to $704 million for 2025, compared to $674 million in 2024.

Life insurance premium income increased 3% to $3.4 billion over the prior-year total of $3.3 billion. Life net sales increased 3% to $615 million for the year ended 2025 as compared to the year ago period. First-year collected life premium increased 2% to $463 million. Life underwriting margin, as a percent of premium, increased to 45% for 2025 from 41% in 2024. Underwriting margin increased to $1.5 billion in 2025, compared to $1.4 billion in 2024.

Health insurance premium income increased 9% to $1.5 billion over the prior-year total of $1.4 billion. Health net sales rose 36% to $333 million for the year ended 2025. First-year collected health premium rose 10% to $241 million. Health underwriting margin, as a percent of premium, was 26% for 2025 down from 27% in 2024. Health underwriting margin increased to $390 million for the year ended 2025, compared to $372 million in 2024.

Excess investment income, the measure of profitability of our investment segment, declined 16% during the year ended 2025 to $138 million from $164 million in 2024. Excess investment income per common share, reflecting the impact of our share repurchase program, declined 8% to $1.68 from $1.83 when compared with the same period in 2024.

Insurance administrative expenses increased 4% primarily due to higher employee costs, which include salaries and other costs in addition to higher information technology expenses in 2025 when compared with the prior-year period. These expenses were 7.3% as a percent of premium for 2025, unchanged from 2024.

For the year ended December 31, 2025, the Company repurchased 5.4 million shares of Globe Life Inc. common stock at a total cost of $685 million for an average share price of $126.41.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

The discussions of our segments are presented in the manner we view our operations, as described in *[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916)*.

We use three measures as indicators of premium growth and sales over the near term: "annualized premium in force", "net sales," and "first-year collected premium."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Annualized premium in force is defined as the premium income that would be received over the following twelve months at any given date on all active policies if those policies remain in force throughout the 12-month period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales is calculated as annualized premium issued, net of cancellations in the first 30 days after issue, except in the case of Direct to Consumer, where net sales is annualized premium issued at the time the first full premium is paid after any introductory offer period (typically one month) has expired. Management considers net sales to be a better indicator of the rate of premium growth than annualized premium issued since annualized premium issued is before cancellations, as cancellations do not contribute to premium income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• First-year collected premium is defined as the premium collected during the reporting period for all policies in their first policy year. First-year collected premium takes lapses into account in the first year when lapses are more likely to occur, and thus is a useful indicator of how much new premium is expected to be added to premium income in the future. First-year collected premiums are lower than net sales over the prior 12 months because premiums are not collected on lapsed policies after the date of lapse.

Cancellations are not included in lapses.

See further discussion of the distribution channels below for *[Life](#ia1583f94e55d42afa319983b2df261d2_211)* and *[Health](#ia1583f94e55d42afa319983b2df261d2_250)*.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**LIFE INSURANCE** 

Life insurance is the Company's predominant segment. During 2025, life premium represented 69% of total premium and life underwriting margin represented 79% of the total underwriting margin. Additionally, investments supporting the reserves for life products produce the majority of income attributable to the investment segment.

The following table presents the summary of results of life insurance. Further discussion of the results by distribution channel is included below.

**Life Insurance**

**Summary of Results**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of**<br>**Premium** | **Amount** | **% of**<br>**Premium** | **Amount** | **% of**<br>**Premium** |
| Premium and policy charges | $3363470 | 100 | $3261347 | 100 | $3137244 | 100 |
| Policy obligations | 1924929 | 57 | 2000977 | 62 | 2050789 | 65 |
| Required interest on reserves | (845875) | (25) | (811147) | (25) | (772701) | (24) |
| &nbsp;&nbsp;&nbsp;Net policy obligations | 1079054 | 32 | 1189830 | 37 | 1278088 | 41 |
| Amortization of acquisition costs | 386450 | 12 | 356223 | 11 | 327426 | 10 |
| Commission expense | 174029 | 5 | 159703 | 5 | 145678 | 5 |
| Premium taxes | 68132 | 2 | 68360 | 2 | 64571 | 2 |
| Non-deferred acquisition costs | 146444 | 4 | 134634 | 4 | 128509 | 4 |
| &nbsp;&nbsp;&nbsp;Total expense | 1854109 | 55 | 1908750 | 59 | 1944272 | 62 |
| **Insurance underwriting margin**  | $1509361 | 45 | $1352597 | 41 | $1192972 | 38 |

---

Net policy obligations amounted to 32% of premiums for the year ended December 31, 2025, compared to 37% in 2024 and 41% in 2023. This improvement was primarily due to improved mortality and the annual assumption changes which were based upon our review of lapses, mortality, and morbidity resulting in a remeasurement gain of $130.9 million in 2025 compared to a remeasurement gain of $56.8 million in 2024 and a remeasurement loss of $2.0 million in 2023. Refer to *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_670)* for further discussion of the Company's annual assumptions review.

To enhance comparability of underlying operating performance across periods, the Company also evaluates life underwriting margin on a normalized basis that excludes the impacts of annual assumption updates. As discussed above, assumption unlocking results in a cumulative catch-up remeasurement gain or loss recognized in policy obligations. While required under GAAP, these remeasurement effects can introduce volatility unrelated to current-period underwriting performance.

Normalized life underwriting margin is a non-GAAP financial measure defined as insurance underwriting margin excluding the impacts of assumption unlocking recognized in the period. Management believes this measure provides investors and other users of the financial statements with additional insight into the underlying profitability and trends of the in force life business by removing the effects of assumption changes that vary by period. On a normalized basis, life underwriting margin for 2025 was $1.4 billion or 41% of premium, compared with $1.3 billion or 40% of premium in 2024. In 2023, assumption unlocking had minimal impact with underwriting margin remaining unchanged at 38% of premium. This increase in normalized life underwriting margin in the current year reflects improved underlying mortality and persistency experience and favorable expense efficiency across our Divisions.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

The table below summarizes life underwriting margin by distribution channel for the last three years.

**Life Insurance**

**Underwriting Margin by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of Premium** | **Amount** | **% of Premium** | **Amount** | **% of Premium** |
| American Income | $870088 | 49 | $799946 | 47 | $719378 | 45 |
| Direct to Consumer | 320613 | 33 | 281948 | 29 | 234893 | 24 |
| Liberty National | 171343 | 44 | 140136 | 38 | 114646 | 33 |
| Other<sup>(1)</sup> | 147317 | 73 | 130567 | 64 | 124055 | 60 |
| &nbsp;&nbsp;**Total**  | $1509361 | 45 | $1352597 | 41 | $1192972 | 38 |

---

(1) Includes a gain of $14 million related to the recapture of reinsurance for the year ended December 31, 2025 as disclosed in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* under the caption *Reinsurance and Recapture.*

The following table presents Globe Life's life premium distribution channel for the last three years.

**Life Insurance**

**Premium by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| American Income | $1791356 | 53 | $1698209 | 52 | $1588702 | 51 |
| Direct to Consumer | 981006 | 29 | 988522 | 30 | 991406 | 31 |
| Liberty National | 390094 | 12 | 371061 | 12 | 349736 | 11 |
| Other | 201014 | 6 | 203555 | 6 | 207400 | 7 |
| &nbsp;&nbsp;**Total**  | $3363470 | 100 | $3261347 | 100 | $3137244 | 100 |

---

Annualized life premium in force was $3.4 billion at December 31, 2025, an increase of 4% over $3.3 billion a year earlier.

The following table presents life net sales, an indicator of new business production, by distribution channel for each of the last three years.

**Life Insurance**

**Net Sales by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| American Income | $393681 | 64 | $381945 | 64 | $322658 | 59 |
| Direct to Consumer | 112027 | 18 | 106310 | 18 | 116454 | 21 |
| Liberty National | 99252 | 16 | 98162 | 16 | 95459 | 18 |
| Other | 9965 | 2 | 8936 | 2 | 9701 | 2 |
| &nbsp;&nbsp;**Total**  | $614925 | 100 | $595353 | 100 | $544272 | 100 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

The table below discloses first-year collected life premium by distribution channel for the last three years.

**Life Insurance**

**First-Year Collected Premium by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| American Income | $317492 | 69 | $305165 | 67 | $266429 | 63 |
| Direct to Consumer | 61222 | 13 | 67452 | 15 | 77570 | 19 |
| Liberty National | 76481 | 16 | 74553 | 16 | 67618 | 16 |
| Other | 7988 | 2 | 7678 | 2 | 8542 | 2 |
| &nbsp;&nbsp;**Total**  | $463183 | 100 | $454848 | 100 | $420159 | 100 |

---

A discussion of life operations by distribution channel follows.

The **American Income Life Division** is an exclusive agency that markets to members of labor unions and other affinity groups and continues to diversify its lead sources by utilizing internally generated leads, third-party internet vendor leads and referrals to facilitate sustainable growth. This Division is Globe Life's largest contributor of life premium of any distribution channel at 53% of the Company's 2025 total life premium. In 2025, the average monthly life premium issued per policy was $60 as compared to $56 in 2024. Net sales were $394 million in 2025, up from $382 million in 2024. The underwriting margin, as a percent of premium, was 49% in 2025, up from 47% in 2024.

The average producing agent count increased 2% over the year-ago period. The increase in average producing agent count was driven by an increase in new agent recruiting. Sales growth in this Division, as well as within our other exclusive agencies, is generally dependent on growth in the size of the agency force.

Below is the average producing agent count as of the indicated periods for the American Income Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** | **2025 Change** | **%** | **2024 Change** | **%** |
| American Income | 11920 | 11741 | 10579 | 179 | 2 | 1162 | 11 |

---

American Income Life continues to focus on growing and strengthening the agency force, specifically through emphasis on agency middle-management growth. In addition to offering financial incentives and training opportunities, the Division has made considerable investments in information technology, including a customer relationship management ("CRM") tool for the agency force. This tool is designed to provide dashboards and drive productivity in lead distribution, conservation of business, and new agent recruiting. Additionally, this Division has invested in and successfully implemented technology that allows the agency force to engage in virtual recruiting, training, and sales activity. The agents have generated the vast majority of sales through virtual presentations. We find this flexibility to be attractive to new recruits as well as a driver of retention in our agency force.

The **Direct to Consumer Division** ("DTC") markets adult and juvenile life insurance through a variety of channels, including direct mail, insert media, and digital marketing. The different media channels support and complement one another in the Division's efforts to provide consumer outreach. All three channels work as part of an omnichannel approach. Sales from the internet and inbound phone calls continue to outpace the activity from direct mail. DTC's long-term growth has been fueled by consistent innovation and brand awareness. Additionally, the DTC Division provides valuable support to our agency business through brand impressions and inquiries that lead to sales in our exclusive agency channels. This Division has implemented new technology to enhance the underwriting process which has improved the conversion of customer inquiries into sales. New initiatives are continuously introduced to help increase response rates, issue rates, and create a seamless customer experience. The juvenile insurance market is an important source of sales as well as a vehicle to reach the parents and grandparents of existing juvenile insureds, who are more likely to respond favorably to a direct to consumer solicitation for life insurance

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

coverage on themselves in comparison to the general adult population. Additionally, future offerings to parents and grandparents for adult and juvenile insurance are sources of lower acquisition-cost life insurance sales in the future.

DTC net sales increased 5% to $112 million in 2025, compared with $106 million for the same period a year ago. This increase is the result of new technology and improvement in conversion of customer inquiries into sales, as noted above, with the expectation that we are not incurring incremental underwriting risk. This Division has been focused on improving profitability and improving underwriting margin. In 2025, DTC's underwriting margin, as a percent of premium, was 33%, compared with 29% in 2024. In 2025, the average monthly life premium issued for DTC adults was $18 as compared to $15 for the same period in the prior year.

The **Liberty National Division** is an exclusive agency that markets individual life insurance to middle-income households and worksite customers. Recent investments in new sales technologies as well as growth in agency middle management within the Division are expected to support increased sales. Underwriting margin increased 22% from the year ago period to $171 million and premium increased 5% to $390 million. The underwriting margin as a percent of premium increased to 44% in 2025, compared to 38% in 2024. In 2025, the average monthly life premium issued per policy was $45 as compared to $43 in 2024.

Below is the average producing agent count as of the indicated periods for the Liberty National Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** | **2025 Change** | **%** | **2024 Change** | **%** |
| Liberty National | 3846 | 3664 | 3229 | 182 | 5 | 435 | 13 |

---

The Liberty National Division's average producing agent count increased when compared with the prior-year comparable periods. This Division continues to execute a long-term plan to grow through expansion from small-town markets in the Southeast to more densely populated areas with larger pools of potential agent recruits and customers. Expansion of this Division's presence in larger geographic cities with less penetrated areas will help create long-term sustainable agency growth. Additionally, the Division continues to help improve the ability of agents to develop new worksite business. A CRM platform and enhanced analytical capabilities have helped the agents develop additional worksite marketing and improve the productivity of agents selling in the individual life market. As this Division continues to gain momentum in its sales and recruiting initiatives through advances in technology and utilization of a CRM platform, it anticipates continued growth in recruiting activity, average producing agent count, and net sales.

The **Other** agency distribution channels primarily include non-exclusive independent agencies selling primarily life insurance. The Other distribution channels contributed $201 million of life premium income, or 6% of Globe Life's total life premium income in 2025, and contributed 2% of net sales for the year.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**HEALTH INSURANCE**

Health insurance sold by the Company primarily includes Medicare Supplement insurance as well as retiree health insurance, accident coverage, and other limited-benefit supplemental health products such as cancer, critical illness, heart disease, accident, intensive care, and other health products.

Health premium accounted for 31% of our total premium in 2025, while the health underwriting margin accounted for 21% of total underwriting margin. Health underwriting margin increased to $390 million compared to $372 million in the prior year. While the Company continues to emphasize life insurance sales relative to health, due to life's long-term profitability and its greater contribution to excess investment income, the health business provides a significant contribution to return on equity as it does not require a substantial amount of up-front capital.

The following table presents the summary of health insurance results. Further discussion of the results by distribution channel is included below.

**Health Insurance** 

**Summary of Results**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of**<br>**Premium** | **Amount** | **% of**<br>**Premium** | **Amount** | **% of**<br>**Premium** |
| Premium | $1526750 | 100 | $1404925 | 100 | $1318773 | 100 |
| Policy obligations | 931141 | 61 | 851577 | 61 | 776362 | 59 |
| Required interest on reserves | (113832) | (8) | (110342) | (8) | (106516) | (8) |
| &nbsp;&nbsp;&nbsp;Net policy obligations | 817309 | 53 | 741235 | 53 | 669846 | 51 |
| Amortization of acquisition costs | 59897 | 4 | 52224 | 3 | 50598 | 4 |
| Commission expense | 173490 | 11 | 158869 | 11 | 150192 | 11 |
| Premium taxes | 29825 | 2 | 28421 | 2 | 26440 | 2 |
| Non-deferred acquisition costs | 56101 | 4 | 51753 | 4 | 43760 | 3 |
| &nbsp;&nbsp;&nbsp;Total expense | 1136622 | 74 | 1032502 | 73 | 940836 | 71 |
| **Insurance underwriting margin**  | $390128 | 26 | $372423 | 27 | $377937 | 29 |

---

Health premium increased 9% in 2025 as compared to 2024. This increase was attributable to significant sales growth in our Medicare supplement plans as a result of what we believe is a consumer shift from Medicare Advantage plans to Medicare supplement plans during the current year. Premium growth in 2025 was also the result of Medicare supplement rate increases that went into effect in 2025 in addition to an increase in agent count and productivity on other health business. Refer to *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_670)* for further discussion of the Company's annual assumptions review.

Consistent with the life segment, the Company also evaluates health underwriting margin on a normalized basis that excludes the impacts of annual assumptions unlocking recognized in policy obligations. Normalized health underwriting margin is a non-GAAP financial measure and should not be considered a substitute for GAAP underwriting margin. Management believes this measure provides useful supplemental information regarding underlying health underwriting performance by removing period specific assumption update effects.

On a normalized basis, health underwriting margin for 2025 was $387 million or 25% of premium, compared with $383 million or 27% of premium in 2024 and $373 million or 28% of premium in 2023. The percentage of premium decline primarily reflects higher claims experience and an increase in the proportion of overall health premium from United American. As with life, reported GAAP underwriting margin for all periods presented was affected by assumption unlocking as discussed above.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

The table below summarizes health underwriting margin by distribution channel for the last three years.

**Health Insurance**

**Underwriting Margin by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of Premium** | **Amount** | **% of Premium** | **Amount** | **% of Premium** |
| United American | $38012 | 6 | $47964 | 8 | $57344 | 11 |
| Family Heritage | 174942 | 37 | 146478 | 34 | 135691 | 34 |
| Liberty National | 102399 | 54 | 106033 | 56 | 105317 | 56 |
| American Income | 72348 | 58 | 67912 | 55 | 74668 | 62 |
| Direct to Consumer | 2427 | 3 | 4036 | 6 | 4917 | 7 |
| &nbsp;&nbsp;**Total**  | $390128 | 26 | $372423 | 27 | $377937 | 29 |

---

The following table presents Globe Life's health premium by distribution channel for the last three years.

**Health Insurance** 

**Premium by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** |
| United American | $666758 | 44 | $591774 | 42 | $545723 | 42 |
| Family Heritage | 468063 | 31 | 427654 | 30 | 396209 | 30 |
| Liberty National | 190468 | 12 | 190381 | 14 | 187934 | 14 |
| American Income | 124947 | 8 | 123123 | 9 | 120332 | 9 |
| Direct to Consumer | 76514 | 5 | 71993 | 5 | 68575 | 5 |
| &nbsp;&nbsp;**Total**  | $1526750 | 100 | $1404925 | 100 | $1318773 | 100 |

---

Premium related to limited-benefit supplemental health products comprises $851 million, or 56%, of the total health premiums for 2025, compared with $786 million, or 56%, in 2024. Premium from Medicare Supplement products comprises the remaining $676 million, or 44%, for 2025, compared with $619 million, or 44%, in 2024.

Annualized health premium in force was $1.65 billion at December 31, 2025, an increase of 12% from $1.48 billion a year earlier.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

Presented below is a table of health net sales, an indicator of new business production, by distribution channel for each of the last three years.

**Health Insurance**

**Net Sales by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** |
| United American | $154476 | 46 | $80296 | 33 | $72208 | 32 |
| Family Heritage | 120311 | 36 | 105623 | 43 | 96093 | 43 |
| Liberty National | 32741 | 10 | 33001 | 13 | 33155 | 15 |
| American Income | 18937 | 6 | 21103 | 9 | 18124 | 8 |
| Direct to Consumer | 6706 | 2 | 5004 | 2 | 3993 | 2 |
| &nbsp;&nbsp;**Total**  | $333171 | 100 | $245027 | 100 | $223573 | 100 |

---

Health net sales related to limited-benefit supplemental health products comprise $207 million, or 62%, of the total health net sales for 2025, compared with $175 million, or 71%, in 2024. Medicare Supplement sales make up the remaining $126 million, or 38%, for 2025, compared with $70 million, or 29%, in 2024.

The following table discloses first-year collected health premium by distribution channel for the last three years.

**Health Insurance** 

**First-Year Collected Premium by Distribution Channel**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** |
| United American | $98635 | 41 | $87190 | 40 | $66002 | 36 |
| Family Heritage | 90828 | 38 | 79934 | 36 | 72362 | 39 |
| Liberty National | 27536 | 11 | 28114 | 13 | 25608 | 14 |
| American Income | 18939 | 8 | 19740 | 9 | 17633 | 9 |
| Direct to Consumer | 5222 | 2 | 4064 | 2 | 3683 | 2 |
| &nbsp;&nbsp;**Total**  | $241160 | 100 | $219042 | 100 | $185288 | 100 |

---

First-year collected premium related to limited-benefit supplemental health plans comprise $160 million, or 66% of total first-year collected premium for 2025, compared with $155 million, or 71%, in 2024. First-year collected premium from Medicare Supplement policies make up the remaining $81 million, or 34%, for 2025, compared with $64 million, or 29%, in 2024.

A discussion of health operations by distribution channel follows.

The **United American Division** consists of non-exclusive independent agents and brokers who may also sell for other companies. The United American Division was Globe Life's largest health Division in terms of health premium revenue, with net sales up 92% from the prior year.

This Division includes different units:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• UA General Agency, which primarily sells individual Medicare Supplement insurance through independent agents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Special Markets, which markets retiree health insurance to employer and union groups through brokers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Globe Life Group Benefits, which offers group worksite supplemental limited benefit health insurance through brokers.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

The majority of the premium revenue comes from Medicare Supplement which has seen increased demand primarily due to changes in the Medicare Advantage market. Underwriting margin as a percent of premium for the Division was 6% in 2025 and 8% in 2024. The decline in underwriting margin as a percent of premium when compared to prior years is primarily attributable to increased claims utilization during the current year from Medicare Supplement. We adjust premium rates based upon an annual review of utilization and claim cost trends and submit rates for approval to the insurance department regulators and the new premium rates generally become effective in the following year on new business issued.

The **Family Heritage Division** is an exclusive agency that primarily markets individual limited-benefit supplemental health insurance to small to medium-sized businesses. Most of its policies include a return of premium feature, where premium paid is returned less any claims paid to the policyholder at the end of a specified period stated within the insurance policy. Underwriting margin as a percent of premium was 37% in 2025 and 34% in 2024.

The Division experienced a 14% rise in health net sales in 2025 as compared with 2024, primarily due to increased agent count and increased agent productivity. The Division will continue to implement incentive and retention programs to further these increases in the number of producing agents.

Below is the average producing agent count as of the indicated periods for the Family Heritage Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year. The average producing agent count increased 9% compared with the same period a year ago. Along with the Division's increased efforts to grow agent count, it is also focused on the further training and development of its agency middle management. While growth in net sales and earned premium is impacted by agent productivity, growth in the number of average producing agents is the primary driver of future growth in sales, similar to other exclusive agencies.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** | **2025 Change** | **%** | **2024 Change** | **%** |
| Family Heritage | 1527 | 1399 | 1334 | 128 | 9 | 65 | 5 |

---

The **Liberty National Division** represented 12% of all Globe Life health premium income in 2025. The Liberty National Division markets limited-benefit supplemental health products, consisting primarily of cancer, critical illness and accident insurance. Much of Liberty National's health business is generated through worksite marketing targeting small businesses. Health premium at the Liberty National Division was $190 million in 2025, flat when compared with 2024. Liberty National's first-year collected premium was unchanged at $28 million when compared with the prior year. Health net sales fell 1% from 2024. Underwriting margin as a percent of premium was 54% in 2025, compared with 56% in 2024, primarily due to an increase in policy obligations in the current year.

While both the **American Income Life Division** and the **Direct to Consumer Division** primarily sell life insurance, they also market health products. The American Income Life Division primarily markets accident plans. The Direct to Consumer Division primarily markets Medicare Supplements to employer or union-sponsored groups. On a combined basis, these other channels accounted for 13% of health premium in 2025 and 14% in 2024.

**INVESTMENTS**

We manage our capital resources, including investments and cash flow, through the investment segment. Excess investment income represents the profit margin attributable to investment operations and is the measure that we use to evaluate the performance of the investment segment as described in *[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916)*. It is defined as net investment income less the required interest attributable to policy liabilities.

Management views excess investment income per diluted common share as an important and useful measure to evaluate the performance of the investment segment. It is defined as excess investment income divided by the total diluted weighted-average shares outstanding, representing the contribution by the investment segment to the consolidated earnings per share of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Excess Investment Income*.** The following table summarizes Globe Life's net investment income, excess investment income, and excess investment income per diluted common share.

**Analysis of Excess Investment Income**

(Dollar amounts in thousands except per share data)

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Net investment income | $1130198 | $1135631 | $1056884 |
| &nbsp;&nbsp;Interest on policy liabilities<sup>(1)</sup> | (991805) | (971227) | (926502) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Excess investment income**  | $138393 | $164404 | $130382 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Excess investment income per diluted common share**  | $1.68 | $1.83 | $1.35 |
| Mean invested assets (at amortized cost) | $21534153 | $21337531 | $20411093 |
| Average insurance policy liabilities | 17920587 | 17527857 | 16772861 |

---

(1)Interest on policy liabilities, at original rates, is a component of total policyholder benefits, a GAAP measure.

**Excess investment income** declined $26 million, or 16%, in 2025 when compared with 2024. In 2024, excess investment income increased $34 million, or 26%, when compared with 2023. Excess investment income per diluted common share was $1.68 during 2025, a decrease of 8% over the prior-year period ended 2024. Excess investment income per diluted common share was $1.83 during 2024, an increase of 36% over the period ended 2023. Excess investment income per diluted common share generally increases or decreases at a different pace than excess investment income because the number of diluted shares outstanding generally decreases from year to year as a result of our share repurchase program.

**Net investment income** increased at a compound annual growth rate of 4% over the three years ending 2025. Mean invested assets increased at a compound annual growth rate of 3% during the same period. The effective annual yield rate earned on the fixed maturity portfolio was 5.27% in 2025, compared to 5.26% in 2024. Generally, investment income grows at a slower rate than the assets when the yield on new investments is lower than the yield on dispositions or the average portfolio yield. It also increases at a faster rate than the assets when new investment yields exceed the yield on dispositions or the average portfolio yield. Net investment income declined in the current period due to lower growth in invested assets and lower earned yields on short-term investments, commercial mortgage loans, and limited partnerships compared to the prior year. Invested asset growth was constrained by the impact of reinsurance transactions and higher dividend distributions from the insurance subsidiaries to the Parent, which reduced cash retained at the insurance companies and, accordingly, funds available for new investment acquisitions. In addition to fixed maturities, the Company has also invested in commercial mortgage loans and limited partnerships with debt-like characteristics that diversify risk and enhance risk-adjusted, capital-adjusted returns on the portfolio. The earned yield on the Company's commercial mortgage loans for the year ended December 31, 2025 was 6.41%. The earned yield on limited partnership investments for the year ended December 31, 2025 was 7.56%. See additional information in *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_577)*. The following chart presents the growth in net investment income and the growth in mean invested assets.

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Growth in net investment income | (0.5)% | 7.5% | 6.6% |
| Growth in mean invested assets (at amortized cost) | 0.9% | 4.5% | 3.5% |

---

Globe Life's net investment income benefits from higher interest rates on new investments. While increasing interest rates has resulted in a net unrealized loss from our available-for-sale debt securities included in accumulated other comprehensive income (loss) as of December 31, 2025, we are not concerned because we do not generally intend to sell, nor is it likely that we will be required to sell, the fixed maturities prior to their anticipated recovery.

**Required interest on insurance policy liabilities** reduces excess investment income, as it is the amount of net investment income necessary to cover the interest-related growth on insurance policy liabilities. As such, it is reclassified from the insurance segment to the investment segment.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

As discussed in *[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916),* management regards this as a more meaningful analysis of the investment and insurance segments. Required interest is based on the original discount rate assumptions for our insurance policies in force.

The vast majority of our life and health insurance policies are fixed interest rate protection policies, not investment products, and are accounted for under current GAAP accounting guidance for long-duration insurance products which mandates that interest rate assumptions for a particular block of business be "locked in" for the life of that block of business. Each calendar year, we set the original discount rate to be used to calculate the benefit reserve liability for all insurance policies issued that year. The liability reported on the on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)* is updated in subsequent periods using current discount rates as of the end of the relevant reporting period with a corresponding adjustment to other comprehensive income.

The discount rate used for policies issued in the current year has no impact on the in force policies issued in prior years, as the rates of all prior issue years are also locked in for purposes of recognizing income. As such, the overall original discount rate for the entire in force block of 5.5% is a weighted average of the discount rates being used from all issue years. Changes in the overall weighted-average discount rate over time are caused by changes in the mix of the reserves on the entire block of in force business. Business issued in the current year has little impact on the overall weighted-average original discount rate due to the size of our in force business.

Information about interest on policy liabilities is shown in the following table.

**Required Interest on Insurance Policy Liabilities**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Required**<br>**Interest** | **Average Net**<br>**Insurance**<br>**Policy** <br>**Liabilities**<sup>(2)</sup> | **Average**<br>**Discount**<br>**Rate**<sup>(1)</sup> |
| **2025:** | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Life and Health | $959707 | $17243734 | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Annuity | 9683 | 191270 | 5.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;FHLB Funding Agreement | 18367 | 397731 | 4.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposit Funds | 4048 | 87852 | 4.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $991805 | $17920587 | 5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in 2025 | 2.1% | 2.2% |  |
| **2024:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life and Health | $921489 | $16502133 | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Annuity | 28769 | 640506 | 4.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;FHLB Funding Agreement | 16525 | 295089 | 5.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposit Funds | 4444 | 90129 | 4.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $971227 | $17527857 | 5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in 2024 | 4.8% | 4.5% |  |
| **2023:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life and Health | $879217 | $15739423 | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Annuity | 38224 | 861676 | 4.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;FHLB Funding Agreement | 4536 | 79036 | 5.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposit Funds | 4525 | 92726 | 4.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $926502 | $16772861 | 5.5 |

---

(1)Reflects the average discount rate applicable to the current period, which is used to accrue interest on the insurance policy liabilities for each of the years presented.

(2)Average net insurance policy liabilities are net of accumulated other comprehensive income ("AOCI").

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Realized Gains and Losses.*** Our life and health insurance companies collect premium income from policyholders for the eventual payment of policyholder benefits, sometimes paid many years or even decades in the future. Since benefits are expected to be paid in future periods, premium receipts in excess of current expenses are invested to provide for these obligations. For this reason, we hold a significant investment portfolio as a part of our core insurance operations. This portfolio consists primarily of high-quality fixed maturities containing an adequate yield to provide for the cost of carrying these long-term insurance product obligations. As a result, fixed maturities are generally held for long periods to support these obligations. Expected yields on these investments are taken into account when setting insurance premium rates and product profitability expectations.

Despite our intent to hold fixed maturity investments for a long period of time, investments are occasionally sold, exchanged, called, or experience a credit loss event, resulting in a realized gain or loss. Gains or losses are only secondary to our core insurance operations of providing insurance coverage to policyholders. In a bond exchange offer, bondholders may consent to exchange their existing bonds for another class of debt securities. The Company also has investments in certain limited partnerships, held under the fair value option, with fair value changes recognized in *Realized gains (losses)* on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436).* 

Realized gains and losses can be significant in relation to the earnings from core insurance operations, and as a result, can have a material positive or negative impact on net income. The significant fluctuations caused by gains and losses can cause period-to-period trends of net income that are not indicative of historical core operating results or predictive of the future trends of core operations. Accordingly, they have no bearing on core insurance operations or segment results as we view operations. For these reasons, and in line with industry practice, we remove the effects of realized gains and losses when evaluating overall insurance operating results.

The following table summarizes our tax-effected realized gains (losses) by component for each of the three years ended December 31, 2025.

**Analysis of Realized Gains (Losses), Net of Tax**

(Dollar amounts in thousands, except for per share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Amount** | **Per**<br>**Share** | **Amount** | **Per<br>Share** | **Amount** | **Per<br>Share** |
| Fixed maturities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Sales<sup>(3)</sup> | $(9617) | $(0.12) | $(9290) | $(0.10) | $(59463) | $(0.62) |
| &nbsp;&nbsp;&nbsp;Matured or other redemptions<sup>(1)</sup> | (8726) | (0.10) | 155 |  | (1604) | (0.02) |
| &nbsp;&nbsp;&nbsp;Provision for credit losses | (103) |  | (2590) | (0.03) | (5621) | (0.06) |
| Fair value option—change in fair value | (7958) | (0.10) | (13206) | (0.15) | 11931 | 0.12 |
| Mortgages | (2225) | (0.03) | (3138) | (0.04) | (4427) | (0.04) |
| Other investments | (1297) | (0.01) | 2319 | 0.03 | 1415 | 0.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total realized gains (losses)—investments**  | (29926) | (0.36) | (25750) | (0.29) | (57769) | (0.60) |
| Other gains (losses)<sup>(2)</sup> | 7974 | 0.09 | 6642 | 0.08 | 5885 | 0.06 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total realized gains (losses)**  | $(21952) | $(0.27) | $(19108) | $(0.21) | $(51884) | $(0.54) |

---

(1)During the three years ended December 31, 2025, 2024, and 2023, the Company recorded $288.5 million, $105.6 million, and $50.9 million, respectively, of exchanges of fixed maturity securities (noncash transactions) that resulted in $(2.3) million, $0, and $(1.5) million, respectively, in realized gains (losses), net of tax.

(2)Other realized gains (losses) are primarily a result of changes in the fair value for assets held in connection with non-qualified deferred compensation plans.

(3)During the year ended December 31, 2023, the Company incurred a $52 million after-tax realized loss due to the disposal of holdings in Signature Bank New York and First Republic Bank as a result of the banks entering receivership.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Investment Acquisitions*.** Globe Life's investment policy calls for investing primarily in investment grade fixed maturities that meet our quality and yield objectives. We generally invest in securities with longer-term maturities because they more closely match the long-term nature of our life and health policy liabilities. We believe this strategy is appropriate since our expected future cash flows are generally stable and predictable and the likelihood that we will need to sell invested assets to raise cash is low.

The following table summarizes selected information for fixed maturity investments. The effective annual yield shown is based on the acquisition price and call features, if any, of the securities. For non-callable bonds, the yield is calculated to maturity date. For callable bonds acquired at a premium, the yield is calculated to the earliest known call date and call price after acquisition ("first call date"). For all other callable bonds, the yield is calculated to maturity date.

**Fixed Maturity Acquisitions Selected Information**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Cost of acquisitions:  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment-grade corporate securities | $727259 | $1258203 | $967588 |
| &nbsp;&nbsp;&nbsp;Investment-grade municipal securities | 114621 | 94658 | 572654 |
| &nbsp;&nbsp;Other securities | 76259 | 29577 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturity acquisitions**<sup>(1)</sup>  | $918139 | $1382438 | $1540242 |
| Effective annual yield (one year compounded)<sup>(2)</sup> | 6.37% | 5.93% | 6.13% |
| Average life (in years, to next call) | 29.7 | 29.4 | 18.0 |
| Average life (in years, to maturity) | 33.9 | 33.3 | 24.8 |
| Average rating | A | A- | A |

---

(1)Fixed maturity acquisitions included unsettled trades of $0 in 2025, $3.2 million in 2024, and $3.8 million in 2023.

(2)Tax-equivalent basis, where the yield on tax-exempt securities is adjusted to produce a yield equivalent to the pretax yield on taxable securities.

For investments in callable bonds, the actual life of the investment will depend on whether the issuer calls the investment prior to the maturity date. Given our investments in callable bonds, the actual average life of our investments cannot be known at the time of the investment. Absent sales and "make-whole calls," however, the average life will not be less than the average life to next call and will not exceed the average life to maturity. Data for both of these average life measures is provided in the above chart.

During 2025 and 2024, acquisitions consisted primarily of corporate and municipal bonds with securities spanning a diversified range of issuers, industry sectors, and geographical regions. For the year ended December 31, 2025, we invested primarily in the industrial, financial, and utility sectors. For the entire portfolio, the taxable equivalent effective yield earned was 5.27%, up approximately 1 basis points from the yield in 2024. The increase in taxable equivalent effective yield was primarily due to new purchases at yields exceeding the yield on dispositions and the average portfolio yield.

New cash flow available for investment has been primarily provided through our insurance operations, cash received on existing investments, and proceeds from dispositions. Dispositions of fixed maturities were $937 million in 2025 and $1.42 billion in 2024. Dispositions in 2024 included $462 million related to a coinsurance agreement to cede a majority of annuity business to a third-party insurer that was entered into during 2024.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

In addition to the fixed maturity acquisitions, Globe Life invested in commercial mortgage loans and in other long-term investments. See *[Note—4 Investments](#ia1583f94e55d42afa319983b2df261d2_577)* for further discussion.

The following table summarizes Globe Life's other investment acquisitions of the following assets.

**Other Investment Acquisitions**

(Dollar amounts in thousands)

---

| | | |
|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** |
| Limited partnerships | $210532 | $238812 |
| Commercial mortgage loans | 139967 | 174517 |
| Common stock | 3197 | 19869 |
| Convertible notes |  | 2850 |
| Company-owned life insurance | 35000 | 200000 |
| &nbsp;&nbsp;**Total**  | $388696 | $636048 |

---

Since fixed maturities represent such a significant portion of our investment portfolio, 87% of total amortized cost, net of allowance for credit losses, at December 31, 2025, the remainder of the discussion of portfolio composition will focus on fixed maturities. Selected information concerning the fixed maturity portfolio is as follows:

**Fixed Maturity Portfolio Selected Information**

---

| | | |
|:---|:---|:---|
| | **At December 31,** | **At December 31,** |
| | **2025** | **2024** |
| Average annual effective yield<sup>(1)</sup> | 5.29% | 5.25% |
| Average life, in years, to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Next call<sup>(2)</sup> | 15.2 | 15.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Maturity<sup>(2)</sup> | 19.4 | 19.3 |
| Effective duration to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Next call<sup>(23)</sup> | 8.7 | 8.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Maturity<sup>(23)</sup> | 10.5 | 10.6 |

---

(1)Tax-equivalent basis. The yield on tax-exempt securities is adjusted to produce a yield equivalent to the pretax yield on taxable securities.

(2)Globe Life calculates the average life and duration of the fixed maturity portfolio two ways:

&nbsp;&nbsp;&nbsp;&nbsp;(a) based on the next call date which is the next call date for callable bonds and the maturity date for noncallable bonds; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) based on the maturity date of all bonds, whether callable or not.

(3)Effective duration is a measure of the price sensitivity of a fixed-income security to a 1% change in interest rates.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Credit Risk Sensitivity****.* The following tables summarize certain information about the major corporate sectors and security types held in our fixed maturity portfolio at December 31, 2025 and 2024.

**Fixed Maturities by Sector**

**December 31, 2025** 

(Dollar amounts in thousands)

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Below Investment Grade** | **Below Investment Grade** | **Below Investment Grade** | **Below Investment Grade** | **Total Fixed Maturities** | **Total Fixed Maturities** | **Total Fixed Maturities** | **Total Fixed Maturities** | **% of Total** <br>**Fixed Maturities** | **% of Total** <br>**Fixed Maturities** |  |
| | **Amortized<br>Cost, net** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **Amortized<br>Cost, net** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **At Amortized Cost, net** | **At Fair Value** |  |
| | **Amortized<br>Cost, net** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **Amortized<br>Cost, net** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **At Amortized Cost, net** | **At Fair Value** | **Corporates:** |
| &nbsp;&nbsp;&nbsp;**Financial** | | | | | | | | | | |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance - life, health, P&C | $7978 | $119 | $— | $8097 | $2898137 | $80468 | $(175533) | $2803072 | 16 | 16 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Banks | 60268 | 278 | (2738) | 57808 | 916529 | 31873 | (37643) | 910759 | 5 | 5 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other financial | 74975 |  | (7670) | 67305 | 1167521 | 21764 | (120790) | 1068495 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total financial | 143221 | 397 | (10408) | 133210 | 4982187 | 134105 | (333966) | 4782326 | 27 | 27 |  |
| &nbsp;&nbsp;&nbsp;**Industrial** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Energy | 44500 | 55 | (3120) | 41435 | 1313734 | 50113 | (56624) | 1307223 | 7 | 7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic materials | 41620 |  | (9835) | 31785 | 1116746 | 29964 | (91011) | 1055699 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Consumer, non-cyclical |  |  |  |  | 2092995 | 23547 | (198498) | 1918044 | 11 | 11 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other industrials | 25000 |  | (4187) | 20813 | 1096807 | 27723 | (78215) | 1046315 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Communications | 20258 | 263 | (3709) | 16812 | 800452 | 16981 | (80227) | 737206 | 4 | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Transportation |  |  |  |  | 618817 | 15863 | (30939) | 603741 | 3 | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Consumer, cyclical | 104813 | 133 | (19375) | 85571 | 407404 | 6353 | (44746) | 369011 | 2 | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 50270 | 3545 |  | 53815 | 340930 | 4620 | (65103) | 280447 | 2 | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total industrial | 286461 | 3996 | (40226) | 250231 | 7787885 | 175164 | (645363) | 7317686 | 41 | 42 |  |
| &nbsp;&nbsp;**Utilities** | 58199 | 110 | (6118) | 52191 | 2093010 | 71582 | (93086) | 2071506 | 11 | 12 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total corporates**  | 487881 | 4503 | (56752) | 435632 | 14863082 | 380851 | (1072415) | 14171518 | 79 | 81 |  |
| **States, municipalities, and political divisions:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;General obligations |  |  |  |  | 917006 | 5961 | (179707) | 743260 | 5 | 4 |  |
| &nbsp;&nbsp;Revenues | 1961 |  | (210) | 1751 | 2468427 | 20994 | (352055) | 2137366 | 13 | 12 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total states, municipalities, and political divisions**  | 1961 |  | (210) | 1751 | 3385433 | 26955 | (531762) | 2880626 | 18 | 16 |  |
| **Other fixed maturities:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Government (U.S. and foreign) |  |  |  |  | 456618 | 299 | (33518) | 423399 | 2 | 2 |  |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities | 31490 | 136 |  | 31626 | 112034 | 1877 | (112) | 113799 | 1 | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities**  | $521332 | $4639 | $(56962) | $469009 | $18817167 | $409982 | $(1637807) | $17589342 | 100 | 100 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**Fixed Maturities by Sector**

**December 31, 2024** 

(Dollar amounts in thousands)

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Below Investment Grade** | **Below Investment Grade** | **Below Investment Grade** | **Below Investment Grade** | **Total Fixed Maturities** | **Total Fixed Maturities** | **Total Fixed Maturities** | **Total Fixed Maturities** | **% of Total** <br>**Fixed Maturities** | **% of Total** <br>**Fixed Maturities** |  |
| | **Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **At Amortized Cost, net** | **At Fair Value** |  |
| | **Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** | **At Amortized Cost, net** | **At Fair Value** | **Corporates:** |
| &nbsp;&nbsp;&nbsp;**Financial** | | | | | | | | | | |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance - life, health, P&C | $38584 | $32 | $(7801) | $30815 | $2817161 | $49928 | $(206943) | $2660146 | 15 | 15 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Banks | 65718 | 254 | (3506) | 62466 | 1026367 | 17023 | (59795) | 983595 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other financial | 74973 |  | (14917) | 60056 | 1162847 | 15647 | (146305) | 1032189 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total financial | 179275 | 286 | (26224) | 153337 | 5006375 | 82598 | (413043) | 4675930 | 27 | 27 |  |
| &nbsp;&nbsp;&nbsp;**Industrial** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Energy | 44580 |  | (5410) | 39170 | 1318501 | 33825 | (77700) | 1274626 | 7 | 7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic materials |  |  |  |  | 1147932 | 20121 | (91699) | 1076354 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Consumer, non-cyclical | 640 |  | (3) | 637 | 2087181 | 11222 | (255241) | 1843162 | 11 | 11 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other industrials | 25000 |  | (4796) | 20204 | 1089118 | 14847 | (108283) | 995682 | 6 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Communications |  |  |  |  | 832355 | 12085 | (90817) | 753623 | 4 | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Transportation |  |  |  |  | 572829 | 9800 | (38953) | 543676 | 3 | 3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Consumer, cyclical | 128674 | 331 | (28378) | 100627 | 492653 | 3113 | (75592) | 420174 | 3 | 3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 50278 |  | (2419) | 47859 | 341407 | 597 | (67045) | 274959 | 2 | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total industrial | 249172 | 331 | (41006) | 208497 | 7881976 | 105610 | (805330) | 7182256 | 42 | 42 |  |
| &nbsp;&nbsp;&nbsp;**Utilities** | 58996 | 22 | (6797) | 52221 | 2081366 | 39716 | (118007) | 2003075 | 11 | 12 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total corporates** | 487443 | 639 | (74027) | 414055 | 14969717 | 227924 | (1336380) | 13861261 | 80 | 81 |  |
| **States, municipalities, and political divisions:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;General obligations |  |  |  |  | 909765 | 3695 | (177021) | 736439 | 5 | 4 |  |
| &nbsp;&nbsp;Revenues |  |  |  |  | 2391136 | 16967 | (357738) | 2050365 | 13 | 12 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total states, municipalities, and political divisions**  |  |  |  |  | 3300901 | 20662 | (534759) | 2786804 | 18 | 16 |  |
| **Other fixed maturities:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Government (U.S., municipal, and foreign) |  |  |  |  | 438636 | 19 | (51664) | 386991 | 2 | 2 |  |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations | 36923 | 5943 |  | 42866 | 36923 | 5943 |  | 42866 |  |  |  |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities | 4754 | 10 |  | 4764 | 79237 | 39 | (2186) | 77090 |  | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities** | $529120 | $6592 | $(74027) | $461685 | $18825414 | $254587 | $(1924989) | $17155012 | 100 | 100 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

Corporate securities, which consist of bonds and redeemable preferred stocks, were the largest component of the fixed-maturity portfolio as of December 31, 2025, representing 79% of amortized cost, net, and 81% of fair value. The remainder of the portfolio is invested primarily in securities issued by the U.S. government and U.S. municipalities. The Company holds insignificant amounts in foreign government bonds, asset-backed securities, and mortgage-backed securities. Corporate securities are diversified over a variety of industry sectors and issuers. At December 31, 2025, the total fixed maturity portfolio consisted of 1,010 issuers.

Fixed maturities had a fair value of $17.6 billion at December 31, 2025, compared to $17.2 billion at December 31, 2024. The net unrealized loss position in the fixed-maturity portfolio decreased from $1.7 billion at December 31, 2024 to $1.2 billion at December 31, 2025 due to a change in market rates during the period.

For more information about our fixed-maturity portfolio by component at December 31, 2025 and December 31, 2024, including a discussion of allowance for credit losses, an analysis of unrealized investment losses, and a schedule of maturities, see *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_529)*.

An analysis of the fixed-maturity portfolio by composite quality rating at December 31, 2025 and December 31, 2024, is shown in the following tables. The company uses the NAIC designation for credit quality ratings. The NAIC designation is generally determined using the second lowest rating available from nationally recognized statistical rating organizations ("NRSRO") when three or more ratings are available and the lowest rating when two or fewer rating are available. When NRSRO ratings are unavailable the rating may be assigned by the Securities Valuation Office ("SVO") of the NAIC.

**Fixed Maturities by Rating**

**At December 31, 2025** 

(Dollar amounts in thousands)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Amortized Cost, net** | **% of Total** | **Fair<br>Value** | **% of Total** | **Average Composite Quality Rating on Amortized Cost, net** |
| **Investment grade:** | | | | | |
| &nbsp;&nbsp;&nbsp;AAA | $955561 | 5 | $872139 | 5 |  |
| &nbsp;&nbsp;&nbsp;AA | 3455082 | 18 | 2941349 | 16 |  |
| &nbsp;&nbsp;&nbsp;A | 6016228 | 32 | 5778006 | 33 |  |
| &nbsp;&nbsp;&nbsp;BBB+ | 3133353 | 17 | 3007623 | 17 |  |
| &nbsp;&nbsp;&nbsp;BBB | 3717938 | 20 | 3554535 | 20 |  |
| &nbsp;&nbsp;&nbsp;BBB- | 1017673 | 5 | 966681 | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total investment grade**  | 18295835 | 97 | 17120333 | 97 | A |
| **Below investment grade:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;BB | 452809 | 3 | 410286 | 3 |  |
| &nbsp;&nbsp;&nbsp;B | 64364 |  | 54774 |  |  |
| &nbsp;&nbsp;&nbsp;Below B | 4159 |  | 3949 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total below investment grade**  | 521332 | 3 | 469009 | 3 | BB |
|  | $18817167 | 100 | $17589342 | 100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | A- |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**Fixed Maturities by Rating**

**At December 31, 2024** 

(Dollar amounts in thousands)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Amortized<br>Cost, net** | **% of Total** | **Fair**<br>**Value** | **% of Total** | **Average Composite Quality Rating on Amortized Cost** |
| **Investment grade:** | | | | | |
| &nbsp;&nbsp;&nbsp;AAA | $968220 | 5 | $855165 | 5 |  |
| &nbsp;&nbsp;&nbsp;AA | 3225044 | 17 | 2691908 | 15 |  |
| &nbsp;&nbsp;&nbsp;A | 5508446 | 29 | 5147203 | 30 |  |
| &nbsp;&nbsp;&nbsp;BBB+ | 3267101 | 17 | 3040313 | 18 |  |
| &nbsp;&nbsp;&nbsp;BBB | 4087323 | 22 | 3799696 | 22 |  |
| &nbsp;&nbsp;&nbsp;BBB- | 1240160 | 7 | 1159042 | 7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total investment grade**  | 18296294 | 97 | 16693327 | 97 | A- |
| **Below investment grade:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;BB | 397823 | 2 | 349028 | 2 |  |
| &nbsp;&nbsp;&nbsp;B | 92176 | 1 | 67593 | 1 |  |
| &nbsp;&nbsp;&nbsp;Below B | 39121 |  | 45064 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total below investment grade**  | 529120 | 3 | 461685 | 3 | BB- |
|  | $18825414 | 100 | $17155012 | 100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | &nbsp;&nbsp;&nbsp;&nbsp;**Weighted average composite quality rating**  | A- |

---

The overall quality rating of the portfolio is A-, the same as of year-end 2024. Fixed maturities rated BBB are 42% of the total portfolio at December 31, 2025, down from 46% at December 31, 2024. While this ratio may be high relative to our peers, it is at its lowest level since 2003 and we have limited exposure to higher-risk assets such as derivatives, equities, and asset-backed securities. Additionally, the Company does not participate in securities lending and has no off-balance sheet investments as of December 31, 2025. Of our fixed maturity purchases, BBB securities generally provide the Company with the best risk-adjusted, capital-adjusted returns largely due to our ability to hold securities to maturity regardless of fluctuations in interest rates or equity markets. Our allocation to BBB rated bonds has decreased over the past few years as we have found better risk-adjusted, capital-adjusted value in higher-rated bonds.

An analysis of changes in our portfolio of below-investment grade fixed maturities at amortized cost, net of allowance for credit losses, is as follows:

**Below-Investment Grade Fixed Maturities**

(Dollar amounts in thousands)

---

| | | |
|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** |
| **Balance at beginning of period**  | $529120 | $529511 |
| &nbsp;&nbsp;&nbsp;Downgrades by rating agencies | 130225 | 101018 |
| &nbsp;&nbsp;&nbsp;Upgrades by rating agencies | (30565) | (76754) |
| &nbsp;&nbsp;Dispositions | (126293) | (40907) |
| &nbsp;&nbsp;Acquisitions | 26735 | 20292 |
| &nbsp;&nbsp;&nbsp;Provision for credit losses | (130) | (3280) |
| &nbsp;&nbsp;&nbsp;Amortization and other | (7760) | (760) |
| **Balance at end of period**  | $521332 | $529120 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

Our investment policy calls for investing primarily in fixed maturities that are investment grade and meet our quality and yield objectives. Thus, the balance of below-investment grade issues is primarily the result of ratings downgrades of existing holdings. Below-investment grade bonds at amortized cost, net of allowance for credit losses, were 3% of total fixed maturities at amortized cost as of December 31, 2025.

**OPERATING EXPENSES** 

Operating expenses are classified into two categories: insurance administrative expenses and expenses of the Parent Company. Insurance administrative expenses generally include expenses incurred after a policy has been issued. As these expenses relate to premium for a given period, management measures the expenses as a percentage of premium income. The Company also views stock-based compensation expense as a Parent Company expense. Expenses associated with the issuance of our insurance policies are reflected as acquisition expenses and included in the determination of underwriting margin.

The following table is an analysis of operating expenses for the three years ended December 31, 2025.

**Operating Expenses Selected Information**

(Dollar amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Amount** | **% of<br>Premium** | **Amount** | **% of<br>Premium** | **Amount** | **% of<br>Premium** |
| Insurance administrative expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries | $137015 | 2.8 | $129369 | 2.8 | $119699 | 2.7 |
| &nbsp;&nbsp;&nbsp;Other employee costs | 41609 | 0.8 | 36176 | 0.8 | 35905 | 0.8 |
| &nbsp;&nbsp;&nbsp;Information technology costs | 82573 | 1.7 | 80555 | 1.7 | 64998 | 1.5 |
| &nbsp;&nbsp;&nbsp;Legal costs | 22510 | 0.5 | 30478 | 0.6 | 15335 | 0.3 |
| &nbsp;&nbsp;&nbsp;Other administrative costs | 71888 | 1.5 | 65852 | 1.4 | 65224 | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total insurance administrative expenses | 355595 | 7.3 | 342430 | 7.3 | 301161 | 6.8 |
| Parent company expense | 14182 |  | 12400 |  | 10866 |  |
| Stock compensation expense | 53355 |  | 40118 |  | 30736 |  |
| Legal proceedings | 17053 |  | 21575 |  | 900 |  |
| Other expenses | 2183 |  | 2620 |  | 4170 |  |
| **Total operating expenses, per *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | $442368 |  | $419143 |  | $347833 |  |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Amount** | **%** | **Amount** | **%** | **Amount** | **%** |
| Total insurance administrative expenses increase (decrease) over prior year | $13165 | 3.8 | $41269 | 13.7 | $1820 | 0.6 |
| Total operating expenses increase (decrease) over prior year | 23225 | 5.5 | 71310 | 20.5 | (6121) | (1.7) |

---

Total operating expenses for December 31, 2025 increased in comparison with the prior year primarily due to increases in insurance administrative expenses as well as stock compensation. Insurance administrative expenses increased $13 million primarily due to higher employee costs, which include salaries and other costs. Insurance administrative expenses as a percent of premium were 7.3% for the year ended December 31, 2025 and 2024. Total operating expense for December 31, 2025, increased in comparison with the prior year primarily due to increases in insurance administrative expenses and costs associated with existing stock compensation plans.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**SHARE REPURCHASES**

Globe Life has an ongoing share repurchase program that began in 1986. The share repurchase program is reviewed with the Board of Directors quarterly, and continues indefinitely unless and until the Board of Directors decides to suspend, terminate or modify the program. On November 18, 2024, the Board of Directors authorized the repurchase of up to $1.8 billion under the Company's existing share repurchase program. Management generally determines the amount of repurchases based on the amount of excess cash flows and other available sources after the payment of dividends to the Parent Company shareholders, general market conditions, and other alternative uses. At December 31, 2025, we had slightly more than $1.1 billion remaining under the authorization to repurchase. Since implementing our share repurchase program in 1986, we have used $11.0 billion to repurchase Globe Life Inc. common shares, after determining that the repurchases provide a greater risk-adjusted after-tax return than other alternatives and we expect to continue this program into the future.

Excess cash flow at the Parent Company is primarily comprised of dividends received from the insurance subsidiaries less interest expense paid on its debt and other limited operating activities. Additionally, when stock options are exercised, proceeds from these exercises and the resulting tax benefit are used to repurchase additional shares on the open market to minimize dilution as a result of the option exercises.

The following table summarizes share repurchases for each of the last three years.

**Analysis of Share Purchases**

(Amounts in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| **Purchases with:** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** |
| &nbsp;&nbsp;Excess cash flow at the Parent Company<sup>(1)</sup> | 5420 | $685151 | 10086 | $945637 | 3369 | $380103 |
| &nbsp;&nbsp;Option exercise proceeds | 1469 | 189669 | 501 | 48026 | 1080 | 127155 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 6889 | $874820 | 10587 | $993663 | 4449 | $507258 |

---

(1)Excludes excise tax on the repurchase of treasury stock of $6 million in 2025, $8 million in 2024, and $4 million in 2023.

During 2024, the amount of share repurchases was higher as we accelerated repurchases given favorable market conditions and the use of additional capital raised during the year. Refer to *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_865)* for further details. Throughout the remainder of this discussion, share repurchases will only refer to those made from excess cash flow at the Parent Company and exclude anti-dilutive share repurchases related to stock options exercised.

**FINANCIAL CONDITION**

***Liquidity.*** Liquidity provides Globe Life with the ability to meet on demand the cash commitments required to support our business operations and meet our financial obligations. Our liquidity is primarily derived from multiple sources: positive cash flow from operations, a portfolio of marketable securities, pre-capitalized trust securities facility, a revolving credit facility, commercial paper, and advances from the Federal Home Loan Bank.

***Insurance Subsidiary Liquidity*.** The operations of our insurance subsidiaries have historically generated substantial cash inflows in excess of immediate cash needs. Cash inflows for the insurance subsidiaries primarily include premium and investment income. In addition to investment income, maturities and scheduled repayments in the investment portfolio are cash inflows. Cash outflows from operations include policy benefit payments, commissions, administrative expenses, and taxes. A portion of cash inflows in the current year will provide for the payment of future policy benefits and are invested primarily in long-term fixed maturities as they better match the long-term nature of these obligations. The subsidiary dividends are generally paid in amounts equal to the subsidiaries' prior year statutory net income excluding net realized capital gains. While the insurance subsidiaries annually generate more operating cash inflows than cash outflows, the companies also have the entire available-for-sale fixed-maturity portfolio available to create additional cash flows if required. GL Re will pay dividends to the parent subject to limitations stipulated by the BMA.

Four of our insurance subsidiaries are members of the FHLB of Dallas. FHLB membership provides the insurance subsidiaries with access to various low-cost collateralized borrowings and funding agreements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

While not the only source of liquidity, the FHLB could provide the insurance subsidiaries with an additional source of liquidity, if needed. Refer to *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_883)* for further details.

***Parent Company Liquidity.*** An important source of Parent Company liquidity is the dividends from its insurance subsidiaries. These dividends are received throughout the year and are used by the Parent Company to pay dividends on common and preferred stock, interest and principal repayment requirements on Parent Company debt, and operating expenses of the Parent Company.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | (Amounts in Thousands) | (Amounts in Thousands) | (Amounts in Thousands) | (Amounts in Thousands) |
| | **Projected 2026** | **2025** | **2024** | **2023** |
| **Liquidity Sources:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividends from Subsidiaries | $719000 | $815741 | $692690 | $459535 |
| &nbsp;&nbsp;Excess Cash Flows<sup>(1)</sup> | 650000 | 890311 | 455013 | 416081 |

---

(1)Excess cash flows are reported gross of shareholder dividends. For the year ended December 31, 2025, 2024, and 2023, shareholder dividends were $86 million, $85 million, and $84 million, respectively.

For more information on the restrictions on the payment of dividends by subsidiaries, see the *[Restrictions](#ia1583f94e55d42afa319983b2df261d2_895)* section of *[Note 13—Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_895).* Although these restrictions exist, dividend availability from subsidiaries historically has been more than sufficient for the cash flow needs of the Parent Company.

Dividends from subsidiaries and excess cash flows are projected to be lower in 2026 than in 2025 primarily due to nonrecurring extraordinary dividends received of $192 million in late 2024 and $80 million in 2025 which increased excess cash flows in 2025. Additional sources of liquidity for the Parent Company are cash, intercompany receivables, intercompany borrowings, debt markets, term loans, pre-capitalized trust securities facility discussed below and a revolving credit facility. See *[Schedule II](#ia1583f94e55d42afa319983b2df261d2_1018)* for more information. The credit facility is discussed below under the caption *[Sh](#ia1583f94e55d42afa319983b2df261d2_349)[ort-](#ia1583f94e55d42afa319983b2df261d2_349)[T](#ia1583f94e55d42afa319983b2df261d2_349)[erm Borrow](#ia1583f94e55d42afa319983b2df261d2_349)[ings](#ia1583f94e55d42afa319983b2df261d2_349)*.

In 2025, we entered into a 30-year facility agreement ("Facility Agreement") with a Delaware Trust (the "Trust") formed by us in connection with the sale by the trust of $500 million pre-capitalized trust securities redeemable May 15, 2055 in a Rule 144A private placement. The Trust invested the proceeds from the sale of its securities in a portfolio of principal and interest strips of U.S. Treasury securities (the "Strips").

The Facility Agreement provides us with the right to sell at any time to the Trust up to $500 million of our 6.580% Senior Notes due 2055 (the "6.580% Senior Notes") in exchange for a corresponding amount of the Strips held by the Trust (the "Issuance Right"). Our capacity under the agreement is based on the value of the Strips which was $499 million as of December 31, 2025. We agreed to pay a semi-annual facility fee of 1.789% per annum on the unexercised portion of the Issuance Right.

The Company can redeem the 6.580% Senior Notes at any time, in whole or in part, at a price equal to the greater of par or a make-whole redemption price. At December 31, 2025, the Company had no senior note issuances under the Facility Agreement.

***Short-Term Borrowings.*** An additional source of Parent Company liquidity is a credit facility with a group of lenders. The facility was amended on March 29, 2024, resulting in an increased capacity of $250 million. The facility allows for unsecured borrowings and stand-by letters of credit up to $1 billion, which could be increased up to $1.25 billion. While the Parent Company may request the increase, it is not guaranteed. The updated five-year credit agreement will mature on March 29, 2029. Up to $250 million in letters of credit can be issued against the facility. The facility serves as a backup line of credit for a commercial paper program under which commercial paper may be issued at any time, with total commercial paper outstanding not to exceed the facility maximum less any letters of credit issued. Interest charged on the commercial paper program resembles variable rate debt due to its short term nature. As of December 31, 2025, we had available $579 million of additional borrowing capacity under this facility, compared with $466 million a year earlier. Globe Life has consistently been able to issue commercial paper as needed during the three years ended December 31, 2025. As of December 31, 2025, the Parent Company was in full compliance with all covenants related to the aforementioned debt.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

As a part of the credit facility, Globe Life has stand-by letters of credit. These letters are issued among our insurance subsidiaries, one of which is an offshore captive reinsurer, and have no impact on company obligations as a whole. Any future regulatory changes that restrict the use of off-shore captive reinsurers might require Globe Life to obtain third-party financing, which could cause an increase in financing costs. On March 29, 2023, the letters of credit were amended to reduce the amount outstanding from $125 million to $115 million. The outstanding letters of credit remained at $115 million at December 31, 2025.

The Parent Company expects to have readily available funds for 2026 and the foreseeable future to conduct its operations and to maintain target capital ratios in the insurance subsidiaries. In the unlikely event that more liquidity is needed, the Company could generate additional funds through multiple sources including, but not limited to, the issuance of debt, an additional short-term credit facility, and intercompany borrowings. Refer to *[Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_595)* and the discussion surrounding the Company's obligations over the next five years. As noted above, the Parent Company had access to $76 million of liquid assets available as of December 31, 2025. This liquidity is available to the Company in the event additional funds are needed to support the targeted capital levels within our insurance subsidiaries.

***Consolidated Liquidity.*** Consolidated net cash inflows provided from operations were $1.40 billion in 2025 and 2024. The Company sold shorter term securities and reinvested in longer term investments, extending duration and taking advantage of higher current interest rates during the year ended December 31, 2025. As noted under the caption *[Credit Facility](#ia1583f94e55d42afa319983b2df261d2_874)*[in](#ia1583f94e55d42afa319983b2df261d2_874)*[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_874),* the Parent Company has in place a revolving credit facility and a P-CAPS facility. The insurance companies have no additional outstanding credit facilities.

Cash and short-term investments were $459 million at the end of 2025, compared with $250 million at the end of 2024. In addition to these liquid assets, $17.6 billion (fair value at December 31, 2025) of fixed income securities are available for sale in the event of an unexpected need. Approximately $1.4 billion, at fair value, are pledged for outstanding FHLB advances and reinsurance. Further, approximately 98% of our fixed income securities are publicly traded, freely tradable under SEC Rule 144, or qualified for resale under SEC Rule 144A. While our fixed income securities are classified as available for sale, we have the ability and general intent to hold any securities to recovery or maturity. Our strong cash flows from operations, on-going investment maturities, and available liquidity under our credit facility, FHLB, and P-CAPS facility make any need to sell securities for liquidity highly unlikely.

***Capital Resources.*** The Parent Company's capital structure consists of short-term debt (the commercial paper facility and current maturities of long-term debt)*,* long-term debt, and shareholders' equity. It does not include short-term FHLB borrowings, which are obligations of the insurance subsidiaries and typically repaid over the course of the year.

*<u>Debt:</u>* The carrying value of the long-term debt was $2.3 billion at December 31, 2025 and 2024. A complete analysis and description of long-term debt issues outstanding is presented in *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_865)*.

**Financing costs** consist primarily of interest on our various debt instruments. The table below presents the components of financing costs and reconciles interest expense per the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436).*

**Analysis of Financing Costs**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Interest on funded debt | $94431 | $77258 | $72641 |
| Interest on term loan | 15240 | 13823 | 7684 |
| Interest on short-term debt | 26900 | 35979 | 21958 |
| Other | 4650 | 32 | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Financing costs**  | $141221 | $127092 | $102316 |

---

In 2025, financing costs increased 11% compared with the prior year. The increase in financing costs is primarily due to higher average balances in the current year compared to the prior year due to the issuance of debt in the third quarter of 2024. More information on our debt transactions is disclosed in the *[Financial Condition](#ia1583f94e55d42afa319983b2df261d2_340)* section of this report and in *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_865).*

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

*<u>Subsidiary Capital</u>:* The National Association of Insurance Commissioners has established a risk-based factor approach for determining threshold risk-based capital levels for all insurance companies. This approach was designed to assist the regulatory bodies in identifying companies that may require regulatory attention. A Risk-Based Capital ratio is typically determined by dividing adjusted total statutory capital by the amount of RBC determined using the NAIC's factors. If a company's RBC ratio approaches two times the RBC amount, the company must file a plan with the NAIC for improving its capital levels (this level is commonly referred to as "Company Action Level" RBC). Companies typically hold a multiple of the Company Action Level RBC depending on their particular business needs and risk profile.

Our goal is to maintain statutory capital within our insurance subsidiaries at levels necessary to support our current ratings. Globe Life targets a consolidated Company Action Level RBC ratio of 300% to 320%. The Company has concluded that this capital level is more than adequate and sufficient to support its current ratings, given the nature of its business and its risk profile. For 2025, our consolidated Company Action Level RBC ratio was 316%. The Parent Company is committed to maintaining the targeted consolidated RBC ratio at its insurance subsidiaries and has sufficient liquidity available to provide additional capital if necessary.

Our Bermuda-based insurance subsidiaries are subject to regulation in Bermuda and the BMA has capital requirements and solvency standards including limitations on dividends or distributions to shareholders, The minimum solvency margin that must be maintained by a Class C insurer is the greater of : (i) $0.5 million; or (ii) 1.5 percent of assets; or (iii) 25 percent of its enhanced capital requirement ("ECR") as reported at the end of the relevant year.

A Class C insurer is also required to maintain available statutory economic capital and surplus at a level equal to or in excess of its ECR, which is established by reference to either the Bermuda Solvency Capital Requirement ("BSCR") model or a Bermuda-approved internal capital model. While not specifically referred to in the Insurance Act, the BMA has also established a target capital level ("TCL") equal to 120 percent of an insurer's ECR. The TCL serves as an early warning tool for the BMA and failure to maintain statutory capital at least equal to the TCL will likely result in increased regulatory oversight.

We are in the process of completing Globe Life Re's capital and solvency return in respect of the year ended December 31, 2025, which includes the BSCR. We expect that Globe Life Re's level of capitalization will exceed the minimum solvency margin and result in its statutory economic capital and surplus being in excess of the TCL.

*<u>Shareholder's Equity</u>:* As noted under the caption *[Analysis of Share Purchases](#ia1583f94e55d42afa319983b2df261d2_334)* within this report, we have an ongoing share repurchase program.

Globe Life has continually increased the quarterly dividend on its common shares over the past three years.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **Projected 2026** | **2025** | **2024** | **2023** |
| Quarterly dividend by annual year | $0.3300 | $0.2700 | $0.2400 | $0.2250 |

---

Shareholders' equity was $6.0 billion at December 31, 2025. This compares with $5.3 billion at December 31, 2024, an increase of $669 million or 13%. Shareholders' equity increased $819 million, or 18%, during 2024 from $4.5 billion in 2023.

During 2025, shareholders' equity increased as a result of net income of $1.2 billion, but was offset by share repurchases of $685 million and an additional $190 million in share repurchases to offset the dilution from stock option exercises. Additionally, the balance of AOCI increased $258 million primarily due to increased interest rates and discount rates over the period. During 2024, shareholders' equity increased as a result of net income of $1.1 billion, offset by share repurchases of $946 million and an additional $48 million in share repurchases to offset the dilution from stock option exercises. In addition, the balance of AOCI increased $743 million due to changes in interest rates and discount rates over the 2024 period.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

We plan to use excess cash available at the Parent Company as efficiently as possible in the future. Excess cash flow, as we define it, results primarily from the dividends received by the Parent Company from its insurance subsidiaries less the interest paid on debt. The cash received by the Parent Company from our insurance subsidiaries is after they have made substantial investments during the year to grow the business. Possible uses of excess cash flow include, but are not limited to, share repurchases, acquisitions, shareholder dividend payments, subsidiary capital contributions, investments in securities, or repayment of short-term debt. We will determine the best use of excess cash after ensuring that targeted capital levels are maintained in our insurance subsidiaries. If market conditions are favorable, we currently expect that share repurchases will continue to be a primary use of those funds.

Future policy benefits are computed using current discount rates with the impact of changes in discount rates included in accumulated other comprehensive income. Additionally, the liability for future policy benefits is calculated using net premiums rather than gross premiums. Given that gross premiums are considerably higher than net premiums for our business, as seen in *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613)*, the measurement of the liability is higher than what it would be had it been computed using gross premiums. This is an important consideration when analyzing shareholders' equity.

We maintain a significant available-for-sale fixed maturity portfolio to support our insurance policy liabilities. Current accounting guidance requires that we revalue our portfolio to fair market value at the end of each accounting period. The period-to-period changes in fair value, net of their associated impact on income tax, are reflected directly in shareholders' equity. Changes in the fair value of the portfolio can result from changes in market rates.

While a majority of invested assets are revalued, accounting rules do not permit interest-bearing insurance policy liabilities to be valued at fair value in a consistent manner as that of assets, with changes in value applied directly to shareholders' equity. Due to the size of our policy liabilities in relation to our shareholders' equity, an inconsistency exists in measurement, which may have a material impact on the reported value of shareholders' equity. Fluctuations in interest rates cause undue volatility in the period-to-period presentation of our shareholders' equity, capital structure, and financial ratios. Due to the long-term nature of our fixed maturity investments and liabilities and the strong cash flows consistently generated by our insurance subsidiaries, we have the ability to hold our securities to maturity. As such, we do not expect to incur losses due to fluctuations in market value of fixed maturities caused by market rate changes and temporarily illiquid markets. Accordingly, our management, credit rating agencies, lenders, many industry analysts, and certain other financial statement users prefer to remove the effect of this accounting rule when analyzing our balance sheet, capital structure, and financial ratios.

***Financial Strength Ratings.*** The financial strength of our major insurance subsidiaries is rated by Standard & Poor's and A. M. Best. The following table presents these ratings for our five largest insurance subsidiaries at December 31, 2025.

---

| | | |
|:---|:---|:---|
| | **Standard<br>& Poor's** | **A.M. <br>Best** |
| Liberty National Life Insurance Company | AA- | A |
| Globe Life And Accident Insurance Company | AA- | A |
| United American Insurance Company | AA- | A |
| American Income Life Insurance Company | AA- | A |
| Family Heritage Life Insurance Company of America | NR | A |

---

A.M. Best states that it assigns an A (Excellent) rating to insurance companies that have, in its opinion, an excellent ability to meet their ongoing insurance obligations.

The AA financial strength rating category is assigned by Standard & Poor's Corporation (S&P) to those insurers which have very strong capacity to meet its financial commitments. The plus sign (+) or minus sign (-) shows the relative standing within the major rating category.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

**OTHER ITEMS**

***Litigation.*** For more information concerning litigation, please refer to *[Note 5—Commitments and Contingencies](#ia1583f94e55d42afa319983b2df261d2_610).*

**CRITICAL ACCOUNTING ESTIMATES**

**Application of Critical Accounting Estimates.** Critical accounting estimates are those estimates made in accordance with GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations. The preparation of financial statements in conformity with GAAP requires the application of accounting estimates that often involve a significant degree of judgment. Management reviews these key estimates and assumptions used in the preparation of financial statements on a timely basis. If management determines that modifications are necessary due to current facts and circumstances, the Company's results of operations and financial position as reported in the consolidated financial statements could possibly change significantly. Information on our accounting policies is disclosed in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)*.

***Future Policy Benefits.*** Considerable information concerning the policies, procedures, and other relevant data related to the valuation of our liability for future policy benefits is presented in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* and *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613)*.

The liability for future policy benefits for traditional and limited-payment long duration life and health products comprises the vast majority of the total liability for future policy benefits for the Company. The liability is determined each reporting period based on the net level premium method. This method requires the liability for future policy benefits to be calculated as the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders.

The Company reviews, and updates as necessary, its cash flow assumptions (mortality, morbidity, and lapses) used to calculate the change in the liability for future policy benefits at least annually. These cash flow assumptions are reviewed at the same time every year, or more frequently, if suggested by experience. If cash flow assumptions are changed, the net premium ratio is recalculated from the original issue date, or the Transition Date, using actual experience and projected future cash flows. As cash flow assumptions are changed, the liability for future policy benefits is adjusted with changes recognized in policyholder benefits on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*.

The following table illustrates the sensitivity of our liability for future policy benefits, including the corresponding pre-tax impact on OCI, and net income, as of December 31, 2025, to changes in cash flow assumptions. This information is useful in understanding the potential financial impact on our financial statements from changes in these items and the expected impact to our liability for future policy benefits. We could experience impacts that are more or less significant than noted in the following analysis; however the sensitivities provide insight regarding the direction and magnitude of those potential impacts.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
| (Dollar amounts in thousands) | (Dollar amounts in thousands) | (Dollar amounts in thousands) | (Dollar amounts in thousands) | (Dollar amounts in thousands) |
| **Assumptions** | **Sensitivity** | **Future policy benefits** | **OCI**<sup>(1)</sup> | **Net Income** |
| Mortality | 1% increase | $48504 | $(1337) | $(47167) |
|  | 1% decrease | (48640) | (328) | 48967 |
| Morbidity | 5% increase | 65040 | 3611 | (68651) |
|  | 5% decrease | (51319) | (4846) | 56165 |
| Lapses | 10% increase | (111575) | 15880 | 95695 |
|  | 10% decrease | 118804 | (17724) | (101080) |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

(1)Represents the associated impact to OCI from updating the net premium ratio based upon the cash flow assumptions and the remeasurement of the liability for future policy benefits using the current discount rate.

The liability for future policy benefits is discounted using a current upper-medium grade fixed-income instrument yield that reflects the duration characteristics of the liability for future policy benefits. Accordingly, the discount rate assumption is key in determining the change in the value of the liability for future benefits for long duration life and health contracts. Since the liability for future policy benefits for traditional and limited-payment long duration life and health products comprises approximately 93% of the total liability for future policy benefits, it is subject to interest rate risk. A decrease in discount rates will cause an increase in the obligation with a corresponding change in AOCI.

The following table illustrates the interest rate sensitivity of our liability for future policy benefits as of December 31, 2025. This table measures the effect of a parallel shift in discount rates on the liability. The data measures the change in reported value arising from an immediate change in rates in increments of 50 and 100 basis points, which would be recorded as a component of OCI.

**Value of Liability for Future Policy Benefits**

(Dollar amounts in thousands)

---

| | |
|:---|:---|
|<br>**Change in Discount Rates**<sup>(1)</sup> | **At December 31,**<br>**2025** |
| (200) | $27523393 |
| (100) | 22707449 |
| (50) | 20809077 |
| 0 | 19169687 |
| 50 | 17744418 |
| 100 | 16497497 |
| 200 | 14429228 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In basis points.

***Deferred Acquisition Costs.*** Certain costs of acquiring new insurance business are deferred and recorded as an asset. These costs are capitalized on a grouped contract basis and amortized over the expected term of the related contracts, and are essential for the acquisition of new insurance business.

Deferred Acquisition Costs ("DAC") are amortized on a constant-level basis over the expected term of the grouped contracts, with the related expense included in amortization of deferred acquisition costs on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. The in force metric used to compute the DAC amortization rate is annualized premium in force. The assumptions used to amortize acquisition costs include mortality, morbidity, and lapses, and are consistent with those used in calculating the liability for future policy benefits.

Value of business acquired ("VOBA") is amortized on a basis that is consistent with DAC, as described above, and is subject to periodic recoverability and loss recognition testing to determine if there is a premium deficiency. These tests evaluate whether the present value of future contract-related cash flows will support the capitalized VOBA asset. These cash flows consist primarily of premium income, less benefits and expenses. The present value of these cash flows, less the reserve liability, is then compared with the unamortized balance. In the event the estimated present value of net cash flows is less, the deficiency would be recognized by a charge to earnings and either a reduction of unamortized acquisition costs or an increase in the liability for future benefits.

***Policy Claims and Other Benefits Payable.*** This liability consists of known benefits currently payable and an estimate of claims that have been incurred but not yet reported to us. The estimate of unreported claims is based on prior experience and is made after careful evaluation of all information available to us. However, the factors upon which these estimates are based can be subject to change from historical patterns. Factors involved include the litigation environment, regulatory mandates, and the introduction of policy types for which claim patterns are not well established, and medical trend rates and medical cost inflation as they affect our health claims. Changes in these estimates, if any, are reflected in the earnings of the period in which the adjustment is made. The Company concludes that the estimates used to produce the liability for claims and other benefits, including the estimate of

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

unsubmitted claims, are the most appropriate under the circumstances. However, there is no certainty that the resulting stated liability will be our ultimate obligation. At this time, we do not expect any change in this estimate to have a material impact on earnings or financial position consistent with our historical experience. There were no significant changes in the claims process in the current year.

***Valuation of Fixed Maturities.*** We hold a substantial investment in high-quality fixed maturities to provide for the funding of our future policy contractual obligations over long periods of time. While these securities are generally expected to be held to maturity, they are classified as available for sale and are sold from time to time to maximize risk-adjusted, capital-adjusted returns or for other general purposes. We report this portfolio at fair value. Fair value is the price that we would expect to receive upon sale of the asset in an orderly transaction. The fair value of the fixed maturity portfolio is primarily affected by changes in interest rates in financial markets. Because of the size of our fixed maturity portfolio and the long average life, small changes in rates can have a significant effect on the portfolio and the reported financial position of the Company. This impact is disclosed in 100 basis point increments under the caption *Market Risk Sensitivity* in this report. However, as discussed under the caption *[Financial Condition](#ia1583f94e55d42afa319983b2df261d2_340)* in this report, the Company regards these unrealized fluctuations in value as having no meaningful impact on our actual financial condition and, as such, we remove them from consideration when viewing our financial position and financial ratios.

At times, the values of our fixed maturities can also be affected by illiquidity in the financial markets. Illiquidity may contribute to a spread widening, and accordingly to unrealized losses, on many securities that we would expect to be fully recoverable. Even though our fixed maturity portfolio is available for sale, we have the ability and general intent to hold the securities until maturity as a result of our strong and stable cash flows generated from our insurance products. Considerable information concerning the policies, procedures, classification levels, and other relevant data concerning the valuation of our fixed maturity investments is presented in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* and in *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_544)* under the captions *Fair Value Measurements* in both notes. There were no significant changes in the valuation process in the current year.

***Market Risk Sensitivity.*** Globe Life's investment securities are exposed to interest rate risk, meaning the effect of changes in financial market interest rates on the current fair value of the Company's investment portfolio. Since 86% of the carrying value of our investments is attributable to fixed maturity investments and these investments are predominately fixed-rate investments, the portfolio is highly subject to market risk. Declines in market interest rates generally result in the fair value of the investment portfolio rising, and increases in interest rates cause the fair value to decline. Under normal market conditions, we are not concerned about unrealized losses that are interest rate driven since we would not expect to realize them. Globe Life does not generally intend to sell the securities prior to maturity and, likely, will not be required to sell the securities prior to recovery of amortized cost. The long-term nature of our insurance policy liabilities and strong operating cash-flow substantially mitigate any future need to liquidate portions of the portfolio.

The following table illustrates the interest rate sensitivity of our fixed maturity portfolio at December 31, 2025. This table measures the effect of a parallel shift in interest rates (as represented by the U.S. Treasury curve) on the fair value of the fixed maturity portfolio. The data measures the change in fair value arising from an immediate and sustained change in interest rates in increments of 100 basis points.

**Market Value of Fixed Maturity Portfolio**

(Dollar amounts in thousands)

---

| | |
|:---|:---|
| | **At December 31,** |
|<br>**Change in Interest Rates**<sup>(1)</sup> | **2025** |
| (200) | $21383000 |
| (100) | 19376000 |
| 0 | 17589000 |
| 100 | 15992000 |
| 200 | 14561000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In basis points.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**GLOBE LIFE INC.**

**Management's Discussion & Analysis** 

***Investments: Allowance for Credit Losses.*** We continually monitor our investment portfolio for investments where fair value has declined below carrying value to determine if a credit loss event has occurred. When a credit event does occur, an allowance for credit loss is recorded and the corresponding provision is recognized on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* in Realized Gains or Losses. Non-credit related fluctuations in the fair value are recorded in Other Comprehensive Income. The policies and procedures that we use to evaluate and account for allowance for credit losses are disclosed in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* and the discussions under the captions *Investments* and *Realized Gains and Losses* in this report. While every effort is made to make the best estimate of status and value with the information available regarding an allowance for credit loss, it is difficult to predict the future prospects of a distressed or impaired security.

***Defined Benefit Pension Plans.*** We maintain funded defined benefit plans covering most full-time employees. We also have an unfunded nonqualified defined benefit plan covering a limited number of officers. Our obligations under these plans are determined actuarially based on specified actuarial assumptions. In accordance with GAAP, an expense is recorded each year as these pension obligations grow due to the increase in the service period of employees and the interest cost associated with the passage of time. These obligations are offset, at least in part, by the growth in value of the assets in the funded plans. At December 31, 2025, our gross liability under these plans was $677 million, but was offset by assets of $684 million.

The actuarial assumptions used in determining our obligations/expenses for pensions include: employee mortality and turnover, retirement age, the expected return on plan assets, projected salary increases, and the discount rate at which future obligations could be settled. Additionally, a corridor approach is used to amortize any unrecognized gains or losses outside the corridor (the standard 10% of the greater of plan PBO and fair value assets) and have an amortization service period of approximately nine years. These assumptions have an important effect on the pension obligation. A decrease in the discount rate will cause an increase in the pension obligation. A decrease in projected salary increases will cause a decrease in this obligation. Small changes in assumptions may cause significant differences in reported results for these plans. For example, a sensitivity analysis is presented below for the impact of change in the discount rate and the long-term rate of return on assets assumed on our defined benefit pension plans expense for the year 2025 and projected benefit obligation as of December 31, 2025.

**Pension Assumptions**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| **Assumption** | **Change**<sup>(1)</sup> | **Impact on Expense** | **Impact on Projected Benefit Obligation** |
| **Discount Rate**<sup>(2)</sup>**:** | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase | 25 | $(962) | $(20826) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease | (25) | 858 | 21944 |
| **Expected Return**<sup>(3)</sup>**:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase | 25 | (1673) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease | (25) | 1673 |  |

---

(1)In basis points.

(2)The discount rate for determining the net periodic benefit cost was 5.81% for 2025. The discount rate used for determining the projected benefit obligation as of December 31, 2025 was 5.81%.

(3)The expected long-term return rate assumed was 7.33% at December 31, 2025, and 7.18% in the prior year. Management considers both historical and future yields to determine the expected return.

The Company determines mortality assumptions through the use of published mortality tables that reflect broad-based studies of mortality and published longevity improvement scales.

The criteria used to determine the primary assumptions are discussed in *[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_814).* While we have used our best efforts to determine the most reliable assumptions, given the information available from Company experience, economic data, independent consultants, and other sources, we cannot be certain that actual results will be the same as expected. The assumptions are reviewed annually and revised, if necessary, based on more current information available to us. *[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_814)* also contains information about pension plan assets, investment policies, and other related data. There were no significant changes in the assumptions in the current year.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Item 7A. Quantitative and Qualitative Disclosures About Market Risk** 

Information required by this item is found under the heading *Market Risk Sensitivity* in *[Item](#ia1583f94e55d42afa319983b2df261d2_139) [7](#ia1583f94e55d42afa319983b2df261d2_139)* of this report.

**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

**Consolidated Financial Statements Index**

---

| | |
|:---|:---|
| | **Page** |
| [Report of Independent Registered Public Accounting Firm](#ia1583f94e55d42afa319983b2df261d2_424)(PCAOB No. 34) | [55](#ia1583f94e55d42afa319983b2df261d2_424) |
| [Consolidated Financial Statements:](#ia1583f94e55d42afa319983b2df261d2_430) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Balance Sheets at December 31,](#ia1583f94e55d42afa319983b2df261d2_433)2025[, and](#ia1583f94e55d42afa319983b2df261d2_433)2024 | [57](#ia1583f94e55d42afa319983b2df261d2_433) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Operations for each of the three years in the period ended December 31,](#ia1583f94e55d42afa319983b2df261d2_436)2025 | [58](#ia1583f94e55d42afa319983b2df261d2_436) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the period ended December 31,](#ia1583f94e55d42afa319983b2df261d2_439)2025 | [59](#ia1583f94e55d42afa319983b2df261d2_439) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Shareholders' Equity for each of the three years in the period ended December 31,](#ia1583f94e55d42afa319983b2df261d2_442)2025 | [60](#ia1583f94e55d42afa319983b2df261d2_442) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Cash Flows for each of the three years in the period ended December 31,](#ia1583f94e55d42afa319983b2df261d2_445)2025 | [61](#ia1583f94e55d42afa319983b2df261d2_445) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Notes to Consolidated Financial Statements](#ia1583f94e55d42afa319983b2df261d2_448) | [62](#ia1583f94e55d42afa319983b2df261d2_448) |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Shareholders and the Board of Directors of Globe Life Inc.

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Globe Life Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes and the schedules listed in the Index at Item 15 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

***Future Policy Benefits at Current Discount Rates and Amortization of Deferred Acquisition Costs — Certain Underlying Assumptions for Certain Products – Refer to Notes 1, 6 and 7 to the Financial Statements***

*Critical Audit Matter Description* 

The Company estimates the liability for future policy benefits based on the net level premium method, which requires a calculation of the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

The Company estimates the amortization of deferred acquisition costs on a constant-level basis over the expected term of the grouped contracts.

The most significant assumptions used to estimate the liability for future policy benefits and amortization of deferred acquisition costs for certain products are mortality, morbidity and lapse. The Company regularly reviews these assumptions, which are updated as necessary in the third quarter of every year, or more frequently if suggested by experience. The mortality, morbidity, and lapse assumptions are determined based upon Company experience and industry data.

Given the inherent uncertainty and extent of specialized skill required in assessing the mortality, morbidity and lapse assumptions, auditing the development of these assumptions for certain products involved especially subjective judgment.

*How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to management's judgments regarding the mortality, morbidity, and lapse assumptions used in the development of future policy benefits and the amortization of deferred acquisition costs for certain insurance products, included the following, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the effectiveness of controls over the development of these assumptions used in the valuation of future policy benefits and the amortization of deferred acquisition costs for certain insurance products, including the effectiveness of the controls over the underlying data.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the underlying data used in the development of these assumptions as well as in the valuation of future policy benefits and the amortization of deferred acquisition costs for certain insurance products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• With the assistance of our actuarial specialists, we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ evaluated management's methods, calculations and judgments regarding the development of these assumptions used in the valuation of future policy benefits and the amortization of deferred acquisition costs for certain products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ evaluated on a sample basis, through independent calculation of future policy benefits and amortization of deferred acquisition costs, the mathematical accuracy of management's calculations, the appropriateness of valuation models, and whether these assumptions were properly applied.

/s/ Deloitte & Touche LLP

Dallas, Texas

February 25, 2026

We have served as the Company's auditor since 1999.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Consolidated Balance Sheets** 

(Dollar amounts in thousands, except per share data)

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Investments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed maturities—available for sale, at fair value (amortized cost: 2025—$18,820,464; <br>2024—$18,835,809, allowance for credit losses: 2025— $3,297; 2024— $10,395) | $17589342 | $17155012 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mortgage loans | 428517 | 396088 |
| &nbsp;&nbsp;&nbsp;&nbsp;Policy loans | 741375 | 699669 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term investments (includes: 2025—$1,109,719; 2024—$986,766 under the fair value option) | 1396064 | 1235759 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 314711 | 85035 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments | 20470009 | 19571563 |
| &nbsp;&nbsp;&nbsp;Cash | 144704 | 165325 |
| &nbsp;&nbsp;&nbsp;Accrued investment income | 272818 | 269791 |
| &nbsp;&nbsp;&nbsp;Other receivables | 768592 | 691907 |
| &nbsp;&nbsp;&nbsp;Deferred acquisition costs | 6999136 | 6495589 |
| &nbsp;&nbsp;&nbsp;Goodwill | 490446 | 490446 |
| &nbsp;&nbsp;&nbsp;Other assets | 1667987 | 1391560 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $30813692 | $29076181 |
| **Liabilities:** |  |  |
| &nbsp;&nbsp;Future policy benefits at current discount rates: (at original discount rates: 2025—$18,129,506; 2024—$17,552,564) | $19169687 | $18457263 |
| &nbsp;&nbsp;&nbsp;Unearned and advance premium | 270663 | 257631 |
| &nbsp;&nbsp;&nbsp;Policy claims and other benefits payable | 540832 | 532832 |
| &nbsp;&nbsp;&nbsp;Other policyholders' funds | 532047 | 468604 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total policy liabilities | 20513229 | 19716330 |
| &nbsp;&nbsp;&nbsp;Current and deferred income taxes | 859628 | 731255 |
| &nbsp;&nbsp;&nbsp;Short-term debt | 304656 | 415401 |
| &nbsp;&nbsp;Long-term debt (estimated fair value: 2025—$2,225,320; 2024—$2,122,772) | 2320793 | 2324251 |
| &nbsp;&nbsp;&nbsp;Other liabilities | 840807 | 583424 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 24839113 | 23770661 |
| **Commitments and Contingencies (Note 5)** |  |  |
| **Shareholders' equity:** |  |  |
| &nbsp;&nbsp;Preferred stock, par value $1 per share—5,000,000 shares authorized; outstanding: 0 in 2025 and 2024 |  |  |
| &nbsp;&nbsp;Common stock, par value $1 per share—320,000,000 shares authorized; outstanding: (2025—92,218,183 issued; 2024—97,218,183 issued) | 92218 | 97218 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | 536363 | 527795 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (1771444) | (2029720) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 8546807 | 8002521 |
| &nbsp;&nbsp;Treasury stock, at cost: (2025—13,125,082 shares; 2024—13,240,616 shares) | (1429365) | (1292294) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 5974579 | 5305520 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $30813692 | $29076181 |

---

See accompanying Notes to Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Consolidated Statements of Operations** 

(Dollar amounts in thousands, except per share data)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Revenue:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life premium | $3363470 | $3261347 | $3137244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health premium | 1526750 | 1404925 | 1318773 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium | 4890220 | 4666272 | 4456017 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 1130198 | 1135631 | 1056884 |
| &nbsp;&nbsp;&nbsp;&nbsp;Realized gains (losses) | (27788) | (24188) | (65676) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income | 1688 | 354 | 308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 5994318 | 5778069 | 5447533 |
| **Benefits and expenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life policyholder benefits<sup>(1)</sup> | 1924929 | 2000977 | 2050789 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health policyholder benefits<sup>(2)</sup> | 931141 | 851577 | 776362 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other policyholder benefits | 28224 | 41889 | 37100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total policyholder benefits | 2884294 | 2894443 | 2864251 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred acquisition costs | 447760 | 410001 | 379700 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commissions, premium taxes, and non-deferred acquisition costs | 642700 | 600753 | 559167 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating expense | 442368 | 419143 | 347833 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 141221 | 127092 | 102316 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total benefits and expenses | 4558343 | 4451432 | 4253267 |
| Income before income taxes | 1435975 | 1326637 | 1194266 |
| Income tax benefit (expense) | (274737) | (255875) | (223511) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income**  | $1161238 | $1070762 | $970755 |
| **Basic net income per common share**  | $14.27 | $11.99 | $10.21 |
| **Diluted net income per common share**  | $14.07 | $11.94 | $10.07 |

---

(1)Net of total remeasurement, including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a gain (loss) of $192.2 million, $107.0 million, and $29.4 million for the year ended December 31, 2025, 2024, and 2023, respectively.

(2)Net of total remeasurement, including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a gain (loss) of $20.1 million, $(3.2) million, and $11.8 million for the year ended December 31, 2025, 2024, and 2023, respectively.

See accompanying Notes to Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Consolidated Statements of Comprehensive Income (Loss)** 

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Net income**  | $1161238 | $1070762 | $970755 |
| Other comprehensive income (loss): |  |  |  |
| &nbsp;&nbsp;&nbsp;**Investments:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gains (losses) on fixed maturities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized holding gains (losses) arising during period | 429290 | (630042) | 671211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other reclassification adjustments included in net income | 14714 | 3764 | 80238 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange adjustment on fixed maturities recorded at fair value | (1427) | 3469 | (715) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total unrealized investment gains (losses) | 442577 | (622809) | 750734 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less applicable tax (expense) benefit | (92941) | 130787 | (157658) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gains (losses) on investments, net of tax | 349636 | (492022) | 593076 |
| &nbsp;&nbsp;**Future Policy benefits:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in discount rate on future policy benefits | (142514) | 1567530 | (731883) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less applicable tax (expense) benefit | 29928 | (329181) | 153696 |
| &nbsp;&nbsp;&nbsp;&nbsp;Future policy benefit adjustments, net of tax | (112586) | 1238349 | (578187) |
| &nbsp;&nbsp;&nbsp;**Foreign exchange translation:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange translation adjustments, other than securities | 16094 | (33516) | 8102 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less applicable tax (expense) benefit | (3381) | 7040 | (1702) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange translation adjustments, other than securities, net of tax | 12713 | (26476) | 6400 |
| &nbsp;&nbsp;&nbsp;**Pension:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of pension costs | 253 | 474 | (390) |
| &nbsp;&nbsp;&nbsp;&nbsp;Plan amendments |  | (1212) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Experience gain (loss) | 10522 | 29659 | (3907) |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension adjustments | 10775 | 28921 | (4297) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less applicable tax (expense) benefit | (2262) | (6073) | 902 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension adjustments, net of tax | 8513 | 22848 | (3395) |
| Other comprehensive income (loss) | 258276 | 742699 | 17894 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Comprehensive income (loss)**  | $1419514 | $1813461 | $988649 |

---

See accompanying Notes to Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Consolidated Statements of Shareholders' Equity** 

(Dollar amounts in thousands, except per share data)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Preferred Stock** | **Common Stock** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Treasury Stock** | **Total Shareholders' Equity** |
| **<u>Year Ended December 31, 2023</u>** | | | | | | | |
| **Balance at January 1, 2023**  | $— | $105218 | $529661 | $(2790313) | $6894535 | $(789524) | $3949577 |
| Comprehensive income (loss) |  |  |  | 17894 | 970755 |  | 988649 |
| Common dividends declared <br>($0.90 per share) |  |  |  |  | (85139) |  | (85139) |
| Acquisition of treasury stock |  |  |  |  |  | (511100) | (511100) |
| Stock-based compensation |  |  | 18466 |  |  | 12270 | 30736 |
| Exercise of stock options |  |  |  |  | (19395) | 133475 | 114080 |
| Retirement of treasury stock |  | (3000) | (15653) |  | (281943) | 300596 |  |
| &nbsp;&nbsp;&nbsp;**Balance at December 31, 2023** |  | 102218 | 532474 | (2772419) | 7478813 | (854283) | 4486803 |
| **<u>Year Ended December 31, 2024</u>** |  |  |  |  |  |  |  |
| **Balance at January 1, 2024**  |  | 102218 | 532474 | (2772419) | 7478813 | (854283) | 4486803 |
| Comprehensive income (loss) |  |  |  | 742699 | 1070762 |  | 1813461 |
| Common dividends declared <br>($0.96 per share) |  |  |  |  | (84539) |  | (84539) |
| Acquisition of treasury stock |  |  |  |  |  | (1002109) | (1002109) |
| Stock-based compensation |  |  | 22277 |  | (438) | 18279 | 40118 |
| Exercise of stock options |  |  |  |  | (6358) | 58144 | 51786 |
| Retirement of treasury stock |  | (5000) | (26956) |  | (455719) | 487675 |  |
| &nbsp;&nbsp;&nbsp;**Balance at December 31, 2024** |  | 97218 | 527795 | (2029720) | 8002521 | (1292294) | 5305520 |
| **<u>Year Ended December 31, 2025</u>** |  |  |  |  |  |  |  |
| **Balance at January 1, 2025**  |  | 97218 | 527795 | (2029720) | 8002521 | (1292294) | 5305520 |
| Comprehensive income (loss) |  |  |  | 258276 | 1161238 |  | 1419514 |
| Common dividends declared <br>($1.08 per share) |  |  |  |  | (87275) |  | (87275) |
| Acquisition of treasury stock |  |  |  |  |  | (880983) | (880983) |
| Stock-based compensation |  |  | 37404 |  |  | 15951 | 53355 |
| Exercise of stock options |  |  |  |  | (21402) | 185850 | 164448 |
| Retirement of treasury stock |  | (5000) | (28836) |  | (508275) | 542111 |  |
| &nbsp;&nbsp;&nbsp;**Balance at December 31, 2025** | $— | $92218 | $536363 | $(1771444) | $8546807 | $(1429365) | $5974579 |

---

See accompanying Notes to Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**Consolidated Statements of Cash Flows** 

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Net income**  | $1161238 | $1070762 | $970755 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to cash provided from operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in future policy benefits | 582136 | 731417 | 834366 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in other policy benefits | 21124 | 19268 | 5448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferral of policy acquisition costs | (941922) | (913544) | (850169) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred policy acquisition costs | 447760 | 410001 | 379700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in current and deferred income taxes | 98887 | 77930 | 101448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized (gains) losses | 27788 | 24188 | 65676 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (620) | (17582) | (24799) |
| **Cash provided from (used for) operating activities**  | 1396391 | 1402440 | 1482425 |
| **Cash provided from (used for) investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investments sold or matured: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fixed maturities available for sale—sold | 623792 | 1207237 | 602556 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fixed maturities available for sale—matured or other redemptions | 313676 | 214442 | 250652 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage loans | 65724 | 54157 | 44004 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term investments | 128281 | 43362 | 151262 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments sold or matured | 1131473 | 1519198 | 1048474 |
| &nbsp;&nbsp;&nbsp;Acquisition of investments: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fixed maturities—available for sale | (921339) | (1379238) | (1536409) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage loans | (139817) | (174665) | (158823) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term investments | (247052) | (459660) | (155700) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments acquired | (1308208) | (2013563) | (1850932) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (increase) decrease in policy loans | (41706) | (42649) | (42154) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (increase) decrease in short-term investments | (229676) | (3295) | 32381 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to property and equipment | (142484) | (71045) | (49553) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other investing activities |  | 96 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in low-income housing interests | (53017) | (30258) | (64365) |
| **Cash provided from (used for) investing activities**  | (643618) | (641516) | (926149) |
| **Cash provided from (used for) financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Issuance of common stock | 164448 | 51786 | 114080 |
| &nbsp;&nbsp;&nbsp;Cash dividends paid to shareholders | (86067) | (85485) | (84116) |
| &nbsp;&nbsp;&nbsp;Repayment of debt |  |  | (165612) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of debt |  | 530000 | 170000 |
| &nbsp;&nbsp;&nbsp;Payment for debt issuance costs | (6399) | (7253) | (757) |
| &nbsp;&nbsp;&nbsp;Net borrowing (repayment) of commercial paper | 102638 | (13878) | 32961 |
| &nbsp;&nbsp;&nbsp;Proceeds from commercial paper with original maturities greater than 90 days | 487610 | 484726 |  |
| &nbsp;&nbsp;&nbsp;Repayment of commercial paper with original maturities greater than 90 days | (700993) | (372011) |  |
| &nbsp;&nbsp;&nbsp;Acquisition of treasury stock | (880983) | (1002109) | (511100) |
| &nbsp;&nbsp;&nbsp;Amounts paid to reinsurer |  | (413779) |  |
| &nbsp;&nbsp;&nbsp;Net receipts (payments) from deposit-type products | 151694 | 112168 | (96943) |
| **Cash provided from (used for) financing activities**  | (768052) | (715835) | (541487) |
| Effect of foreign exchange rate changes on cash | (5342) | 17080 | (4192) |
| Net increase (decrease) in cash | (20621) | 62169 | 10597 |
| Cash at beginning of year | 165325 | 103156 | 92559 |
| Cash at end of year | $144704 | $165325 | $103156 |

---

See accompanying Notes to Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

 **Note 1—Significant Accounting Policies** 

*<u>Business</u>:* (Globe Life), (the Company), refers to Globe Life Inc., an insurance holding company incorporated in Delaware in 1979, and Globe Life Inc. subsidiaries and affiliates. Globe Life Inc.'s direct or indirect primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The underwriting companies are owned by their ultimate corporate parent, Globe Life Inc. (Parent Company).

Globe Life provides a variety of life and supplemental health insurance products to a broad base of customers. The Company is organized into three reportable segments: life insurance, supplemental health insurance, and investments.

Globe Life markets its insurance products through a number of distribution channels, each of which sells the products of one or more of Globe Life's insurance segments. Our distribution channels consist of the following exclusive agencies: American Income Life Division (American Income), Liberty National Division (Liberty National) and Family Heritage Division (Family Heritage); an independent agency, United American Division (United American); and our Direct to Consumer Division (DTC).

*<u>Basis of Presentation</u>:* The accompanying consolidated financial statements of Globe Life have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), under guidance issued by the Financial Accounting Standards Board ("FASB"). The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

*<u>Use of Estimates</u>*<u>:</u> The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. See further documentation in the significant accounting policies or the accompanying notes.

*<u>Principles of Consolidation</u>:* The consolidated financial statements include the results of Globe Life Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. When Globe Life acquires a subsidiary or a block of business, the assets acquired and the liabilities assumed are measured at fair value at the acquisition date. Any excess of acquisition cost over the fair value of net assets is recorded as goodwill. Expenses incurred to effect the acquisition are charged to earnings as of the acquisition date. Upon acquisition, the accounts and results of operations are consolidated as of and subsequent to the acquisition date.

*<u>Investments</u>:* Globe Life classifies all of its fixed maturity investments as available for sale. Investments classified as available for sale are carried at fair value with unrealized gains and losses, net of taxes, reflected directly in accumulated other comprehensive income ("AOCI"). Income from investments is recorded in "Net investment income" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. Gains and losses from sales, maturities, or other redemptions of investments are recorded in "Realized gains (losses)." Gains and losses realized on the disposition of investments are determined on a specific identification basis. Interest income and prepayment fees are recognized when earned. Premiums and discounts are amortized using the effective yield method. When amortized cost of a callable debt security exceeds the first call price, the premium is amortized to the earliest call date. Otherwise, the period of amortization or accretion generally extends from the purchase date to the maturity date.

"Policy loans," which represent loans provided to policyholders using cash values as collateral, are carried at unpaid principal balances.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

"Mortgage loans" or commercial mortgage loans, are investments that may be either shared among investors or held solely by the Company, and accounted for as financing receivables. The commercial mortgage loans are managed by third parties. The Company purchased the legal rights to interests in commercial mortgage loans which are secured by properties such as hotels, retail, multiple family, or offices. The commercial mortgage loans typically have a term of 3 years with the option to extend up to 2 years. The commercial mortgage loans are recorded at unpaid principal balance, net of unamortized origination fees and net of allowance for loan losses. Interest income, net of the amortization of origination fees, is recorded in "Net investment income" under the effective yield method. Our unfunded commitment balance to the commercial loan borrowers was $21 million as of December 31, 2025.

"Other long-term investments" include investment funds, equity securities, company-owned life insurance ("COLI") and real estate. Investments in equity securities are reported at fair value with changes in fair value, net of taxes, reflected directly in "Realized gains (losses)" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. COLI is reported at the cash surrender value; changes in the cash surrender value are recorded in net investment income. Investments in real estate are reported at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful life.

The investment funds consist of limited partnerships whereby the Company has a minority pro-rata share of ownership. For each investment, the Company has elected the fair value option, but would have been otherwise accounted for as an equity method investment. The fair value option is assessed for each individual investment at the inception of the investment.

Each limited partnership investment is evaluated under applicable GAAP to determine if it is a variable interest entity ("VIE") and would qualify for consolidation. Primary beneficiaries are required to consolidate VIEs. The investments are not consolidated because the Company has no power to control the activities that most significantly affect the economic performance of these entities and therefore the Company is not the primary beneficiary of any of these interests. Globe Life's involvement is limited to its limited partnership interest in the entities. The Company has not provided any other financial support to the entities beyond its commitments to fund its limited partnership interests, and there are no arrangements or agreements with any of the interests to provide other financial support. The maximum loss exposure relative to these interests is limited to their carrying value and future commitments. The Company has approximately 3% of total assets in low-income housing tax credits and certain limited partnerships (investment funds) that qualify as unconsolidated VIEs.

The limited partnership investments are reported at the Company's pro-rata share of the investment fund's net asset value or its equivalent ("NAV"), as a practical expedient for fair value. Changes in the NAV are recorded in net income and increase the carrying value on the balance sheet. The amount of change in NAV attributable to the net operating results of the fund is recorded in "Net investment income" with the remaining balance of the change reflected in "Realized gains (losses)." Distributions received from the funds reduce the carrying value. Our maximum exposure to loss is equal to the outstanding carrying value and future funding commitments. The Company had $251 million of capital called during the year from existing investment funds, reducing our unfunded commitments. Our unfunded commitments were $558 million as of December 31, 2025.

"Short-term investments" include investments in interest-bearing assets with original maturities of twelve months or less.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Fair Value Measurements, Investments in Securities</u>*: Globe Life measures the fair value of its "Fixed maturities" based on a hierarchy consisting of three levels which indicate the quality of the fair value measurements as described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 1—*fair values are based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 2—*fair values are based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, or inputs that can otherwise be corroborated by observable market data.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 3—*fair values are based on inputs that are considered unobservable where there is little, if any, market activity for the asset or liability as of the measurement date. In this circumstance, the Company has to rely on values derived by independent brokers or internally-developed assumptions. Unobservable inputs are developed based on the best information available to the Company which may include the Company's own data or bid and ask prices in the dealer market.

Certain investments, such as investment funds, that are measured at fair value using the net asset value per share or its equivalent, as a practical expedient, have not been classified in the fair value hierarchy. The net asset value is provided by general partners or managers.

The great majority of Globe Life's "Fixed maturities" are not actively traded and direct quotes are not generally available. Management therefore determines the fair values of these securities after consideration of data provided by third-party pricing services, independent broker/dealers, and other resources. At December 31, 2025, the Company's investments in fixed maturities were primarily composed of the following significant security types: corporate securities, state and municipal securities, U.S. government direct, guaranteed, and government-sponsored enterprises securities. The remaining security types represented approximately 1% of the total in the aggregate.

Approximately 98% of the fair value of "Fixed maturities" reported at December 31, 2025 was determined using data provided by third-party pricing services. Prices provided by these services are not binding offers but are estimated exit values. Third-party pricing services use proprietary pricing models to determine security values by discounting cash flows using a market-adjusted spread to a benchmark yield.

For all asset classes within Globe Life's significant security types, third-party pricing services use a common valuation technique to model the price of the investments using observable market data. The foundation for these models consists of developing yield spreads based on multiple observable market inputs, including but not limited to: benchmark yield curves, actual trading activity, new issue yields, broker-dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, sector-specific data, economic data, and other inputs that are corroborated in the market. Pricing vendors monitor and review their pricing data continuously with current market and economic data feeds, augmented by ongoing communication within the dealer community.

Using the observable market inputs described above, spreads to an appropriate benchmark yield are further developed by the vendors for each security based on security-specific and/or sector-specific risk factors, such as a security's terms and conditions (coupon, maturity, and call features), credit rating, sector, liquidity, collateral or other cash flow options, and other factors that could impact the risk of the security. Embedded repayment options, such as call and redemption features, are also taken into account in the pricing models. When the spread is determined, it is added to the security's benchmark yield. The security's expected cash flows are discounted using this spread-adjusted yield, and the resulting present value of the discounted cash flows is the evaluated price.

When third-party vendor prices are not available, the Company attempts to obtain valuations from other sources, including but not limited to broker/dealers, broker quotes, and prices on comparable securities.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

When valuations have been obtained for all securities in the portfolio, management reviews and analyzes the prices to ensure their reasonableness, taking into account available and observable information. The Company utilizes pricing from multiple pricing providers and applies a hierarchy of sources to determine price. When two or more valuations are available for a security and the variance between the prices is 10% or less, the close correlation suggests similar observable inputs were used in deriving the price, and the price is selected based on hierarchy of pricing providers. Securities valued in this manner are classified as Level 2. When the variance between two or more valuations for a security exceeds 10%, additional analysis is performed to evaluate the reasonableness of the fair value using the hierarchy and upon the evaluation company may elect to use the hierarchy of pricing providers or use additional resources such as broker quotes, prices on comparable securities, recent trades, and any other observable market data to corroborate the pricing provider. If fair value differences from pricing providers are determined to be unreasonable and additional pricing resources utilizing observable market data cannot corroborate the price within a reasonable tolerance, then the security will be classified as Level 3.

Globe Life invests in private placement fixed maturities. Private placement fixed maturities are generally not an active market. Private placement valuations are based on observable inputs, such as the benchmark treasury rate, published sector indices, and/or publicly traded comparables and unobservable inputs such as an internally-developed credit ratings, public private spreads and/or private letter ratings assigned by the nationally recognized statistical rating organizations. If observable inputs cannot be corroborated, the fair values are classified as Level 3. Refer to *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_544)* under the caption *Quantitative Information about Level 3 Fair Value Measurements*.

The fair values for each class of security and by valuation hierarchy level are indicated in *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_544)* under the caption *Fair value measurements,* and *[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_823)* under the caption *Pension Assets*.

*<u>Fair Value Measurements, Other Financial Instruments</u>:* Fair values for cash and cash equivalents, short-term investments, short-term debt, receivables, and payables approximate carrying value. Cash and cash equivalents are classified as Level 1. Fair values of commercial mortgage loans are determined based upon expected cash flows discounted at an appropriate risk-adjusted rate and are classified as Level 3. The fair value of investments in limited partnerships that provide low-income housing tax credits is based on discounted projected cash flows and are classified as Level 3. Policy loans are an integral part of Globe Life's subsidiaries' life insurance policies in force and their fair values cannot be valued separately from the insurance contracts. Investment funds are based on net asset value and are excluded from the fair value hierarchy.

The fair values of Globe Life's long and short-term debt issues are based on the same methodology as investments in fixed maturities. At December 31, 2025, observable inputs were available for these debt securities and as such were classified as Level 2 in the valuation hierarchy. The fair value for each debt instrument as of December 31, 2025 is disclosed in *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_865).*

As described in *[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_814)*, Globe Life maintains a nonqualified supplemental retirement plan. Accordingly, the assets that support the liability for this plan are considered general assets of the Company. These assets consist of the cash value of company-owned life insurance policies and exchange traded funds ("ETFs"). Fair values for the ETFs are derived from direct quotes and are considered Level 1 in the fair value hierarchy.

*<u>Current Expected Credit Loss Reserve (fixed maturities)</u>:* At the onset of the evaluation, the Company individually assesses each fixed maturity, on a quarterly basis, to determine whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria are met, the Company will write down the fixed maturity's amortized cost basis to fair value through "Realized gains (losses)."

If neither of the aforementioned criteria are met, the Company will evaluate whether the decline in fair value has resulted from a credit event. The Company will evaluate many factors, as further described below, to determine the present value of the expected cash flows. A credit loss occurs when the present value of the expected cash flows is less than the amortized cost basis.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

This will result in the recording of an allowance for credit losses as a contra asset account to the amortized cost basis with an offsetting provision for credit losses in *"*Realized gains (losses)" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. Additionally, the current expected credit loss ("CECL") methodology includes a fair value floor where the allowance for credit loss for a security cannot exceed the difference between fair value and amortized cost. When it is determined that there is not a credit loss, the decline in fair value is recognized in *[Other Comprehensive Income](#ia1583f94e55d42afa319983b2df261d2_439)*.

All changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses recorded to the allowance for credit losses are management's best estimate of the uncollectibility of principal and interest of a fixed maturity.

The evaluation of Globe Life's securities for credit losses is a process that is undertaken at least quarterly and is overseen by a team of investment and accounting professionals. The process for making this determination is highly subjective and involves the careful consideration of many factors. The factors considered include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company's lack of intent to sell the debt security before recovery;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Whether it is more likely than not the Company will be required to sell prior to maturity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The reason(s) for the credit related losses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The financial condition of the issuer and the prospects for recovery in fair value of the security; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected future cash flows.

The relative weight given to each of these factors can change over time as facts and circumstances change. In many cases, management believes it is appropriate to give more consideration to prospective factors than to retrospective factors. Prospective factors that are given more weight include prospects for recovery, the Company's ability and general intent to hold the security until anticipated recovery, and expected future cash flows.

Among the facts and information considered in the process are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Financial statements of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in credit ratings of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The value of underlying collateral;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• News and information included in press releases issued by the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• News and information reported in the media concerning the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• News and information published by or otherwise provided by securities, economic, or research analysts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The nature and amount of recent and expected future sources and uses of cash;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Default on a required payment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Issuer bankruptcy filings.

The expected cash flows are determined using judgment and the best information available to the Company. Inputs used to derive expected cash flows generally include expected default rates, current levels of subordination, and estimated recovery rate. The discount rate utilized in the discounted cash flows is the effective interest rate, which is the rate of return implicit in the asset at acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Current Expected Credit Loss Reserve (mortgage loans)</u>:* The Company evaluates the performance and credit quality of the commercial mortgage loan portfolio at least on a quarterly basis, or as needed, by utilizing common metrics such as loan-to-value or debt-service ratios as well as covenants, local market conditions, borrower quality, and underlying collateral. The fair value of the underlying collateral is based on a third-party appraisal of the property at origination of the loan. The fair value is assessed on an annual basis or more frequently when a loan is materially underperforming, 30 days delinquent, or in technical default. The Company determines the probability of estimated losses for the performing commercial mortgage loan portfolio on a pool basis each quarter and records an allowance. The allowance for credit losses is based on estimates, historical experience, probability of loss, value of the underlying collateral, and macro factors that affect the collectability of the loan.

If management determines that foreclosure of a particular property is probable, or determines the loan is collateral dependent, the company may elect the practical expedient for an individual mortgage loan to estimate the expected credit losses, which are based on the fair value of the property less amortized cost, adjusted for selling and other associated costs. See *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_565)* for current activity.

*<u>Cash</u>: "*Cash" consists of balances on hand and on deposit in banks and financial institutions.

*<u>Accrued Investment Income</u>:* "Accrued investment income" consists of interest income or dividends earned on the investment portfolio, but which are yet to be received as of the balance sheet date. The Company will write off accrued investment income that is deemed to be uncollectible related to the fixed maturities.

"Accrued investment income" also consists of interest income earned on the commercial mortgage loan portfolio, but which is yet to be received as of the balance sheet date. Accrued investment income will be placed in non-accrual status at the time the loan is 90 days delinquent or otherwise deemed to be uncollectible by management. Accrued investment income that is deemed to be uncollectible will be written off. As of December 31, 2025, the accrued interest receivable for commercial mortgage loans was $2.4 million. Mortgage loans generally pay interest monthly, therefore accrued interest is typically for a period of less than 30 days.

As a practical expedient, the Company excludes the accrued investment income from the amortized cost basis of the investment and separately reports it in another financial statement line item, "Accrued investment income." Accordingly, the amount will be excluded from disclosures within *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_529)*.

*<u>Other Receivables</u>:* Agent debit balances primarily represent commissions advanced to insurance agents, a common industry practice. Generally, commissions are paid to an agent when due over the life of a policy as premiums are paid. However, when an agent sells a policy, the agent may qualify to have their commissions (primarily first-year commissions) paid in advance of when commissions are earned. When the commissions are advanced to the agent, the collection of the advance is made for as long as the policy stays in force or until fully repaid. To the extent an advance is made, we will generally advance up to 65% of first year commissions. This creates an agent debit balance which is classified within "Other receivables." These balances are repaid to the Company over time, generally one year, as the premiums associated with the advanced commissions are collected by the Company and a portion of the agents' commissions on such premiums are retained in order to repay the balances. If an agent has an agent debit balance with the Company, commissions earned by that agent are generally first applied to reduce the amounts owed to the Company. Any excess will be paid to the agent in cash. The balances were $591 million at December 31, 2025 and $542 million at December 31, 2024. While there is a susceptibility to loss should an agent terminate or excessive policy lapses occur, the ability of the Company to continue to collect an agent's commission over time from in force policies reduces the Company's exposure to loss.

The Company has a very low inherent risk with regard to the collection of agent debit balances and views these balances as recoverable since they are, in aggregate, less than the estimated present value of future commissions discounted at a conservative rate which includes assumptions for lapses and mortality. The Company's security, or collateral, is in the form of future commission streams collected over the life of the policies sold by the respective agents, which ultimately revert to the Company in the event an agent is terminated. The Company evaluated the agent debit balances on a pool basis to determine the allowance for credit losses, as the loans have similar characteristics. A provision for credit losses will be recorded in "Realized gains (losses)" on the *[Consolidated](#ia1583f94e55d42afa319983b2df261d2_436)*

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*[Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* and the asset balance will be reflected in agent debit balances, net of allowance for credit losses ("Other receivables"). The allowance for credit losses was $1.4 million at December 31, 2025 and 2024.

Commissions are earned by the agent over the contract period as long as premium is paid by the policyholder and the policy stays in force. As the commissions are earned by the agent and commission expense is incurred by the Company the agent debit balance is reduced. The portion of commission expense incurred related to non-level commissions is deferred and recorded as "Deferred acquisition cost." The portion of level commission is recognized as an expense within "Commissions, premium taxes, and non-deferred acquisition costs."

*<u>Deferred Acquisition Costs</u>*: Certain costs of acquiring new insurance business are deferred and recorded as an asset. These costs are capitalized on a grouped contract basis and amortized over the expected term of the related contracts, and are essential for the acquisition of new insurance business. Deferred acquisition costs are directly related to the successful issuance of an insurance contract, and primarily include sales commissions, policy issue costs, direct to consumer advertising costs, and underwriting costs. Additionally, DAC includes the value of business acquired, which are the costs of acquiring blocks of insurance from other companies or through the acquisition of other companies. These costs represent the difference between the fair value of the contractual insurance assets acquired and liabilities assumed, compared against the assets and liabilities for insurance contracts that the company issues or holds measured in accordance with GAAP.

DAC is amortized on a constant-level basis over the expected term of the grouped contracts, with the related expense included in amortization of deferred acquisition costs on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. The in force metric used to compute the DAC amortization rate is annualized premium in force. The assumptions used to amortize acquisition costs include mortality, morbidity, and lapses. These assumptions are reviewed at least annually and revised in conjunction with any change in the future policy benefit assumptions. The effect of changes in the assumptions are recognized over the remaining expected contract term as a revision of future amortization amounts.

VOBA is amortized on a basis that is consistent with DAC, as described above, and is subject to periodic recoverability and loss recognition testing to determine if there is a premium deficiency. These tests evaluate whether the present value of future contract-related cash flows will support the capitalized VOBA asset. These cash flows consist primarily of premium income, less benefits and expenses. The present value of these cash flows, less the liability for future policy benefits, is then compared with the unamortized balance. In the event the estimated present value of net cash flows is less, the deficiency would be recognized by a charge to earnings and either a reduction of unamortized acquisition costs or an increase in the liability for future policy benefits. Refer to *[Note 7—Deferred Acquisition Costs](#ia1583f94e55d42afa319983b2df261d2_745)*.

*<u>Advertising Costs</u>*: Costs related to advertising are generally charged to expense as incurred. However, certain Direct to Consumer advertising costs are capitalized when there is a reliable and demonstrated relationship between total costs and future benefits that is a direct result of incurring these costs. Advertising costs consist primarily of internet advertising costs and the production and distribution costs of direct mail advertising materials, and when capitalized are included as a component of DAC. Additionally, they are amortized in the same manner as other DAC. Advertising costs charged to earnings and included in commissions, premium taxes, and non-deferred acquisition costs were $7.1 million, $15.7 million, and $19.2 million in 2025, 2024, and 2023, respectively. Unamortized capitalized advertising costs included within DAC were $1.62 billion at December 31, 2025 and $1.60 billion at December 31, 2024.

*<u>Goodwill</u>:* The excess cost of a business acquired over the fair value of net assets acquired is reported as goodwill. In accordance with the guidance, goodwill is subject to impairment testing on an annual basis, or whenever potential impairment triggers occur. Impairment testing involves the performance of a qualitative analysis, which involves assessing current events and circumstances to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. In the event the fair value is less than the carrying value, further testing is required to determine the amount of impairment, if any. If there is an impairment in the goodwill of any reporting unit, it is written down and charged to earnings in the period of the test. Globe Life tests its goodwill annually as of June 30th for each of the years 2023 through 2025. The Company's goodwill was not impaired in any of those periods.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The Company completed the acquisition of Evry Health during 2024 resulting in an increase in goodwill of $8.7 million.

*<u>Low-Income Housing Tax Credit Interests</u>:* Globe Life invests in limited partnerships that provide low-income housing tax credits and other related federal income tax benefits to the Company. Globe Life holds passive interests in limited partnerships that provide investment returns through the provision of tax benefits (principally from the transfer of federal or state tax credits related to federal low-income housing). These investments are considered to be VIEs and do not qualify for consolidation. The carrying value of the Company's investment in these entities was $476 million and $270 million at December 31, 2025 and 2024, respectively, and was included in "Other assets" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433).* As of December 31, 2025, Globe Life was obligated under future commitments of $255 million, which are recorded in "Other liabilities." For guaranteed investments acquired prior to January 1, 2015, the Company utilizes the effective-yield method of amortization, while the proportional method of amortization is utilized for all non-guaranteed and guaranteed investments acquired on or after January 1, 2015. All net amortization expense and income tax benefits are recorded in "Income tax benefit (expense)" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* for federal low-income housing investments, while tax benefits associated with state low-income housing investments are recorded in "Commissions, premium taxes, and non-deferred acquisition costs".

*<u>Property and Equipment</u>:* Property and equipment, included in "Other assets," is reported at cost less accumulated depreciation. Depreciation is recorded primarily on the straight line method over the estimated useful lives of these assets which range from three to fifteen years for equipment and software, and fifteen to forty years for buildings and improvements. Ordinary maintenance and repairs are charged to income as incurred. Impairments, if any, are recorded when certain events and circumstances become evident that the fair value of the asset is less than its carrying amount. Original cost of property and equipment was $615 million at December 31, 2025 and $527 million at December 31, 2024. Accumulated depreciation was $245 million at the end of 2025 and $242 million at the end of 2024. Depreciation expense was $30 million in 2025, $27 million in 2024, and $21 million in 2023. Internally developed software costs are expensed as incurred in the preliminary project phase and post-implementation phase, and are capitalized during the application development stage. Additionally, implementation costs incurred in a hosting arrangement that is a service contract are capitalized. See below for a breakout of the net balance by asset class for the year ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Property and equipment, net of accumulated depreciation:** |  |  |
| &nbsp;&nbsp;Company occupied real estate | $122411 | $36656 |
| &nbsp;&nbsp;Data processing equipment | 245357 | 219614 |
| &nbsp;&nbsp;Transportation equipment |  | 26346 |
| &nbsp;&nbsp;Furniture and equipment | 1765 | 1656 |
| Total property and equipment, net of depreciation | $369533 | $284272 |

---

On July 3, 2025, Globe Life Inc. completed the acquisition of real estate located in McKinney, Texas for total consideration of $80 million. The acquisition was executed in order to support Company growth and efficiency through modern technological infrastructure and centralized operations. The acquisition includes land, a building structure, parking garage and building improvements. The transaction was executed pursuant to a purchase agreement and is accounted for as an asset acquisition. The purchase price was allocated based upon the relative fair value of land, building and building improvements. The building is being depreciated over its estimated useful life of 40 years on a straight-line basis and recorded as part of other operating expense on the *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. The Company expects to utilize the facility for its own operational needs.

As of the date of this filing, the current occupied facility does not qualify for held for sale classification and no impairment indicators have been identified.

*<u>Future Policy Benefits</u>:* The liability for future policy benefits for traditional and limited-payment long duration life and health products comprises approximately 93% of the total liability for future policy benefits. The liability is

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

determined each reporting period based on the net level premium method. This method requires the liability for future policy benefits be calculated as the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders. Net level premiums reflect a recomputed net premium ratio using actual experience since the issue date or January 1, 2021, the Transition Date<sup>(1)</sup>, and expected future experience. The liability is accrued as premium revenue is recognized and adjusted for differences between actual and expected experience. Long-duration insurance contracts issued by the Company are grouped into cohorts based on the contract issue year, distribution channel, legal entity, and product type.

Both the present value of expected future benefit payments and the present value of expected future net premiums are based primarily on assumptions of discount rates, mortality, morbidity, and lapses. Each quarter, the Company remeasures its liability for future policy benefits using current discount rates with the effect of the change recognized in Other Comprehensive Income, a component of shareholders' equity. In addition, the Company recognizes a liability remeasurement gain or loss within the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* using original discount rates, and relating to actual experience under the net premium calculation, as compared to the prior reporting period assumptions.

The Company regularly reviews its cash flow assumptions (mortality, morbidity, and lapses) used to calculate the change in the liability for future policy benefits. These cash flow assumptions are updated as necessary in the third quarter of every year, or more frequently if suggested by experience. If cash flow assumptions are changed, the net premium ratio is recalculated from the original issue date, or the Transition Date, using actual experience and projected future cash flows. When the expected future net premiums exceed the expected future gross premiums (capping), or the present value of future policyholder benefits exceeds the present value of expected future gross premiums (flooring), the liability for future policy benefits is adjusted with changes recognized in policyholder benefits on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. The cash flow assumptions do not include an adjustment for adverse deviation. Mortality tables used for individual life insurance include various industry tables and reflect modifications based on Company experience. Morbidity assumptions for individual health are based on Company experience and industry data. Lapse assumptions are based on Company experience.

The liability for future policy benefits is discounted as noted above, using a current upper-medium grade fixed-income instrument yield that reflects the duration characteristics of the liability for future policy benefits. The methodology for determining current discount rates consists of constructing a discount rate curve intended to be reflective of the currency and tenor of the insurance liability cash flows. The methodology is designed to prioritize observable inputs based on market data available in the local debt markets denominated in the same currency as the policies. For the discount rates applicable to tenors for which the single-A debt market is not liquid or there is little or no observable market data, the Company will use estimation techniques consistent with the fair value guidance in ASC 820. We further accrete interest as a component of policyholder benefits using the original discount rate that is locked-in during the year of contract issuance. The original discount rates (or the locked-in discount rates) are used for interest accretion purposes and for the determination of net premiums, whereas the current discount rates are used for purposes of valuing the liability.

The liability for future policy benefits for annuity and interest sensitive life-type products is represented by policy account value. For limited-payment contracts, a deferred profit liability is also recorded, with changes recognized in income over the life of the contract in proportion to the amount of insurance in force. Refer to *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613)*.

<sup>(1)</sup> On January 1, 2023, the Company adopted ASU 2018-12, *Financial Services - Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts* (ASU 2018-12) on a modified retrospective basis as the transition date (Transition Date) of January 1, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Reinsurance and Recapture</u>*: In the normal course of business, Globe Life insurance subsidiaries will enter into reinsurance agreements to limit their exposure to the risk of loss as well as enhance their capital position. To qualify for reinsurance accounting in accordance with applicable guidance, the assuming company (reinsurer) must have the "reasonable possibility" that it may realize a "significant loss." In instances where the ceding company does not transfer significant insurance risk to the reinsurer, deposit accounting is utilized. Any risk charges payable related to reinsurance agreements where deposit accounting is applicable are recorded within "Other liabilities" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*. Any balances due to the Company under the terms of the reinsurance agreement are recorded as a reinsurance recoverable within "Other assets" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433).* Any ceding commission due to the Company under the terms of the reinsurance agreement are recorded in income over the remaining life of the ceding contracts.

On March 6, 2025, the Company entered into a coinsurance transaction with funds withheld agreement with a third-party reinsurer with an agreement effective date of January 1, 2025. Under the terms of the agreement Globe Life ceded 100% of the liabilities, net of existing reinsurance, associated with certain term and whole life insurance policies. Reserves ceded under this agreement were $458 million. The contract is accounted for under deposit accounting as it did not pass the risk transfer requirements for reinsurance treatment on a GAAP basis. Since the agreement is subject to deposit accounting and meets the right of offset conditions outlined in the accounting policy the Company recorded the initial coinsurance, ceding commission and funds withheld balance on a net basis. At inception, no cash was exchanged between the parties and subsequently, a risk charge was recorded as a component of "Net investment income" on the *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*, with net cash settlements occurring quarterly between the parties.

On March 31, 2025, the Company entered into a recapture and termination agreement with a third-party reinsurer to recapture certain policies that had previously been ceded under a reinsurance agreement dated November 12, 2001. The recapture was executed to accomplish common objectives between the Company and the reinsurer. As a result of the transaction, the Company received net proceeds of $39 million, which are reflected as operating cash flows on the *[Consolidated Statement of Cash Flows](#ia1583f94e55d42afa319983b2df261d2_445)*. The Company also recognized a gain of approximately $14 million in policyholder benefits on the *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*.

The Company's U.S. insurance subsidiaries entered into an affiliated 100% quota share coinsurance agreement with Globe Life Re Ltd, a Bermuda-domiciled reinsurer, effective December 1, 2025, under which certain in force whole life and term life policies were ceded to GL Re. In connection with the transaction, the affiliates transferred assets of $1.2 billion to a Regulation 114 Trust for their benefit, with the fair value equal to the statutory reserves on the reinsured business. GL Re accounts for the arrangement as assumed reinsurance and recognize assumed reserves and related deferred acquisition costs in accordance with Globe's direct long-duration insurance accounting policies. Since GL Re and affiliates are under common control the effect of the affiliated reinsurance transaction is eliminated in the accompanying consolidated financial statements of Globe Life.

In the fourth quarter of 2024, the Company entered into a coinsurance agreement to cede a majority of its annuity business to a third-party reinsurer. The annuity reserves ceded totaled $462 million. The pre-tax ceding commission under the agreement was approximately $50 million and is being recognized into income over the remaining life of the ceded contracts. Amounts paid to the reinsurer upon entering into the coinsurance agreement were $413 million, which were reflected as a cash outflow within financing activities in the *[Consolidated Statement of Cash Flows](#ia1583f94e55d42afa319983b2df261d2_445).* The underlying policies ceded are deposit-type contracts and the coinsurance agreement transfers only timing risk to the reinsurer. Net amounts paid to the reinsurer and reimbursements for losses after inception of the coinsurance agreement are reported as financing activities within "Net receipts (payments) from deposit-type products." Under the terms of the agreement, the assuming company will be required to maintain assets in trust at 105% of reserves.

*<u>Unearned and Advanced Premium</u>*: Premium collected from both life and health policies that have not been earned and recognized in accordance with applicable GAAP. Refer to *Recognition of Premium Revenue* below.

*<u>Policy Claims and Other Benefits Payable</u>:* Globe Life establishes a liability for known policy benefits payable and an estimate of claims that have been incurred but not yet reported to the Company. Globe Life makes an estimate of

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

unreported claims after careful evaluation of all information available to the Company. This estimate is based on prior experience and is reviewed quarterly. However, there is no certainty the stated liability for claims and other benefits, including the estimate of unsubmitted claims, will be Globe Life's ultimate obligation. For more information, see *[Note 8—Liability for Unpaid Claims](#ia1583f94e55d42afa319983b2df261d2_769)*.

*<u>Current and Deferred Income Taxes</u>:* Current and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement book values and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

*<u>Postretirement Benefits</u>:* Globe Life accounts for its postretirement defined benefit plans by recognizing the funded status of those plans on its *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)* in accordance with accounting guidance. Periodic gains and losses attributable to changes in plan assets and liabilities that are not recognized as components of net periodic benefit costs are recognized as components of other comprehensive income, net of tax. The supplemental executive retirement plan is accounted for consistent with the qualified noncontributory pension plan. The assets are included in a Rabbi Trust and recorded in Other Assets on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433).* More information concerning the accounting and disclosures for postretirement benefits is found in *[Note 10—Postretirement Benefits](#ia1583f94e55d42afa319983b2df261d2_814).*

*<u>Treasury Stock</u>:* Globe Life accounts for purchases of treasury stock on the cost method. Issuance of treasury stock is accounted for using the weighted-average cost method. More information is found in *[Note 13—Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_886).*

*<u>Recognition of Premium Revenue</u>:* Premium income for traditional long-duration life and health insurance products is recognized evenly over the contract period and when due from the policyholder. Premiums for short-duration health contracts are recognized as revenue over the contract period in proportion to the insurance protection provided. Premiums for universal life-type and annuity contracts are added to the policy account value, and revenues for such products are recognized as charges to the policy account value for mortality, administration, and surrenders (retrospective deposit method). Life premium includes policy charges of $11.7 million, $12.3 million, and $12.9 million for the years ended December 31, 2025, 2024, and 2023, respectively. Other premium consists of annuity policy charges in each year. For limited-payment life insurance products, the profits are recognized over the contract period.

*<u>Commission, Premium Taxes, and Non-Deferred Acquisition Costs</u>:* Commissions represent commission-related amounts that are not deferred. Premium taxes are taxes incurred on premiums written within a state jurisdiction. Non-deferred acquisition costs relate to expenses incurred in the selling or issuing of business which are non-deferrable.

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Commissions | $342189 | $317576 | $295877 |
| Premium taxes | 97966 | 96790 | 91021 |
| Non-deferred acquisition costs | 202545 | 186387 | 172269 |
| &nbsp;&nbsp;Total | $642700 | $600753 | $559167 |

---

*<u>Stock-Based Compensation</u>:* Globe Life accounts for stock-based compensation by recognizing an expense in the consolidated financial statements based on the "fair value method." The fair value method requires that a fair value be assigned to a stock option or other stock grant on its grant date and that this value be amortized over the grantees' service period.

The fair value method requires the use of an option valuation model to value employee stock options. Globe Life has elected to use the Black-Scholes valuation model for option expensing.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

A summary of assumptions for options granted in each of the three years 2023 through 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Volatility factor | 29.9% | 22.0% | 23.0% |
| Dividend yield | 0.8% | 0.7% | 0.7% |
| Expected term (in years) | 5.13 | 5.10 | 5.10 |
| Risk-free rate | 4.0% | 4.3% | 4.1% |

---

The expected term is generally derived from Company experience. However, expected terms are determined based on the simplified method as permitted under the ASC 718, *Stock Compensation,* topic when Company experience is insufficient. On April 26, 2018, the shareholders approved the Globe Life Inc. 2018 Incentive Plan, formerly the Torchmark Corporation 2018 Incentive Plan (the "2018 Incentive Plan"). The 2018 Incentive Plan replaced all previous plans. The 2018 Incentive Plan allows for option grants for employees with a seven-year contractual term which vest over three years in addition to ten-year grants which vest over five years as permitted by the previous plans. Director grants vest over six months. Volatility and risk-free interest rates are assumed over a period of time consistent with the expected term of the option. Volatility is measured on a historical basis. Monthly data points are utilized to derive volatility for periods three years and longer. Expected dividend yield is based on current dividend yield held constant over the expected term. Once the fair value of an option has been determined, it is amortized on a straight-line basis over the employee's service period for that grant (from the grant date to the date the grant is fully vested).

Expenses for restricted stock and restricted stock units are based on the grant date fair value allocated on a straight-line basis over the service period. Performance share expense is recognized based on management's estimate of the probability of meeting the metrics identified in the performance share award agreement, assigned to each service period as these estimates develop.

Stock-based compensation expense is included in "Other operating expense" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. Globe Life management views all stock-based compensation expense as part of insurance administration expense and, therefore, presents as such in its segment analysis. More information concerning the Company's segments is provided in *[Note 15—Business Segments](#ia1583f94e55d42afa319983b2df261d2_916)*.

*<u>Earnings per Share</u>:* Globe Life presents basic and diluted earnings per common share (EPS) on the face of the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* for income from operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average common shares outstanding for the period. Diluted EPS is calculated by adding to shares outstanding the additional net effect of potentially dilutive securities or contracts, such as stock options, which could be exercised or converted into common shares. For more information on earnings per share, see *[Note 13—Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_886).* 

*<u>Accounting Pronouncements Adopted in the Current Year</u>*: **ASU No. 2023-09**, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, adds disclosure requirements to disaggregate information related to the effective tax rate reconciliation and information on income taxes paid. The disclosures enhance the assessment of an entity's operations and related tax risks.

This standard is effective for the Company for annual periods beginning on January 1, 2025, and has been implemented on a prospective basis. The standard did not have a material impact on the consolidated financial statements. The guidance requires only additional disclosure, and as a result there has been no effects on our financial position, results of operations or cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Accounting Pronouncements Yet to be Adopted</u>*: **ASU No. 2024-03**, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, adds disclosure requirements to disaggregate information related to an entity's income statement. The disclosures will allow for enhanced transparency of an entity's expenses.

This standard is effective for the Company for annual periods beginning on January 1, 2027. The Company is evaluating the standard.

**ASU No. 2025-06**, *Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software*, provides guidance for the evaluation of determining whether criteria is met to begin the capitalization of internal-use software costs. ASC 350 (*Intangibles—Goodwill and Other)* requires the capitalization of internal-use software costs begin when both of the following criteria are met: (1) when management has authorized and committed to funding the software project and (2) the probability that the project will be completed and will be used to perform the function intended. If uncertainty exists under the guidance issued in Subtopic 350-40 then a probable to complete threshold will not exist and any costs would be expensed until uncertainties are resolved.

The updated guidance also requires the application of disclosure requirements in ASC 360 (*Plant, Property, and Equipment*) for all capitalized costs regardless of presentation in the financial statements. This standard is effective for the Company for annual periods beginning on January 1, 2028 and interim periods within the annual reporting periods. The Company is evaluating the standard.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 2—Statutory Accounting** 

U.S. based life insurance subsidiaries of Globe Life are required to file statutory financial statements with state insurance regulatory authorities. Accounting principles used to prepare these statutory financial statements differ from GAAP. Consolidated net income and shareholders' equity (capital and surplus) on a statutory basis for the insurance subsidiaries were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Net Income** | **Net Income** | **Net Income** | **Shareholders' Equity** | **Shareholders' Equity** |
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **At December 31,** | **At December 31,** |
| | **2025** | **2024** | **2023** | **2025** | **2024** |
| U.S. Life insurance subsidiaries | $748754 | $688665 | $434952 | $1614929 | $1690663 |

---

The excess, if any, of shareholders' equity of the insurance subsidiaries on a GAAP basis over that determined on a statutory basis is not available for distribution by the insurance subsidiaries to the Parent Company without regulatory approval. Insurance subsidiaries' statutory capital and surplus necessary to satisfy regulatory requirements in the aggregate was $590 million at December 31, 2025. More information on the restrictions on the payment of dividends can be found in *[Note 13—Shareholders' Equity](#ia1583f94e55d42afa319983b2df261d2_886).*

The Company's statutory financial statements are presented on the basis of accounting practices prescribed by the insurance department of the state of domicile of each insurance subsidiary. While all states have adopted the National Association of Insurance Commissioners' ("NAIC") statutory accounting practices ("NAIC SAP") as the basis for statutory accounting, certain states have retained prescribed practices of their respective insurance code or administrative code which can differ from NAIC SAP. For Globe Life's life insurance companies, there are no significant differences between NAIC SAP and the accounting practices prescribed by the states of domicile.

Our Bermuda-based insurance subsidiaries are subject to regulation in Bermuda and the BMA has capital requirements and solvency standards including limitations on dividends or distributions to shareholders, The minimum solvency margin that must be maintained by a Class C insurer is the greater of : (i) $0.5 million; or (ii) 1.5 percent of assets; or (iii) 25 percent of its enhanced capital requirement ("ECR") as reported at the end of the relevant year.

A Class C insurer is also required to maintain available statutory economic capital and surplus at a level equal to or in excess of its ECR, which is established by reference to either the Bermuda Solvency Capital Requirement ("BSCR") model or a Bermuda-approved internal capital model. While not specifically referred to in the Insurance Act, the BMA has also established a target capital level ("TCL") equal to 120 percent of an insurer's ECR. The TCL serves as an early warning tool for the BMA and failure to maintain statutory capital at least equal to the TCL will likely result in increased regulatory oversight.

We are in the process of completing Bermuda subsidiaries capital and solvency return in respect to the year ended December 31, 2025, which includes the BSCR. We expect that our Bermuda subsidiaries' level of capitalization will exceed the minimum solvency margin and result in its statutory economic capital and surplus being in excess of the TCL. Statutory capital and surplus of our Bermuda subsidiaries, based on Bermuda statutory accounting practices, was $609.8 million and $142.5 million at December 31, 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 3—Supplemental Information about Changes to Accumulated Other Comprehensive Income** 

*<u>Components of Accumulated Other Comprehensive Income</u>*: An analysis of the change in balance by component of Accumulated Other Comprehensive Income is as follows for each of the years 2023 through 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Available for Sale Assets** | **Future Policy Benefits** | **Foreign Exchange** | **Pension Adjustments** | **Total** |
| **For the year ended December 31, 2023:** | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at January 1, 2023 | $(1420672) | $(1369204) | $(1681) | $1244 | $(2790313) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications, net of tax | 529688 | (578187) | 6400 | (3087) | (45186) |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassifications, net of tax | 63388 |  |  | (308) | 63080 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | 593076 | (578187) | 6400 | (3395) | 17894 |
| **Balance at December 31, 2023**  | (827596) | (1947391) | 4719 | (2151) | (2772419) |
| **For the year ended December 31, 2024:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications, net of tax | (494996) | 1238349 | (26476) | 22474 | 739351 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassifications, net of tax | 2974 |  |  | 374 | 3348 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | (492022) | 1238349 | (26476) | 22848 | 742699 |
| **Balance at December 31, 2024**  | (1319618) | (709042) | (21757) | 20697 | (2029720) |
| **For the year ended December 31, 2025:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications, net of tax | 338012 | (112586) | 12713 | 8312 | 246451 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassifications, net of tax | 11624 |  |  | 201 | 11825 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | 349636 | (112586) | 12713 | 8513 | 258276 |
| **Balance at December 31, 2025**  | $(969982) | $(821628) | $(9044) | $29210 | $(1771444) |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Reclassification adjustments</u>*: Reclassification adjustments out of accumulated other comprehensive Income are presented below for the three years ended December 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Affected line items in the Statement of Operations** |
|<br>**Component Line Item** | **2025** | **2024** | **2023** | **Affected line items in the Statement of Operations** |
| **Unrealized investment (gains) losses on available for sale assets:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Realized (gains) losses | $23348 | $14843 | $84416 | Realized (gains) losses |
| &nbsp;&nbsp;&nbsp;Amortization of (discount) premium | (8634) | (11079) | (4178) | Net investment income |
| &nbsp;&nbsp;&nbsp;&nbsp;Total before tax | 14714 | 3764 | 80238 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax | (3090) | (790) | (16850) | Income taxes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total after-tax | 11624 | 2974 | 63388 |  |
| **Pension adjustments:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of prior service cost | 1168 | 1071 | 1075 | Other operating expense |
| &nbsp;&nbsp;&nbsp;Amortization of actuarial (gain) loss | (915) | (597) | (1465) | Other operating expense |
| &nbsp;&nbsp;&nbsp;&nbsp;Total before tax | 253 | 474 | (390) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax | (52) | (100) | 82 | Income taxes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total after-tax | 201 | 374 | (308) |  |
| **Total reclassification (after-tax)**  | $11825 | $3348 | $63080 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 4—Investments** 

*<u>Portfolio Composition</u>:* Summaries of fixed maturities available for sale by amortized cost, fair value, and allowance for credit losses at December 31, 2025 and 2024, and the corresponding amounts of gross unrealized gains and losses recognized in accumulated other comprehensive income (loss) are as follows. Redeemable preferred stock is included within "Corporates, by sector."

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
| | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair**<br> **Value**<sup>(1)</sup> | **% of Total**<br>**Fixed**<br>**Maturities**<sup>(2)</sup> |
| **Fixed maturities available for sale:** | | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $409170 | $— | $161 | $(25478) | $383853 | 2 |
| &nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions | 3385433 |  | 26955 | (531762) | 2880626 | 16 |
| &nbsp;&nbsp;&nbsp;Foreign governments | 47448 |  | 138 | (8040) | 39546 |  |
| &nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 7787885 |  | 175164 | (645363) | 7317686 | 42 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 4982187 |  | 134105 | (333966) | 4782326 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 2093010 |  | 71582 | (93086) | 2071506 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 14863082 |  | 380851 | (1072415) | 14171518 | 81 |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities | 115331 | (3297) | 1877 | (112) | 113799 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities**  | $18820464 | $(3297) | $409982 | $(1637807) | $17589342 | 100 |

---

(1)Amount reported in the balance sheet.

(2)At fair value.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
| | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair**<br> **Value**<sup>(1)</sup> | **% of Total**<br>**Fixed**<br>**Maturities**<sup>(2)</sup> |
| **Fixed maturities available for sale:** | | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $401753 | $— | $1 | $(42794) | $358960 | 2 |
| &nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions | 3300901 |  | 20662 | (534759) | 2786804 | 16 |
| &nbsp;&nbsp;&nbsp;Foreign governments | 36883 |  | 18 | (8870) | 28031 |  |
| &nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 7889074 | (7098) | 105610 | (805330) | 7182256 | 42 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 5006375 |  | 82598 | (413043) | 4675930 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 2081366 |  | 39716 | (118007) | 2003075 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 14976815 | (7098) | 227924 | (1336380) | 13861261 | 81 |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations | 36923 |  | 5943 |  | 42866 |  |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities | 82534 | (3297) | 39 | (2186) | 77090 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities**  | $18835809 | $(10395) | $254587 | $(1924989) | $17155012 | 100 |

---

(1)Amount reported in the balance sheet.

(2)At fair value.

The Company had unfunded commitments of $313 million and $167 million in fixed maturities at December 31, 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

A schedule of fixed maturities available for sale by contractual maturity date at December 31, 2025, is shown below on an amortized cost basis, net of allowance for credit losses, and on a fair value basis. Actual disposition dates could differ from contractual maturities due to call or prepayment provisions.

---

| | | |
|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** |
| | **Amortized<br>Cost, net** | **Fair<br>Value** |
| **Fixed maturities available for sale:** | | |
| &nbsp;&nbsp;&nbsp;Due in one year or less | $121194 | $122154 |
| &nbsp;&nbsp;&nbsp;Due after one year through five years | 816125 | 847246 |
| &nbsp;&nbsp;&nbsp;Due after five years through ten years | 1873144 | 1938627 |
| &nbsp;&nbsp;&nbsp;Due after ten years through twenty years | 8965771 | 8521420 |
| &nbsp;&nbsp;&nbsp;Due after twenty years | 6928887 | 6046084 |
| &nbsp;&nbsp;&nbsp;Mortgage-backed and asset-backed securities | 112046 | 113811 |
|  | $18817167 | $17589342 |

---

*<u>Analysis of investment operations:</u>* "Net investment income" for the three years ended December 31, 2025 is summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Fixed maturities available for sale | $974111 | $981439 | $944628 |
| Policy loans | 55876 | 52625 | 49011 |
| Mortgage loans | 28064 | 27809 | 19541 |
| Other long-term investments<sup>(1)</sup> | 90321 | 81834 | 54655 |
| Short-term investments | 9178 | 11151 | 6322 |
|  | 1157550 | 1154858 | 1074157 |
| Less investment expense | (27352) | (19227) | (17273) |
| &nbsp;&nbsp;**Net investment income**  | $1130198 | $1135631 | $1056884 |

---

(1)For the years ended 2025, 2024, and 2023, the investment funds, accounted for under the fair value option method, recorded $76.2 million, $74.8 million, and $52.3 million, respectively, in net investment income. Refer to *[Other Long-Term Investments](#ia1583f94e55d42afa319983b2df261d2_577)* below for further discussion on the investment funds.

Selected information about sales of fixed maturities available for sale is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Fixed maturities available for sale:** |  |  |  |
| &nbsp;&nbsp;Proceeds from sales<sup>(1)</sup> | $623792 | $1207237 | $602556 |
| &nbsp;&nbsp;&nbsp;Gross realized gains | 8378 | 21196 | 5554 |
| &nbsp;&nbsp;&nbsp;Gross realized losses | (20551) | (32956) | (80823) |

---

(1)Includes unsettled trades of $0, $866 thousand, and $0 as of December 31, 2025, 2024, and 2023, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

An analysis of "realized gains (losses)" is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Realized investment gains (losses):** |  |  |  |
| &nbsp;&nbsp;&nbsp;Fixed maturities available for sale: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and other<sup>(1)</sup> | $(30447) | $(11563) | $(77301) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for credit losses | 7098 | (3280) | (7115) |
| &nbsp;&nbsp;Fair value option—change in fair value | (10074) | (16717) | 15102 |
| &nbsp;&nbsp;Mortgage loans | (2817) | (3972) | (5603) |
| &nbsp;&nbsp;&nbsp;Other investments | (1642) | 2936 | 1792 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Realized gains (losses) from investments**  | (37882) | (32596) | (73125) |
| &nbsp;&nbsp;Other gains (losses)  | 10094 | 8408 | 7449 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total realized gains (losses)**  | (27788) | (24188) | (65676) |
| &nbsp;&nbsp;&nbsp;Applicable tax | 5836 | 5080 | 13792 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Realized gains (losses), net of tax**  | $(21952) | $(19108) | $(51884) |

---

(1)For the years ended 2025, 2024, and 2023, the Company recorded $288.5 million, $105.6 million, and $50.9 million of issuer-initiated exchanges of fixed maturities (noncash transactions) that resulted in $(3.0) million, $0, and $(1.9) million, respectively, in realized gains (losses). During the year ended December 31, 2023, the Company sold $66 million in securities relating to holdings in Signature Bank New York and First Republic Bank, which entered receivership during the first half of 2023.

An analysis of the net change in unrealized investment gains (losses) is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Change in unrealized investment gains (losses) on:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Fixed maturities available for sale | $442577 | $(622809) | $750734 |

---

*<u>Fair value measurements:</u>* The following tables represent the fair value of fixed maturities measured on a recurring basis at December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Measurement at December 31, 2025:** | **Fair Value Measurement at December 31, 2025:** | **Fair Value Measurement at December 31, 2025:** | **Fair Value Measurement at December 31, 2025:** |
| | **Quoted Prices in<br>Active Markets<br>for Identical<br>Assets (Level 1)** | **Significant Other<br>Observable<br>Inputs (Level 2)** | **Significant<br>Unobservable<br>Inputs (Level 3)** | **Total Fair<br>Value** |
| **Fixed maturities available for sale** | | | | |
| &nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $— | $383853 | $— | $383853 |
| &nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions |  | 2880626 |  | 2880626 |
| &nbsp;&nbsp;&nbsp;Foreign governments |  | 39546 |  | 39546 |
| &nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Industrials |  | 7232179 | 85507 | 7317686 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial |  | 4661175 | 121151 | 4782326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Utilities |  | 1968840 | 102666 | 2071506 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates |  | 13862194 | 309324 | 14171518 |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities |  | 27898 | 85901 | 113799 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities**  | $— | $17194117 | $395225 | $17589342 |
| &nbsp;&nbsp;&nbsp;Percentage of total | —% | 98% | 2% | 100% |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Measurement at December 31, 2024:** | **Fair Value Measurement at December 31, 2024:** | **Fair Value Measurement at December 31, 2024:** | **Fair Value Measurement at December 31, 2024:** |
| | **Quoted Prices in<br>Active Markets<br>for Identical<br>Assets (Level 1)** | **Significant Other<br>Observable<br>Inputs (Level 2)** | **Significant<br>Unobservable<br>Inputs (Level 3)** | **Total Fair<br>Value** |
| **Fixed maturities available for sale** | | | | |
| &nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $— | $358960 | $— | $358960 |
| &nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions |  | 2786804 |  | 2786804 |
| &nbsp;&nbsp;&nbsp;Foreign governments |  | 28031 |  | 28031 |
| &nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Industrials |  | 6998900 | 183356 | 7182256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial |  | 4551737 | 124193 | 4675930 |
| &nbsp;&nbsp;&nbsp;&nbsp;Utilities |  | 1890559 | 112516 | 2003075 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates |  | 13441196 | 420065 | 13861261 |
| &nbsp;&nbsp;&nbsp;Collateralized debt obligations |  |  | 42866 | 42866 |
| &nbsp;&nbsp;&nbsp;Other asset-backed securities |  | 65907 | 11183 | 77090 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total fixed maturities**  | $— | $16680898 | $474114 | $17155012 |
| Percentage of total | —% | 97% | 3% | 100% |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables represent changes in fixed maturities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)** | **Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)** | **Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)** | **Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)** |
| | **Asset-<br>backed<br>Securities** | **Collateralized<br>Debt<br>Obligations** | **Corporates** | **Total** |
| **Balance at January 1, 2023**  | $— | $50364 | $478083 | $528447 |
| &nbsp;&nbsp;Included in realized gains / losses |  |  |  |  |
| &nbsp;&nbsp;Included in other comprehensive income |  | (8230) | 4541 | (3689) |
| &nbsp;&nbsp;Acquisitions<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;Sales |  |  |  |  |
| &nbsp;&nbsp;Amortization |  | 4569 | 155 | 4724 |
| &nbsp;&nbsp;Other<sup>(2)</sup> |  | (4557) | (28046) | (32603) |
| &nbsp;&nbsp;Transfers into Level 3<sup>(3)</sup> |  |  |  |  |
| &nbsp;&nbsp;Transfers out of Level 3<sup>(3)</sup> |  |  |  |  |
| **Balance at December 31, 2023**  |  | 42146 | 454733 | 496879 |
| &nbsp;&nbsp;Included in realized gains / losses |  |  | 740 | 740 |
| &nbsp;&nbsp;Included in other comprehensive income | 37 | 907 | (4607) | (3663) |
| &nbsp;&nbsp;Acquisitions<sup>(1)</sup> | 8948 |  | 14800 | 23748 |
| &nbsp;&nbsp;Sales |  |  |  |  |
| &nbsp;&nbsp;Amortization |  | 4548 | 217 | 4765 |
| &nbsp;&nbsp;Other<sup>(2)</sup> |  | (4735) | (45818) | (50553) |
| &nbsp;&nbsp;Transfers into Level 3<sup>(3)</sup> | 2198 |  |  | 2198 |
| &nbsp;&nbsp;Transfers out of Level 3<sup>(3)</sup> |  |  |  |  |
| **Balance at December 31, 2024**  | 11183 | 42866 | 420065 | 474114 |
| &nbsp;&nbsp;Included in realized gains / losses |  | (588) | (2563) | (3151) |
| &nbsp;&nbsp;Included in other comprehensive income | 350 | (5943) | 10618 | 5025 |
| &nbsp;&nbsp;Acquisitions<sup>(1)</sup> | 74368 |  | 44015 | 118383 |
| &nbsp;&nbsp;Sales |  | (36398) | (118379) | (154777) |
| &nbsp;&nbsp;Amortization |  | 1512 | (209) | 1303 |
| &nbsp;&nbsp;Other<sup>(2)</sup> |  | (1449) | (44223) | (45672) |
| &nbsp;&nbsp;Transfers into Level 3<sup>(3)</sup> |  |  |  |  |
| &nbsp;&nbsp;Transfers out of Level 3<sup>(3)</sup> |  |  |  |  |
| **Balance at December 31, 2025**  | $85901 | $— | $309324 | $395225 |
| (1)Acquisitions of Level 3 investments in each of the years 2023 through 2025 are comprised of private placement fixed maturities and equities. <br>(2)Includes capitalized interest, foreign exchange adjustments, and principal repayments. <br>(3)Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available. | (1)Acquisitions of Level 3 investments in each of the years 2023 through 2025 are comprised of private placement fixed maturities and equities. <br>(2)Includes capitalized interest, foreign exchange adjustments, and principal repayments. <br>(3)Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available. | (1)Acquisitions of Level 3 investments in each of the years 2023 through 2025 are comprised of private placement fixed maturities and equities. <br>(2)Includes capitalized interest, foreign exchange adjustments, and principal repayments. <br>(3)Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available. | (1)Acquisitions of Level 3 investments in each of the years 2023 through 2025 are comprised of private placement fixed maturities and equities. <br>(2)Includes capitalized interest, foreign exchange adjustments, and principal repayments. <br>(3)Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available. | (1)Acquisitions of Level 3 investments in each of the years 2023 through 2025 are comprised of private placement fixed maturities and equities. <br>(2)Includes capitalized interest, foreign exchange adjustments, and principal repayments. <br>(3)Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available. |
| Changes in unrealized gains and losses for Level 3 securities during the period included in accumulated other comprehensive income for assets held at the end of the reporting period: | Changes in unrealized gains and losses for Level 3 securities during the period included in accumulated other comprehensive income for assets held at the end of the reporting period: | Changes in unrealized gains and losses for Level 3 securities during the period included in accumulated other comprehensive income for assets held at the end of the reporting period: | Changes in unrealized gains and losses for Level 3 securities during the period included in accumulated other comprehensive income for assets held at the end of the reporting period: | Changes in unrealized gains and losses for Level 3 securities during the period included in accumulated other comprehensive income for assets held at the end of the reporting period: |
|  | **Asset-<br>backed<br>Securities** | **Collateralized<br>Debt<br>Obligations** | **Corporates** | **Total** |
| &nbsp;&nbsp;&nbsp;&nbsp;**2023**  | $— | $(8230) | $4541 | $(3689) |
| &nbsp;&nbsp;&nbsp;&nbsp;**2024**  | 37 | 907 | (4607) | (3663) |
| &nbsp;&nbsp;&nbsp;&nbsp;**2025**  | 350 | (5943) | 10618 | 5025 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Transfers between levels within the hierarchy occur when there are changes in the observability of the inputs and market data. Transfers into Level 3 occur when there is little observable market activity for the asset/liability as of the measurement date and the Company is required to rely upon internally-developed assumptions or third parties. Transfers out of Level 3 occur when quoted prices in active markets become available for identical assets/liabilities or the ability to corroborate by observable market data.

The following table represents quantitative information about Level 3 fair value measurements:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Quantitative Information about Level 3 Fair Value Measurements** | **Quantitative Information about Level 3 Fair Value Measurements** | **Quantitative Information about Level 3 Fair Value Measurements** | **Quantitative Information about Level 3 Fair Value Measurements** | **Quantitative Information about Level 3 Fair Value Measurements** |
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| | **Fair Value** | **Valuation<br>Techniques** | **Significant Unobservable<br>Input** | **Range** | **Weighted-**<br>**Average**<sup>(1)</sup> |
| Private placement fixed maturities | $309324 | Determination of credit spread | Credit rating | B to AA | BBB+ |
| Asset-backed securities | 85901 | Determination of credit spread | Credit rating | CC to A- | BBB- |
|  | $395225 |  |  |  |  |

---

(1)Unobservable inputs were weighted by the relative fair value of the instruments.

Private placement fixed maturities and asset-backed securities are valued based on the contractual cash flows discounted by a yield determined as a treasury benchmark rate adjusted for a credit spread. The credit spread is developed from observable indices for similar securities and unobservable indices for private securities or private comparable securities for corresponding credit ratings. The credit ratings for the securities may be considered unobservable inputs, as they are private letter ratings issued by a nationally recognized statistical rating organization or are assigned by the third-party investment manager based on a quantitative and qualitative assessment of the credit underwritten. A higher (lower) credit rating would result in a higher (lower) valuation.

The collateral underlying collateralized debt obligations consists primarily of trust preferred securities issued by banks and insurance companies. Collateralized debt obligations are valued at the present value of expected future cash flows using an unobservable discount rate. Expected cash flows are determined by scheduling the projected repayment of the collateral assuming no future defaults, deferrals, or recoveries. The discount rate is risk-adjusted to take these items into account. A significant increase (decrease) in the discount rate will produce a significant decrease (increase) in fair value. Additionally, a significant increase (decrease) in the cash flow expectations would result in a significant increase (decrease) in fair value. For more information regarding valuation procedures, please refer to *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* under the caption *Fair Value Measurements, Investments in Securities.*

*<u>Unrealized Loss Analysis</u>:* The following table discloses information about fixed maturities available for sale in an unrealized loss position.

---

| | | | |
|:---|:---|:---|:---|
| | **Less than Twelve Months** | **Twelve Months or Longer** | **Total** |
| **Number of issues (CUSIPs) held:** | | | |
| &nbsp;&nbsp;&nbsp;As of December 31, 2025 | 395 | 1583 | 1978 |
| &nbsp;&nbsp;&nbsp;As of December 31, 2024 | 705 | 1498 | 2203 |

---

Globe Life's entire fixed maturity portfolio consisted of 2,576 issues by 1,010 different issuers at December 31, 2025 and 2,552 issues by 1,014 different issuers at December 31, 2024. The weighted-average quality rating of all unrealized loss positions at amortized cost was A as of December 31, 2025 and A- as of December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables disclose unrealized investment losses by class and major sector of fixed maturities available for sale at December 31, 2025 and December 31, 2024.

**Analysis of Gross Unrealized Investment Losses**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
| | **Less than Twelve Months** | **Less than Twelve Months** | **Twelve Months or Longer** | **Twelve Months or Longer** | **Total** | **Total** |
| | **Fair<br>Value** | **Unrealized<br>Loss** | **Fair<br>Value** | **Unrealized<br>Loss** | **Fair<br>Value** | **Unrealized<br>Loss** |
| **Fixed maturities available for sale:** | | | | | | |
| &nbsp;&nbsp;&nbsp;**Investment grade securities:** | | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $4894 | $(454) | $368750 | $(25024) | $373644 | $(25478) |
| &nbsp;&nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions | 535186 | (12491) | 1731104 | (519061) | 2266290 | (531552) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign governments | 5616 | (26) | 25370 | (8014) | 30986 | (8040) |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 680126 | (14131) | 3667956 | (591006) | 4348082 | (605137) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 469436 | (29118) | 1806739 | (294440) | 2276175 | (323558) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 302325 | (4274) | 555085 | (82694) | 857410 | (86968) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 1451887 | (47523) | 6029780 | (968140) | 7481667 | (1015663) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other asset-backed securities | 18217 | (62) | 1379 | (50) | 19596 | (112) |
| &nbsp;&nbsp;&nbsp;Total investment grade securities | 2015800 | (60556) | 8156383 | (1520289) | 10172183 | (1580845) |
| &nbsp;&nbsp;&nbsp;**Below investment grade securities:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions |  |  | 1751 | (210) | 1751 | (210) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 35564 | (6631) | 141446 | (33595) | 177010 | (40226) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 6185 | (36) | 101427 | (10372) | 107612 | (10408) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 5025 | (60) | 38121 | (6058) | 43146 | (6118) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 46774 | (6727) | 280994 | (50025) | 327768 | (56752) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other asset-backed securities |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Total below investment grade securities | 46774 | (6727) | 282745 | (50235) | 329519 | (56962) |
| **Total fixed maturities**  | $2062574 | $(67283) | $8439128 | $(1570524) | $10501702 | $(1637807) |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
| | **Less than Twelve Months** | **Less than Twelve Months** | **Twelve Months or Longer** | **Twelve Months or Longer** | **Total** | **Total** |
| | **Fair<br>Value** | **Unrealized<br>Loss** | **Fair<br>Value** | **Unrealized<br>Loss** | **Fair<br>Value** | **Unrealized<br>Loss** |
| **Fixed maturities available for sale:** | | | | | | |
| &nbsp;&nbsp;&nbsp;**Investment grade securities:** | | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | $11268 | $(290) | $347527 | $(42504) | $358795 | $(42794) |
| &nbsp;&nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions | 778244 | (32894) | 1532264 | (501865) | 2310508 | (534759) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign governments |  |  | 24925 | (8870) | 24925 | (8870) |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 1487940 | (73404) | 3433034 | (690920) | 4920974 | (764324) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 961932 | (52946) | 1785130 | (333873) | 2747062 | (386819) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 546965 | (20214) | 540077 | (90996) | 1087042 | (111210) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 2996837 | (146564) | 5758241 | (1115789) | 8755078 | (1262353) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other asset-backed securities | 23231 | (95) | 42639 | (2091) | 65870 | (2186) |
| &nbsp;&nbsp;&nbsp;Total investment grade securities | 3809580 | (179843) | 7705596 | (1671119) | 11515176 | (1850962) |
| &nbsp;&nbsp;&nbsp;**Below investment grade securities:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporates, by sector: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrials | 54199 | (2656) | 142638 | (38350) | 196837 | (41006) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial | 2990 | (53) | 126811 | (26171) | 129801 | (26224) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities | 19263 | (1113) | 24003 | (5684) | 43266 | (6797) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total corporates | 76452 | (3822) | 293452 | (70205) | 369904 | (74027) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other asset-backed securities |  |  | 2198 |  | 2198 |  |
| &nbsp;&nbsp;&nbsp;Total below investment grade securities | 76452 | (3822) | 295650 | (70205) | 372102 | (74027) |
| **Total fixed maturities**  | $3886032 | $(183665) | $8001246 | $(1741324) | $11887278 | $(1924989) |

---

Gross unrealized losses may fluctuate quarter over quarter due to factors in the market that affect the holdings, such as changes in interest rates or credit spreads. The Company considers many factors when determining whether an allowance for a credit loss should be recorded. While the Company holds securities that may be in an unrealized loss position, Globe Life does not generally intend to sell and it is unlikely that the Company will be required to sell the fixed maturities prior to their anticipated recovery or maturity due to the strong cash flows generated by its insurance operations.

Gross unrealized losses decreased from $1.92 billion at December 31, 2024 to $1.64 billion at December 31, 2025, a decrease of $287 million. The decrease in the gross unrealized losses from the prior year was primarily attributable to the change in market interest rates.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Fixed Maturities, Allowance for Credit Losses</u>:* A summary of the activity in the allowance for credit losses is as follows. Refer to *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* for factors considered in the recording of the allowance for credit losses.

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Allowance for credit losses beginning balance**  | $10395 | $7115 |
| &nbsp;&nbsp;Additions to allowance for which credit losses were not previously recorded |  | 3297 |
| &nbsp;&nbsp;Additions (reductions) to allowance for fixed maturities that previously had an allowance | 20 | (17) |
| &nbsp;&nbsp;Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period | (7118) |  |
| **Allowance for credit losses ending balance**  | $3297 | $10395 |

---

As of December 31, 2025, the Company had two fixed maturity securities in non-accrual status with an amortized cost of $9.2 million and an allowance of $3.3 million. As of December 31, 2024, there was one fixed maturity security in non-accrual status with an amortized cost of $5.5 million and an allowance of $3.3 million.

*<u>Concentrations of Credit Risk</u>:* Globe Life maintains a diversified investment portfolio with limited concentration in any given issuer. At December 31, 2025, the investment portfolio, at fair value, consisted of the following:

---

| | |
|:---|:---|
| **Investment grade fixed maturities:** | |
| &nbsp;&nbsp;&nbsp;Corporates | 67% |
| &nbsp;&nbsp;&nbsp;States, municipalities, and political subdivisions | 14 |
| &nbsp;&nbsp;&nbsp;U.S. Government direct, guaranteed, and government-sponsored enterprises | 2 |
| &nbsp;&nbsp;&nbsp;Other | 1 |
| **Below investment grade fixed maturities:** |  |
| &nbsp;&nbsp;Corporates | 2 |
|  | 86 |
| **Other** |  |
| &nbsp;&nbsp;&nbsp;Policy loans, which are secured by the underlying insurance policy values | 4 |
| &nbsp;&nbsp;&nbsp;Other investments | 10 |
|  | 100% |

---

As of December 31, 2025, state and municipal governments represented 14% of invested assets at fair value. Such investments are made throughout the U.S. At December 31, 2025, the state and municipal bond portfolio at fair value was invested in securities issued within the following states: Texas (21%), California (9%), New York (8%), Florida (4%), and Pennsylvania (4%). Otherwise, there was no concentration within any given state greater than 4%.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Corporate fixed maturities represent 69% of Globe Life's invested assets. These investments are spread across a wide range of industries. Below are the ten largest industry concentrations held in the portfolio of corporate fixed maturities at December 31, 2025, based on fair value:

---

| | |
|:---|:---|
| Insurance | 19 |
| Electric utilities | 11 |
| Banks | 6 |
| Oil and natural gas pipelines | 6 |
| Chemicals | 5 |
| Transportation | 4 |
| Diversified financial services | 3 |
| Food | 3 |
| Telecommunications | 3 |
| Gas utilities | 3 |

---

At December 31, 2025, 2% of invested assets at fair value were represented by fixed maturities rated below investment grade. Par value of these investments was $624 million, amortized cost was $521 million, and fair value was $469 million. While these investments could be subject to additional credit risk, such risk should generally be reflected in their fair value.

Securities, cash, and short-term investments held on deposit with various state and federal regulatory authorities had an amortized cost and fair value, respectively, of $1.0 billion and $983 million at December 31, 2025 and $1.0 billion and $955 million at December 31, 2024.

*<u>Mortgage Loans (commercial mortgage loans):</u>* Summaries of commercial mortgage loans by property type and geographical location at December 31, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** |
| | **Carrying Value** | **% of Total** | **Carrying Value** | **% of Total** |
| **Property type:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Industrial | $155208 | 36 | $110456 | 28 |
| &nbsp;&nbsp;&nbsp;Hospitality | 99492 | 23 | 73931 | 19 |
| &nbsp;&nbsp;&nbsp;Multi-family | 99212 | 23 | 111234 | 28 |
| &nbsp;&nbsp;&nbsp;Retail | 76059 | 18 | 65612 | 16 |
| &nbsp;&nbsp;&nbsp;Office | 3061 | 1 | 6539 | 2 |
| &nbsp;&nbsp;&nbsp;Mixed use |  |  | 35960 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total recorded investment | 433032 | 101 | 403732 | 102 |
| &nbsp;&nbsp;&nbsp;Less allowance for credit losses | (4515) | (1) | (7644) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Carrying value, net of allowance for credit losses**  | $428517 | 100 | $396088 | 100 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** |
| | **Carrying Value** | **% of Total** | **Carrying Value** | **% of Total** |
| **Geographic location:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Florida | $88681 | 21 | $63308 | 16 |
| &nbsp;&nbsp;&nbsp;Texas | 66597 | 15 | 75131 | 19 |
| &nbsp;&nbsp;&nbsp;North Carolina | 42358 | 10 | 23253 | 6 |
| &nbsp;&nbsp;&nbsp;New Jersey | 37130 | 9 | 51744 | 13 |
| &nbsp;&nbsp;&nbsp;Alabama | 36750 | 9 | 35850 | 9 |
| &nbsp;&nbsp;&nbsp;New York | 31948 | 7 | 34975 | 9 |
| &nbsp;&nbsp;&nbsp;Other | 129568 | 30 | 119471 | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total recorded investment | 433032 | 101 | 403732 | 102 |
| &nbsp;&nbsp;&nbsp;Less allowance for credit losses | (4515) | (1) | (7644) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Carrying value, net of allowance for credit losses**  | $428517 | 100 | $396088 | 100 |

---

The following tables are reflective of the key factors, debt service coverage ratios, and loan-to-value ("LTV") ratios that are utilized by management to monitor the performance of the portfolios. The Company only makes new investments in commercial mortgage loans that have a LTV ratio less than 80%. LTV ratios that exceed 80% are generally as a result of decreases in the valuation of the underlying property. Generally, a higher LTV ratio and a lower debt service coverage ratio can potentially equate to higher risk of loss.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** |
| | **Debt Service Coverage Ratios**<sup>(1)</sup> | **Debt Service Coverage Ratios**<sup>(1)</sup> | **Debt Service Coverage Ratios**<sup>(1)</sup> | | |
| | **<1.00x** | **1.00x—1.20x** | **>1.20x** |<br>**Total** |<br>**% of Gross Total** |
| **Loan-to-value ratio**<sup>(2)</sup>**:** | | | | | |
| &nbsp;&nbsp;Less than 70% | $61159 | $50009 | $313634 | $424802 | 98 |
| &nbsp;&nbsp;70% to 80% |  |  |  |  |  |
| &nbsp;&nbsp;81% to 90% |  |  |  |  |  |
| &nbsp;&nbsp;Greater than 90% | 8230 |  |  | 8230 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $69389 | $50009 | $313634 | 433032 | 100 |
| &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | (4515) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | $428517 |  |

---

(1)Annual net operating income divided by annual mortgage debt service (principal and interest).

(2)Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** | **Recorded Investment** |
| | **Debt Service Coverage Ratios**<sup>(1)</sup> | **Debt Service Coverage Ratios**<sup>(1)</sup> | **Debt Service Coverage Ratios**<sup>(1)</sup> | | |
| | **<1.00x** | **1.00x—1.20x** | **>1.20x** |<br>**Total** |<br>**% of Gross Total** |
| **Loan-to-value ratio**<sup>(2)</sup>**:** | | | | | |
| &nbsp;&nbsp;Less than 70% | $88507 | $64494 | $196867 | $349868 | 87 |
| &nbsp;&nbsp;70% to 80% |  |  |  |  |  |
| &nbsp;&nbsp;81% to 90% |  |  |  |  |  |
| &nbsp;&nbsp;Greater than 90% | 16136 | 37728 |  | 53864 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $104643 | $102222 | $196867 | 403732 | 100 |
| &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | &nbsp;&nbsp;Less allowance for credit losses | (7644) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total, net of allowance for credit losses**  | $396088 |  |

---

(1)Annual net operating income divided by annual mortgage debt service (principal and interest).

(2)Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

As of December 31, 2025, the Company had 36 loans in the portfolio. During the quarter, the Company evaluated its commercial mortgage loan portfolio on both an individual and pooling basis to determine the allowance for credit losses and determined three loans were collateral dependent or likely to foreclose. The allowance for credit losses on the three loans was determined using the practical expedient which was based on an estimate of fair value of the underlying collateral plus costs to sell the asset. The total principal balance of the three loans was $4.3 million and the allowance, determined using the practical expedient, was $659 thousand as of December 31, 2025. One loan with an outstanding principal value of $7.0 million was removed from the evaluation and returned to the pool assessment during the year ended December 31, 2025. Additionally, four loans with an outstanding principal balance of $45.8 million were removed due to foreclosure and transferred into limited partnerships, held under the fair value option, in other long-term investments. For the year ended December 31, 2025, the allowance for credit losses decreased by $3.1 million to $4.5 million.

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Allowance for credit losses beginning balance**  | $7644 | $3672 |
| Provision (reversal) for credit losses | (852) | 3972 |
| Loans charged-off | (2277) |  |
| **Allowance for credit losses ending balance**  | $4515 | $7644 |

---

As of December 31, 2025, the Company had two commercial mortgage loans in non-accrual status with an outstanding principal balance of $3 million and no commercial mortgage loans were delinquent. At December 31, 2024, there were five commercial mortgage loans in non-accrual status with an outstanding principal balance of $53 million and one delinquent commercial mortgage loan with outstanding interest of $31 thousand. The Company's unfunded commitment balance to commercial loan borrowers was $21 million as of December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Other Long-Term Investments</u>:* Other long-term investments consist of the following assets:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| Investment funds | $1109719 | $986766 |
| Company-owned life insurance<sup>(1)</sup> | 243721 | 202734 |
| Other | 42624 | 46259 |
| &nbsp;&nbsp;**Total**  | $1396064 | $1235759 |

---

(1) Company-owned life insurance is reported at cash surrender value.

The following table presents additional information about the Company's investment funds as of December 31, 2025 and December 31, 2024 at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value** | **Fair Value** | **Unfunded Commitments**<sup>(2)</sup> | |
|<br>**Investment Category** | **2025** | **2024** | **2025** |<br>**Redemption Term/Notice**<sup>(1)</sup> |
| Commercial mortgage loans | $614080 | $566142 | $260229 | Fully redeemable and non-redeemable with varying terms. |
| Opportunistic and private credit | 223665 | 202008 | 222080 | Fully redeemable and non-redeemable with varying terms. |
| Infrastructure | 187964 | 179627 | 21791 | Fully redeemable and non-redeemable with varying terms. |
| Other | 84010 | 38989 | 53665 | Non-redeemable with varying terms |
| &nbsp;&nbsp;&nbsp;&nbsp;Total investment funds | $1109719 | $986766 | $557765 |  |

---

 

(1)&nbsp;&nbsp;&nbsp;&nbsp;Non-redeemable funds generally have an expected life of 7 to 12 years from fund closing with extension options of 1 to 4 years. Redemptions are paid out throughout the life of the funds at the General Partner's discretion. Redeemable funds can generally be redeemed over 6 to 36 months upon request from limited partners.

(2) Unfunded commitments include unfunded balances during the investment period. After an investment period ends, the fund can call capital based on limited and specified reasons. As of December 31, 2025, unfunded commitments totaled $716 million, including funds past the investment period.

The Company had $251 million of capital called during the period from existing investment funds. The Company's unfunded commitments were $558 million as of December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 5—Commitments and Contingencies** 

*<u>Reinsurance</u>:* Insurance affiliates of Globe Life reinsure a portion of insurance risk that is in excess of their retention limits with unaffiliated reinsurers. Current retention limits for new business written on ordinary life insurance range up to $500 thousand per life. Life insurance ceded to unaffiliated reinsurers represented 0.2% and 0.3% of total life insurance in force at December 31, 2025 and 2024, respectively. Insurance ceded on life and accident and health products represented 0.8% and 0.2% of premium income for 2025 and 2024, respectively. In the fourth quarter of 2024, the Company entered into a coinsurance agreement to cede a majority of its annuity business to a third-party insurer. Annuities ceded represented 69% of the direct annuity fund balance as of December 31, 2025. Effective January 1, 2025, Globe Life entered into a 100% coinsurance with funds withheld agreement with a third party reinsurer covering certain term and whole life policies. The insurance affiliates of Globe Life would be liable for the reinsured risks ceded to other companies to the extent that such reinsuring companies are unable to meet their obligations.

Insurance affiliates also assume insurance risks of other external companies. Life reinsurance assumed represented approximately 0.8% of life insurance in force at December 31, 2025 and 2024 and reinsurance assumed on life and accident and health products represented 0.6% and 0.9% of premium income for 2025 and 2024, respectively.

*<u>Leases</u>:* Globe Life leases office space and other equipment under a variety of operating lease arrangements.

Rental expense for the three years ended December 31, 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Rental expense | $3494 | $3208 | $3519 |

---

Future minimum rental commitments required under operating leases having remaining noncancelable lease terms in excess of one year at December 31, 2025 were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2026** | **2027** | **2028** | **2029** | **2030** | **Thereafter** |
| Operating lease commitments | $6962 | $7144 | $6527 | $5923 | $5453 | $33367 |

---

*<u>Purchase Commitments</u>*: Globe Life has various long-term noncancelable purchase commitments as well as commitments to provide capital for low-income housing tax credit interests. See further discussion related to tax credits in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463).*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2026** | **2027** | **2028** | **2029** | **2030** | **Thereafter** |
| Purchase commitments<sup>(1)</sup> | $74111 | $113814 | $87983 | $30065 | $24693 | $204093 |

---

(1) Includes low-income housing tax credits with non-funded commitments of $255 million at December 31, 2025.

*<u>Investments</u>*: Globe Life is committed to invest under certain contracts related to investments in fixed maturities, limited partnerships and commercial mortgage loans. See *[Note 4—Investments](#ia1583f94e55d42afa319983b2df261d2_577)* for unfunded commitments.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Guarantees</u>:* At December 31, 2025, the Company had one performance guarantee in effect. Per the Pre-capitalized Trust Securities agreement signed on July 1, 2025, Globe Life Inc. is required to purchase any treasury securities in default. Management believes it is unlikely the Company will have to make any material payments under this agreement due to default.

Globe Life has guaranteed letters of credit in connection with its credit facility with a group of banks as disclosed in *[Note 12—Debt](#ia1583f94e55d42afa319983b2df261d2_874)*. The letters of credit were issued by TMK Re, Ltd., a wholly-owned subsidiary, to secure TMK Re, Ltd.'s obligation for claims on certain policies reinsured by TMK Re, Ltd. that were sold by other Globe Life insurance companies. These letters of credit facilitate TMK Re, Ltd.'s ability to reinsure the business of Globe Life's insurance carriers. The agreement was amended on March 29, 2024 and now expires in 2029. The maximum amount of letters of credit available is $250 million. The Parent Company would be liable to the extent that TMK Re, Ltd. does not pay the reinsured party. The amount of letters of credit outstanding at December 31, 2025 was $115 million.

*<u>Unclaimed Property Audits</u>:* Globe Life subsidiaries are currently the subject of audits regarding the identification, reporting and escheatment of unclaimed property arising from life insurance policies and a limited number of annuity contracts. These audits are being conducted by private entities that have contracted with forty-seven states through their respective Departments of Revenue, and have not resulted in any financial assessment from any state nor indicated any liability. The audits are wide-ranging and seek large amounts of data regarding claims handling, procedures, and payments of contract benefits arising from unreported death claims. No estimate of range can be made at this time for loss contingencies related to possible administrative penalties or amounts that could be payable to the states for the escheatment of abandoned property.

*<u>Litigation</u>*: Globe Life Inc. and its subsidiaries, in common with the insurance industry in general, are subject to litigation, including: putative class action litigation; alleged breaches of contract; torts, including bad faith and fraud claims based on alleged wrongful or fraudulent acts of agents of Globe Life Inc.'s insurance subsidiaries; alleged employment discrimination; alleged worker misclassification; and miscellaneous other causes of action. Based upon information presently available, and in light of legal and other factual defenses available to Globe Life Inc. and its subsidiaries, management does not believe that it is reasonably possible that such litigation will have a material adverse effect on Globe Life Inc.'s financial condition, future operating results or liquidity; however, assessing the eventual outcome of litigation necessarily involves forward-looking speculation as to judgments to be made by judges, juries and appellate courts in the future. This bespeaks caution, particularly in states with reputations for high punitive damage verdicts.

On April 30, 2024, a putative securities class action was filed against Globe Life Inc. and six of its current/former executives and directors in the United States District Court for the Eastern District of Texas (*City of Miami Gen. Emp. & Sanitation Emp. Ret. Trust, et al. v. Globe Life Inc., et al.*, Case No. 4:24-cv-00376). On July 24, 2024, the Court appointed Lead Plaintiffs and Lead Counsel for the putative class of shareholders. The Lead Plaintiffs filed a Consolidated Complaint on October 4, 2024 that asserts claims under §§ 10(b), 20(a), and 20(A) of the Securities Exchange Act of 1934 and SEC Rules 10b-5(a), 10b-5(b), and 10b-5(c) promulgated thereunder, on behalf of a putative class of purchasers of Globe Life Inc.'s securities from May 8, 2019 through April 10, 2024. The Consolidated Complaint added four additional executives as defendants and alleges that certain of Globe Life Inc.'s disclosures about financial performance and certain other public statements during the putative class period were materially false or misleading. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the individual defendants, Globe Life Inc. has agreed to indemnify the defendants for all expenses and losses related to the litigation, subject to the terms of those indemnification agreements. Defendants filed a motion to dismiss the litigation on December 3, 2024, which motion was denied on September 29, 2025. Globe Life Inc. plans to vigorously defend against the lawsuit. The outcome of litigation of this type is inherently uncertain, and there is always the possibility that a court rules in a manner that is adverse to the interests of Globe Life Inc. and the individual defendants. However, the amount of any such loss in that outcome cannot be reasonably estimated at this time.

Also pending in the Eastern District of Texas is a consolidated shareholder derivative suit that is closely related to the putative securities class action disclosed above (the "*City of Miami* Matter"). On November 7, 2024, Globe Life

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Inc. shareholder Jui Cheng Hsiao ("Hsiao") filed a shareholder derivative complaint against Globe Life Inc. as a nominal defendant, as well as certain current and former Globe Life Inc. executives and members of its Board of Directors. On November 14, 2024, Globe Life Inc. shareholder Gautam Jadhav ("Jadhav") filed a shareholder derivative complaint against the same set of defendants. Each shareholder derivative complaint asserts one claim for breach of fiduciary duty against the individual defendants and alleges that the individual defendants breached their fiduciary duties to Globe Life Inc. by causing or permitting Globe Life Inc. to make misleading statements about its performance and financial results. The allegations are substantially similar to the allegations made in the *City of Miami* Matter and derive from a short seller report. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the individual defendants, Globe Life Inc. has agreed to indemnify them for all expenses and losses related to the litigation, subject to the terms of those indemnification agreements. On January 3, 2025, the Court consolidated the two actions and appointed Hsiao and Jadhav as Lead Plaintiffs and their counsel as Lead Counsel for the consolidated derivative action (*In re Globe Life Inc. Stockholder Derivative Litigation*, Lead Case No. 4:24-cv-00993-ALM (E.D. Tex.)). On January 25, 2025, the Court granted the parties' joint motion to stay such proceedings pending the Court's resolution of the motion to dismiss filed by Globe Life Inc. in the *City of Miami* Matter. On October 14, 2025, the parties informed the Court that the motion to dismiss in the *City of Miami* Matter was denied and of their agreement for the terms of the stay to remain in place as they coordinated a schedule. On October 27, 2025 and December 5, 2025, the parties again notified the Court of their continued agreement for the terms of the stay to remain in place and further notified the Court of two related derivative cases filed in the Eastern District of Texas by Globe Life Inc. shareholders, as referenced below.

On November 19, 2025, Globe Life Inc. shareholder Plymouth County Retirement Association ("Plymouth") filed a Verified Shareholder Derivative Action Complaint in the United States District Court for the Eastern District of Texas against Globe Life Inc. as a nominal defendant, as well as certain current and former Globe Life Inc. executives and members of its Board of Directors (*Plymouth County Retirement Association v. Darden, et al*., No. 4:25-cv-01246-ALM (E.D. Tex.)). On November 21, 2025, Globe Life Inc. shareholder Catherine M. Sugarbaker Family Trust ("Sugarbaker") filed a Verified Shareholder Derivative Action Complaint against Globe Life Inc. as a nominal defendant, as well as certain current and former Globe Life Inc. executives and members of its Board of Directors (*Catherine M. Sugarbaker Family Trust v. Gary L. Coleman, et al*., No. 4:25-cv-01274-ALM (E.D. Tex.)). Both the *Plymouth* and the *Sugarbaker* shareholder derivative complaints assert a claim for breach of fiduciary duty against the individual defendants and allege that the individual defendants breached their fiduciary duties to Globe Life Inc. by causing or permitting Globe Life Inc. to make misleading statements about its performance and financial results, as well as a claim against the individual defendants under Section 14(A) of the Securities Exchange Act of 1934, and SEC Rule 14a-9 promulgated thereunder, for allegedly causing Globe Life Inc. to make false and misleading statements in its 2024 Proxy Statement and Notice of Annual Meeting of Shareholders. In addition, Plymouth's shareholder derivative complaint asserts claims for violation of § 10(b) of the Securities Exchange Act of 1934, and SEC Rule 10b-5(b) promulgated thereunder, on behalf of a putative class of purchasers of Globe Life Inc.'s securities from January 1, 2022 through April 11, 2024, alleging that certain of Globe Life Inc.'s disclosures about financial performance and certain other public statements during the putative class period were materially false or misleading, and that certain individuals traded in Globe Life Inc.'s securities while in possession of material non-public information. The allegations in both complaints are substantially similar to the allegations made in the *City of Miami* Matter and the consolidated federal derivative action and derive from a short seller report. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the individual defendants, Globe Life Inc. has agreed to indemnify them for all expenses and losses related to the *Plymouth* and *Sugarbaker* litigation, subject to the terms of those indemnification agreements. On December 11, 2025, defendants filed a notice of related case in the action filed by Plymouth to inform the Court that the matter should be consolidated with the consolidated federal derivative action. On December 9, 2025, Sugarbaker filed notices of related case in its own action and in the consolidated federal derivative action to inform the respective courts that Sugarbaker's action should be consolidated with the consolidated federal derivative action.

On September 19, 2025, a shareholder filed a derivative lawsuit in the Business Court for Dallas County, Texas, against Globe Life Inc. as a nominal defendant, as well as certain current and former Globe Life Inc. executives and members of its Board of Directors (*James E. Walker v. Gary L. Coleman, et al.*, Case No. 25-BC01B-0041). Like the consolidated shareholder derivative lawsuit disclosed above, this litigation is largely similar to the *City of Miami* Matter and derives in part from a short seller report. The petition asserts three causes of action relating to the 2019

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

through 2024 time period, including: (i) a breach of fiduciary duty claim for failing to provide adequate oversight to prevent purportedly widespread corporate misconduct including fraud, discrimination and harassment; (ii) a breach of fiduciary duty claim against certain individual defendants who allegedly engaged in insider trading; and (iii) a claim for wasting corporate assets by paying excessive compensation and/or bonuses to certain of its executive officers. The petition alleges that Globe Life Inc. was thus exposed to potential legal liability and costs, and that Globe Life Inc. repurchased shares at an artificially inflated price. The petition seeks monetary damages as well as restitution, governance reforms, and accountability for executives and board members. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the individual defendants, Globe Life Inc. has agreed to indemnify them for all expenses and losses related to the litigation, subject to the terms of those indemnification agreements. Globe Life Inc. intends to mount a robust defense against the litigation. Defendants filed a motion to dismiss the petition on November 20, 2025 for failure to plead demand futility, and a motion to stay the proceedings in the Texas Business Court pending final resolution of the related *City of Miami* Matter if the Court determines that demand futility is satisfied. On November 19, 2025, Plymouth filed a motion to intervene in the matter and requested that the Court stay the action in favor of the consolidated derivative action in the Eastern District of Texas, or in the alternative, to limit the preclusive effect of the Court's order on the motion to dismiss for lack of demand futility. On December 1, 2025, the Lead Plaintiffs in the consolidated federal derivative action (Hsiao and Jadhav) also filed a motion to intervene and stay the Texas Business Court proceedings in favor of their consolidated federal derivative action, or in the alternative, to limit the preclusive effect of the Court's order on the motion to dismiss the petition for lack of demand futility. On December 4, 2025, plaintiff James E. Walker Jr. ("Walker") filed a motion to strike Plymouth's motion to intervene. On December 15, 2025, Walker filed a motion to strike the motion to intervene filed by the Lead Plaintiffs in the consolidated federal derivative action. On February 5, 2026, the Court cancelled the hearing it had scheduled for February 6, 2026 to hear all of the above motions and stayed the case pending further order of the Court.

On September 26, 2024, Globe Life Inc. and its subsidiary, American Income Life Insurance Company, were notified by the Equal Employment Opportunity Commission (EEOC) that the EEOC conducted an investigation of charges filed against Globe Life Inc. and/or American Income Life Insurance Company by five former sales agents and one then-current sales agent. The EEOC asserts that there is reasonable cause to believe the six complainants were employees, not independent contractors, of Globe Life Inc. and/or American Income Life Insurance Company and were discriminated against on the basis of sex, and that one complainant was also discriminated against on the basis of race. In addition, the EEOC asserts that there is reasonable cause to believe that a class of female workers were employees, not independent contractors, and were subject to unlawful conduct which also constitutes a pattern-or-practice of discrimination. The EEOC's investigative findings are not binding on Globe Life Inc. The EEOC's procedures provide for a conciliation process that has concluded without achieving a resolution. The EEOC may elect to file a lawsuit in federal court on behalf of the workers based on the alleged statutory violations. However, since the conclusion of the conciliation process on October 31, 2024, Globe Life Inc. and American Income Life Insurance Company have not received any further communication from the EEOC regarding the aforementioned investigative findings. As a result, Globe Life Inc. intends to remove disclosures related to this matter from future filings unless there are any material updates.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 6—Policy Liabilities**

The liability for future policy benefits is determined based on the net level premium method, which requires the liability be calculated as the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders.

The following tables summarize balances and changes in the net liability for future policy benefits, before reinsurance, for traditional life long-duration contracts for the three years ended December 31, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Balance at January 1, 2023**  | $4273156 | $5910224 | $1094407 | $470741 | $11748528 |
| Beginning balance at original discount rates | 4246723 | 5680864 | 1066123 | 449209 | 11442919 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 14265 | 36170 | 5178 | 8419 | 64032 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (155293) | (306004) | (40961) | (18441) | (520699) |
| **Adjusted balance at January 1, 2023**  | 4105695 | 5411030 | 1030340 | 439187 | 10986252 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 733702 | 579363 | 127048 | 27959 | 1468072 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 200363 | 287615 | 54147 | 22804 | 564929 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (521521) | (613749) | (133704) | (46001) | (1314975) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | 5090 |  |  |  | 5090 |
| Ending balance at original discount rates | 4523329 | 5664259 | 1077831 | 443949 | 11709368 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 158559 | 388392 | 51885 | 34103 | 632939 |
| **Balance at December 31, 2023**  | $4681888 | $6052651 | $1129716 | $478052 | $12342307 |
| **Balance at January 1, 2024**  | $4681888 | $6052651 | $1129716 | $478052 | $12342307 |
| Beginning balance at original discount rates | 4523329 | 5664259 | 1077831 | 443949 | 11709368 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | (82348) | (28366) | (29292) | (982) | (140988) |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (229772) | (311659) | (42620) | (14436) | (598487) |
| **Adjusted balance at January 1, 2024**  | 4211209 | 5324234 | 1005919 | 428531 | 10969893 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 798952 | 491440 | 120683 | 23911 | 1434986 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 220959 | 292843 | 55198 | 22875 | 591875 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (551066) | (603605) | (134778) | (45041) | (1334490) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | (23344) |  |  |  | (23344) |
| Ending balance at original discount rates | 4656710 | 5504912 | 1047022 | 430276 | 11638920 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | (10793) | 117994 | 1425 | 9771 | 118397 |
| **Balance at December 31, 2024**  | $4645917 | $5622906 | $1048447 | $440047 | $11757317 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Balance at January 1, 2025**  | $4645917 | $5622906 | $1048447 | $440047 | $11757317 |
| Beginning balance at original discount rates | 4656710 | 5504912 | 1047022 | 430276 | 11638920 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | (136473) | (89711) | (52204) | (5160) | (283548) |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (216259) | (292327) | (37586) | (18358) | (564530) |
| **Adjusted balance at January 1, 2025**  | 4303978 | 5122874 | 957232 | 406758 | 10790842 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 730495 | 496861 | 110014 | 23370 | 1360740 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 225062 | 285411 | 52794 | 22044 | 585311 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (562742) | (584033) | (131197) | (43223) | (1321195) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | 13510 |  |  |  | 13510 |
| Ending balance at original discount rates | 4710303 | 5321113 | 988843 | 408949 | 11429208 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 81850 | 221503 | 19695 | 16389 | 339437 |
| **Balance at December 31, 2025**  | $4792153 | $5542616 | $1008538 | $425338 | $11768645 |

---

(1)Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.

(2)The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.

(3)Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in force business.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Balance at January 1, 2023**  | $9119104 | $9225451 | $3429256 | $3976150 | $25749961 |
| Beginning balance at original discount rates | 8409761 | 8477892 | 3272980 | 3403704 | 23564337 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 13344 | 34407 | 6156 | 11661 | 65568 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (164900) | (318687) | (46341) | (24195) | (554123) |
| **Adjusted balance at January 1, 2023**  | 8258205 | 8193612 | 3232795 | 3391170 | 23075782 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 733700 | 579365 | 127062 | 27959 | 1468086 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 452640 | 458587 | 174995 | 204083 | 1290305 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (396031) | (574812) | (196600) | (116353) | (1283796) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | 13319 |  |  |  | 13319 |
| Ending balance at original discount rates | 9061833 | 8656752 | 3338252 | 3506859 | 24563696 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 1101794 | 1057764 | 267140 | 732764 | 3159462 |
| **Balance at December 31, 2023**  | $10163627 | $9714516 | $3605392 | $4239623 | $27723158 |
| **Balance at January 1, 2024**  | $10163627 | $9714516 | $3605392 | $4239623 | $27723158 |
| Beginning balance at original discount rates | 9061833 | 8656752 | 3338252 | 3506859 | 24563696 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | (104498) | (50106) | (41836) | (2027) | (198467) |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (251310) | (335087) | (50759) | (20954) | (658110) |
| **Adjusted balance at January 1, 2024**  | 8706025 | 8271559 | 3245657 | 3483878 | 23707119 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 794225 | 491437 | 120702 | 23912 | 1430276 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 492966 | 474451 | 178617 | 210344 | 1356378 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (426723) | (576499) | (204757) | (136066) | (1344045) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | (57904) |  |  |  | (57904) |
| Ending balance at original discount rates | 9508589 | 8660948 | 3340219 | 3582068 | 25091824 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 362103 | 464164 | 37298 | 378895 | 1242460 |
| **Balance at December 31, 2024**  | $9870692 | $9125112 | $3377517 | $3960963 | $26334284 |
| **Balance at January 1, 2025**  | $9870692 | $9125112 | $3377517 | $3960963 | $26334284 |
| Beginning balance at original discount rates | 9508589 | 8660948 | 3340219 | 3582068 | 25091824 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | (189172) | (129189) | (89154) | (9081) | (416596) |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (240487) | (319650) | (49507) | (27496) | (637140) |
| **Adjusted balance at January 1, 2025**  | 9078930 | 8212109 | 3201558 | 3545491 | 24038088 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 730489 | 496856 | 110030 | 23370 | 1360745 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 514553 | 476278 | 177656 | 214860 | 1383347 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (451405) | (568314) | (197354) | (140329) | (1357402) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate | 32864 |  |  |  | 32864 |
| Ending balance at original discount rates | 9905431 | 8616929 | 3291890 | 3643392 | 25457642 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 452623 | 588687 | 79285 | 410608 | 1531203 |
| **Balance at December 31, 2025**  | $10358054 | $9205616 | $3371175 | $4054000 | $26988845 |

---

(1)Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.

(2)The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.

(3)Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $4538504 | $2992493 | $2260421 | $3062910 | $12854328 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | 943235 | 669372 | 215255 | 698661 | 2526523 |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 297 | 3315 | 5764 | 62 | 9438 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 5482036 | 3665180 | 2481440 | 3761633 | 15390289 |
| &nbsp;&nbsp;Reinsurance recoverable | (141) |  | (7719) | (37848) | (45708) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $5481895 | $3665180 | $2473721 | $3723785 | $15344581 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $4851879 | $3156036 | $2293197 | $3151792 | $13452904 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | 372896 | 346170 | 35873 | 369124 | 1124063 |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 122 | 18 |  | 33 | 173 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 5224897 | 3502224 | 2329070 | 3520949 | 14577140 |
| &nbsp;&nbsp;Reinsurance recoverable | (167) |  | (7953) | (35368) | (43488) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $5224730 | $3502224 | $2321117 | $3485581 | $14533652 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $5195128 | $3295816 | $2303047 | $3234443 | $14028434 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | 370773 | 367184 | 59590 | 394219 | 1191766 |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 160 |  |  | 26 | 186 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 5566061 | 3663000 | 2362637 | 3628688 | 15220386 |
| &nbsp;&nbsp;Reinsurance recoverable | (184) |  | (8103) | (14) | (8301) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $5565877 | $3663000 | $2354534 | $3628674 | $15212085 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables summarize balances and changes in the net liability for future policy benefits for long-duration health contracts for the three years ended December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** | **Present value of expected future net premiums** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **DTC** | **Total** |
| **Balance at January 1, 2023**  | $2908501 | $1594992 | $423490 | $190296 | $90143 | $5207422 |
| Beginning balance at original discount rates | 2941262 | 1729219 | 415442 | 192631 | 87751 | 5366305 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 466883 | (30255) | (56964) | (6061) | 16553 | 390156 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (27178) | (69878) | (36850) | (11152) | (2850) | (147908) |
| **Adjusted balance at January 1, 2023**  | 3380967 | 1629086 | 321628 | 175418 | 101454 | 5608553 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 377097 | 266375 | 59768 | 39825 | 14467 | 757532 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 139824 | 67743 | 18255 | 8528 | 4616 | 238966 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (272085) | (180031) | (51081) | (22325) | (10657) | (536179) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | 423 |  | 423 |
| Ending balance at original discount rates | 3625803 | 1783173 | 348570 | 201869 | 109880 | 6069295 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 71968 | (71432) | 9902 | 4512 | 5483 | 20433 |
| **Balance at December 31, 2023**  | $3697771 | $1711741 | $358472 | $206381 | $115363 | $6089728 |
| **Balance at January 1, 2024**  | $3697771 | $1711741 | $358472 | $206381 | $115363 | $6089728 |
| Beginning balance at original discount rates | 3625803 | 1783173 | 348570 | 201869 | 109880 | 6069295 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 9892 | (8117) | (3463) | 12207 | 4449 | 14968 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (43846) | (56720) | (29652) | (16088) | (2937) | (149243) |
| **Adjusted balance at January 1, 2024**  | 3591849 | 1718336 | 315455 | 197988 | 111392 | 5935020 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 480412 | 265166 | 58538 | 44350 | 26149 | 874615 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 174269 | 75188 | 16566 | 9787 | 5838 | 281648 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (297675) | (190817) | (52284) | (24852) | (11460) | (577088) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | (2132) |  | (2132) |
| Ending balance at original discount rates | 3948855 | 1867873 | 338275 | 225141 | 131919 | 6512063 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | (63325) | (132998) | (1156) | (1894) | 1458 | (197915) |
| **Balance at December 31, 2024**  | $3885530 | $1734875 | $337119 | $223247 | $133377 | $6314148 |
| **Balance at January 1, 2025**  | $3885530 | $1734875 | $337119 | $223247 | $133377 | $6314148 |
| Beginning balance at original discount rates | 3948855 | 1867873 | 338275 | 225141 | 131919 | 6512063 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 625460 | (72130) | 29 | 12588 | 25985 | 591932 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (30520) | (52503) | (25751) | (17214) | (1304) | (127292) |
| **Adjusted balance at January 1, 2025**  | 4543795 | 1743240 | 312553 | 220515 | 156600 | 6976703 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 858558 | 277165 | 56531 | 39969 | 51254 | 1283477 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 207580 | 79122 | 15883 | 10912 | 7481 | 320978 |
| &nbsp;&nbsp;Net premiums collected<sup>(3)</sup> | (336658) | (203724) | (53553) | (27353) | (13886) | (635174) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | 1257 |  | 1257 |
| Ending balance at original discount rates | 5273275 | 1895803 | 331414 | 245300 | 201449 | 7947241 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 56806 | (73791) | 5429 | 3100 | 5874 | (2582) |
| **Balance at December 31, 2025**  | $5330081 | $1822012 | $336843 | $248400 | $207323 | $7944659 |

---

(1)Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.

(2)The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.

(3)Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in force business.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** | **Present value of expected future policy benefits** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **DTC** | **Total** |
| **Balance at January 1, 2023**  | $3046829 | $3005664 | $941574 | $312750 | $87532 | $7394349 |
| Beginning balance at original discount rates | 3080633 | 3336344 | 904865 | 303713 | 85212 | 7710767 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 464652 | (32428) | (60437) | (6407) | 15930 | 381310 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (26718) | (74797) | (36910) | (12661) | (3325) | (154411) |
| **Adjusted balance at January 1, 2023**  | 3518567 | 3229119 | 807518 | 284645 | 97817 | 7937666 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 376573 | 266375 | 59158 | 39825 | 14446 | 756377 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 147082 | 134107 | 45614 | 15070 | 4616 | 346489 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (300692) | (122912) | (95471) | (24987) | (12378) | (556440) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | 878 |  | 878 |
| Ending balance at original discount rates | 3741530 | 3506689 | 816819 | 315431 | 104501 | 8484970 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 72798 | (190809) | 48989 | 20073 | 4981 | (43968) |
| **Balance at December 31, 2023**  | $3814328 | $3315880 | $865808 | $335504 | $109482 | $8441002 |
| **Balance at January 1, 2024**  | $3814328 | $3315880 | $865808 | $335504 | $109482 | $8441002 |
| Beginning balance at original discount rates | 3741530 | 3506689 | 816819 | 315431 | 104501 | 8484970 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 10680 | (5054) | (2775) | 20293 | 7733 | 30877 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (35532) | (63595) | (30258) | (18601) | (2420) | (150406) |
| **Adjusted balance at January 1, 2024**  | 3716678 | 3438040 | 783786 | 317123 | 109814 | 8365441 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 479653 | 265166 | 57862 | 44353 | 26116 | 873150 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 180235 | 147615 | 42809 | 16577 | 5837 | 393073 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (349706) | (138777) | (93317) | (25214) | (13792) | (620806) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | (4128) |  | (4128) |
| Ending balance at original discount rates | 4026860 | 3712044 | 791140 | 348711 | 127975 | 9006730 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | (66428) | (375498) | 13555 | 6592 | 1302 | (420477) |
| **Balance at December 31, 2024**  | $3960432 | $3336546 | $804695 | $355303 | $129277 | $8586253 |
| **Balance at January 1, 2025**  | $3960432 | $3336546 | $804695 | $355303 | $129277 | $8586253 |
| Beginning balance at original discount rates | 4026860 | 3712044 | 791140 | 348711 | 127975 | 9006730 |
| &nbsp;&nbsp;Effect of changes in assumptions on future cash flows | 622917 | (79615) | 210 | 16611 | 22160 | 582283 |
| &nbsp;&nbsp;Effect of actual variances from expected experience | (38119) | (60780) | (27632) | (21464) | (1653) | (149648) |
| **Adjusted balance at January 1, 2025**  | 4611658 | 3571649 | 763718 | 343858 | 148482 | 9439365 |
| &nbsp;&nbsp;Issuances<sup>(1)</sup> | 857105 | 277163 | 55935 | 39967 | 51187 | 1281357 |
| &nbsp;&nbsp;Interest accrual<sup>(2)</sup> | 210924 | 157549 | 41117 | 18370 | 7481 | 435441 |
| &nbsp;&nbsp;Benefit payments<sup>(3)</sup> | (383504) | (160713) | (94806) | (24496) | (15878) | (679397) |
| &nbsp;&nbsp;Effect of changes in the foreign exchange rate |  |  |  | 2383 |  | 2383 |
| Ending balance at original discount rates | 5296183 | 3845648 | 765964 | 380082 | 191272 | 10479149 |
| &nbsp;&nbsp;Effect of change from original to current discount rates | 49270 | (258740) | 27891 | 13517 | 5460 | (162602) |
| **Balance at December 31, 2025**  | $5345453 | $3586908 | $793855 | $393599 | $196732 | $10316547 |

---

(1)Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.

(2)The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.

(3)Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period based on the revised expected assumptions.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** | **Net liability for future policy benefits as of December 31, 2023** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **Direct to Consumer** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $115727 | $1723516 | $468249 | $113562 | $(5379) | $2415675 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | 830 | (119377) | 39087 | 15561 | (502) | (64401) |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 10980 | 84 | 9567 | 857 | 6653 | 28141 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 127537 | 1604223 | 516903 | 129980 | 772 | 2379415 |
| &nbsp;&nbsp;Reinsurance recoverable | (3287) | (10718) | (1317) |  |  | (15322) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $124250 | $1593505 | $515586 | $129980 | $772 | $2364093 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** | **Net liability for future policy benefits as of December 31, 2024** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **Direct to Consumer** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $78005 | $1844171 | $452865 | $123570 | $(3944) | $2494667 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | (3103) | (242500) | 14711 | 8486 | (156) | (222562) |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 24920 | 22 | 10310 | 814 | 4865 | 40931 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 99822 | 1601693 | 477886 | 132870 | 765 | 2313036 |
| &nbsp;&nbsp;Reinsurance recoverable | (2768) |  | (986) |  |  | (3754) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $97054 | $1601693 | $476900 | $132870 | $765 | $2309282 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** | **Net liability for future policy benefits as of December 31, 2025** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **Direct to Consumer** | **Total** |
| **Net liability for future policy benefits at original discount rates**  | $22908 | $1949845 | $434550 | $134782 | $(10177) | $2531908 |
| &nbsp;&nbsp;Effect of changes in discount rate assumptions | (7536) | (184949) | 22462 | 10417 | (414) | (160020) |
| &nbsp;&nbsp;Other adjustments<sup>(1)</sup> | 63806 | 122 | 14274 | 766 | 11216 | 90184 |
| **Net liability for future policy benefits, after other adjustments, at current discount rates**  | 79178 | 1765018 | 471286 | 145965 | 625 | 2462072 |
| &nbsp;&nbsp;Reinsurance recoverable | (2144) |  | (729) |  |  | (2873) |
| **Net liability for future policy benefits, after reinsurance recoverable, at current discount rates**  | $77034 | $1765018 | $470557 | $145965 | $625 | $2459199 |

---

(1)Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Remeasurement Gain or Loss</u>*—In accordance with the accounting guidance, the Company reviews, and updates as necessary, its assumptions utilized in the calculation of the liability for future benefits annually in the third quarter and recalculates the net premium ratio. The revised net premium ratio is used to update the liability for future policy benefits as of the beginning of the current reporting period, and is compared to the liability using prior cash flow assumptions. The difference is recorded as a component of the remeasurement gain or loss for the current period, along with the effect of the difference between actual and expected experience for the period. The total remeasurement gain or loss is within life and health policyholder benefits included in the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436).* 

The following tables include the total remeasurement gain or loss, bifurcated between the gain or loss due to differences between actual and expected experience and the amount due to assumption updates, for the three years ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** | **2023** |
| **Life Remeasurement Gain (Loss)—Experience:** |  |  |  |
| &nbsp;&nbsp;American Income | $22903 | $19606 | $9430 |
| &nbsp;&nbsp;Direct to Consumer | 25121 | 21681 | 12201 |
| &nbsp;&nbsp;Liberty National | 6327 | 3966 | 5013 |
| &nbsp;&nbsp;Other | 6934 | 4872 | 4760 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Life Remeasurement Gain (Loss)—Experience**  | 61285 | 50125 | 31404 |
| **Life Remeasurement Gain (Loss)—Assumption Updates:** |  |  |  |
| &nbsp;&nbsp;American Income | 52731 | 21974 | 308 |
| &nbsp;&nbsp;Direct to Consumer | 39480 | 21744 | 1763 |
| &nbsp;&nbsp;Liberty National | 35068 | 12224 | (1248) |
| &nbsp;&nbsp;Other | 3647 | 904 | (2836) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Life Remeasurement Gain (Loss)—Assumption Updates**  | 130926 | 56846 | (2013) |
| **Total Life Remeasurement Gain (Loss)**  | 192211 | 106971 | 29391 |
| **Health Remeasurement Gain (Loss)—Experience:** |  |  |  |
| &nbsp;&nbsp;United American | 576 | (4890) | (134) |
| &nbsp;&nbsp;Family Heritage | 7821 | 6756 | 4638 |
| &nbsp;&nbsp;Liberty National | 4047 | 2640 | 628 |
| &nbsp;&nbsp;American Income | 4186 | 2742 | 1461 |
| &nbsp;&nbsp;Direct to Consumer | 106 | 22 | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Health Remeasurement Gain (Loss)—Experience**  | 16736 | 7270 | 6616 |
| **Health Remeasurement Gain (Loss)—Assumption Updates:** |  |  |  |
| &nbsp;&nbsp;United American | 279 | 1205 | 762 |
| &nbsp;&nbsp;Family Heritage | 7492 | (3063) | 2173 |
| &nbsp;&nbsp;Liberty National | (339) | (234) | 2171 |
| &nbsp;&nbsp;American Income | (4094) | (8036) | 119 |
| &nbsp;&nbsp;Direct to Consumer | 19 | (373) | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Health Remeasurement Gain (Loss)—Assumption Updates**  | 3357 | (10501) | 5233 |
| **Total Health Remeasurement Gain (Loss)**  | $20093 | $(3231) | $11849 |

---

The Company performed its annual review of assumptions during the third quarter, resulting in favorable changes to its mortality and lapse assumptions on life and health. The assumption review process of the life and health segments resulted in a $134.3 million net remeasurement gain ($130.9 million and $3.4 million gains related to life and health, respectively) before tax for the year ended December 31, 2025 as compared to a $46.3 million net remeasurement gain ($56.8 million gain and $10.5 million loss related to life and health, respectively) before tax in 2024, and a $3.2 million net remeasurement gain ($2.0 million loss and $5.2 million gain related to life and health, respectively) before tax in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

For the year ended December 31, 2025, life assumption changes reflect continued favorable mortality experience along with slightly higher lapse rates which resulted in lower life policy obligations compared to our previous assumptions anticipated. Health assumption changes reflect slightly higher lapse rates and benefit enhancements implemented last year.

Excluding the impact of assumption changes, the Company's results for actual variances from expected experience for both life and health produced a $78.0 million net remeasurement gain ($61.3 million and $16.7 million gains related to life and health, respectively) before tax for the year ended December 31, 2025, a $57.4 million net remeasurement gain before tax in 2024 ($50.1 million and $7.3 million gains related to life and health, respectively), and a $38.0 million net remeasurement gain ($31.4 million and $6.6 million gains related to life and health, respectively) before tax in 2023.

The following table reconciles the liability for future policy benefits to the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)* as of December 31, 2025, 2024, and 2023:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At Original Discount Rates** | **At Original Discount Rates** | **At Original Discount Rates** | **At Current Discount Rates** | **At Current Discount Rates** | **At Current Discount Rates** |
| | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Life<sup>(1)</sup>: |  |  |  |  |  |  |
| &nbsp;&nbsp;American Income | $5195264 | $4851995 | $4538775 | $5566061 | $5224897 | $5482036 |
| &nbsp;&nbsp;Direct to Consumer | 3295819 | 3156039 | 2992493 | 3663000 | 3502224 | 3665180 |
| &nbsp;&nbsp;Liberty National | 2303047 | 2293197 | 2260421 | 2362637 | 2329070 | 2481440 |
| &nbsp;&nbsp;Other | 3234468 | 3151824 | 3062966 | 3628688 | 3520949 | 3761633 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net liability for future policy benefits—long duration life | 14028598 | 13453055 | 12854655 | 15220386 | 14577140 | 15390289 |
| Health<sup>(1)</sup>: |  |  |  |  |  |  |
| &nbsp;&nbsp;United American | 79700 | 100480 | 124021 | 79178 | 99822 | 127537 |
| &nbsp;&nbsp;Family Heritage | 1949955 | 1844186 | 1723581 | 1765018 | 1601693 | 1604223 |
| &nbsp;&nbsp;Liberty National | 447908 | 462712 | 476559 | 471286 | 477886 | 516903 |
| &nbsp;&nbsp;American Income | 135514 | 124309 | 114407 | 145965 | 132870 | 129980 |
| &nbsp;&nbsp;Direct to Consumer | 603 | 738 | 737 | 625 | 765 | 772 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net liability for future policy benefits—long duration health | 2613680 | 2532425 | 2439305 | 2462072 | 2313036 | 2379415 |
| Deferred profit liability | 186088 | 178199 | 174717 | 186088 | 178199 | 174717 |
| Deferred annuity | 580669 | 656573 | 773039 | 580669 | 656573 | 773039 |
| Interest sensitive life | 711687 | 723389 | 732948 | 711687 | 723389 | 732948 |
| Other | 8784 | 8923 | 9951 | 8785 | 8926 | 9945 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total future policy benefits**  | $18129506 | $17552564 | $16984615 | $19169687 | $18457263 | $19460353 |

---

(1)Balances are presented net of the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables provide the weighted-average original and current discount rates for the liability for future policy benefits and the additional insurance liabilities as of December 31, 2025, 2024, and 2023:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Original discount rate** | **Current discount rate** | **Original discount rate** | **Current discount rate** | **Original discount rate** | **Current discount rate** |
| **Life** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 5.7% | 5.4% | 5.7% | 5.4% | 5.7% | 4.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 6.0% | 5.4% | 6.0% | 5.5% | 6.0% | 5.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 5.6% | 5.4% | 5.6% | 5.5% | 5.6% | 5.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 6.2% | 5.5% | 6.2% | 5.5% | 6.2% | 5.0% |
| **Health** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United American | 5.1% | 5.2% | 5.1% | 5.2% | 5.1% | 4.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Family Heritage | 4.2% | 5.3% | 4.2% | 5.3% | 4.3% | 4.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 5.8% | 5.2% | 5.8% | 5.4% | 5.8% | 4.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 5.8% | 5.2% | 5.8% | 5.2% | 5.8% | 4.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 5.1% | 5.2% | 5.1% | 5.2% | 5.1% | 4.8% |

---

The following table provides the weighted-average durations of the liability for future policy benefits and the additional insurance liabilities as of December 31, 2025, 2024, and 2023:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **At original discount rates** | **At current discount rates** | **At original discount rates** | **At current discount rates** | **At original discount rates** | **At current discount rates** |
| **Life** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 22.32 | 22.06 | 22.73 | 22.76 | 23.01 | 23.45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 18.67 | 19.38 | 19.24 | 20.31 | 19.58 | 21.21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 15.26 | 15.04 | 15.30 | 15.33 | 15.13 | 15.81 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 15.56 | 16.16 | 15.99 | 16.92 | 16.26 | 17.92 |
| **Health** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United American | 12.43 | 11.13 | 11.72 | 10.65 | 11.46 | 10.89 |
| &nbsp;&nbsp;&nbsp;&nbsp;Family Heritage | 16.25 | 14.86 | 15.33 | 14.23 | 14.99 | 14.54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 9.53 | 9.33 | 9.31 | 9.19 | 9.17 | 9.49 |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 13.25 | 13.12 | 12.49 | 12.56 | 12.21 | 12.84 |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 12.43 | 11.13 | 11.72 | 10.65 | 11.46 | 10.89 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables summarize the amount of gross premiums and interest related to long duration life and health contracts that are recognized on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* for the three years ended December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **Year Ended<br>December 31, 2025** | **Year Ended<br>December 31, 2025** | **Year Ended<br>December 31, 2024** | **Year Ended<br>December 31, 2024** | **Year Ended<br>December 31, 2023** | **Year Ended<br>December 31, 2023** |
| | **Gross<br> Premiums** | **Required Interest** <br>**Expense** | **Gross<br> Premiums** | **Required Interest** <br>**Expense** | **Gross<br> Premiums** | **Required Interest** <br>**Expense** |
| American Income | $1790023 | $289491 | $1696918 | $272007 | $1587304 | $252277 |
| Direct to Consumer | 970233 | 190793 | 977302 | 181470 | 979739 | 170745 |
| Liberty National | 387167 | 124370 | 367278 | 122727 | 345196 | 120083 |
| Other | 199746 | 192340 | 202234 | 185619 | 205998 | 179513 |
| &nbsp;&nbsp;Total | $3347169 | $796994 | $3243732 | $761823 | $3118237 | $722618 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **Year Ended<br>December 31, 2025** | **Year Ended<br>December 31, 2025** | **Year Ended<br>December 31, 2024** | **Year Ended<br>December 31, 2024** | **Year Ended<br>December 31, 2023** | **Year Ended<br>December 31, 2023** |
| | **Gross<br> Premiums** | **Required Interest** <br>**Expense** | **Gross<br> Premiums** | **Required Interest** <br>**Expense** | **Gross<br> Premiums** | **Required Interest** <br>**Expense** |
| United American | $493272 | $3133 | $439125 | $5739 | $401834 | $7002 |
| Family Heritage | 468063 | 78425 | 427640 | 71900 | 396211 | 65892 |
| Liberty National | 189690 | 25130 | 189650 | 26144 | 187095 | 27248 |
| American Income | 119209 | 7457 | 117644 | 6790 | 113605 | 6542 |
| Direct to Consumer | 17073 |  | 15033 |  | 14283 |  |
| &nbsp;&nbsp;Total | $1287307 | $114145 | $1189092 | $110573 | $1113028 | $106684 |

---

Gross premiums are included within life and health premium on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*, while the related interest expense is included in life and health policyholder benefits.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables provide the undiscounted and discounted expected future net premiums, expected future gross premiums, and expected future policy benefits, at both original and current discount rates, for life and health contracts for the three years ended December 31, 2025:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2023** | **As of December 31, 2023** | **As of December 31, 2023** |
| | **Not discounted** | **At original discount rates** | **At current discount rates** | **Not discounted** | **At original discount rates** | **At current discount rates** | **Not discounted** | **At original discount rates** | **At current discount rates** |
| **American Income** | | | | | | | | | |
| &nbsp;&nbsp;PV of expected future gross premiums | $26709794 | $15068860 | $15424780 | $25492032 | $14410088 | $14471277 | $24265464 | $13695495 | $14264077 |
| &nbsp;&nbsp;PV of expected future net premiums | 8350443 | 4710303 | 4792153 | 8233110 | 4656710 | 4645917 | 8001107 | 4523329 | 4681888 |
| &nbsp;&nbsp;PV of expected future policy benefits | 33211854 | 9905431 | 10358054 | 31831310 | 9508589 | 9870692 | 30623947 | 9061833 | 10163627 |
| **DTC** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $17249507 | $9027497 | $9390147 | $17372446 | $9077304 | $9258880 | $17506091 | $9150049 | $9761706 |
| &nbsp;&nbsp;PV of expected future net premiums | 10110468 | 5321113 | 5542616 | 10481376 | 5504912 | 5622906 | 10774655 | 5664259 | 6052651 |
| &nbsp;&nbsp;PV of expected future policy benefits | 25607204 | 8616929 | 9205616 | 25841419 | 8660948 | 9125112 | 25723752 | 8656752 | 9714516 |
| **Liberty National** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $4980287 | $2900642 | $2917146 | $4837598 | $2817204 | $2775304 | $4660783 | $2720264 | $2784916 |
| &nbsp;&nbsp;PV of expected future net premiums | 1744779 | 988843 | 1008538 | 1849200 | 1047022 | 1048447 | 1897696 | 1077831 | 1129716 |
| &nbsp;&nbsp;PV of expected future policy benefits | 9008086 | 3291890 | 3371175 | 9073624 | 3340219 | 3377517 | 8905815 | 3338252 | 3605392 |
| **Other** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $3473311 | $1783847 | $1912248 | $3627855 | $1844670 | $1942849 | $3726111 | $1889930 | $2088668 |
| &nbsp;&nbsp;PV of expected future net premiums | 838315 | 408949 | 425338 | 885362 | 430276 | 440047 | 910786 | 443949 | 478052 |
| &nbsp;&nbsp;PV of expected future policy benefits | 12293519 | 3643392 | 4054000 | 12466943 | 3582068 | 3960963 | 12431963 | 3506859 | 4239623 |
| **Total** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $52412899 | $28780846 | $29644321 | $51329931 | $28149266 | $28448310 | $50158449 | $27455738 | $28899367 |
| &nbsp;&nbsp;PV of expected future net premiums | 21044005 | 11429208 | 11768645 | 21449048 | 11638920 | 11757317 | 21584244 | 11709368 | 12342307 |
| &nbsp;&nbsp;PV of expected future policy benefits | 80120663 | 25457642 | 26988845 | 79213296 | 25091824 | 26334284 | 77685477 | 24563696 | 27723158 |

---

As of December 31, 2025 for the life segment using current discount rates, the Company anticipates $29.6 billion of expected future gross premiums and $11.8 billion of expected future net premiums. As of December 31, 2024 and 2023 using current discount rates, the Company anticipated $28.4 billion and $28.9 billion of expected future gross premiums and $11.8 billion and $12.3 billion in expected future net premiums, respectively. For each respective period, only expected future net premiums are included in the determination of the liability for future policy benefits on the balance sheet, while the difference between the expected future gross premiums and the expected future net premiums is not.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2023** | **As of December 31, 2023** | **As of December 31, 2023** |
| | **Not discounted** | **At original discount rates** | **At current discount rates** | **Not discounted** | **At original discount rates** | **At current discount rates** | **Not discounted** | **At original discount rates** | **At current discount rates** |
| **United American** | | | | | | | | | |
| &nbsp;&nbsp;PV of expected future gross premiums | $12730369 | $7651632 | $7732883 | $9350851 | $5738332 | $5643454 | $8682707 | $5295148 | $5396402 |
| &nbsp;&nbsp;PV of expected future net premiums | 8782379 | 5273275 | 5330081 | 6442648 | 3948855 | 3885530 | 5955294 | 3625803 | 3697771 |
| &nbsp;&nbsp;PV of expected future policy benefits | 8864386 | 5296183 | 5345453 | 6584800 | 4026860 | 3960432 | 6148565 | 3741530 | 3814328 |
| **Family Heritage** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $7541348 | $4394554 | $4239286 | $7242884 | $4220293 | $3938234 | $6739913 | $3982571 | $3844287 |
| &nbsp;&nbsp;PV of expected future net premiums | 3238994 | 1895803 | 1822012 | 3188017 | 1867873 | 1734875 | 2997954 | 1783173 | 1711741 |
| &nbsp;&nbsp;PV of expected future policy benefits | 7540691 | 3845648 | 3586908 | 7176690 | 3712044 | 3336546 | 6655694 | 3506689 | 3315880 |
| **Liberty National** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $2004452 | $1277288 | $1320341 | $2039441 | $1299234 | $1316967 | $2089005 | $1325869 | $1390066 |
| &nbsp;&nbsp;PV of expected future net premiums | 492640 | 331414 | 336843 | 500297 | 338275 | 337119 | 518008 | 348570 | 358472 |
| &nbsp;&nbsp;PV of expected future policy benefits | 1345596 | 765964 | 793855 | 1374959 | 791140 | 804695 | 1413211 | 816819 | 865808 |
| **American Income** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $2001778 | $1059232 | $1100150 | $1770862 | $992641 | $1012919 | $1768231 | $991448 | $1047348 |
| &nbsp;&nbsp;PV of expected future net premiums | 462290 | 245300 | 248400 | 400512 | 225141 | 223247 | 359248 | 201869 | 206381 |
| &nbsp;&nbsp;PV of expected future policy benefits | 821453 | 380082 | 393599 | 709637 | 348711 | 355303 | 640326 | 315431 | 335504 |
| **Direct to Consumer** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $419608 | $249370 | $257172 | $248646 | $157812 | $159862 | $236776 | $149119 | $156612 |
| &nbsp;&nbsp;PV of expected future net premiums | 339996 | 201449 | 207323 | 208577 | 131919 | 133377 | 174738 | 109880 | 115363 |
| &nbsp;&nbsp;PV of expected future policy benefits | 316089 | 191272 | 196732 | 204099 | 127975 | 129277 | 163087 | 104501 | 109482 |
| **Total** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;PV of expected future gross premiums | $24697555 | $14632076 | $14649832 | $20652684 | $12408312 | $12071436 | $19516632 | $11744155 | $11834715 |
| &nbsp;&nbsp;PV of expected future net premiums | 13316299 | 7947241 | 7944659 | 10740051 | 6512063 | 6314148 | 10005242 | 6069295 | 6089728 |
| &nbsp;&nbsp;PV of expected future policy benefits | 18888215 | 10479149 | 10316547 | 16050185 | 9006730 | 8586253 | 15020883 | 8484970 | 8441002 |

---

As of December 31, 2025 for the health segment using current discount rates, the Company anticipates $14.6 billion of expected future gross premiums and $7.9 billion of expected future net premiums. As of December 31, 2024 and 2023 using current discount rates, the Company anticipated $12.1 billion and $11.8 billion of expected future gross premiums and $6.3 billion and $6.1 billion in expected future net premiums, respectively. For each respective period, only expected future net premiums are included in the determination of the liability for future policy benefits on the balance sheet, while the difference between the expected future gross premiums and the expected future net premiums is not.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following table summarizes the balances of, and changes in, policyholders' account balances for the three years ended December 31, 2025:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** | **Policyholders' Account Balances** |
| | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
| | **Interest Sensitive Life** | **Deferred Annuity**<sup>(1)</sup> | **Other Policy-holders' Funds** | **Interest Sensitive Life** | **Deferred Annuity** | **Other Policy-holders' Funds** | **Interest Sensitive Life** | **Deferred Annuity** | **Other Policy-holders' Funds** |
| **Balance at January 1,**  | $723389 | $656573 | $468604 | $732948 | $773039 | $236958 | $739105 | $954318 | $123236 |
| &nbsp;&nbsp;Issuances |  | 1040 |  |  | 875 |  |  | 896 |  |
| &nbsp;&nbsp;Premiums and deposits received | 19653 | 12584 | 191812 | 20928 | 11332 | 240802 | 22036 | 13209 | 122136 |
| &nbsp;&nbsp;Policy charges | (11730) |  |  | (12295) |  |  | (12926) |  |  |
| &nbsp;&nbsp;Surrenders and withdrawals | (23007) | (64145) | (132566) | (22479) | (107707) | (13897) | (21215) | (165584) | (13042) |
| &nbsp;&nbsp;Benefit payments | (30565) | (46070) |  | (30512) | (43955) |  | (29909) | (57937) |  |
| &nbsp;&nbsp;Interest credited | 27344 | 20589 | 22617 | 27790 | 23634 | 21165 | 28320 | 28150 | 9314 |
| &nbsp;&nbsp;Other | 6603 | 98 | (18420) | 7009 | (645) | (16424) | 7537 | (13) | (4686) |
| **Balance at December 31,**  | $711687 | $580669 | $532047 | $723389 | $656573 | $468604 | $732948 | $773039 | $236958 |
| Weighted-average credit rate | 3.81% | 3.33% | 4.52% | 3.82% | 3.31% | 6.00% | 3.85% | 3.26% | 5.17% |
| Net amount at risk | $1560633 | N/A | N/A | $1663496 | N/A | N/A | $1766170 | N/A | N/A |
| Cash surrender value | $667217 | $580669 | $532047 | $677111 | $656573 | $468604 | $671596 | $773039 | $236958 |

---

(1) At December 31, 2025, $400 million has been reinsured with third-party reinsurers under existing reinsurance agreements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following tables present the policyholders' account balances by range of guaranteed minimum crediting rates and the related range of difference, if any, in basis points between rates being credited to policyholders and the respective guaranteed minimums as of December 31, 2025, 2024, and 2023:

---

| | | | |
|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
|<br>**Range of guaranteed minimum crediting rates** | **Interest Sensitive Life** | **Deferred Annuity**<sup>(1)</sup> | **Other Policyholders' Funds** |
| **At guaranteed minimum:** | | | |
| &nbsp;&nbsp;Less than 3.00% | $— | $2115 | $438586 |
| &nbsp;&nbsp;3.00%-3.99% | 29355 | 406105 | 3128 |
| &nbsp;&nbsp;4.00%-4.99% | 592935 | 172449 | 55299 |
| &nbsp;&nbsp;Greater than 5.00% | 89397 |  | 35034 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | 711687 | 580669 | 532047 |
| **51-150 basis points above:** |  |  |  |
| &nbsp;&nbsp;Less than 3.00% |  |  |  |
| &nbsp;&nbsp;3.00%-3.99% |  |  |  |
| &nbsp;&nbsp;4.00%-4.99% |  |  |  |
| &nbsp;&nbsp;Greater than 5.00% |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Grand Total**  | $711687 | $580669 | $532047 |

---

(1) At December 31, 2025, $400 million has been reinsured with third-party reinsurers under existing reinsurance agreements.

---

| | | | |
|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
|<br>**Range of guaranteed minimum crediting rates** | **Interest Sensitive Life** | **Deferred Annuity**<sup>(1)</sup> | **Other Policyholders' Funds** |
| **At guaranteed minimum:** | | | |
| &nbsp;&nbsp;Less than 3.00% | $— | $1812 | $373584 |
| &nbsp;&nbsp;3.00%-3.99% | 29251 | 473191 | 3182 |
| &nbsp;&nbsp;4.00%-4.99% | 604412 | 181570 | 55876 |
| &nbsp;&nbsp;Greater than 5.00% | 89726 |  | 35962 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | 723389 | 656573 | 468604 |
| **51-150 basis points above:** |  |  |  |
| &nbsp;&nbsp;Less than 3.00% |  |  |  |
| &nbsp;&nbsp;3.00%-3.99% |  |  |  |
| &nbsp;&nbsp;4.00%-4.99% |  |  |  |
| &nbsp;&nbsp;Greater than 5.00% |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Grand Total**  | $723389 | $656573 | $468604 |

---

(1) At December 31, 2024, $449 million has been reinsured with third-party reinsurers under existing reinsurance agreements.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | |
|:---|:---|:---|:---|
| | **At December 31, 2023** | **At December 31, 2023** | **At December 31, 2023** |
|<br>**Range of guaranteed minimum crediting rates** | **Interest Sensitive Life** | **Deferred Annuity** | **Other Policyholders' Funds** |
| **At guaranteed minimum:** | | | |
| &nbsp;&nbsp;Less than 3.00% | $— | $1945 | $138684 |
| &nbsp;&nbsp;3.00%-3.99% | 29086 | 574939 | 3790 |
| &nbsp;&nbsp;4.00%-4.99% | 613704 | 195390 | 6861 |
| &nbsp;&nbsp;Greater than 5.00% | 90158 | 765 | 37556 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | 732948 | 773039 | 186891 |
| **51-150 basis points above:** |  |  |  |
| &nbsp;&nbsp;Less than 3.00% |  |  |  |
| &nbsp;&nbsp;3.00%-3.99% |  |  |  |
| &nbsp;&nbsp;4.00%-4.99% |  |  | 50067 |
| &nbsp;&nbsp;Greater than 5.00% |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  |  |  | 50067 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Grand Total**  | $732948 | $773039 | $236958 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 7—Deferred Acquisition Costs**

The following tables roll forward the deferred policy acquisition costs for the three years ended December 31, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Life** | **Life** | **Life** | **Life** | **Life** |
| | **American Income** | **DTC** | **Liberty National** | **Other** | **Total** |
| **Balance at January 1, 2023**  | $2258291 | $1676931 | $610723 | $298346 | $4844291 |
| &nbsp;&nbsp;Capitalizations | 471771 | 159650 | 107230 | 13053 | 751704 |
| &nbsp;&nbsp;Amortization expense | (159898) | (99464) | (51534) | (16530) | (327426) |
| &nbsp;&nbsp;Foreign exchange adjustment | 3206 |  |  |  | 3206 |
| **Balance at December 31, 2023**  | $2573370 | $1737117 | $666419 | $294869 | $5271775 |
| **Balance at January 1, 2024**  | $2573370 | $1737117 | $666419 | $294869 | $5271775 |
| &nbsp;&nbsp;Capitalizations | 524980 | 145538 | 119203 | 12172 | 801893 |
| &nbsp;&nbsp;Amortization expense | (181431) | (101425) | (56832) | (16535) | (356223) |
| &nbsp;&nbsp;Foreign exchange adjustment | (16690) |  |  |  | (16690) |
| **Balance at December 31, 2024**  | $2900229 | $1781230 | $728790 | $290506 | $5700755 |
| **Balance at January 1, 2025**  | $2900229 | $1781230 | $728790 | $290506 | $5700755 |
| &nbsp;&nbsp;Capitalizations | 546709 | 140809 | 124461 | 12443 | 824422 |
| &nbsp;&nbsp;Amortization expense | (207054) | (103919) | (62264) | (13213) | (386450) |
| &nbsp;&nbsp;Foreign exchange adjustment | 9023 |  |  |  | 9023 |
| **Balance at December 31, 2025**  | $3248907 | $1818120 | $790987 | $289736 | $6147750 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Health** | **Health** | **Health** | **Health** | **Health** | **Health** |
| | **United American** | **Family Heritage** | **Liberty National** | **American Income** | **DTC** | **Total** |
| **Balance at January 1, 2023**  | $77394 | $416608 | $133096 | $57811 | $1854 | $686763 |
| &nbsp;&nbsp;Capitalizations | 1941 | 63366 | 20309 | 12849 |  | 98465 |
| &nbsp;&nbsp;Amortization expense | (5846) | (27131) | (13464) | (3982) | (175) | (50598) |
| &nbsp;&nbsp;Foreign exchange adjustment |  |  |  | 105 |  | 105 |
| **Balance at December 31, 2023**  | $73489 | $452843 | $139941 | $66783 | $1679 | $734735 |
| **Balance at January 1, 2024**  | $73489 | $452843 | $139941 | $66783 | $1679 | $734735 |
| &nbsp;&nbsp;Capitalizations | 2608 | 70311 | 23775 | 14955 | 2 | 111651 |
| &nbsp;&nbsp;Amortization expense | (5567) | (27035) | (14796) | (4678) | (148) | (52224) |
| &nbsp;&nbsp;Foreign exchange adjustment |  |  |  | (741) |  | (741) |
| **Balance at December 31, 2024**  | $70530 | $496119 | $148920 | $76319 | $1533 | $793421 |
| **Balance at January 1, 2025**  | $70530 | $496119 | $148920 | $76319 | $1533 | $793421 |
| &nbsp;&nbsp;Capitalizations | 2852 | 80747 | 18951 | 14949 | 1 | 117500 |
| &nbsp;&nbsp;Amortization expense | (5430) | (33487) | (15661) | (5184) | (135) | (59897) |
| &nbsp;&nbsp;Foreign exchange adjustment |  |  |  | 362 |  | 362 |
| **Balance at December 31, 2025**  | $67952 | $543379 | $152210 | $86446 | $1399 | $851386 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The following table presents a reconciliation of deferred policy acquisition costs to the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)* the three years ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2023** |
| **Life** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | $3248907 | $2900229 | $2573370 |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 1818120 | 1781230 | 1737117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 790987 | 728790 | 666419 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 289736 | 290506 | 294869 |
| **Total DAC—Life**  | 6147750 | 5700755 | 5271775 |
| **Health** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United American | 67952 | 70530 | 73489 |
| &nbsp;&nbsp;&nbsp;&nbsp;Family Heritage | 543379 | 496119 | 452843 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liberty National | 152210 | 148920 | 139941 |
| &nbsp;&nbsp;&nbsp;&nbsp;American Income | 86446 | 76319 | 66783 |
| &nbsp;&nbsp;&nbsp;&nbsp;Direct to Consumer | 1399 | 1533 | 1679 |
| **Total DAC—Health**  | 851386 | 793421 | 734735 |
| **Annuity**  |  | 1413 | 2967 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Tota**l  | $6999136 | $6495589 | $6009477 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 8—Liability for Unpaid Claims** 

Activity in the liability for unpaid health claims is summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Balance at January 1,**  | $210994 | $194809 | $184286 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less reinsurance recoverables | (1521) | (2157) | (2084) |
| **Net balance at January 1,**  | 209473 | 192652 | 182202 |
| &nbsp;&nbsp;&nbsp;Incurred related to: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current year | 851946 | 767076 | 697521 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior years | (1831) | (10460) | (4853) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total incurred | 850115 | 756616 | 692668 |
| &nbsp;&nbsp;&nbsp;Paid related to: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current year | 659556 | 587473 | 535971 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior years | 176028 | 152322 | 146247 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total paid | 835584 | 739795 | 682218 |
| **Net balance at December 31,**  | 224004 | 209473 | 192652 |
| &nbsp;&nbsp;&nbsp;&nbsp;Plus reinsurance recoverables | 1233 | 1521 | 2157 |
| **Balance at December 31,**  | $225237 | $210994 | $194809 |

---

At the end of each period, the liability for unpaid health claims includes an estimate of claims incurred but not yet reported to the Company. Such estimates are updated regularly based upon the Company's most recent claims data with recognition of emerging experience trends. Due to the nature of the Company's health business, the payment lags are relatively short and most claims are fully paid within a year from the time incurred. Fluctuations in claims experience can lead to either over or under estimation of the liability for any given year. The difference between the estimate made at the end of the prior period and the actual experience during the period is reflected above under the caption "Incurred related to: Prior years."

Below is the reconciliation of the liability of "Policy claims and other benefits payable" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*.

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Policy claims and other benefits payable:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life insurance | $315595 | $321838 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health insurance | 225237 | 210994 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $540832 | $532832 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 9—Income Taxes** 

The following table discloses significant components of income taxes for each year presented:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Income tax expense (benefit) from operations:** |  |  |  |
| &nbsp;&nbsp;Current income tax expense (benefit)*—*federal | $196988 | $217929 | $145700 |
| &nbsp;&nbsp;Current income tax expense (benefit)*—*state | 219 | 206 | 180 |
| &nbsp;&nbsp;Deferred income tax expense (benefit)*—*federal | 77530 | 37740 | 77631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income tax expense (benefit) | 274737 | 255875 | 223511 |
| **Shareholders' equity:** |  |  |  |
| &nbsp;&nbsp;Other comprehensive income (loss) | 68656 | 197427 | 4762 |
|  | $343393 | $453302 | $228273 |

---

In each of the years 2023 through 2025, deferred income tax expense (benefit) was incurred because of certain differences between net income before income tax expense (benefit) as reported on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* and taxable income as reported on Globe Life's income tax returns. As explained in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_451),* these differences caused the consolidated financial statement book values of some assets and liabilities to be different from their respective tax bases.

The effective income tax rate differed from the expected U.S. federal statutory rate of 21.0% as shown below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **%** | **2024** | **%** | **2023** | **%** |
| **U.S. federal statutory tax rate**  | $301555 | 21.0 | $278594 | 21.0 | $250796 | 21.0 |
| **State and local income taxes, net of federal income tax effect**<sup>(1)</sup>  | 173 |  | 163 |  | 142 |  |
| **Tax credits:** |  |  |  |  |  |  |
| &nbsp;&nbsp;LIH credits | (11906) | (0.8) | (9700) | (0.7) | (14291) | (1.2) |
| &nbsp;&nbsp;Purchased solar credits | (4988) | (0.3) | (3000) | (0.2) |  |  |
| &nbsp;&nbsp;Increasing research activities credit | (1400) | (0.1) | (2000) | (0.2) |  |  |
| **Nontaxable or nondeductible items:** |  |  |  |  |  |  |
| &nbsp;&nbsp;Share-based awards | 377 |  | 1341 | 0.1 | (4724) | (0.4) |
| &nbsp;&nbsp;Tax exempt investment income | (9522) | (0.7) | (9644) | (0.7) | (9644) | (0.8) |
| **Other adjustments**  | 448 |  | 121 |  | 1232 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Effective tax rate**  | $274737 | 19.1 | $255875 | 19.3 | $223511 | 18.7 |

---

(1)State taxes in Texas and California made up the majority (greater than 50 percent) of the tax effect in this category.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state and foreign taxes:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Federal | $140527 | $128005 | $120658 |
| State | 173 | 189 | 144 |
| Foreign | 226 | 201 | 232 |
| &nbsp;&nbsp;**Total income taxes paid (received)**  | $140926 | $128395 | $121034 |

---

The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **%** | **2024** | **%** | **2023** | **%** |
| Federal | $140527 | 99.7 | $128005 | 99.7 | $120658 | 99.7 |
| Other | 399 | 0.3 | 390 | 0.3 | 376 | 0.3 |
| &nbsp;&nbsp;**Total**  | $140926 | 100.0 | $128395 | 100.0 | $121034 | 100.0 |

---

Domestic income from continuing operations before income tax expense was $1.4 billion, $1.3 billion, and $1.2 billion for the year ended December 31, 2025, 2024, and 2023, respectively. The Company had no income from foreign operations.

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Income tax expense (or benefit) from continuing operations:** |  |  |  |
| &nbsp;&nbsp;Federal | $274518 | $255669 | $223331 |
| &nbsp;&nbsp;State | 219 | 206 | 180 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | $274737 | $255875 | $223511 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Deferred tax assets:** |  |  |
| &nbsp;&nbsp;Unrealized losses | $460158 | $532756 |
| &nbsp;&nbsp;Carryover of tax losses | 15052 | 10342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross deferred tax assets | 475210 | 543098 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less valuation allowance | (2632) | (3383) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net deferred tax assets | 472578 | 539715 |
| **Deferred tax liabilities:** |  |  |
| &nbsp;&nbsp;Employee and agent compensation | 115604 | 104385 |
| &nbsp;&nbsp;Deferred acquisition costs | 961915 | 961406 |
| &nbsp;&nbsp;Future policy benefits, unearned and advance premiums, and policy claims | 254277 | 228117 |
| &nbsp;&nbsp;Other liabilities | 75843 | 24432 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross deferred tax liabilities | 1407639 | 1318340 |
| **Net deferred tax liability**  | $935061 | $778625 |

---

*<u>Bermuda Corporate Income Tax Act:</u>* The Bermuda Corporate Income Tax Act (the "Act") was enacted on December 27, 2023, and included a new corporate income tax ("CIT"). The CIT is in effect for years beginning after January 1, 2025. The CIT is applicable to the Company; however, due to having a small international footprint, the Company is out of scope for 2025 and will be subject to the CIT beginning in 2030. Additionally, the Company does not expect the Act to have a material impact on the consolidated financials.

*<u>Income Tax Return</u>*: Globe Life Inc. and its subsidiaries file a life-nonlife consolidated federal income tax return. The statutes of limitations for the Internal Revenue Service's examination and assessment of additional tax are closed for all tax years prior to 2017 with respect to Globe Life's consolidated federal income tax returns. Management concludes that adequate provision has been made in the consolidated financial statements for any potential assessments that may result from current or future tax examinations and other tax-related matters for all open years. The Company's Bermuda subsidiaries have made, or intend to make, the election under Internal Revenue Code Section 953(d) to be taxed as a U.S. Corporation effective with their date of incorporation.

*<u>Valuations</u>*: Globe Life has a $71.7 million net operating loss ("NOL") carryforward at December 31, 2025, of which $7.2 million was created prior to 2018 and will begin to expire in 2035 if not otherwise used to offset future taxable income. The remaining NOL carryforward of $64.5 million may be carried forward indefinitely. A valuation allowance is to be recorded when it is more likely than not that deferred tax assets will not be realized by the Company. A valuation allowance has been established in the amount of $2.6 million related to pre-acquisition and post-acquisition NOL carryforward deferred tax assets from an acquisition in 2024 as management has determined that the acquired companies will more than likely not have sufficient taxable income in future periods to realize the deferred tax assets.

Globe Life's tax liability is adjusted to include a provision for uncertain tax positions taken or expected to be taken in a tax return. However, during the years 2023 through 2025, Globe Life did not have any uncertain tax positions which resulted in unrecognized tax benefits.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 10—Postretirement Benefits** 

Globe Life has qualified noncontributory defined benefit pension plans (the "Pension Plans") and contributory savings plans that cover substantially all employees. There is also a nonqualified noncontributory supplemental executive retirement plan ("SERP") that covers a limited number of officers. The tables included herein will focus on the Pension Plans and SERP.

The total cost of these retirement plans charged to operations was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Plan Type:** |  |  |  |
| &nbsp;&nbsp;Defined Contribution Plans<sup>(1)</sup> | $6870 | $6605 | $6390 |
| &nbsp;&nbsp;Defined Benefit Pension Plans<sup>(2)</sup> | 15984 | 16458 | 15225 |

---

(1)401K plans.

(2)Qualified pension plans and SERP.

Globe Life accrues expense for the defined contribution plans based on a percentage of the employees' contributions. The plans are funded by the employee contributions and a Globe Life contribution equal to the amount of accrued expense. Plan contributions are both mandatory and discretionary, depending on the terms of the plan.

*<u>Pension Plans:</u>* Cost for the Pension Plans has been calculated on the projected unit credit actuarial cost method. All plan measurements for the pension plans are as of December 31 of the respective year. The pension plans covering the majority of employees are qualified and funded. Contributions are made to funded pension plans subject to minimums required by regulation and maximums allowed for tax purposes.

Globe Life's SERP provides an additional supplemental defined pension benefit to a limited number of officers. The supplemental benefit is based on the participant's qualified plan benefit without consideration to the regulatory limits on compensation and benefit payments applicable to qualified plans, except that eligible compensation is capped at $1 million. The SERP is nonqualified and unfunded. However, a Rabbi Trust has been established to support the liability for this plan. The Rabbi Trust consists of life insurance policies on the lives of plan participants with an unaffiliated insurance carrier as well as an investment account. Since this plan is nonqualified, the investments and the policyholder value of the insurance policies in the Rabbi Trust are not included as defined benefit plan assets, but rather assets of the Company. They are included in "Other Assets" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*.

Defined benefit and SERP plan contributions were $26.5 million in 2025, $24.8 million in 2024, and $24.4 million in 2023. In 2026, the Company does not expect to increase contributions to the plans from what was contributed in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Pension Assets:</u>* Plan assets in the funded plans consist primarily of investments in marketable fixed maturities and equity securities that are valued at fair value. Globe Life measures the fair value of its financial assets, including the assets in its benefit plans, in accordance with accounting guidance which establishes a hierarchy for asset values and provides a methodology for the measurement of value. Please refer to *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_463)* under the caption *Fair Value Measurements*, *Investments in Securities* for a complete discussion of valuation procedures.

The following table presents the assets of the Company's Pension Plans at December 31, 2025 and 2024:

**Pension Assets by Component at December 31, 2025** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Fair Value Determined by:** | **Fair Value Determined by:** | **Fair Value Determined by:** | | |
| | **Quoted Prices in**<br>**Active Markets**<br>**for Identical**<br>**Assets (Level 1)** | **Significant**<br>**Observable**<br>**Inputs (Level 2)** | **Significant<br>Unobservable<br>Inputs (Level 3)** |<br>**Total**<br>**Amount** |<br>**% of<br>Total** |
| Exchange traded fund<sup>(4)</sup> | $53437 | $— | $— | $53437 | 8 |
| Equity exchange traded fund<sup>(1)</sup> | 344409 |  |  | 344409 | 50 |
| U.S. Government and Agency |  | 180974 |  | 180974 | 26 |
| Other bonds |  | 3 |  | 3 |  |
| Guaranteed annuity contract<sup>(2)</sup> |  | 46341 |  | 46341 | 7 |
| Short-term investments | 6957 |  |  | 6957 | 1 |
| Other | 3747 |  |  | 3747 | 1 |
|  | $408550 | $227318 | $— | 635868 | 93 |
| Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | 48411 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | $684279 | 100 |

---

(1)A fund including marketable securities that mirror the S&P 500 index.

(2)Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.

(3)Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of December 31, 2025, the Globe Life Inc. Pension Plan owned less than 1% of three long-term investment funds.

(4)A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Pension Assets by Component at December 31, 2024**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Fair Value Determined by:** | **Fair Value Determined by:** | **Fair Value Determined by:** | | |
|  | **Quoted Prices in**<br>**Active Markets**<br>**for Identical**<br>**Assets (Level 1)** | **Significant**<br>**Observable**<br>**Inputs (Level 2)** | **Significant**<br>**Unobservable**<br>**Inputs (Level 3)** |<br>**Total**<br>**Amount** |<br>**% of<br>Total** |
| Exchange traded fund<sup>(4)</sup> | $35483 | $— | $— | $35483 | 6 |
| Equity exchange traded fund<sup>(1)</sup> | 322846 |  |  | 322846 | 53 |
| U.S. Government and Agency |  | 179418 |  | 179418 | 29 |
| Other bonds |  | 4 |  | 4 |  |
| Guaranteed annuity contract<sup>(2)</sup> |  | 43893 |  | 43893 | 7 |
| Short-term investments | 1235 |  |  | 1235 |  |
| Other | 1420 |  |  | 1420 |  |
|  | $360984 | $223315 | $— | 584299 | 95 |
| Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | Other long-term investments<sup>(3)</sup> | 30546 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total pension assets**  | $614845 | 100 |

---

(1)A fund including marketable securities that mirror the S&P 500 index.

(2)Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.

(3)Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of December 31, 2024, the Globe Life Inc. Pension Plan owned less than 1% of two long-term investment funds.

(4)A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

Globe Life's investment objectives and goals for its plan assets include generating strong risk-adjusted returns, maintaining diversification, investing in accordance with the liabilities of the plan, and satisfying the liquidity needs of the plan. Globe Life seeks to accomplish these objectives by investing in public and private markets and diversifying across asset classes, industries, sectors, and entities. Globe Life intends to maintain an asset mix that when combined with future plan contributions will produce adequate long-term risk adjusted returns relative to expected changes in the liability as a result of changes to interest rates or earned benefits.

The majority of the securities in the portfolio are highly marketable so that there will be adequate liquidity to meet projected payments. There are no specific policies calling for asset durations to match those of benefit obligations.

Allowed investments include equity, fixed income, real assets, and short-term investments. Equity securities include common stocks or equivalents, preferred stocks, and/or funds investing primarily in private or public equity investments. Fixed income securities include loans of corporations or commercial real estate as well as marketable debt securities issued by either the U.S. Government, Agencies of the U.S. Government, state, local and municipal governments, domestic and foreign corporations, Special Purpose Vehicles secured by pools of financial assets, and other U.S. financial institutions. Real Assets include equity interest in core or non-core real estate or infrastructure with U.S. or non-U.S. exposure. Short-term investments consist of fixed income securities maturing in one year or less.

The assets are to be invested in a mix of allowed investments that best serve the objectives of the pension plan. Factors to be considered in determining the asset mix include funded status, annual pension expense, annual pension contributions, and balance sheet liability. The investment portfolio is well diversified to avoid undue exposure to an asset class, sector, industry, business, or security. The Company does not employ any other special risk management techniques, such as derivatives, in managing the pension investment portfolio.

Globe Life's public equity within the pension plan assets consists of an exchange traded fund that mirrors the S&P 500 index which better aligns with a passive approach rather than an actively managed portfolio.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

At December 31, 2025, there were no restricted investments contained in the portfolio. Plan contributions have been invested primarily in fixed maturity and equity securities during the three years ended December 31, 2025.

The following table presents additional information about the Company's other long-term investments included in pension plan assets as of December 31, 2025 and December 31, 2024 at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value** | **Fair Value** | **Unfunded Commitments**<sup>(2)</sup> | |
|<br>**Investment Category** | **2025** | **2024** | **2025** |<br>**Redemption Term/Notice**<sup>(1)</sup> |
| Multi-asset class | $7541 | $12383 | $— | Non-redeemable |
| Private equity | 35824 | 18163 | 37666 | Non-redeemable |
| Infrastructure | 5046 |  | 26132 | Non-redeemable |
| &nbsp;&nbsp;&nbsp;&nbsp;Total  | $48411 | $30546 | $63798 |  |

---

(1)Non-redeemable funds generally have an expected life of 7 to 10 years from fund closing with extension options of 2 to 4 years. Redemptions are paid out throughout the life of the funds at the General Partner's discretion.

(2)Unfunded commitments include unfunded balances during the investment period. After an investment period ends, the fund can call capital based on limited and specified reasons. As of December 31, 2025, unfunded commitments totaled $78.1 million, including funds past the investment period.

*<u>SERP:</u>* The following tables include premiums paid for COLI for the three years ended December 31, 2025 and investments of the Rabbi Trust for the two years ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Premiums paid for insurance coverage | $— | $443 | $443 |
|  |  | **At December 31,** | **At December 31,** |
|  |  | **2025** | **2024** |
| **Total investments:** |  |  |  |
| &nbsp;&nbsp;COLI | &nbsp;&nbsp;COLI | $59008 | $57210 |
| &nbsp;&nbsp;Exchange traded funds | &nbsp;&nbsp;Exchange traded funds | 111470 | 98314 |
|  |  | $170478 | $155524 |

---

*<u>Pension Plans and SERP Liabilities:</u>* The following table presents the projected benefit obligation (PBO) and accumulated benefit obligation (ABO) for the Pension Plans and SERP at December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **PBO** | **ABO** | **PBO** | **ABO** |
| Pension plans | $597695 | $531741 | $561615 | $500010 |
| SERP | 79093 | 72666 | 73441 | 68428 |
| &nbsp;&nbsp;**Benefit obligation**  | $676788 | $604407 | $635056 | $568438 |

---

For the year ended December 31, 2025, the Pension Plans have plan assets with fair values in excess of projected benefit obligations. The projected benefit obligations and the fair value of plan assets were as follows:

---

| | | |
|:---|:---|:---|
| | **At December 31,** | **At December 31,** |
| | **2025** | **2024** |
| Funded benefit pension plans PBO | $597695 | $561615 |
| Funded benefit pension plans fair value of plan assets | 684279 | 614845 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

For the year ended December 31, 2025, the funded benefit pension plans have plan assets with fair value in excess of the accumulated benefit obligations. The accumulated benefit obligations and the fair value of plan assets were as follows:

---

| | | |
|:---|:---|:---|
| | **At December 31,** | **At December 31,** |
| | **2025** | **2024** |
| Funded benefit pension plans ABO | $531741 | $500010 |
| Funded benefit pension plans fair value of plan assets | 684279 | 614845 |

---

The following table discloses the assumptions used to determine Globe Life's pension liabilities and costs for the appropriate periods. The discount and compensation increase rates are used to determine current year projected benefit obligations and subsequent year pension expense. The long-term rate of return is used to determine current year expense. Differences between assumptions and actual experience are included in actuarial gain or loss.

**Weighted Average Pension Plan Assumptions**

---

| | | | |
|:---|:---|:---|:---|
| ***For Benefit Obligations at December 31:*** |  | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Discount rate | &nbsp;&nbsp;&nbsp;Discount rate | 5.81% | 5.81% |
| &nbsp;&nbsp;&nbsp;Rate of compensation increase | &nbsp;&nbsp;&nbsp;Rate of compensation increase | 4.44 | 4.46 |
| ***For Periodic Benefit Cost for the Year:*** | **2025** | **2024** | **2023** |
| &nbsp;&nbsp;&nbsp;Discount rate | 5.81% | 5.40% | 5.71% |
| &nbsp;&nbsp;&nbsp;Expected long-term returns | 7.33 | 7.18 | 6.98 |
| &nbsp;&nbsp;&nbsp;Rate of compensation increase | 4.46 | 4.40 | 4.40 |

---

The discount rate is determined based on the expected duration of plan liabilities. A yield is then derived based on the current market yield of a hypothetical portfolio of high quality corporate bonds that match the liability's average life. The rate of compensation increase is projected based on Company experience, modified as appropriate for future expectations. The expected long-term rate of return on plan assets is management's best estimate of the average rate of earnings expected to be received on the assets invested in the plan over the benefit period. In determining this assumption, consideration is given to the historical rate of return earned on the assets, the projected returns over future periods, and the discount rate used to compute benefit obligations.

*<u>Net Periodic Benefit Cost:</u>* The following table presents the net periodic benefit cost for the defined benefit plans by expense component for the three years ended December 31, 2025 as follows:

**Components of Net Periodic Benefit Cost**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Service cost—benefits earned during the period | $24969 | $24898 | $21568 |
| Interest cost on projected benefit obligation | 36081 | 33123 | 31367 |
| Expected return on assets | (46278) | (42580) | (38625) |
| Amortization of prior service cost (credit) | 1167 | 1071 | 1075 |
| Recognition of actuarial gain (loss) | 45 | (54) | (160) |
| &nbsp;&nbsp;**Net periodic benefit cost**  | $15984 | $16458 | $15225 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

An analysis of the impact on other comprehensive income (loss) concerning pensions and other postretirement benefits is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Balance at January 1**  | $26194 | $(2727) | $1570 |
| &nbsp;&nbsp;&nbsp;Amortization of: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior service cost (credit) | 1168 | 1071 | 1075 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net actuarial (gain) loss<sup>(1)</sup> | (915) | (597) | (1465) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total amortization | 253 | 474 | (390) |
| &nbsp;&nbsp;&nbsp;Plan amendments |  | (1212) |  |
| &nbsp;&nbsp;Experience gain (loss)<sup>(2)</sup> | 10522 | 29659 | (3907) |
| **Balance at December 31**  | $36969 | $26194 | $(2727) |

---

(1)Includes amortization of postretirement benefits other than pensions of $(959) thousand in 2025, $(622) thousand in 2024, and $(732) thousand in 2023.

(2)The increase in the experience gain (loss) is related to an increase in discount rate.

The following table presents a reconciliation from the beginning to the end of the year of the PBO for the Pension Plans and SERP, and the plan assets for the Pension Plans. This table also presents the amounts previously recognized as a component of accumulated other comprehensive income.

**Pension Benefits**

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Changes in PBO:** |  |  |
| &nbsp;&nbsp;&nbsp;PBO at beginning of year | $635056 | $627560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service cost | 24969 | 24898 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest cost | 36081 | 33123 |
| &nbsp;&nbsp;&nbsp;&nbsp;Plan amendments |  | 1212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial loss (gain) | 10252 | (22964) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (29570) | (28773) |
| &nbsp;&nbsp;&nbsp;PBO at end of year | 676788 | 635056 |
| **Changes in plan assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Fair value at beginning of year | 614845 | 570767 |
| &nbsp;&nbsp;&nbsp;&nbsp;Return on assets | 67459 | 48084 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions | 26488 | 24767 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (29570) | (28773) |
| &nbsp;&nbsp;&nbsp;Fair value at end of year | 679222 | 614845 |
| **Funded status at year end**  | $2434 | $(20211) |

---

Changes in the PBO related to actuarial losses (gains) are primarily attributed to changes in the discount rate.

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| **Amounts recognized in accumulated other comprehensive income consist of:** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Net loss (gain) | $(39917) | $(28720) |
| &nbsp;&nbsp;&nbsp;Prior service cost | 5468 | 6636 |
| &nbsp;&nbsp;&nbsp;Net amounts recognized at year end | $(34449) | $(22084) |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Globe Life has estimated its expected postretirement benefits to be paid over the next ten years as of December 31, 2025. These estimates use the same assumptions that measure the benefit obligation at December 31, 2025, taking estimated future employee service into account. Those estimated benefits are as follows:

---

| | |
|:---|:---|
| **For the year(s):** | |
| &nbsp;&nbsp;&nbsp;&nbsp;2026 | $33125 |
| &nbsp;&nbsp;&nbsp;&nbsp;2027 | 36024 |
| &nbsp;&nbsp;&nbsp;&nbsp;2028 | 38950 |
| &nbsp;&nbsp;&nbsp;&nbsp;2029 | 42143 |
| &nbsp;&nbsp;&nbsp;&nbsp;2030 | 44682 |
| &nbsp;&nbsp;&nbsp;&nbsp;2031-2035 | 260402 |

---

**Note 11—Supplemental Disclosures of Cash Flow Information** 

The following table summarizes Globe Life's noncash transactions for the three years ended December 31, 2025, which are not reflected on the *[Consolidated Statements of Cash Flows](#ia1583f94e55d42afa319983b2df261d2_445)*:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Stock-based compensation not involving cash | $53355 | $40118 | $30736 |
| Commitments for low-income housing interests | 234753 | 35000 |  |
| Exchanges of fixed maturity investments | 288491 | 105595 | 50936 |
| Net unsettled security trades | 408 | 2334 | 3833 |
| Noncash tax credits |  |  | 1083 |

---

The following table summarizes certain amounts paid during the period:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Interest paid | $144680 | $116993 | $99545 |
| Income taxes paid<sup>(1)</sup> | 175907 | 175400 | 121034 |

---

(1)Income taxes paid includes cash paid of $35 million, $47 million, and $0 for the purchase of transferable tax credits as of December 31, 2025, 2024, and 2023, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 12—Debt** 

The following table presents information about the terms and outstanding balances of Globe Life's debt.

**Selected Information about Debt Issues**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | | | | **2025** | **2025** | **2025** | **2025** | **2024** |
| **Instrument** | **Issue Date** | **Maturity Date** | **Coupon Rate** | **Par<br>Value** | **Unamortized Discount & Issuance Costs** | **Book<br>Value** | **Fair<br>Value** | **Book<br>Value** |
| Senior notes | 09/27/2018 | 09/15/2028 | 4.550% | $550000 | $(2252) | $547748 | $555115 | $546999 |
| Senior notes | 08/21/2020 | 08/15/2030 | 2.150% | 400000 | (2396) | 397604 | 361852 | 397132 |
| Senior notes<sup>(1)</sup> | 05/19/2022 | 06/15/2032 | 4.800% | 250000 | (3308) | 246692 | 251923 | 246272 |
| Senior notes | 08/23/2024 | 09/15/2034 | 5.850% | 450000 | (4782) | 445218 | 472792 | 444814 |
| Junior subordinated debentures | 11/17/2017 | 11/17/2057 | 5.275% | 125000 | (1539) | 123461 | 123290 | 123443 |
| Junior subordinated debentures | 06/14/2021 | 06/15/2061 | 4.250% | 325000 | (7528) | 317472 | 217750 | 317387 |
| Term loan<sup>(2)</sup> | 05/11/2023 | 08/15/2027 | 5.353% | 250000 | (1110) | 248890 | 248890 | 248204 |
| &nbsp;&nbsp;Subtotal | &nbsp;&nbsp;Subtotal | &nbsp;&nbsp;Subtotal | &nbsp;&nbsp;Subtotal | 2350000 | (22915) | 2327085 | 2231612 | 2324251 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs<sup>(3)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs<sup>(3)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs<sup>(3)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs<sup>(3)</sup> |  | (6292) | (6292) | (6292) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total long-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total long-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total long-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total long-term debt**  | 2350000 | (29207) | 2320793 | 2225320 | 2324251 |
| Commercial paper | Commercial paper | Commercial paper | Commercial paper | 306000 | (1344) | 304656 | 304656 | 415401 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total short-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total short-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total short-term debt**  | &nbsp;&nbsp;&nbsp;&nbsp;**Total short-term debt**  | 306000 | (1344) | 304656 | 304656 | 415401 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total debt**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total debt**  | $2656000 | $(30551) | $2625449 | $2529976 | $2739652 |

---

(1)An additional $150 million par value and book value is held by insurance subsidiaries that eliminates in consolidation.

(2)Interest calculated quarterly using Secured Overnight Financing Rate (SOFR) plus 135 basis points. The term loan was amended on August 15, 2024 extending the maturity date from November 11, 2024 to August 15, 2027 and increasing the principal amount from $170 million to $250 million.

(3)Unamortized issuance costs for P-CAPS facility agreement.

The commercial paper has the highest priority of all unsecured debt, followed by senior notes then junior subordinated debentures. The senior notes are callable under a make-whole provision, and the junior subordinated debentures are subject to an optional redemption five years from issuance. Interest on the 4.25% junior subordinated debentures and the term loan are payable quarterly while all other long-term debt is payable semi-annually.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Contractual Debt Obligations</u>:* The following table presents expected scheduled principal payments under our contractual debt obligations:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2026** | **2027** | **2028** | **2029** | **2030** | **Thereafter** |
| Debt obligations | $306000 | $250000 | $550000 | $— | $400000 | $1150000 |

---

*<u>Credit Facility</u>:* Globe Life has in place a credit facility which provides for a $1 billion revolving credit facility that may be increased to $1.25 billion. The credit facility matures March 29, 2029 and may be extended up to two one-year periods upon the Company's request. Pursuant to this agreement, the participating lenders have agreed to make revolving loans to Globe Life and to issue secured or unsecured letters of credit. The Company has not drawn on any of the credit to date.

The facility is further designated as a back-up credit line for a commercial paper program under which the Company may either borrow from the credit line or issue commercial paper at any time, with total commercial paper outstanding not to exceed the facility maximum of $1 billion, less any letters of credit issued. Interest is charged at variable rates. In accordance with the agreement, Globe Life is subject to certain covenants regarding capitalization.

As of December 31, 2025, the Company was in full compliance with these covenants.

*<u>Pre-capitalized Trust Securities</u>*: On July 1, 2025, the Company entered into a 30-year Facility Agreement with a Delaware trust (the "Trust") following the completion of a private placement of Trust securities for $500 million of Pre-Capitalized Trust Securities ("P-CAPS"), conducted pursuant to Rule 144A under the Securities Act. The Trust invested the proceeds from this offering in a portfolio of U.S. Treasury principal and interest strips ("Treasury securities"). P-CAPS provide the Company with a source of liquidity, the proceeds of which, if drawn, would be used for general corporate purposes.

Under the Facility Agreement, the Company has the right, on one or more occasions, to issue and sell up to $500 million of its 6.580% Senior Notes to the Trust in exchange for a corresponding amount of Treasury securities held by the Trust. In consideration for this right, the Company pays the Trust a semi-annual facility fee at a rate of 1.789% per annum on the unexercised portion of the facility. These fees are recorded in Interest Expense in the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)*. The Company also reimburses the Trust for its administrative expenses. The Issuance Right will be exercised automatically in full upon (i) our failure to pay the facility fee or to purchase any Strips required to be purchased under the Facility, if the failure to pay is not cured within 30 days, or (ii) certain bankruptcy events involving the Company. We are also required to exercise the Issuance Right in full if our consolidated stockholders' equity (excluding AOCI) falls below $1.85 billion, subject to certain adjustments. As of December 31, 2025, the Company had no senior note issuances under the Facility Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Commercial Paper</u>:* Commercial paper outstanding and any long-term debt due within one year are reported as short-term debt on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*. The following tables present selected information concerning Globe Life's commercial paper borrowings.

**Credit Facility—Commercial Paper**

(Dollar amounts in thousands)

---

| | | |
|:---|:---|:---|
| | **At December 31,** | **At December 31,** |
| | **2025** | **2024** |
| Balance commercial paper at end of period (at par value) | $306000 | $419000 |
| Annualized interest rate | 4.05% | 5.22% |
| Letters of credit outstanding | $115000 | $115000 |
| Remaining amount available under credit line | 579000 | 466000 |

---

**Credit Facility—Commercial Paper Activity**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Average balance of commercial paper outstanding during period (par value) | $412705 | $405573 | $290024 |
| Daily-weighted average interest rate (annualized) | 4.77% | 5.65% | 5.40% |
| Maximum daily amount outstanding during period (par value) | $605500 | $633425 | $477700 |
| Commercial paper issued during period (par value) | 2369500 | 2052056 | 2029000 |
| Commercial paper matured during period (par value) | (2482500) | (1952056) | (1995000) |
| Net commercial paper issued (matured) during period (par value) | (113000) | 100000 | 34000 |

---

The Company reduced the commercial paper borrowings by $113 million from the prior year. The Company was able to issue commercial paper as needed under this facility during the year ended December 31, 2025 and 2024.

*<u>Federal Home Loan Bank</u>:* FHLB membership provides certain of our insurance subsidiaries with access to various low-cost collateralized borrowings and funding agreements. The membership requires ownership of FHLB common stock, as well as the purchase of activity-based common stock equal to approximately 4.1% of outstanding borrowings.

Globe Life owned $32.5 million in FHLB common stock as of December 31, 2025 and $34.5 million as of December 31, 2024. The FHLB stock is restricted from redemption or repurchases for the duration of the membership and recorded at cost (par) as required by applicable guidance. The FHLB stock is included in "Other long-term investments*"* on the *[Consolidated Balance Sheets.](#ia1583f94e55d42afa319983b2df261d2_433)* Borrowings with the FHLB are subject to the availability of pledged assets at the insurance subsidiaries of Globe Life. As of December 31, 2025, Globe Life's insurance subsidiaries' maximum borrowing capacity under the FHLB facility was approximately $730 million, net of outstanding funding agreements and short-term borrowings, on pledged assets with a fair value of $1.4 billion. As of December 31, 2025, $437 million in funding agreements were outstanding with the FHLB, compared to $372 million as of December 31, 2024. This amount is included in "Other policyholders' funds" on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*. The Company had no short-term borrowings from the FHLB as of December 31, 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 13—Shareholders' Equity** 

*<u>Share Data:</u>* A summary of common share activity is presented in the following chart.

---

| | | |
|:---|:---|:---|
| | **Common Stock** | **Common Stock** |
| | **Issued** | **Treasury<br>Stock** |
| **2023:** | | |
| &nbsp;&nbsp;&nbsp;Balance at January 1, 2023 | 105218183 | (8478288) |
| &nbsp;&nbsp;&nbsp;Grants of restricted stock |  | 7110 |
| &nbsp;&nbsp;&nbsp;Vesting of performance shares |  | 84298 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock due to exercise of stock options |  | 1375313 |
| &nbsp;&nbsp;&nbsp;Treasury stock acquired |  | (4415287) |
| &nbsp;&nbsp;&nbsp;Retirement of treasury stock | (3000000) | 3000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Balance at December 31, 2023**  | 102218183 | (8426854) |
| **2024:** |  |  |
| &nbsp;&nbsp;&nbsp;Grants of restricted stock |  | 7375 |
| &nbsp;&nbsp;&nbsp;Vesting of performance shares |  | 143211 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock due to exercise of stock options |  | 584993 |
| &nbsp;&nbsp;&nbsp;Treasury stock acquired |  | (10549341) |
| &nbsp;&nbsp;&nbsp;Retirement of treasury stock | (5000000) | 5000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Balance at December 31, 2024**  | 97218183 | (13240616) |
| **2025:** |  |  |
| &nbsp;&nbsp;&nbsp;Grants of restricted stock |  | 6530 |
| &nbsp;&nbsp;&nbsp;Vesting of performance shares |  | 152680 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock due to exercise of stock options |  | 1842860 |
| &nbsp;&nbsp;&nbsp;Treasury stock acquired |  | (6886536) |
| &nbsp;&nbsp;&nbsp;Retirement of treasury stock | (5000000) | 5000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Balance at December 31, 2025**  | 92218183 | (13125082) |

---

There was no activity related to the preferred stock in years 2023 through 2025.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

*<u>Acquisition of Common Shares</u>:* Globe Life shares are acquired through open market purchases under the Globe Life stock repurchase program when it is determined to be the best use of Globe Life's excess cash flows. This yields a return that is better than available alternatives and exceeds our cost of equity. When stock options are exercised, proceeds from the exercises are generally used to repurchase approximately the number of shares available with those funds in order to reduce dilution. See the following summary below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Globe Life Share Repurchase Program** | **Globe Life Share Repurchase Program** | **Globe Life Share Repurchase Program** | **Share Repurchase for Dilution Purposes** | **Share Repurchase for Dilution Purposes** | **Share Repurchase for Dilution Purposes** |
| | **Shares Acquired <br>(in thousands)** | **Total Cost** | **Average Price** | **Shares Acquired <br>(in thousands)** | **Total Cost** | **Average Price** |
| **2025**  | 5420 | $685151 | $126.41 | 1469 | $189669 | $129.14 |
| **2024**  | 10086 | 945637 | 93.76 | 501 | 48026 | 95.75 |
| **2023**  | 3369 | 380103 | 112.84 | 1080 | 127155 | 117.72 |

---

*<u>Restrictions</u>:* Restrictions exist on the flow of funds to Globe Life Inc. from its insurance subsidiaries. Statutory regulations require life insurance subsidiaries to maintain certain minimum amounts of capital and surplus. Dividends from insurance subsidiaries of Globe Life Inc. are restricted based on regulations by their states of domicile. Additionally, insurance company distributions are generally not permitted in excess of statutory surplus. Subsidiaries are also subject to certain minimum capital requirements. Subsidiaries of Globe Life paid cash dividends to the Parent Company in the amount of $816 million in 2025, $693 million in 2024, and $460 million in 2023. As of December 31, 2025, dividends from our U.S. insurance subsidiaries to the Parent Company available to be paid in 2026 are limited to the amount of $211 million without regulatory approval, such that $1.4 billion was considered restricted net assets of the subsidiaries. Dividends exceeding these limitations may be available during the year pending regulatory approval. While there are no legal restrictions on the payment of dividends to shareholders from Globe Life's retained earnings, retained earnings as of December 31, 2025 were restricted by lenders' covenants which require the Company to maintain and not distribute $5.6 billion from its total consolidated retained earnings of $8.5 billion.

*<u>Earnings per Share</u>:* A reconciliation of basic and diluted weighted-average shares outstanding used in the computation of basic and diluted earnings per share is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Basic weighted average shares outstanding | 81376845 | 89278574 | 95098474 |
| Weighted average dilutive options outstanding | 1148147 | 382848 | 1265367 |
| Diluted weighted average shares outstanding | 82524992 | 89661422 | 96363841 |
| Antidilutive shares |  | 2140787 | 422739 |

---

Antidilutive shares are excluded from the calculation of diluted earnings per share. All antidilutive shares noted above result from outstanding out of the money employee and Director stock options.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 14—Stock-Based Compensation** 

Globe Life's stock-based compensation consists of stock options, restricted stock, restricted stock units, and performance shares. Certain employees and members of the board of directors (directors) have been granted fixed equity options to buy shares of Globe Life Inc. stock at the market value of the stock on the date of grant, under the provisions of the Globe Life stock option plans. The options are exercisable during the period commencing from the date they vest until expiring according to the terms of the grant. Options generally expire the earlier of employee termination or option contract term, which are either seven-year or ten-year terms. However, depending on the circumstances of termination, options may be exercised for a period of time following termination of employment or upon death or disability. Options generally vest in accordance with the following schedule:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Shares vested by period** | **Shares vested by period** | **Shares vested by period** | **Shares vested by period** |
| |<br>**Contract Period** | **6 Months** | **Year 1** | **Year 2** | **Year 3** |
| **Directors**  | 7 years | 100% | —% | —% | —% |
| **Employees**  | 7 years | —% | —% | 50% | 50% |

---

All employee options vest immediately upon retirement on or after the attainment of age 65, upon death, or disability. Globe Life generally issues shares for the exercise of stock options from treasury stock. The Company generally uses the proceeds from option exercises to buy shares of Globe Life common stock in the open market to reduce the dilution from option exercises.

A summary of stock compensation activity for each of the three years ended December 31, 2025 is presented below:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Stock-based compensation expense recognized<sup>(1)</sup> | $53355 | $40118 | $30736 |
| Tax benefit recognized | 10829 | 7085 | 11178 |

---

(1)No stock-based compensation expense was capitalized in any period in accordance with applicable GAAP.

Additional stock compensation information is as follows at December 31:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Unrecognized compensation<sup>(1)</sup> | $49461 | $46956 |
| Weighted average period of expected recognition (in years)<sup>(1)</sup> | 0.64 | 0.53 |

---

(1)Includes stock options, restricted stock units and performance shares.

No equity awards were cash settled during the three years ended December 31, 2025.

*<u>Options:</u>* The following table summarizes information about stock options outstanding at December 31, 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Options Outstanding** | **Options Outstanding** | **Options Outstanding** | **Options Exercisable** | **Options Exercisable** |
|<br>**Range of<br>Exercise Prices** | **Number<br>Outstanding** | **Weighted-<br>Average<br>Remaining<br>Contractual<br>Life (Years)** | **Weighted-<br>Average<br>Exercise<br>Price** | **Number<br>Exercisable** | **Weighted-<br>Average<br>Exercise<br>Price** |
| $50.64 - $98.32 | 1283918 | 1.89 | $92.51 | 1283918 | $92.51 |
| 100.74 | 745000 | 1.15 | 100.74 | 745000 | 100.74 |
| 103.23 | 935490 | 3.14 | 103.23 | 935490 | 103.23 |
| 105.56 - 128.40 | 1339536 | 4.97 | 124.90 | 266584 | 118.92 |
| $50.64 - $128.40 | 4303944 | 2.99 | $106.34 | 3230992 | $99.69 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

An analysis of option activity for each of the three years ended December 31, 2025, is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **Options** | **Weighted-Average<br>Exercise Price** | **Options** | **Weighted-Average<br>Exercise Price** | **Options** | **Weighted-Average<br>Exercise Price** |
| **Outstanding—beginning of year**  | 5825957 | $99.74 | 5940320 | $96.19 | 6962374 | $91.73 |
| &nbsp;&nbsp;&nbsp;Granted: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7-year term | 349342 | 127.43 | 520810 | 128.32 | 497060 | 120.49 |
| &nbsp;&nbsp;&nbsp;Exercised | (1842860) | 89.23 | (584993) | 88.52 | (1375313) | 82.95 |
| &nbsp;&nbsp;&nbsp;Expired and forfeited | (28495) | 120.48 | (50180) | 106.62 | (143801) | 90.92 |
| **Outstanding—end of year**  | 4303944 | $106.34 | 5825957 | $99.74 | 5940320 | $96.19 |
| **Exercisable at end of year**  | 3230992 | $99.69 | 4376436 | $93.73 | 4003028 | $91.23 |

---

Additional information about Globe Life's stock option activity as of December 31, 2025 and 2024 is as follows:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| **Outstanding options:** |  |  |
| &nbsp;&nbsp;&nbsp;Weighted-average remaining contractual term (in years) | 2.99 | 3.15 |
| &nbsp;&nbsp;&nbsp;Aggregate intrinsic value | $144251 | $81703 |
| **Exercisable options:** |  |  |
| &nbsp;&nbsp;&nbsp;Weighted-average remaining contractual term (in years) | 2.24 | 2.48 |
| &nbsp;&nbsp;&nbsp;Aggregate intrinsic value | $129787 | $77946 |

---

Selected stock option activity for the three years ended December 31, 2025, is presented below:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Weighted-average grant-date fair value of options granted <br>(per share) | $39.92 | $33.80 | $32.25 |
| Intrinsic value of options exercised | 73970 | 17127 | 49163 |
| Cash received from options exercised | 164448 | 51786 | 114080 |
| Actual tax benefit received | 8101 | 2489 | 9379 |

---

Additional information concerning Globe Life's unvested options is as follows at December 31:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Number of shares outstanding | 1072952 | 1449521 |
| Weighted-average exercise price (per share) | $126.38 | $117.88 |
| Weighted-average remaining contractual term (in years) | 5.25 | 5.19 |
| Aggregate intrinsic value | $14464 | $3757 |

---

Globe Life expects that substantially all unvested options will vest.

*<u>Restricted Stock:</u>* Restricted stock grants consist of time-vested grants, restricted stock units, and performance shares. Time-vested restricted stock is available to directors and vests over six months. The directors' restricted stock units vest over six months and are converted to shares upon their retirement from the Board. Employees' restricted stock units vest and become non-forfeitable on the vesting date (generally three years from the grant date) or upon meeting certain retirement criteria, or in the event of death or disability. Director restricted stock and restricted stock units are generally granted on the first business day of the calendar year. Performance shares are

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

granted to a limited number of senior executives. Performance shares have a three-year performance period and are not settled in shares until the certification of the achievement of the performance objectives for three-year performance period. While the grant specifies a stated target number of shares, the determination of the actual settlement in shares will be based on the achievement of certain performance objectives of Globe Life over the three-year performance period. Certain executive restricted stock and performance share grants contain terms related to age that could accelerate vesting.

Following are the restricted stock units outstanding for each of the three years ended December 31, 2025:

---

| | |
|:---|:---|
| **Year of grants** | **Outstanding as of year end** |
| 2023 | 163108 |
| 2024 | 219864 |
| 2025<sup>(1)</sup> | 312663 |

---

(1)Includes dividend equivalent units.

Below is the final determination of the performance share grants in 2021 to 2023:

---

| | | |
|:---|:---|:---|
| **Year of grants** | **Final settlement of shares** | **Final settlement date** |
| 2021 | 143,211 | February 28, 2024 |
| 2022 | 152,680 | February 26, 2025 |
| 2023 | 149,755 | February 25, 2026 |

---

For the 2024 and 2025 performance share grants, actual shares that could be distributed range from 0 to 145 thousand for the 2024 grants and 0 to 297 thousand shares for the 2025 grants.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

A summary of restricted stock grants for each of the years in the three-year period ended December 31, 2025, is presented in the table below:

---

| | | | |
|:---|:---|:---|:---|
| | **2025**<sup>(1)</sup> | **2024** | **2023** |
| **Directors restricted stock:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares | 6530 | 7375 | 7110 |
| &nbsp;&nbsp;&nbsp;&nbsp;Price per share | $115.20 | $122.06 | $119.59 |
| &nbsp;&nbsp;&nbsp;&nbsp;Aggregate value | $752 | $900 | $850 |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent vested | 100% | 100% | 100% |
| **Directors restricted stock units (including dividend equivalents):** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares | 9582 | 4854 | 9479 |
| &nbsp;&nbsp;&nbsp;&nbsp;Price per share | $114.84 | $120.16 | $117.73 |
| &nbsp;&nbsp;&nbsp;&nbsp;Aggregate value | $1100 | $583 | $1116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent vested | 100% | 100% | 100% |
| **Employees restricted stock units:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares | 106089 | 101011 | 96975 |
| &nbsp;&nbsp;&nbsp;&nbsp;Price per share | $127.43 | $127.29 | $120.18 |
| &nbsp;&nbsp;&nbsp;&nbsp;Aggregate value | $13519 | $12858 | $11654 |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent vested | —% | —% | —% |
| **Performance shares:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Target shares | 148688 | 96800 | 81300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Target price per share | $127.44 | $128.40 | $120.49 |
| &nbsp;&nbsp;&nbsp;&nbsp;Aggregate value | $18948 | $12429 | $9796 |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent vested | —% | —% | —% |

---

(1)Includes dividend equivalent units.

Time-vested restricted stockholders are entitled to dividend payments on the unvested stock. Director restricted stock unit holders are entitled to dividend equivalents. These equivalents are granted in the form of additional restricted stock units and vest immediately upon grant. Dividend equivalents are applicable only to directors' restricted stock units and beginning in 2025 employee performance shares and restricted stock unit awards. Prior to 2025, the performance awards and restricted stock units held by employees were not entitled to dividend equivalents and not entitled to dividend payments until the shares vest and are settled.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

An analysis of nonvested restricted stock is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Executive<br>Performance<br>Shares** | **Directors<br>Restricted<br>Stock** | **Directors<br>Restricted<br>Stock<br>Units** | **Employees**<br>**Restricted**<br>**Stock**<br>**Units** | **Total** |
| **2023:** | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at December 31, 2022 | 398535 |  |  |  | 398535 |
| Grants | 81300 | 7110 | 9479 | 96975 | 194864 |
| Additional performance shares<sup>(1)</sup> | (28857) |  |  |  | (28857) |
| Restriction lapses | (84298) | (7110) | (9479) |  | (100887) |
| Forfeitures | (12600) |  |  | (4410) | (17010) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at December 31, 2023 | 354080 |  |  | 92565 | 446645 |
| **2024:** |  |  |  |  |  |
| Grants | 96800 | 7375 | 4854 | 101011 | 210040 |
| Additional performance shares<sup>(1)</sup> | 84712 |  |  |  | 84712 |
| Restriction lapses | (143211) | (7375) | (4854) | (437) | (155877) |
| Forfeitures | (6000) |  |  | (10008) | (16008) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at December 31, 2024 | 386381 |  |  | 183131 | 569512 |
| **2025:** |  |  |  |  |  |
| Grants | 148688 | 6530 | 9582 | 106089 | 270889 |
| Additional performance shares<sup>(1)</sup> | 83626 |  |  |  | 83626 |
| Restriction lapses | (152680) | (6530) | (9582) | (2473) | (171265) |
| Forfeitures |  |  |  | (20399) | (20399) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at December 31, 2025 | 466015 |  |  | 266348 | 732363 |

---

(1)Estimated additional (reduced) share grants expected due to achievement of performance criteria.

An analysis of the weighted-average grant-date fair values per share of non-vested restricted stock is as follows for the year 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Executive Performance Shares** | **Directors Restricted Stock** | **Directors Restricted Stock Units** | **Employees**<br>**Restricted**<br>**Stock**<br>**Units** |
| **Grant-date fair value per share at January 1, 2025**  | $115.78 | $— | $— | $124.02 |
| Grants | 127.44 | 115.20 | 114.34 | 127.18 |
| Estimated additional performance shares | 126.75 |  |  |  |
| Restriction lapses | (103.23) | (115.20) | (114.34) | (119.99) |
| Forfeitures |  |  |  | (125.89) |
| **Grant-date fair value per share at December 31, 2025**  | 125.58 |  |  | 125.17 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

**Note 15—Business Segments** 

Globe Life is organized into three operating segments: life, health, and investments.

Globe Life's reportable insurance segments are based on the insurance product lines it markets and administers: life insurance and supplemental health insurance. There is also an investment segment that manages the investment portfolio and cash flow for the insurance segments. The Company's chief operating decision makers (the "CODM"), our Co-CEOs, evaluate the overall performance of the operations of the Company in accordance with these segments.

Life insurance products marketed by Globe Life include traditional whole life and term life insurance. Health insurance products are generally guaranteed renewable and include Medicare Supplement, cancer, critical illness, accident, and other limited-benefit supplemental hospital and surgical products.

The following tables present segment premium revenue by each of Globe Life's distribution channels.

**Premium Income by Distribution Channel**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year 2025** | **For the Year 2025** | **For the Year 2025** | **For the Year 2025** | **For the Year 2025** | **For the Year 2025** |
| | **Life** | **Life** | **Health** | **Health** | **Total** | **Total** |
|<br>**Distribution Channel** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** | **Amount** | **% of<br>Total** |
| American Income | $1791356 | 53 | $124947 | 8 | $1916303 | 39 |
| Direct to Consumer | 981006 | 29 | 76514 | 5 | 1057520 | 21 |
| Liberty National | 390094 | 12 | 190468 | 12 | 580562 | 12 |
| United American | 6188 |  | 666758 | 44 | 672946 | 14 |
| Family Heritage | 7404 |  | 468063 | 31 | 475467 | 10 |
| Other | 187422 | 6 |  |  | 187422 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total premium | $3363470 | 100 | $1526750 | 100 | $4890220 | 100 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year 2024** | **For the Year 2024** | **For the Year 2024** | **For the Year 2024** | **For the Year 2024** | **For the Year 2024** |
| | **Life** | **Life** | **Health** | **Health** | **Total** | **Total** |
|<br>**Distribution Channel** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** |
| American Income | $1698209 | 52 | $123123 | 9 | $1821332 | 39 |
| Direct to Consumer | 988522 | 30 | 71993 | 5 | 1060515 | 23 |
| Liberty National | 371061 | 12 | 190381 | 14 | 561442 | 12 |
| United American | 6600 |  | 591774 | 42 | 598374 | 13 |
| Family Heritage | 6661 |  | 427654 | 30 | 434315 | 9 |
| Other | 190294 | 6 |  |  | 190294 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total premium | $3261347 | 100 | $1404925 | 100 | $4666272 | 100 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year 2023** | **For the Year 2023** | **For the Year 2023** | **For the Year 2023** | **For the Year 2023** | **For the Year 2023** |
| | **Life** | **Life** | **Health** | **Health** | **Total** | **Total** |
|<br>**Distribution Channel** | **Amount** | **% of**<br>**Total** | **Amount** | **% of**<br>**Total** | **Amount** | **% of<br>Total** |
| American Income | $1588702 | 51 | $120332 | 9 | $1709034 | 38 |
| Direct to Consumer | 991406 | 32 | 68575 | 5 | 1059981 | 24 |
| Liberty National | 349736 | 11 | 187934 | 14 | 537670 | 12 |
| United American | 7311 |  | 545723 | 42 | 553034 | 13 |
| Family Heritage | 6134 |  | 396209 | 30 | 402343 | 9 |
| Other | 193955 | 6 |  |  | 193955 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total premium | $3137244 | 100 | $1318773 | 100 | $4456017 | 100 |

---

Due to the nature of the life and health insurance industry, Globe Life has no individual or group which would be considered a major customer. Substantially all of Globe Life's business is conducted in the United States.

The measure of profitability established by the CODMs for the insurance segments is underwriting margin before other income and administrative expenses, in accordance with the manner in which the segments are managed. It essentially represents gross profit margin on insurance products before insurance administrative expenses and consists primarily of premium less net policy benefits, acquisition expenses, and commissions. Required interest on policy liabilities is reflected as a component of the Investment segment (rather than as a component of underwriting margin in the insurance segment) in order to match this cost with the investment income earned on the assets supporting the policy liabilities.

The measure of profitability for the Investment segment is excess investment income, representing the net income earned on the investment portfolio in excess of policy requirements. Other than the required interest on the insurance segments, no other intersegment revenues or expenses are recognized. Expenses directly attributable to corporate operations are included in the "Corporate & Other" category. Stock-based compensation expense is considered a corporate expense by Globe Life management and is included in this category. All other unallocated revenues and expenses on a pretax basis, including insurance administrative expense and interest on debt, are also included in the "Corporate & Other" segment category.

Globe Life holds a sizable investment portfolio to support its insurance liabilities, the yield from which is used to offset policy benefit, acquisition, administrative, and tax expenses. This yield or investment income is taken into account when establishing premium rates and profitability expectations for its insurance products. From time to time, investments are sold or called, or experience a credit loss event, each of which are reflected by the Company as realized gain (loss)—investments. These gains or losses generally occur as a result of disposition due to issuer calls, compliance with Company investment policies, or other reasons often beyond management's control. Unlike investment income, realized gains and losses are incidental to insurance operations, and only overall yields are considered when setting premium rates or insurance product profitability expectations. While these gains and losses are not relevant to segment profitability or core operating results, they can have a material positive or negative result on net income. For these reasons, management removes realized investment gains and losses when it views its segment operations.

Management also removes non-operating items unrelated to the Company's core insurance activities when evaluating those results. Therefore, these items are excluded in its presentation of segment results because accounting guidance requires that operating segment results be presented as management views its business. All of these items are included in "Other operating expense" on the *[Consolidated Statements of Operations](#ia1583f94e55d42afa319983b2df261d2_436)* for the appropriate year. See additional detail below in the tables.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| **Revenue:** | | | | |
| &nbsp;&nbsp;Premium | $3363470 | $1526750 | $— | $4890220 |
| &nbsp;&nbsp;Net investment income |  |  | 1130198 | 1130198 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment revenue | 3363470 | 1526750 | 1130198 | 6020418 |
| &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | (27788) |
| &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | 1688 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue  | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue  | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue  | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue  | $5994318 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;Policy obligations<sup>(1)</sup> | 1924929 | 931141 | 22415 | 2878485 |
| &nbsp;&nbsp;Required interest on reserves | (845875) | (113832) | 969390 | 9683 |
| &nbsp;&nbsp;Amortization of acquisition costs | 386450 | 59897 |  | 446347 |
| &nbsp;&nbsp;Commissions | 174029 | 173490 |  | 347519 |
| &nbsp;&nbsp;Premium taxes | 68132 | 29825 |  | 97957 |
| &nbsp;&nbsp;Non-deferred acquisition costs | 146444 | 56101 |  | 202545 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment profit or (loss)  | $1509361 | $390128 | $138393 | 2037882 |
| &nbsp;&nbsp;**Insurance administrative expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | 137015 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | 41609 |
| &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | 82573 |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | 22510 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | 71888 |
| &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | 14182 |
| &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | 53355 |
| &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | 141221 |
| &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | 17053 |
| &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | 2183 |
| &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | (7782) |
| &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | 4558343 |
| **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | $1435975 |

---

(1)Policy obligations are based upon policyholder behavior and impacts related to lapses, mortality, and morbidity. For detailed information, including remeasurement gains and losses, see *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613).* 

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| **Revenue:** | | | | |
| &nbsp;&nbsp;Premium | $3261347 | $1404925 | $— | $4666272 |
| &nbsp;&nbsp;Net investment income |  |  | 1135631 | 1135631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment revenue | 3261347 | 1404925 | 1135631 | 5801903 |
| Realized gains (losses) | Realized gains (losses) | Realized gains (losses) | Realized gains (losses) | (24188) |
| Other income | Other income | Other income | Other income | 354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | $5778069 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;Policy obligations<sup>(1)</sup>  | 2000977 | 851577 | 20969 | $2873523 |
| &nbsp;&nbsp;Required interest on reserves | (811147) | (110342) | 950258 | 28769 |
| &nbsp;&nbsp;Amortization of acquisition costs | 356223 | 52224 |  | 408447 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commissions | 159703 | 158869 |  | 318572 |
| &nbsp;&nbsp;&nbsp;&nbsp;Premium taxes | 68360 | 28421 |  | 96781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-deferred acquisition costs | 134634 | 51753 |  | 186387 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment profit or (loss)  | $1352597 | $372423 | $164404 | 1889424 |
| &nbsp;&nbsp;**Insurance administrative expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | 129369 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | 36176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | 80555 |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | 30478 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | 65852 |
| &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | 12400 |
| &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | 40118 |
| &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | 127092 |
| &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | 21575 |
| &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | 2620 |
| &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | (7282) |
| &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | &nbsp;&nbsp;&nbsp;&nbsp; Total expenses | 4451432 |
| **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | **Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | $1326637 |

---

(1)Policy obligations are based upon policyholder behavior and impacts related to lapses, mortality, and morbidity. For detailed information, including remeasurement gains and losses, see *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613).* 

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| **Revenue:** | | | | |
| &nbsp;&nbsp;Premium | $3137244 | $1318773 | $— | $4456017 |
| &nbsp;&nbsp;Net investment income |  |  | 1056884 | 1056884 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment revenue | 3137244 | 1318773 | 1056884 | 5512901 |
| &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | &nbsp;&nbsp;Realized gains (losses) | (65676) |
| &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | &nbsp;&nbsp;Other income | 308 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | &nbsp;&nbsp;&nbsp;&nbsp;Total consolidated revenue | $5447533 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;Policy obligations<sup>(1)</sup>  | 2050789 | 776362 | 9061 | $2836212 |
| &nbsp;&nbsp;Required interest on reserves | (772701) | (106516) | 917441 | 38224 |
| &nbsp;&nbsp;Amortization of acquisition costs | 327426 | 50598 |  | 378024 |
| &nbsp;&nbsp;Commissions | 145678 | 150192 |  | 295870 |
| &nbsp;&nbsp;Premium taxes | 64571 | 26440 |  | 91011 |
| &nbsp;&nbsp;Non-deferred acquisition costs | 128509 | 43760 |  | 172269 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment profit or (loss) | $1192972 | $377937 | $130382 | 1701291 |
| &nbsp;&nbsp;**Insurance administrative expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | &nbsp;&nbsp;&nbsp;&nbsp;Salaries | 119699 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | &nbsp;&nbsp;&nbsp;&nbsp;Other employee costs | 35905 |
| &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | &nbsp;&nbsp;&nbsp;&nbsp;Information technology costs | 64998 |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | &nbsp;&nbsp;&nbsp;&nbsp;Legal costs | 15335 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | &nbsp;&nbsp;&nbsp;&nbsp;Other administrative costs | 65224 |
| &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | &nbsp;&nbsp;Parent expense | 10866 |
| &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | &nbsp;&nbsp;Stock-based compensation expense | 30736 |
| &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | 102316 |
| &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | &nbsp;&nbsp;Legal proceedings | 900 |
| &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | &nbsp;&nbsp;Other expenses | 4170 |
| &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | &nbsp;&nbsp;Annuity | (8492) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 4253267 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | &nbsp;&nbsp;&nbsp;&nbsp;**Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | &nbsp;&nbsp;&nbsp;&nbsp;**Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | &nbsp;&nbsp;&nbsp;&nbsp;**Income before income taxes per *[Consolidated Statement of Operations](#ia1583f94e55d42afa319983b2df261d2_436)***  | $1194266 |

---

(1)Policy obligations are based upon policyholder behavior and impacts related to lapses, mortality, and morbidity. For detailed information, including remeasurement gains and losses, see *[Note 6—Policy Liabilities](#ia1583f94e55d42afa319983b2df261d2_613).* 

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Assets for each segment are reported based on a specific identification basis. The insurance segments' assets contain DAC. The investment segment includes the investment portfolio, cash, and accrued investment income. Goodwill is assigned to the insurance segments at the time of purchase. All other assets are included in the annuity and other corporate category. The tables below reconcile segment assets to total assets as reported on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*.

**Assets by Segment**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| Cash and invested assets | $— | $— | $20614713 | $20614713 |
| Accrued investment income |  |  | 272818 | 272818 |
| Deferred acquisition costs | 6147750 | 851386 |  | 6999136 |
| Goodwill | 309609 | 180837 |  | 490446 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total segment assets  | $6457359 | $1032223 | $20887531 | 28377113 |
| Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | 2436579 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | $30813692 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| Cash and invested assets | $— | $— | $19736888 | $19736888 |
| Accrued investment income |  |  | 269791 | 269791 |
| Deferred acquisition costs | 5700755 | 793421 |  | 6494176 |
| Goodwill | 309609 | 180837 |  | 490446 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total segment assets  | $6010364 | $974258 | $20006679 | 26991301 |
| Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | 2084880 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets**  | $29076181 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.**

**Notes to Consolidated Financial Statements**

(Dollar amounts in thousands, except per share data)

Liabilities for each segment are reported also on a specific identification basis similar to the assets. The insurance segments' liabilities contain future policy benefits, unearned and advance premiums, and policy claims and other benefits payable. Other policyholders' funds and annuities are included in annuity and other corporate as well as current and deferred income taxes payable. Debt represents both short and long-term. The tables below reconcile segment liabilities to total liabilities as reported on the *[Consolidated Balance Sheets](#ia1583f94e55d42afa319983b2df261d2_433)*.

**Liabilities by Segment**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| Future policy benefits | $16123927 | $2465091 | $— | $18589018 |
| Unearned and advance premiums | 199011 | 71652 |  | 270663 |
| Policy claims and other benefits payable | 315595 | 225237 |  | 540832 |
| Debt |  |  | 2625449 | 2625449 |
| Other | 95047 |  | 437000 | 532047 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total segment liabilities**  | $16733580 | $2761980 | $3062449 | 22558009 |
| Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | 2281104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | $24839113 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
| | **Life** | **Health** | **Investment** | **Consolidated** |
| Future policy benefits | $15484596 | $2316094 | $— | $17800690 |
| Unearned and advance premiums | 198127 | 59504 |  | 257631 |
| Policy claims and other benefits payable | 321838 | 210994 |  | 532832 |
| Debt |  |  | 2739652 | 2739652 |
| Other | 96604 |  | 372000 | 468604 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total segment liabilities**  | $16101165 | $2586592 | $3111652 | 21799409 |
| Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | Annuity and other corporate | 1971252 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities**  | $23770661 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES**

None.

**Item 9A. Controls and Procedures** 

*<u>Evaluation of Disclosure Controls and Procedures</u>*: Globe Life Inc., under the direction of the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, has established disclosure controls and procedures that are designed to ensure that information required to be disclosed by Globe Life in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. The disclosure controls and procedures are also intended to ensure that such information is accumulated and communicated to Globe Life's management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

As of the end of the fiscal year completed December 31, 2025, an evaluation was performed under the supervision and with the participation of Globe Life management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, of the disclosure controls and procedures (as those terms are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon their evaluation, the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer have concluded that disclosure controls and procedures are effective as of the date of this Form 10-K. In compliance with Section 302 of the Sarbanes Oxley Act of 2002 (18 U.S.C. § 1350), each of these officers executed a Certification included as an exhibit to this Form 10-K.

*<u>Management's Annual Report on Internal Control over Financial Reporting</u>*: Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Management evaluated the design and operating effectiveness of the Company's internal control over financial reporting based on the criteria established in *Internal Control*—*Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based upon their evaluation as of December 31, 2025, the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer have concluded that Globe Life's internal control over financial reporting is effective as of the date of this Form 10-K. In compliance with Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), each of these officers executed a Certification included as an exhibit to this Form 10-K.

*<u>Changes in Internal Control over Financial Reporting</u>*: During the period ended December 31, 2025, there were no changes to Globe Life Inc.'s internal control over financial reporting or in other factors that could significantly affect the internal control over financial reporting subsequent to the date of their evaluation which have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Refer to Deloitte & Touche LLP's, independent registered public accounting firm, attestation report on the Company's internal controls over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

Management at Globe Life is responsible for establishing and maintaining adequate internal control over financial reporting for the Company and for assessing the effectiveness of internal control on an annual basis. As a framework for assessing internal control over financial reporting, the Company utilizes the criteria for effective internal control over financial reporting described in *Internal Control*—*Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

There are inherent limitations in the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding of controls. Accordingly, even effective internal controls can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the effectiveness of internal control may vary over time.

Management evaluated the Company's internal control over financial reporting, and based on its assessment, determined that the Company's internal control over financial reporting was effective as of December 31, 2025. The Company's independent registered public accounting firm has issued an attestation report on the Company's internal control over financial reporting as stated in their report which is included herein.

---

| |
|:---|
| /s/ J. Matthew Darden |
| J. Matthew Darden<br>Co-Chairman and Chief Executive Officer |
| /s/ Frank M. Svoboda |
| Frank M. Svoboda<br>Co-Chairman and Chief Executive Officer |
| /s/ Thomas P. Kalmbach |
| Thomas P. Kalmbach<br>Executive Vice President and Chief Financial Officer |

---

February 25, 2026

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Shareholders and the Board of Directors of Globe Life Inc.

**Opinion on Internal Control over Financial Reporting**

We have audited the internal control over financial reporting of Globe Life Inc. and subsidiaries (the "Company") as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedules as of and for the year ended December 31, 2025 of the Company and our report dated February 25, 2026, expressed an unqualified opinion on those financial statements and financial statement schedules.

**Basis for Opinion** 

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

**Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Dallas, Texas

February 25, 2026

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Item 9B. Other Information**

(b) Trading arrangements

During the three months ended December 31, 2025, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a Non-Rule 10b5-1 trading arrangement, as each term is defined under Item 408(a) of Regulation S-K.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

Not Applicable.

**PART III**

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

**ITEM 11. EXECUTIVE COMPENSATION**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

**1. Equity Compensation Plan Information as of December 31, 2025**

---

| | | | |
|:---|:---|:---|:---|
| | **(a)** | **(b)** | **(c)** |
|<br>**Plan Category** | **Number of securities to be issued upon exercise of outstanding options, warrants, and rights** | **Weighted-average exercise price of outstanding options, warrants, and rights** | **Number of securities remaining available for future issuance under equity compensation plans (excluding securities in column (a))** |
| Equity compensation plans approved by security holders | 4303944 | $106.34 | 2898770 |
| Equity compensation plans not approved by security holders |  |  |  |
| Total | 4303944 | $106.34 | 2898770 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Security ownership of certain beneficial owners:**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Security ownership of management:**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Changes in control:**

Globe Life knows of no arrangements, including any pledges by any person of its securities, the operation of which may at a subsequent date result in a change of control.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

Index of documents filed as a part of this report:

---

| | |
|:---|:---|
| | **Page of this report** |
| Financial Statements: |  |
| Globe Life Inc. and Subsidiaries: |  |
| &nbsp;&nbsp;[Report of Independent Registered Public Accounting Firm](#ia1583f94e55d42afa319983b2df261d2_424) | [55](#ia1583f94e55d42afa319983b2df261d2_424) |
| &nbsp;&nbsp;[Consolidated Balance Sheets at](#ia1583f94e55d42afa319983b2df261d2_433)December 31, 2025[and](#ia1583f94e55d42afa319983b2df261d2_433)2024 | [57](#ia1583f94e55d42afa319983b2df261d2_433) |
| &nbsp;&nbsp;[Consolidated Statements of Operations for each of the three years in the period ended](#ia1583f94e55d42afa319983b2df261d2_436)December 31, 2025 | [58](#ia1583f94e55d42afa319983b2df261d2_436) |
| &nbsp;&nbsp;[Consolidated Statements of Comprehensive Income for each of the three years in the period ended](#ia1583f94e55d42afa319983b2df261d2_439)December 31, 2025 | [59](#ia1583f94e55d42afa319983b2df261d2_439) |
| &nbsp;&nbsp;[Consolidated Statements of Shareholders' Equity for each of the three years in the period ended](#ia1583f94e55d42afa319983b2df261d2_442)December 31, 2025 | [60](#ia1583f94e55d42afa319983b2df261d2_442) |
| &nbsp;&nbsp;[Consolidated Statements of Cash Flows for each of the three years in the period ended](#ia1583f94e55d42afa319983b2df261d2_445)December 31, 2025 | [61](#ia1583f94e55d42afa319983b2df261d2_445) |
| &nbsp;&nbsp;[Notes to Consolidated Financial Statements](#ia1583f94e55d42afa319983b2df261d2_448) | [62](#ia1583f94e55d42afa319983b2df261d2_448) |
| Schedules Supporting Financial Statements for each of the three years in the period ended December 31, 2025: |  |
| [II. Condensed Financial Information of Registrant (Parent Company)](#ia1583f94e55d42afa319983b2df261d2_1018) | [149](#ia1583f94e55d42afa319983b2df261d2_1018) |
| [IV. Reinsurance (Consolidated)](#ia1583f94e55d42afa319983b2df261d2_1021) | [153](#ia1583f94e55d42afa319983b2df261d2_1021) |
| Schedules not referred to have been omitted as inapplicable or not required by Regulation S-X. | Schedules not referred to have been omitted as inapplicable or not required by Regulation S-X. |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**EXHIBITS**

---

| | | | |
|:---|:---|:---|:---|
| **Exhibit No.** | **Description** | **Form** | **Filing Date** |
| 3.1 | [Restated Certificate of Incorporation of Globe Life Inc.](https://www.sec.gov/Archives/edgar/data/320335/000032033519000033/a32restatedcertificateof.htm) | 8-K | August 8, 2019 |
| 3.2 | [Certificate of Amendment of Certificate of Incorporation of Globe Life Inc.](https://www.sec.gov/Archives/edgar/data/320335/000032033523000025/certificateofamendmentof.htm) | 8-K | May 2, 2023 |
| 3.3 | [Amended and Restated By-Laws of Globe Life Inc., as amended August 10, 2023](https://www.sec.gov/Archives/edgar/data/320335/000032033523000046/globelifeincamendedandre.htm) | 8-K | August 15, 2023 |
| 4.1 | [Junior Subordinated Indenture, dated November 2, 2001, between Torchmark Corporation and The Bank of New York defining the rights of the 7 3/4% Junior Subordinated Debentures](https://www.sec.gov/Archives/edgar/data/320335/000093176301501911/dex43.txt) | 8-K | November 2, 2001 |
| 4.2 | [Third Supplemental Indenture dated as of November 17, 2017 between Torchmark Corporation and Regions Bank, as Trustee, supplementing the Junior Subordinated Indenture dated as of November 2, 2001](https://www.sec.gov/Archives/edgar/data/320335/000032033517000048/a3rdsupplementalindenture1.htm) | 8-K | November 17, 2017 |
| 4.3 | [Fourth Supplemental Indenture dated as of June 14, 2021 between Globe Life Inc. and Regions Bank, as Trustee, supplementing the Junior Subordinated Indenture dated as of November 2, 2001](https://www.sec.gov/Archives/edgar/data/320335/000119312521190034/d185215dex42.htm) | 8-K | June 14, 2021 |
| 4.4 | [Senior Indenture, dated as of September 24, 2018, between Torchmark Corporation and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000032033518000037/exhibit41torchmarkbaseinde.htm) | S-3 | September 24, 2018 |
| 4.5 | [First Supplemental Indenture, dated as of September 27, 2018, between Torchmark Corporation and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000032033518000041/exhibit42firstsupplemental.htm) | 8-K | September 27, 2018 |
| 4.6 | [Second Supplemental Indenture, dated as of August 21, 2020, between Globe Life Inc. and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000032033520000044/exhibit42secondsupplemen.htm) | 8-K | August 21, 2020 |
| 4.7 | [Third Supplemental Indenture, dated as of May 19, 2022, between Globe Life Inc. and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000119312522154612/d350057dex42.htm) | 8-K | May 19, 2022 |
| 4.8 | [Fourth Supplemental Indenture, dated as of August 23, 2024, between Globe Life Inc. and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000032033524000052/globelifeinc-fourthsupplem.htm) | 8-K | August 26, 2024 |
| 4.9 | [Fifth Supplemental Indenture, dated as of July 1, 2025, between Globe Life Inc. and Regions Bank, as Trustee](https://www.sec.gov/Archives/edgar/data/320335/000032033525000046/globelife-fifthsupplemen.htm) | 10-Q | August 6, 2025 |
| 10.1 | [Form of Retirement Life Insurance Benefit Agreement ($495,000 face amount limit)\*](https://www.sec.gov/Archives/edgar/data/320335/000093176302000748/dex10aa.txt) | 10-K | March 22, 2002 |
| 10.2 | [Amended and Restated Supplemental Executive Retirement Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033525000013/a10-kexhibit102.htm) | 10-K | February 26, 2025 |
| 10.3 | [Amendment One to the Globe Life Inc. Supplemental Executive Retirement Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033525000066/exhibit101amendmentonetoth.htm) | 8-K | November 6, 2025 |
| 10.4 | [Receivables Purchase Agreement dated as of December 31, 2008 among AILIC Receivables Corporation, American Income Life Insurance Company and TMK Re, Ltd.](https://www.sec.gov/Archives/edgar/data/320335/000119312509001571/dex101.htm) | 8-K | January 6, 2009 |
| 10.5 | [Amendment No.1 to Receivables Purchase Agreement dated as of December 31, 2013 among AILIC Receivables Corporation, American Income Life Insurance Company, and TMK Re, Ltd.](https://www.sec.gov/Archives/edgar/data/320335/000119312514076801/d622095dex1058.htm) | 10-K | February 28, 2014 |
| 10.6 | [Amendment No.2 to Receivables Purchase Agreement dated as of December 31, 2018 among AILIC Receivables Corporation, American Income Life Insurance Company, and TMK Re, Ltd.](https://www.sec.gov/Archives/edgar/data/320335/000032033519000006/tmk201810-kexhibit1017.htm) | 10-K | March 1, 2019 |
| 10.7 | [Amendment No. 3 to Receivables Purchase Agreement dated as of December 31, 2023 among AILIC Receivables Corporation, American Income Life Insurance Company, and TMK Re, Ltd.](a107amendmentno3receivab.htm) | 10-K | February 25, 2026 |
| 10.8 | [Torchmark Corporation 2011 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000119312511125948/dex101.htm) | 8-K | May 4, 2011 |
| 10.9 | [First Amendment to Torchmark Corporation 2011 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000119312514167194/d717090dex101.htm) | 8-K | April 29, 2014 |
| 10.10 | [Torchmark Corporation Amended 2011 Non-Employee Director Compensation Plan, effective January, 2017](https://www.sec.gov/Archives/edgar/data/320335/000032033517000010/tmk201610-kexhibit1055.htm)\* | 10-K | February 27, 2017 |
| 10.11 | [Form of Restricted Stock Unit Award Notice under Torchmark Corporation 2011 Non-Employee Director Compensation Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000119312511049737/dex1059.htm) | 10-K | February 28, 2011 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

---

| | | | |
|:---|:---|:---|:---|
| **Exhibit No.** | **Description** | **Form** | **Filing Date** |
| 10.12 | [Torchmark Corporation 2018 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033518000014/ex101tmk2018incentiveplan.htm) | 8-K | May 2, 2018 |
| 10.13 | [First Amendment to Torchmark Corporation 2018 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/0000320335/000032033520000008/gli201910-kexhibit1031.htm) | 10-K | February 27, 2020 |
| 10.14 | [Second Amendment to Globe Life Inc. 2018 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000030/secondamendmenttoglobeli.htm) | 10-Q | May 9, 2023 |
| 10.15 | [Second Amended and Restated Globe Life Inc. 2018 Non-Employee Director Compensation Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/gli202310-kexhibit1028.htm) | 10-K | February 28, 2024 |
| 10.16 | [Third Amended and Restated Globe Life Inc. 2018 Non-Employee Director Compensation Plan\*](a1016thirdamendedandrest.htm) | 10-K | February 25, 2026 |
| 10.17 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan\*](https://www.sec.gov/Archives/edgar/data/0000320335/000032033520000008/gli201910-kexhibit1036.htm) | 10-K | February 27, 2020 |
| 10.18 | [Form of Seven Year Stock Option under Torchmark Corporation 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions\*](https://www.sec.gov/Archives/edgar/data/320335/000032033518000014/ex1052018formof7yearstock.htm) | 8-K | May 2, 2018 |
| 10.19 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions\*](https://www.sec.gov/Archives/edgar/data/0000320335/000032033520000008/gli201910-kexhibit1038.htm) | 10-K | February 27, 2020 |
| 10.20 | [Form of Ten Year Stock Option under Torchmark Corporation 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions\*](https://www.sec.gov/Archives/edgar/data/320335/000032033518000014/ex1072018formoftenyearstoc.htm) | 8-K | May 2, 2018 |
| 10.21 | [Form of Stock Option under Globe Life Inc. 2018 Non-Employee Director Compensation Plan\*](https://www.sec.gov/Archives/edgar/data/0000320335/000032033520000008/gli201910-kexhibit1044.htm) | 10-K | February 27, 2020 |
| 10.22 | [Form of Restricted Stock Unit Award Notice under Globe Life Inc. 2018 Non-Employee Director Compensation Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033520000008/gli201910-kexhibit1046.htm)  | 10-K | February 27, 2020 |
| 10.23 | [Globe Life Inc. Management Incentive Plan (Effective as of January 1, 2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000056/globelifeincmanagementin.htm) | 8-K | November 9, 2023 |
| 10.24 | [Second Amended and Restated Credit Agreement dated as of March 29, 2024 among Bank of America, N.A., the Lenders party thereto, Globe Life Inc. and TMK RE, LTD](https://www.sec.gov/Archives/edgar/data/320335/000032033524000016/bofa-globelife2024revolv.htm) | 8-K | April 2, 2024 |
| 10.25 | [First Amendment to Second Amended and Restated Credit Agreement dated as of June 20, 2025 among Bank of America, N.A., the Lenders party thereto, Globe Life Inc. and TMK RE, LTD.](https://www.sec.gov/Archives/edgar/data/320335/000032033525000046/globelife-2025revolverxf.htm) | 10-Q | August 6, 2025 |
| 10.26 | [Delayed Draw Term Loan Agreement dated as of April 14, 2023 among Bank of America, N.A., as Administrative Agent, the Lenders party thereto, and Globe Life Inc.](https://www.sec.gov/Archives/edgar/data/320335/000032033523000022/bofa-globelifex2023terml.htm) | 8-K | April 18, 2023 |
| 10.27 | [First Amendment to Delayed Draw Term Loan Agreement dated as of August 15, 2024 among Bank of America, N.A., as Administrative Agent, the Lenders party thereto, and Globe Life Inc.](https://www.sec.gov/Archives/edgar/data/320335/000032033524000050/globelife-2024termloanre.htm) | 8-K | August 15, 2024 |
| 10.28 | [Second Amendment to Delayed Draw Term Loan Agreement dated as of June 20, 2025 among Bank of America, N.A., as Administrative Agent, the Lenders party thereto, and Globe Life Inc.](https://www.sec.gov/Archives/edgar/data/320335/000032033525000046/globelife-2025termloanxs.htm) | 10-Q | August 6, 2025 |
| 10.29 | [Form of Performance Share Award Certificate under Globe Life Inc. 2018 Incentive Plan (2023)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000008/gli202210-kexhibit1047xq4.htm) | 10-K | February 23, 2023 |
| 10.30 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan (2023)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000008/gli202210-kexhibit1048xq4.htm) | 10-K | February 23, 2023 |
| 10.31 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (2023)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000008/gli202210-kexhibit1049xq4.htm) | 10-K | February 23, 2023 |
| 10.32 | [Form of Restricted Stock Unit Award Certificate under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions\*](https://www.sec.gov/Archives/edgar/data/320335/000032033523000008/gli202210-kexhibit1051xq4.htm) | 10-K | February 23, 2023 |
| 10.33 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan (2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/gli202310-kexhibit1053xq4.htm) | 10-K | February 28, 2024 |
| 10.34 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/gli202310-kexhibit1054xq4.htm) | 10-K | February 28, 2024 |
| 10.35 | [Form of Restricted Stock Unit Award Certificate under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/gli202310-kexhibit1057xq4.htm) | 10-K | February 28, 2024 |
| 10.36 | [Form of Performance Share Award Certificate under Globe Life Inc. 2018 Incentive Plan (2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/gli202310-kexhibit1058xq4.htm) | 10-K | February 28, 2024 |
| 10.37 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan (November 2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000067/a102formofemployee7-yearst.htm) | 8-K | November 19, 2024 |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

---

| | | | |
|:---|:---|:---|:---|
| **Exhibit No.** | **Description** | **Form** | **Filing Date** |
| 10.38 | [Form of Seven Year Stock Option under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (November 2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000067/a103formofemployee7-yearst.htm) | 8-K | November 19, 2024 |
| 10.39 | [Form of Restricted Stock Unit Award Agreement under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (November 2024)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000067/a106formofrsuagmntundergl2.htm) | 8-K | November 19, 2024 |
| 10.40 | [Form of Performance Share Award Certificate under Globe Life Inc. 2018 Incentive Plan (2025)\*](https://www.sec.gov/Archives/edgar/data/320335/000032033525000013/a10-kexhibit1042.htm) | 10-K | February 26, 2025 |
| 10.41 | [Form of Seven Year Stock Option Grant Agreement under Globe Life Inc. 2018 Incentive Plan (2026)\*](a10412026employee7-yrsoa.htm) | 10-K | February 25, 2026 |
| 10.42 | [Form of Seven Year Stock Option Grant Agreement under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (2026)\*](a10422026employee7-yrsoa.htm) | 10-K | February 25, 2026 |
| 10.43 | [Form of Restricted Stock Unit Award Agreement under Globe Life Inc. 2018 Incentive Plan (2026)\*](a10432026employeersuagmn.htm) | 10-K | February 25, 2026 |
| 10.44 | [Form of Restricted Stock Unit Award Agreement under Globe Life Inc. 2018 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions (2026)\*](a10442026employeersuagmn.htm) | 10-K | February 25, 2026 |
| 10.45 | [Form of Performance Share Award Certificate under Globe Life Inc. 2018 Incentive Plan (2026)\*](a10452026employeepsaward.htm) | 10-K | February 25, 2026 |
| 10.46 | [Globe Life Inc. Executive Severance Plan\*](https://www.sec.gov/Archives/edgar/data/320335/000032033524000067/a101glexecutiveseverancepl.htm) | 8-K | November 19, 2024 |
| 10.47 | [Globe Life Inc. Long-Term Disability Benefits Summary\*](a1047executivelong-termd.htm) | 10-K | February 25, 2026 |
| 19 | [Globe Life Inc. Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/320335/000032033525000013/aex19globelifeincinsidertr.htm) | 10-K | February 26, 2025 |
| 21 | [Subsidiaries of the Registrant](a10-kexhibit21q42025.htm) | 10-K | February 25, 2026 |
| 23 | [Consent of Deloitte & Touche LLP](a10-kexhibit23q42025.htm) | 10-K | February 25, 2026 |
| 24 | [Powers of Attorney](a10-kexhibit24q42025.htm) | 10-K | February 25, 2026 |
| 31.1 | [Rule 13a-14(a)/15d-14(a) Certification by J. Matthew Darden](a10-kex311dardenq4fy2025.htm) | 10-K | February 25, 2026 |
| 31.2 | [Rule 13a-14(a)/15d-14(a) Certification by Frank M. Svoboda](a10-kex312svobodaq4fy2025.htm) | 10-K | February 25, 2026 |
| 31.3 | [Rule 13a-14(a)/15d-14(a) Certification by Thomas P. Kalmbach](a10-kex313kalmbachq4fy2025.htm) | 10-K | February 25, 2026 |
| 32.1 | [Section 1350 Certification by J. Matthew Darden, Frank M. Svoboda](a10-kexhibit321allq4fy2025.htm)<u>[,](a10-kexhibit321allq4fy2025.htm)</u>[and Thomas P. Kalmbach](a10-kexhibit321allq4fy2025.htm) | 10-K | February 25, 2026 |
| 97 | [Globe Life Inc. Clawback Policy](https://www.sec.gov/Archives/edgar/data/320335/000032033524000006/a10-kexhibit97q42023.htm) | 10-K | February 26, 2024 |
| 101.INS | XBRL Instance Document- the instance document does not appear in the Interactive Data file because the XBRL tags are embedded within the Inline XBRL document. | 10-K | February 25, 2026 |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | 10-K | February 25, 2026 |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | 10-K | February 25, 2026 |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | 10-K | February 25, 2026 |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | 10-K | February 25, 2026 |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | 10-K | February 25, 2026 |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). | 10-K | February 25, 2026 |

---

\* Compensatory plan or arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**(PARENT COMPANY)**

**SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT**

**Condensed Balance Sheets**

(Dollar amounts in thousands)

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Investments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term investments | $32677 | $39404 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 28006 | 29005 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments | 60683 | 68409 |
| &nbsp;&nbsp;&nbsp;Cash | 62865 | 66770 |
| &nbsp;&nbsp;&nbsp;Investment in affiliates | 8541107 | 7740073 |
| &nbsp;&nbsp;&nbsp;Due from affiliates | 68127 | 278301 |
| &nbsp;&nbsp;&nbsp;Taxes receivable from affiliates | 4310 | 15202 |
| &nbsp;&nbsp;&nbsp;Other assets | 212355 | 193363 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $8949447 | $8362118 |
| **Liabilities and shareholders' equity:** |  |  |
| **Liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Short-term debt | $304656 | $415401 |
| &nbsp;&nbsp;&nbsp;Long-term debt | 2470459 | 2473874 |
| &nbsp;&nbsp;&nbsp;Due to affiliates | 36370 | 52568 |
| &nbsp;&nbsp;&nbsp;Other liabilities | 163383 | 114755 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2974868 | 3056598 |
| **Shareholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock | 351 | 351 |
| &nbsp;&nbsp;&nbsp;Common stock | 92218 | 97218 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 886874 | 878306 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | (1771444) | (2029720) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 8546807 | 8002521 |
| &nbsp;&nbsp;&nbsp;Treasury stock | (1780227) | (1643156) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 5974579 | 5305520 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $8949447 | $8362118 |

---

See Notes to Consolidated Financial Statements and accompanying Report of Independent Registered

Public Accounting Firm.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**(PARENT COMPANY)**

**SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT (continued)**

**Condensed Statement of Operations**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net investment income | $32889 | $38341 | $36237 |
| Realized gains (losses) | 5793 | 4158 | 5924 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue**  | 38682 | 42499 | 42161 |
| General operating expenses | 94021 | 75387 | 59051 |
| Reimbursements from affiliates | (75504) | (53136) | (59796) |
| Interest expense | 147673 | 125023 | 107180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total expenses**  | 166190 | 147274 | 106435 |
| Operating income (loss) before income taxes and equity in earnings of affiliates | (127508) | (104775) | (64274) |
| Income tax benefit | 16005 | 19832 | 10706 |
| Net operating loss before equity in earnings of affiliates | (111503) | (84943) | (53568) |
| Equity in earnings of affiliates, net of tax | 1272741 | 1155705 | 1024323 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income**  | 1161238 | 1070762 | 970755 |
| **Other comprehensive income (loss):** |  |  |  |
| &nbsp;&nbsp;&nbsp;Attributable to Parent Company | 10539 | 21326 | 1113 |
| &nbsp;&nbsp;&nbsp;Attributable to affiliates | 247737 | 721373 | 16781 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) | $1419514 | $1813461 | $988649 |

---

See Notes to Consolidated Financial Statements and accompanying Report of Independent Registered

Public Accounting Firm.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**(PARENT COMPANY)**

**SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT (continued)**

**Condensed Statement of Cash Flows**

(Dollar amounts in thousands)

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net income | $1161238 | $1070762 | $970755 |
| Equity in earnings of subsidiaries | (1272741) | (1155705) | (1024323) |
| Cash dividends from subsidiaries | 815741 | 692690 | 459535 |
| Other, net | 79549 | 55243 | 33846 |
| **Cash provided from operations**  | 783787 | 662990 | 439813 |
| **Cash provided from (used for) investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net decrease (increase) in short-term investments | 999 | (28000) | 13996 |
| &nbsp;&nbsp;&nbsp;Investment in subsidiaries | (66300) | (12) |  |
| &nbsp;&nbsp;&nbsp;Acquisition of investments |  | (2850) | (3950) |
| &nbsp;&nbsp;&nbsp;Disposition of investments |  | 1 |  |
| &nbsp;&nbsp;&nbsp;Loaned money to affiliates | (365382) | (557016) | (479629) |
| &nbsp;&nbsp;&nbsp;Repayments from affiliates | 614960 | 394925 | 505929 |
| &nbsp;&nbsp;&nbsp;Additions to properties | (353) | (19147) | (7400) |
| **Cash provided from (used for) investing activities**  | 183924 | (212099) | 28946 |
| **Cash provided from (used for) financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Repayment of debt |  |  | (165612) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of debt |  | 530000 | 170000 |
| &nbsp;&nbsp;&nbsp;Payment for debt issuance costs | (6399) | (7253) | (757) |
| &nbsp;&nbsp;&nbsp;Net change in commercial paper held less than 90 days | 102638 | (13878) | 32961 |
| &nbsp;&nbsp;&nbsp;Proceeds from commercial paper with original maturities greater than 90 days | 487610 | 484726 |  |
| &nbsp;&nbsp;&nbsp;Repayment of commercial paper with original maturities greater than 90 days | (700993) | (372011) |  |
| &nbsp;&nbsp;&nbsp;Issuance of stock | 164448 | 51756 | 114080 |
| &nbsp;&nbsp;&nbsp;Acquisitions of treasury stock | (880983) | (1002109) | (511100) |
| &nbsp;&nbsp;&nbsp;Borrowed money from affiliate | 312000 | 349000 | 290500 |
| &nbsp;&nbsp;&nbsp;Repayments to affiliates | (340600) | (296600) | (290500) |
| &nbsp;&nbsp;&nbsp;Payment of dividends | (109337) | (108755) | (107386) |
| **Cash provided from (used for) financing activities**  | (971616) | (385124) | (467814) |
| Net increase (decrease) in cash | (3905) | 65767 | 945 |
| Cash balance at beginning of period | 66770 | 1003 | 58 |
| Cash balance at end of period | $62865 | $66770 | $1003 |

---

See Notes to Consolidated Financial Statements and accompanying Report of Independent Registered

Public Accounting Firm.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**(PARENT COMPANY)**

**SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT (continued)**

**Notes to Condensed Financial Statements**

(Dollar amounts in thousands)

**Note A—Dividends from Subsidiaries**

Cash dividends paid to Globe Life from the subsidiaries were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Dividends from subsidiaries | $815741 | $692690 | $459535 |

---

**Note B—Supplemental Disclosures of Cash Flow Information**

The following table summarizes non-cash transactions, which are not reflected on the *[Consolidated Statements of Cash Flows](#ia1583f94e55d42afa319983b2df261d2_445)*:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Stock-based compensation not involving cash | $53355 | $40118 | $30736 |
| Investment in subsidiaries | 640065 |  |  |
| Dividends from subsidiaries | 640065 |  |  |

---

The following table summarizes certain amounts paid (received) during the period:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Interest paid | $150019 | $114459 | $104493 |
| Income taxes paid (received) | (21033) | (13126) | (10408) |

---

**Note C—Preferred Stock**

As of December 31, 2025, Globe Life had 351 thousand shares of Cumulative Preferred Stock, Series A, issued and outstanding, of which 280 thousand shares were 6.50% Cumulative Preferred Stock, Series A, and 71 thousand shares were 7.15% Cumulative Preferred Stock, Series A (collectively, the "Series A Preferred Stock"). All issued and outstanding shares of Series A Preferred Stock were held by wholly-owned insurance subsidiaries. In the event of liquidation, the holders of the Series A Preferred Stock at the time outstanding would be entitled to receive a liquidating distribution out of the assets legally available to stockholders in the amount of $1 thousand per share or $351 million in the aggregate, plus any accrued and unpaid dividends, before any distribution is made to holders of Globe Life common stock. Holders of Series A Preferred Stock do not have any voting rights nor have rights to convert such shares into shares of any other class of Globe Life capital stock.

See accompanying Report of Independent Registered Public Accounting Firm.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**Globe Life Inc.** 

**SCHEDULE IV. REINSURANCE (CONSOLIDATED)**

(Dollar Amounts in thousands)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Gross<br>Amount** | **Ceded**<br>**to Other**<br>**Companies**<sup>(1)</sup> | **Assumed<br>from Other<br>Companies** | **Net<br>Amount** | **Percentage<br>of Amount<br>Assumed<br>to Net** |
|<br>**For the Year Ended December 31, 2025** | | | | | |
| Life insurance in force | $229804503 | $430278 | $1734812 | $231109037 | 0.8 |
| Premiums<sup>(2)</sup>: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Life insurance | $3294163 | $(39968) | $17669 | $3351800 | 0.5 |
| &nbsp;&nbsp;&nbsp;Health insurance | 1516215 | 128 | 10663 | 1526750 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium | $4810378 | $(39840) | $28332 | $4878550 | 0.6 |
| **For the Year Ended December 31, 2024** |  |  |  |  |  |
| Life insurance in force | $227975584 | $671056 | $1823957 | $229128485 | 0.8 |
| Premiums<sup>(2)</sup>: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Life insurance | $3235744 | $4649 | $17994 | $3249089 | 0.6 |
| &nbsp;&nbsp;&nbsp;Health insurance | 1384080 | 2449 | 23294 | 1404925 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium | $4619824 | $7098 | $41288 | $4654014 | 0.9 |
| **For the Year Ended December 31, 2023** |  |  |  |  |  |
| Life insurance in force | $225286002 | $685289 | $1996223 | $226596936 | 0.9 |
| Premiums<sup>(2)</sup>: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Life insurance | $3109838 | $4597 | $19104 | $3124345 | 0.6 |
| &nbsp;&nbsp;&nbsp;Health insurance | 1281720 | 2720 | 39773 | 1318773 | 3.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium | $4391558 | $7317 | $58877 | $4443118 | 1.3 |

---

(1)During 2025 the Company recaptured $39 million of reinsurance ceded, as disclosed in *[Note 1—Significant Accounting Policies](#ia1583f94e55d42afa319983b2df261d2_451)*. No amounts have been netted against ceded premium for 2024 and 2023.

(2)Excludes policy charges of $11.7 million, $12.3 million and $12.9 million in each of the years 2025, 2024 and 2023, respectively.

See accompanying Report of Independent Registered Public Accounting Firm.

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

------

<u>[**Table of Contents**](#ia1583f94e55d42afa319983b2df261d2_10)</u>

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Globe Life Inc.** | **Globe Life Inc.** |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;J. MATTHEW DARDEN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
|  | **J. Matthew Darden** |
|  | **Co-Chairman and Chief Executive Officer and Director** |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;FRANK M. SVOBODA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
|  | **Frank M. Svoboda** |
|  | **Co-Chairman and Chief Executive Officer and Director** |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;THOMAS P. KALMBACH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
|  | **Thomas P. Kalmbach** |
|  | **Executive Vice President and Chief Financial Officer** |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;M. SHANE HENRIE&nbsp;&nbsp;&nbsp;&nbsp; |
|  | **M. Shane Henrie** |
|  | **Corporate Senior Vice President and Chief Accounting Officer** |

---

Date: February 25, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | | | |
|:---|:---|:---|:---|
| By: | /s/ MATTHEW J. ADAMS \* | By: | /s/ LINDA L. ADDISON \* |
|  | **Matthew J. Adams** |  | **Linda L. Addison** |
|  | **Director** |  | **Director** |
| By: | /s/ MARILYN A. ALEXANDER \* | By: | /s/ CHERYL D. ALSTON \* |
|  | **Marilyn A. Alexander** |  | **Cheryl D. Alston** |
|  | **Director** |  | **Director** |
| By: | /s/ MARK A. BLINN \* | By: | /s/ JAMES P. BRANNEN \* |
|  | **Mark A. Blinn** |  | **James P. Brannen** |
|  | **Director** |  | **Director** |
| By: | /s/ ALICE S. CHO \* | By: | /s/ PHILIP M. JACOBS \* |
|  | **Alice S. Cho** |  | **Philip M. Jacobs** |
|  | **Director** |  | **Director** |
| By: |  | By: |  |
|  | **Derek T. Kan** |  | **Sandra L. Phillips** |
|  | **Director** |  | **Director** |
| By: | /s/ DAVID A. RODRIGUEZ \* | By: | /s/ MARY E. THIGPEN \* |
|  | **David A. Rodriguez** |  | **Mary E. Thigpen** |
|  | **Director** |  | **Director** |
| Date: February 25, 2026 | Date: February 25, 2026 | \*By: | /s/ THOMAS P. KALMBACH  |
|  |  |  | **Thomas P. Kalmbach** |
|  |  |  | **Attorney-in-fact** |

---

&nbsp;&nbsp;&nbsp;&nbsp;GL 2025 FORM 10-K

## Exhibit 10.7

![](a107amendmentno3receivab001.jpg)

------

![](a107amendmentno3receivab002.jpg)

------

## Exhibit 10.16

![](a1016thirdamendedandrest001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 THIRD AMENDED AND RESTATED GLOBE LIFE INC. 2018 NON-EMPLOYEE DIRECTOR COMPENSATION PLAN SECTION 1. GENERAL PURPOSE OF PLAN; DEFINITIONS The name of this plan is the Globe Life Inc. 2018 Non-Employee Director Compensation Plan (the "Plan"). The purpose of the Plan is to enable Globe Life Inc. (the "Company") and its Subsidiaries and Affiliates to attract and retain directors who contribute to the Company's success by their ability, ingenuity and industry, and to enable such directors to participate in the long-term success and growth of the Company through an equity interest in the Company. The Plan was adopted effective as of April 26, 2018, and replaced and superseded the Company's existing 2011 Non-Employee Director Compensation Plan. The Plan was adopted as a sub-plan of the Globe Life Inc. 2018 Incentive Plan (the "2018 Incentive Plan"). On February 26, 2020 the Board of Directors of the Company approved the amendment of this Plan to change the name of the Plan to the Globe Life Inc. 2018 Non-Employee Director Compensation Plan and all references therein from Torchmark Corporation to Globe Life Inc. effective January 1, 2020. On November 3, 2021, the Plan was amended and restated. On November 8, 2023, the Board of Directors of the Company approved revisions to the manner in which Non-Employee Directors are compensated as reflected in this amendment and restatement. On November 5, 2025, the Board of Directors of the Company approved revisions to the manner in which Non-Employee Directors are compensated as reflected in this amendment and restatement. Capitalized terms used in the Plan but not otherwise defined shall have the meanings given such terms in the 2018 Incentive Plan. In addition, the following terms shall be defined for purposes of the Plan as set forth below: "Annual Compensation" means the total annual retainer, expressed as a dollar amount, payable by the Company to a Non- Employee Director for services as a director at the time and in the form detailed in Section 5 below (excluding, if applicable any retainers or fees payable for services as the member or chairman of a committee of the Board, which shall be payable separate and apart from the provisions of this Plan) of the Company. For the period of January 1, 2026 through December 31, 2026 and for subsequent calendar years unless this paragraph is revised by amendment to this Plan or this Plan is superseded, the annual retainer shall be $300,000. The amount of the Annual Compensation may be changed from time to time. "Award Notice" means a written award notice to a Non-Employee Director from the Company evidencing an award of Stock Options, Restricted Stock or Restricted Stock Units. "Beneficiary" means any person or persons designated by a Participant, in accordance with procedures established by the Committee or Plan Administrator, to receive benefits hereunder in the event of the Participant's death. If any Participant shall fail to designate a Beneficiary or shall designate a Beneficiary who shall fail to survive the Participant, the Beneficiary shall be the Participant's surviving spouse, or, if none, the Participant's surviving descendants (who shall take per stirpes) and if there are no surviving descendants, the Beneficiary shall be the Participant's estate. "Business Day" shall mean a day on which the New York Stock Exchange or any national securities exchange or over-the-counter market on which the Stock is traded is open for business. "Cash Component" means the portion of the Annual Compensation that is initially designated to be paid in cash unless a Participant elects otherwise pursuant to Section 5 of the Plan. The Cash Component is $110,000. "Committee" means the Compensation Committee of the Board. If at any time no Committee shall be in office, then the functions of the Committee specified in the Plan shall be exercised by the Board. "Election Date" means the date by which a Non-Employee Director must submit a valid Election Form to the Plan Administrator. For each calendar year, the Election Date is December 31 of the preceding calendar year; provided, however, that the Election Date for a newly eligible Participant shall be the 30th day following the date on which such individual becomes a Non- Employee Director. "Election Form" means an Election Form pursuant to which a Non-Employee Director elects to receive all or a portion of his or her Annual Compensation in the form of cash, Stock Options, Restricted Stock or Restricted Stock Units, or to defer Annual Compensation under the Plan.

------

![](a1016thirdamendedandrest002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 2 "Equity Component" means the portion of the Annual Compensation that is designated to be paid in one of the forms of equity listed in Section 5 below. The Equity Component is $190,000. "Grantee" means a Non-Employee Director to whom a Stock Option, Restricted Stock, or Restricted Stock Unit has been granted. "Interest Account" means the account established by the Company for each Non-Employee Director for Annual Compensation deferred pursuant to the Plan and which shall be credited with interest on the last day of each calendar quarter (or such other day as determined by Plan Administrator) pursuant to Section 6(f) of the Plan. "Plan" means this 2018 Non-Employee Director Compensation Plan. "Plan Administrator" means one or more agents to whom the Board shall have delegated administrative duties under the Plan or the Committee if no such delegation shall have occurred. "Restricted Stock" means shares of Stock granted to a Participant under Section 5 or 6 that are subject to certain restrictions and to risk of forfeiture. "Restricted Stock Unit" means a right granted to a Participant under Section 6 to receive shares of Stock in the future, which right is subject to certain restrictions and to risk of forfeiture. "Stock Option" means any option granted to a Participant to purchase shares of Stock granted pursuant to Section 6. SECTION 2. ADMINISTRATION. The Plan shall be administered by the Committee. The Committee shall have the discretionary authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it shall, from time to time, deem advisable; to construe and interpret the terms and provisions of the Plan and any award issued under the Plan (and any agreements relating thereto); and to otherwise supervise the administration of the Plan. The Committee may delegate administrative duties under the Plan to one or more agents as it shall deem necessary or advisable. No member of the Committee or the Board or the Plan Administrator shall be personally liable for any action or determination made in good faith with respect to the Plan or any Options, Restricted Stock or Restricted Stock Units, or to any settlement of any dispute between a Non-Employee Director and the Company. All decisions made by the Board or the Committee pursuant to the provisions of the Plan shall be final and binding on all persons, including the Company and Participants. SECTION 3. SOURCE OF SHARES FOR THE PLAN. The shares of Stock that may be issued pursuant to the Plan shall be issued under the 2018 Incentive Plan, subject to all of the terms and conditions of the 2018 Incentive Plan. The terms contained in the 2018 Incentive Plan are incorporated into and made a part of this Plan with respect to Stock Options, Restricted Stock or Restricted Stock Units granted pursuant hereto, and any such Stock Options, Restricted Stock or Restricted Stock Units shall be governed by and construed in accordance with the 2018 Incentive Plan. In the event of any actual or alleged conflict between the provisions of the 2018 Incentive Plan and the provisions of this Plan, the provisions of the 2018 Incentive Plan shall be controlling and determinative. This Plan does not constitute a separate source of shares for the grant of the equity awards described herein. SECTION 4. ELIGIBILITY. All Non-Employee Directors are eligible to participate in the Plan. SECTION 5. ELECTION TO RECEIVE ANNUAL COMPENSATION IN CASH, STOCK OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS OR TO DEFER ANNUAL COMPENSATION. (a) Election Regarding Annual Compensation. With respect to the Cash Component of his or her Annual Compensation, a Non- Employee Director may receive cash, payable in quarterly installments, or may elect (i) to receive Stock Options, Restricted Stock or Restricted Stock Units pursuant to subsections (c), (d) or (e) below, or (ii) to defer receipt of the Cash Component pursuant to subsection (f) below for a calendar year, in either case by delivering a properly completed and signed Election Form to the Plan Administrator on or before the Election Date. With respect to the remaining amount of Annual Compensation, a Non-Employee Director must elect to receive Stock Options, Restricted Stock or Restricted Stock Units pursuant to subsections (c), (d) or (e) below, by delivering a properly completed

------

![](a1016thirdamendedandrest003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 3 and signed Election Form to the Plan Administrator on or before the Election Date. Such election will be effective as of the first day of the calendar year beginning after the Plan Administrator receives the Non-Employee Director's Election Form, or, in the case of a newly eligible Participant, on the Business Day the Plan Administrator receives such Non-Employee Director's Election Form, provided that the Election Form is received within thirty (30) days following the Non-Employee Director's date of initial eligibility to participate in the Plan. If a Non-Employee Director fails to make a timely election under this Section 5(a), he or she will receive the Cash Component of Annual Compensation in the form of cash, payable in quarterly installments, and the Equity Component of Annual Compensation in the form of Stock Options. (b) Irrevocable Election. A Participant may not revoke or change his or her Election Form. (c) Election to Receive Stock Options. A Non-Employee Director may elect to receive the Equity Component or the entire amount of his or her Annual Compensation in Stock Options in accordance with the provisions of this subsection (c). Stock Options granted under this subsection (c) shall be evidenced by an Award Notice in such form as the Committee shall from time to time approve, which agreements shall comply with and be subject to the following terms and conditions: (i) Time of Issuance of Stock Options. If an election is made under this subsection, Stock Options will be issued to the Non-Employee Director on the first Business Day in the calendar year to which the election relates or in the case of a newly elected Participant, the first Business Day the election is received by the Plan Administrator (the "Option Grant Date"). (ii) Number of Stock Options. The number of shares subject to a Stock Option granted pursuant to this Article 5(c) shall be the number of whole Shares equal to A divided by B, where: A = the dollar amount which the Non-Employee Director has elected to receive in Stock Options; and B =the per share value of a Stock Option on the Option Grant Date, as determined by the Committee using any recognized option valuation model selected by the Board in its discretion (such value to be expressed as a percentage of the Fair Market Value per Share on the Option Grant Date). In determining the number of shares subject to a Stock Option, (A) the Board may designate the assumptions to be used in the selected option valuation model, and (B) any fraction of a Share will be rounded up to the next whole number of Shares. (iii) Exercise Price of Stock Options. The exercise price per share of each Stock Option shall be 100% of the Fair Market Value of the underlying Stock on the date of the grant of the Stock Option. (iv) Vesting and Forfeiture of Stock Options. Except as provided in Section 8, Stock Options shall vest (become exercisable) on the six-month anniversary of the Option Grant Date, provided that the Grantee is still serving as a Non-Employee Director at such time. Notwithstanding the foregoing vesting schedule, Stock Option shall become fully vested and exercisable upon Grantee's termination of service as a Non-Employee Director due to death, Disability or Retirement. Upon a Grantee's termination of status as a Non-Employee Director with the Company for any reason other than due to death, Disability or Retirement, any unvested Stock Options held by such Grantee shall be forfeited. (v) Method of Exercise. Any Stock Option granted pursuant to the Plan may be exercised in whole or in part at any time during the option period, by giving written notice of exercise to the Company specifying the number of shares to be purchased, accompanied by payment in full of the purchase price, in cash, by check or such other instrument as may be acceptable to the Committee (including "net" or "cashless exercise" arrangements). Payment in full or in part may also be made in the form of unrestricted Stock already owned by the Grantee (based on the Fair Market Value of the Stock on the date the Option is exercised). No shares of Stock shall be issued upon exercise of a Stock Option until the exercise price has been fully paid or satisfied. (vi) Transferability of Stock Options. Stock Options shall not be transferable by the Grantee otherwise than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable,

------

![](a1016thirdamendedandrest004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 4 during the Grantee's lifetime, only by the Grantee; provided, however, that the Committee may (but need not) permit other transfers where the Committee concludes that such transferability (i) does not result in accelerated taxation, and (ii) is otherwise appropriate and desirable, taking into account any state or federal securities laws applicable to transferable options. (vii) Term of Stock Options. The term of any Stock Option granted pursuant to the Plan shall be for a period of seven years, expiring on the seventh anniversary of the Option Grant Date (the "Expiration Date"). Following Grantee's termination of status as a Non-Employee Director for any reason, vested Stock Options held by such Grantee shall be retained and may thereafter be exercised during the period ending on the Expiration Date. (d) Election to Receive Restricted Stock. A Non-Employee Director may elect to receive the Equity Component or the entire amount of his or her Annual Compensation in Restricted Stock in accordance with the provisions of this subsection (d). Restricted Stock granted under this subsection (d) shall be evidenced by an Award Notice in such form as the Committee shall from time to time approve, which agreements shall comply with and be subject to the following terms and conditions: (i) Time of Issuance of Restricted Stock. If an election is made under this subsection, Restricted Stock will be issued to the Non-Employee Director on the first Business Day in the calendar year to which the election relates or in the case of a newly elected Participant, the first Business Day the election is received by the Plan Administrator (which shall be the "Restricted Stock Grant Date" for purposes of Restricted Stock granted under this Section 5). (ii) Number of Shares of Restricted Stock. The number of shares of Restricted Stock granted pursuant to this Article 5(d) shall be the number of whole Shares equal to A divided by B, where: A= the dollar amount which the Non-Employee Director has elected to receive in shares of Restricted Stock; and B =the Fair Market Value per Share on the Restricted Stock Grant Date. In determining the number of shares of Restricted Stock, any fraction of a Share will be rounded up to the next whole number of Shares. (iii) Terms and Conditions of Restricted Stock. Restricted Stock shall comply with and be subject to the following terms and conditions: (1) Vesting. Except as provided in Section 9, Restricted Stock granted under this Section 5 shall become fully vested on the six-month anniversary of the Restricted Stock Grant Date, provided that the Grantee is still serving as a Non-Employee Director at such time. Notwithstanding the foregoing vesting schedule, Restricted Stock shall become fully vested upon Grantee's termination of service as a Non-Employee Director due to death, Disability or Retirement. (2) Restrictions on Unvested Restricted Stock. Unvested Restricted Stock may not be sold, transferred, exchanged, assigned, pledged, hypothecated or otherwise encumbered. If a Non-Employee Director's service as a director of the Company terminates for any reason other than death, Disability or Retirement, then the Non-Employee Director shall forfeit all of his or her right, title and interest in and to any unvested Restricted Stock as of the date of such termination from the Board, and such Restricted Stock shall be re-conveyed to the Company without further consideration or any act or action by the Non-Employee Director. (3) Rights as a Shareholder. A Non-Employee Director shall have full voting and dividend rights with respect to the Restricted Stock. If a Non-Employee Director forfeits any shares of Restricted Stock, he or she shall no longer have any rights as a stockholder with respect to the Restricted Stock or any interest therein and the Participant shall no longer be entitled to receive dividends on such stock. (e) Election to Receive Restricted Stock Units. A Non-Employee Director may elect to receive the Equity Component or the entire amount of his or her Annual Compensation in Restricted Stock Units in accordance with the provisions of this subsection (e). Restricted Stock Units granted under this

------

![](a1016thirdamendedandrest005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 5 subsection (e) shall be evidenced by an Award Notice in such form as the Committee shall from time to time approve, which agreements shall comply with and be subject to the following terms and conditions: (i) Time of Issuance of Restricted Stock Units. If an election is made under this subsection, Restricted Stock Units will be issued to the Non-Employee Director on the first Business Day in the calendar year to which the election relates or in the case of a newly elected Participant, the first Business Day the election is received by the Plan Administrator (the "Restricted Stock Unit Grant Date"). (ii) Number of Restricted Stock Units. The number of Restricted Stock Units granted pursuant to this Article 6(d) shall be the number of whole Shares equal to A divided by B, where: A= the dollar amount which the Non-Employee Director has elected to receive in Restricted Stock Units; and B = the Fair Market Value per Share on the Restricted Stock Unit Grant Date. In determining the number of Restricted Stock Units, any fraction of a Share will be rounded up to the next whole number of Shares. (iii) Terms and Conditions of Restricted Stock Units. Restricted Stock Units will be credited to a bookkeeping account on behalf of the Non-Employee Director and shall comply with and be subject to the following terms and conditions: (1) Vesting and Forfeiture. Except as provided in Section 8, Restricted Stock Units shall vest and become non-forfeitable on the six-month anniversary of the Restricted Stock Unit Grant Date, provided that the Grantee is still serving as a Non-Employee Director at such time. Notwithstanding the foregoing vesting schedule, Restricted Stock Units shall become fully vested upon Grantee's termination of service as a Non-Employee Director due to death, Disability or Retirement. If a Non-Employee Director's service as a director of the Company terminates for any reason other than death, Disability or Retirement, then the Non-Employee Director shall forfeit all of his or her right, title and interest in and to any unvested Restricted Stock Units as of the date of such termination from the Board, and such Restricted Stock Units shall be reconveyed to the Company without further consideration or any act or action by the Non-Employee Director. (2) Conversion to Common Stock. Unless forfeited prior to vesting, Restricted Stock Units shall be converted to actual shares of Stock on the Non-Employee Director's termination of service as a director of the Company for any reason. Upon conversion, stock certificates evidencing the conversion of Restricted Stock Units into shares of Stock shall be registered on the books of the Company in the Non-Employee Director's name (or in street name to the Non-Employee Director's brokerage account) in uncertificated (book-entry) form unless the Non-Employee Director requests a stock certificate or certificates for the Shares. (3) Dividend Equivalents. If any dividends or other distributions are paid with respect to the Shares while Restricted Stock Units are outstanding, the dollar amount or fair market value of such dividends or distributions with respect to the number of Shares then underlying the outstanding Restricted Stock Units shall be converted into additional Restricted Stock Units in Non-Employee Director's name, based on the Fair Market Value of the Stock as of the date such dividends or distributions were payable, and such additional Restricted Stock Units shall be immediately vested and non-forfeitable upon grant, and shall convert to actual shares of Stock on the Non-Employee Director's termination of service as a director of the Company for any reason. (4) Restrictions on Transfer. Restricted Stock Units are not assignable or transferable other than by will or the laws of descent and distribution. Restricted Stock Units may not be pledged, hypothecated or otherwise encumbered to or in favor of any party other than the Company or an affiliate, or be subjected to any lien, obligation or liability of a Non- Employee Director to any other party other than the Company or an affiliate. (5) Rights as a Shareholder. A Non-Employee Director shall not have voting or any other rights as a shareholder of the Company with respect to the Restricted Stock Units. Upon

------

![](a1016thirdamendedandrest006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 6 conversion of the Restricted Stock Units into shares of Stock, the Non-Employee Director will obtain full voting and other rights as a shareholder of the Company. (f) Election to Defer Cash Component of Annual Compensation. A Non-Employee Director may elect to defer the Cash Component of his or her Annual Compensation to his or her Interest Account. For bookkeeping purposes, the amount of the Cash Component of Annual Compensation, which the Participant elects to defer pursuant to the Plan, shall be transferred to and held in individual Interest Accounts (in annual designations) pending distribution in cash pursuant to subsection (iii) below. (i) Interest Accounts. Amounts in a Participant's Interest Account will be credited with interest as of the last day of each calendar quarter (or such other day as determined by the Plan Administrator) at the rate set from time to time by the Committee to be applicable to the Interest Accounts of all Participants under the Plan. To the extent required for bookkeeping purposes, a Participant's Interest Accounts will be segregated to reflect Deferred Compensation on a year-by-year basis. Within a reasonable time after the end of each calendar year, the Plan Administrator shall report in writing to each Participant the amount held in his or her Interest Accounts at the end of the year. (ii) Payment Commencement Date. Payment of the balances in a Participant's Interest Accounts shall commence on the earliest to occur of (a) December 31 of the fifth year after the year with respect to which the deferral was made, (b) the first Business Day of the fourth month after the Participant's death, or (c) the Participant's termination as a Non-Employee Director of the Company or any of its Subsidiaries or Affiliates, other than by reason of death. (iii) Optional Forms of Payment. Distributions from a Participant's Interest Accounts may be paid to the Participant either in a lump sum or in a number (not to exceed ten) of approximately equal annual installments designated by the Participant on his or her Election Form. In the event of the Participant's death during the payout period, the remaining balance shall be payable to the Participant's Beneficiary in a lump sum on or about the first Business Day of the fourth month after the Participant's death. If a Participant elects to receive a distribution of his or her Interest Accounts in installments, the Plan Administrator may purchase an annuity from an insurance company which annuity will pay the Participant the desired annual installments. If the Plan Administrator purchases an annuity contract, the Participant will have no further rights to receive payments from the Company or the Plan with respect to the amounts subject to the annuity. If the Plan Administrator does not purchase an annuity contract, the value of the Interest Accounts remaining unpaid shall continue to receive allocations of return as provided in subsection (f) above. If the Participant fails to designate a payment method in the Participant's Election Form, the Participant's Account shall be distributed in a lump sum. (iv) Irrevocable Elections. A Participant may elect a different payment form for each year's Annual Compensation deferred under the Plan. The payment form elected or deemed elected on the Participant's election form shall be irrevocable. (v) Acceleration of Payment. If a Participant elects an installment distribution and the aggregate value of the Participant's Interest Accounts at the time the installments are due to commence is less than $16,500, the Plan Administrator will accelerate payment of the Participant's benefits in a single lump sum. (vi) Effect of Adverse Determination. Notwithstanding the Election Form or any provision set forth herein, if the Internal Revenue Service determines that all or any portion of the amounts credited under this Plan is currently includable in the taxable income of any Participant due to a failure of the Plan to meet the requirements of Code Section 409A or the regulations thereunder, then the amounts so determined to be includable in income shall be distributed in a lump sum to such Participant as soon as practicable. (g) Unforeseeable Emergency. The Plan Administrator may, in its sole discretion, accelerate the making of payment to a Participant in the event that a participant incurs a financial hardship as a result of an "unforeseeable emergency" (as such term is defined below). All unforeseeable emergency distributions shall be made in cash in a lump sum. Such payments will be made on a first-in, first-out basis so that the oldest Annual Compensation deferred under the Plan shall be deemed distributed first. For purposes hereof, an "unforeseeable emergency" means a severe financial hardship to the Participant resulting from

------

![](a1016thirdamendedandrest007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 7 illness or accident of the Participant, the Participant's spouse, or a dependent (as defined in Section 152 of the Code without regard to Section l52(b)(I), (b)(2), and (d)(I)(B)) of the Participant, loss of the Participant's property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. The amounts distributable because of an unforeseeable emergency cannot exceed the amounts necessary to satisfy such emergency plus amounts necessary to pay taxes reasonably anticipated as a result of the distribution, after taking into account the extent to which such emergency is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the Participant's assets (to the extent the liquidation of such assets would not itself cause severe financial hardship). Notwithstanding any provision in the Plan to the contrary, any payment made pursuant to this Section 6(g) shall comply with Section 409A(a)(2)(A)(vi) of the Code and the regulations (or similar guidance) promulgated thereunder (or any successor provisions). (h) Payment to Minors and Incapacitated Persons. In the event that any amount is payable to a minor or to any person who, in the judgment of the Plan Administrator, is incapable of making proper disposition thereof, such payment shall be made for the benefit of such minor or such person in any of the following ways as the Plan Administrator, in its sole discretion, shall determine: (i) By payment to the legal representative of such minor or such person; (ii) By payment directly to such minor or such person; (iii) By payment in discharge of bills incurred by or for the benefit of such minor or such person. The Plan Administrator shall make such payments without the necessary intervention of any guardian or like fiduciary, and without any obligation to require bond or to see to the further application of such payment. Any payment so made shall be in complete discharge of the Plan's obligation to the Participant and his or her Beneficiaries. (i) Application for Benefits. The Plan Administrator may require a Participant or Beneficiary to complete and file certain forms as a condition precedent to receiving the payment of benefits. The Plan Administrator may rely upon all such information given to it, including the Participant's current mailing address. It is the responsibility of all persons interested in receiving a distribution pursuant to the Plan to keep the Plan Administrator informed of their current mailing addresses. (j) Designation of Beneficiary. Each Participant from time to time may designate any person or persons (who may be designated contingently or successively and who may be an entity other than a natural person) as his or her Beneficiary or Beneficiaries to whom the Participant's Interest Accounts are to be paid if the Participant dies before receipt of all such benefits. Each Beneficiary designation shall be on the form prescribed by the Plan Administrator and will be effective only when filed with the Plan Administrator during the Participant's lifetime. Each Beneficiary designation filed with the Plan Administrator will cancel all Beneficiary designations previously filed with the Plan Administrator. The revocation of a Beneficiary designation, no matter how effected, shall not require the consent of any designated Beneficiary. SECTION 6. AMENDMENTS AND TERMINATION. The Board may amend, alter, or discontinue the Plan, but no amendment, alteration, or discontinuation shall be made which would impair the right of a Participant or a Grantee of an award of Stock Options, Restricted Stock or Restricted Stock Units heretofore granted, without the Participant's or Grantee's consent. Amendments may be made without stockholder approval except as required to satisfy stock exchange listing requirements or other regulatory requirements. The Board may amend the terms of any Stock Option, Restricted Stock or Restricted Stock Unit award theretofore granted, prospectively or retroactively; provided, however, (a) no such amendment shall impair the rights of any holder without his/her consent; (b) the original term of a Stock Option may not be extended without prior approval of the stockholders of the Company; and (c) the exercise price of a Stock Option may not be reduced, directly or indirectly, without prior approval of the stockholders of the Company.

------

![](a1016thirdamendedandrest008.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;65476912_2 8 SECTION 7. UNFUNDED STATUS OF PLAN. The Plan is intended to constitute an "unfunded" plan for incentive and deferred compensation. With respect to any payments not yet made to a Participant or Grantee by the Company, nothing set forth herein shall give any such Participant or Grantee any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver Stock or payments in lieu of or with respect to awards hereunder, provided, however, that the existence of such trusts or other arrangements is consistent with the unfunded status of the Plan. SECTION 8. CHANGE IN CONTROL. In the event of a "Change in Control," unless otherwise determined by the Board in writing at or after grant, but prior to the occurrence of such Change in Control, any Stock Options awarded under the Plan not previously exercisable and vested shall become fully exercisable and vested, and any Restricted Stock or Restricted Stock Units awarded under the Plan not previously vested shall become fully vested. SECTION 9. GENERAL PROVISIONS. (a) Nothing set forth in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in the specified cases. The adoption of the Plan shall not confer upon any director of the Company, any Subsidiary or any Affiliate, any right to continued retention as a director with the Company, a Subsidiary or an Affiliate, as the case may be. (b) At the time of grant or exercise, the Committee may provide in connection with any grant or exercise made under this Plan that the shares of Stock received as a result of such grant or purchase shall be subject to a right of first refusal, pursuant to which the Participant shall be required to offer to the Company any shares that the participant wishes to sell, with the price being the then Fair Market Value of the Stock, subject to the provisions of Section 9 hereof and to such other terms and conditions as the Board may specify at the time of grant. (c) No member of the Board or the Committee, nor any officer or employee of the Company acting on behalf of the Board or the Committee, shall be personally liable for any action, determination, or interpretation taken or made in good faith with respect to the Plan, and all members of the Board or the Committee and each and any officer or employee of the Company acting on their behalf shall, to the extent permitted by law, be fully indemnified and protected by the Company in respect of any such action, determination or interpretation. (d) In the event that any provision of the Plan or any related Award Notice is held to be invalid, void or unenforceable, the same shall not affect, in any respect whatsoever, the validity of any other provision of the Plan or any related Award Notice. (e) The rights and obligations under the Plan and any related agreements shall inure to the benefit of, and shall be binding upon the Company, its successors and assigns, and the Non-Employee Directors and their beneficiaries. (f) Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of the Plan. (g) The Plan shall be construed, governed and enforced in accordance with the Law of Delaware, except as such laws are preempted by applicable federal law. SECTION 10. EFFECTIVE DATE OF PLAN. The initial effective date of the Plan was April 26, 2018. This amendment and restatement shall be effective as of January 1, 2026. SECTION 11. TERM OF PLAN. No Stock Options, Restricted Stock or Restricted Stock Units shall be granted pursuant to the Plan following the termination of the 2018 Incentive Plan, as applicable, but awards theretofore granted may extend beyond that date.

------

## Exhibit 10.41

![](a10412026employee7-yrsoa001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 GLOBE LIFE INC. NON-QUALIFIED STOCK OPTION GRANT AGREEMENT GLOBE LIFE INC. (the "Company") hereby grants to the Optionee non-qualified stock options in the amount and with the exercise price specified below (the "Option") upon the terms and conditions hereinafter set forth. 1. Stock Incentive Plan. The Option is granted under the provisions of the Globe Life Inc. 2018 Incentive Plan (the "Plan"), as a non-qualified option and is subject to the terms and provisions of the Plan. By accepting the Option, Optionee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms used but not defined herein shall have the meanings given them in the Plan which is incorporated by reference herein. 2. Option Period. The Option will vest in accordance with the vesting schedule below. Notwithstanding any other provision of this Agreement, if the Option is not exercised with respect to all Shares prior to seven (7) years from the Grant Date, the Option shall terminate and the parties hereto shall have no further rights or obligations hereunder. For the purposes of this agreement, "Option Period" shall mean the seven (7) year period commencing on the Grant Date. 3. Method of Exercise. The Option may be exercised in whole or in part at any time during the Option Period, by giving written notice of exercise to the Company specifying the number of Shares to be purchased, accompanied by payment in full of the purchase price, in cash, by check or such other instrument as may be acceptable to the Compensation Committee of the Globe Life Inc. Board of Directors (the "Committee"). Payment in full or in part may also be made in the form of unrestricted stock already owned by the Optionee (based on the fair market value of the stock on the date the Option is exercised). The Optionee shall have the rights to dividends or other rights of a stockholder with respect to the Shares subject to the option when the Optionee has given written notice of exercise and has paid in full for such Shares. 4. Transferability of Option. The Option may be transferred by the Optionee to members of the Optionee's Immediate Family (the children, grandchildren or spouse of the Optionee), to one or more trusts for the benefit of such Immediate Family members or to one or more partnerships where such Immediate Family members are the only partners if (i) the Optionee has received express written approval of such transfer from the Committee and (ii) the Optionee does not receive any consideration in any form whatsoever for said transfer. Except as provided in the foregoing sentence, the Option shall not be transferable by the Optionee other than by will or by the laws of descent and distribution. 5. Termination by Death. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate terminates by reason of death (or if Optionee dies following termination of employment by reason of disability or retirement at or after age 65), the Option shall become immediately exercisable and may thereafter be exercised by the legal representative of the estate or by the legatee of the Optionee under the will of the Optionee, during the period ending on the expiration of the stated term of the Option. 6. Termination by Reason of Disability. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of Disability, the Option shall be

------

![](a10412026employee7-yrsoa002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 immediately exercisable and may thereafter be exercised during the period ending on the expiration of the stated term of the Option. 7. Termination by Reason of Retirement. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of retirement at or after age 65, the Option shall become immediately exercisable and may thereafter be exercised during the period ending on the expiration of the stated term of the Option. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of retirement at or after age 55, the Option shall terminate upon the expiration of the stated term of the Option. In the event of retirement at or after age 55, there shall be no acceleration of vesting of the Option, but the Option shall continue to vest in accordance with its regular schedule and may thereafter be exercised during the period ending on the expiration of the stated term of the Option (the "Continued Vesting Shares"); provided that the Participant's Retirement occurs after the first anniversary of the Grant Date. 8. Termination for Cause. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is terminated for Cause, or the Committee determines that the Optionee has engaged in conduct that would be grounds for termination with Cause, the Option shall be immediately forfeited to the Company upon the giving of notice of termination of employment, and any Shares issued upon exercise of the Option shall be subject to recoupment by the Company based upon a determination by the Committee that recoupment is necessary to recover economic loss associated with the termination with Cause. Any such determination shall be made by the Committee in its sole and absolute discretion. 9. Qualifying Termination. Notwithstanding Section 10, if Optionee is designated as an Eligible Executive under the Globe Life Inc. Executive Severance Plan and if the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is terminated due to a Qualifying Termination as such term is defined in the Globe Life Inc. Executive Severance Plan and Section 7 does not apply, the Option shall terminate three (3) years from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. In the event of such Qualifying Termination, there shall be no acceleration of vesting, but the Option shall continue to vest in accordance with its regular schedule and may only be exercised to the extent it is or becomes exercisable prior to such Qualifying Termination. 10. Other Termination. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is involuntarily terminated by the Optionee's employer without Cause, the Option shall terminate three (3) months from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is voluntarily terminated for any reason, the Option shall terminate one (1) month from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. In the event of involuntary termination without Cause or voluntary termination, there shall be no acceleration of vesting, but the Option shall continue to vest in accordance with its regular schedule and may only be exercised to the extent it is or becomes exercisable prior to such termination. 11. Shares Listed on the Exchange. The Shares for which the Option is hereby granted shall have been listed on the New York Stock Exchange at the time the Option is exercised.

------

![](a10412026employee7-yrsoa003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 12. Shares May be Newly Issued or Purchased. The Shares to be delivered upon exercise of the Option shall be made available, at the discretion of the Company, either from authorized but previously unissued Shares or from Shares held in the treasury of the Company. 13. Adjustment of Shares for Recapitalization. In the event of any merger, reorganization, consolidation, recapitalization, stock dividend, or other change in corporate structure affecting the Stock, a substitution or adjustment shall be made in the number and price of Shares. 14. Payment of Taxes. The Optionee shall, no later than the date as of which the value of any portion of the Option first becomes includable in the Optionee's gross income for Federal income tax purposes, pay to the Company, or make other arrangements satisfactory to the Committee, in its sole discretion, regarding payment of, Federal, state, local or FICA taxes of any kind required by the law to be withheld with respect to the Option. The obligations of the Company under this Agreement shall be conditional on such payment or arrangements. The Optionee may elect, subject to the approval of the Committee, to satisfy the Optionee's Federal, and where applicable, FICA, state and local tax withholding obligations arising from all awards by the reduction in an amount necessary to pay any such withholding tax obligations, of the number of Shares of stock or amount of cash otherwise issuable or payable to said Optionee upon the issuance of Shares or payment of cash in respect of an Option. The Company and, where applicable, its Subsidiaries and Affiliates shall, to the extent permitted by law, have the right to deduct any such withholding taxes owed by an Optionee who is not subject to Section 16 of the 1934 Act from any payment of any kind otherwise due to said Optionee. 15. Headings. The headings contained herein are for convenience of reference only, do not constitute a part of this Grant Agreement and shall not be deemed to limit or affect any of the provisions hereof. 16. Notices. Any notices required by or permitted to be given to the Company under this Agreement shall be made in writing and addressed to the Secretary of the Company in care of the Company's Legal Department, 3700 South Stonebridge Drive, McKinney, Texas 75070. Any such notice shall be deemed to have been given when received by the Company. 17. Recoupment. Options awarded hereunder are subject to the Globe Life Inc. Clawback Policy as it may be amended or revised (the "Clawback Policy"). Any Options awarded hereunder may be cancelled or forfeited and any shares of Stock issued upon exercise of the Option shall be subject to forfeiture and recoupment by the Company based on a later determination that recoupment is required under the Clawback Policy. Any such determination by the Committee (in its sole discretion) shall be deemed a failure by the Participant to meet conditions precedent to payment of the Award and render the payment subject to recoupment. 18. Governing Law/Venue. Except as noted below, this Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, United States of America, regardless of the law that might be applied under principles of conflict of laws. In addition, Participant and the Company agree that any disputes or claims concerning or relating to the terms and provisions of this Agreement shall be filed in Collin County, State of Texas or the United States District Court for the Eastern District of Texas.

------

![](a10412026employee7-yrsoa004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 Company Name Globe Life Inc. Plan Participant Id Participant Name Participant Address Grant/Award Type Grant Amount Grant/Exercise Price Grant/Award Date VESTING SCHEDULE Vesting Date [No. of Shares] Percent

------

## Exhibit 10.42

![](a10422026employee7-yrsoa001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 GLOBE LIFE INC. NON-QUALIFIED STOCK OPTION GRANT AGREEMENT GLOBE LIFE INC. (the "Company") hereby grants non-qualified stock options in the amount and with the exercise price specified below (the "Option") upon the terms and conditions hereinafter set forth. 1. Stock Incentive Plan/Consideration. The Option is granted under the provisions of the Globe Life Inc. 2018 Incentive Plan (the "Plan"), as a non-qualified option and is subject to the terms and provisions of the Plan and in return for Optionee's promises contained herein. By accepting the Option, the Optionee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms used but not defined herein shall have the meanings given them in the Plan which is incorporated by reference herein. 2. Option Period. The Option will vest in accordance with the vesting schedule below. Notwithstanding any other provision of this Agreement, if the Option is not exercised with respect to all Shares prior to seven (7) years from the Grant Date, the Option shall terminate and the parties hereto shall have no further rights or obligations hereunder. For the purposes of this agreement, "Option Period" shall mean the seven (7) year period commencing on the Grant Date. 3. Method of Exercise. The Option may be exercised in whole or in part at any time during the Option Period, by giving written notice of exercise to the Company specifying the number of Shares to be purchased, accompanied by payment in full of the purchase price, in cash, by check or such other instrument as may be acceptable to the Compensation Committee of the Globe Life Inc. Board of Directors (the "Committee"). Payment in full or in part may also be made in the form of unrestricted stock already owned by the Optionee (based on the fair market value of the stock on the date the Option is exercised). The Optionee shall have the rights to dividends or other rights of a stockholder with respect to the Shares subject to the option when the Optionee has given written notice of exercise and has paid in full for such Shares. 4. Transferability of Option. The Option may be transferred by the Optionee to members of the Optionee's Immediate Family (the children, grandchildren or spouse of the Optionee), to one or more trusts for the benefit of such Immediate Family members or to one or more partnerships where such Immediate Family members are the only partners if (i) the Optionee has received express written approval of such transfer from the Committee and (ii) the Optionee does not receive any consideration in any form whatsoever for said transfer. Except as provided in the foregoing sentence, the Option shall not be transferable by the Optionee other than by will or by the laws of descent and distribution. 5. Termination by Death. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate terminates by reason of death (or if Optionee dies following termination of employment by reason of disability or retirement at or after age 65), the Option shall become immediately exercisable and may thereafter be exercised by the legal representative of the estate or by the legatee of the Optionee under the will of the Optionee, during the period ending on the expiration of the stated term of the Option. 6. Termination by Reason of Disability. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of Disability, the Option shall

------

![](a10422026employee7-yrsoa002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 be immediately exercisable and may thereafter be exercised during the period ending on the expiration of the stated term of the Option. 7. Termination by Reason of Retirement. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of Retirement at or after age 65, the Option shall become immediately exercisable (the "Retirement Acceleration") and may thereafter be exercised during the period ending on the expiration of the stated term of the Option. If the Optionee's employment with the Company, any Subsidiary, and/or any Affiliate terminates by reason of Retirement at or after age 55, the Option shall terminate upon the expiration of the stated term of the Option. In the event of Retirement at or after age 55, there shall be no acceleration of vesting of the Option, but the Option shall continue to vest in accordance with its regular schedule and may thereafter be exercised during the period ending on the expiration of the stated term of the Option (the "Continued Vesting Shares"); provided that the Participant's Retirement occurs after the first anniversary of the Grant Date. 8. Termination for Cause. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is terminated for Cause, or the Committee determines that the Optionee has engaged in conduct that would be grounds for termination with Cause, the Option shall be immediately forfeited to the Company upon the giving of notice of termination of employment, and any Shares issued upon exercise of the Option shall be subject to recoupment by the Company based upon a determination by the Committee that recoupment is necessary to recover economic loss associated with the termination with Cause. Any such determination shall be made by the Committee in its sole and absolute discretion. 9. Qualifying Termination. Notwithstanding Section 10, if Optionee is designated as an Eligible Executive under the Globe Life Inc. Executive Severance Plan and if the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is terminated due to a Qualifying Termination as such term is defined in the Globe Life Inc. Executive Severance Plan and Section 7 does not apply, the Option shall terminate three (3) years from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. In the event of such Qualifying Termination, there shall be no acceleration of vesting, but the Option shall continue to vest in accordance with its regular schedule and may only be exercised to the extent it is or becomes exercisable prior to such Qualifying Termination. 10. Other Termination. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is involuntarily terminated by the Optionee's employer without Cause, the Option shall terminate three (3) months from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. If the Optionee's employment with the Company, any Subsidiary and/or any Affiliate is voluntarily terminated for any reason, the Option shall terminate one (1) month from the date of termination of employment or upon the expiration of the stated term of the Option, whichever is shorter. In the event of involuntary termination without Cause or voluntary termination, there shall be no acceleration of vesting, but the Option shall continue to vest in accordance with its regular schedule and may only be exercised to the extent it is or becomes exercisable prior to such termination. 11. Noncompetition/Confidentiality/Nonsolicitation. Upon Participant's separation from employment from the Company for any reason for a period of two (2) years from the date of such separation or in the event of termination under circumstances that entitle him to Retirement Acceleration or Continued Vesting Shares, during the remaining vesting period prior to the Vesting Date, whichever is longer (the "Restriction Period"), Participant agrees not to engage or

------

![](a10422026employee7-yrsoa003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 participate, directly or indirectly, including but not limited to as an employee, consultant, advisor, contractor, partner, owner or otherwise, in a competing business, which is one that provides the same or substantially similar products or services as the Business with which Participant was involved. "Business" is defined as product development, marketing, sales and servicing of life insurance, health insurance and annuity products through captive agents, independent agents and direct response marketing channels. Life insurance includes individual life or group life, with or without return-of-premium benefit. Health insurance includes accidental death or supplemental health insurance products, with or without return-of premium benefits, including cancer, critical illness, hospital indemnity, Medicare supplement. Annuity includes deferred annuities or single premium immediate annuities. (All of the foregoing are referred to collectively as the "Business"). Participant further agrees that he will not serve as a Board member for any company that provides the same or similar products or services as the Business. Participant also agrees and understands that this noncompetition agreement extends to competition in any state in which Participant worked or directed work for the Company (referred to as the "Restricted Area"). Participant acknowledges that the Restricted Area, scope of prohibited activities, and the Restriction Period are reasonable and are no broader than are necessary to protect Company's legitimate business interests. Participant also acknowledges that the Company would not be providing the benefits set forth in this Agreement but for Participant's covenants and promises contained in this Section. Participant further agrees that during the non-competition term, Participant shall immediately notify the Company in writing of any employment, work, or business he undertakes with or on behalf of any person (including himself) or entity other than the Company and acknowledges and agrees that the Company may place Participant's future employer on notice of the Participant's post-employment obligations. Participant further expressly agrees and understands that the Company has disclosed confidential, proprietary and/or trade secret information to Participant. Participant agrees that he will not utilize nor disclose to any third party any of the Company's confidential, proprietary or trade secret information at any time in the future. In consideration of the Company disclosing such information to Participant and/or for the consideration provided to Participant by the Company in this Agreement, which Participant acknowledges is sufficient and reasonable consideration, Participant has agreed to the non-competition provisions set forth herein. In addition, due to the type of information to which Participant has been given access, there are some types of future employment in which Participant would inevitably use and disclose confidential and proprietary information in violation of Participant's promises. Therefore, Participant acknowledges as part of this agreement the potential for such unauthorized inevitable disclosure and agrees that the non-competition provisions set forth herein are necessary and reasonable. Notwithstanding any other provision of this Agreement, nothing herein shall prohibit Participant from reporting possible violations of federal law or regulation to any governmental agency or entity or making other disclosures that are protected pursuant to federal law or regulation. Prior authorization from the Company is not required in order to make any such reports or disclosures and Participant is not required to notify the Company that such reports or disclosures have been made. IMMUNITY NOTICE. Pursuant to the Defend Trade Secrets Act of 2016, Participant may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and solely for the purpose of reporting or investigating a suspected violation of the law; or is made in a complaint or other document filed in a lawsuit or

------

![](a10422026employee7-yrsoa004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 other proceeding, if such filing is made under seal. Should any provision in this Agreement conflict with this provision, this provision shall control. Participant also agrees that during the Restriction Period he will not solicit the clients or customers of the Company in order to request or advise such clients or customers to end, change or curtail their business relationship with the Company. In addition, Participant agrees that during the Restriction Period he will not solicit any employee of the Company in order to request or advise any such employee to end, change or curtail their employment relationship with the Company. If for any reason any court of competent jurisdiction finds any provision of this Section to be unreasonable in duration or scope or otherwise, Company and Participant agree that the court shall reform restrictions and prohibitions contained in this Section so that they shall be effective to the fullest extent allowed under applicable law. Each covenant set forth in this Section shall survive the termination of this Agreement and Participant's employment for any reason and shall be construed as an agreement independent of any other provision of this Agreement. Participant acknowledges and agrees that the covenants, obligations and agreements of Participant contained in this Section concern special, unique and extraordinary matters and that a violation of any of the terms of these covenants, obligations or agreements will cause Company irreparable injury for which adequate remedies at law are not available. Therefore, Participant agrees that Company will be entitled to an injunction, restraining order, or any other equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate to restrain Participant from committing any violation of the covenants, obligations or agreements referred to in this Agreement. These injunctive remedies are cumulative and in addition to any other rights and remedies Company may have against Participant. In addition, Participant agrees that if the terms of this Section are violated or if the terms of this Section are determined to be unenforceable by any court of competent jurisdiction, Participant shall forfeit and not be entitled to receive Retirement Acceleration or the Continued Vesting Shares herein. The Company shall be relieved from any obligation to provide Participant with Retirement Acceleration or the Continued Vesting Shares. If Participant has already received the Retirement Acceleration or the Continued Vesting Shares, Participant agrees to repay the Company the value of the Retirement Acceleration or the Continued Vesting Shares on the date it was received by Participant upon five (5) days written notice. 12. Shares Listed on the Exchange. The Shares for which the Option is hereby granted shall have been listed on the New York Stock Exchange at the time the Option is exercised. 13. Shares May be Newly Issued or Purchased. The Shares to be delivered upon exercise of the Option shall be made available, at the discretion of the Company, either from authorized but previously unissued Shares or from Shares held in the treasury of the Company. 14. Adjustment of Shares for Recapitalization. In the event of any merger, reorganization, consolidation, recapitalization, stock dividend, or other change in corporate structure affecting the Stock, a substitution or adjustment shall be made in the number and price of Shares. 15. Payment of Taxes. The Optionee shall, no later than the date as of which the value of any portion of the Option first becomes includable in the Optionee's gross income for Federal income tax purposes, pay to the Company, or make other arrangements satisfactory to the

------

![](a10422026employee7-yrsoa005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 Committee, in its sole discretion, regarding payment of, the Federal, state, local or FICA taxes of any kind required by the law to be withheld with respect to the Option. The obligations of the Company under this Agreement shall be conditional on such payment or arrangements. The Optionee may elect, subject to the approval of the Committee, to satisfy the Optionee's Federal, and where applicable, FICA, state and local tax withholding obligations arising from all awards by the reduction in an amount necessary to pay any such withholding tax obligations, of the number of Shares of stock or amount of cash otherwise issuable or payable to said Optionee upon the issuance of Shares or payment of cash in respect of an Option. The Company and, where applicable, its Subsidiaries and Affiliates shall, to the extent permitted by law, have the right to deduct any such withholding taxes owed by an Optionee who is not subject to Section 16 of the 1934 Act from any payment of any kind otherwise due to said Optionee. 16. Headings. The headings contained herein are for convenience of reference only, do not constitute a part of this Grant Agreement and shall not be deemed to limit or affect any of the provisions hereof. 17. Notices. Any notices required by or permitted to be given to the Company under this Agreement shall be made in writing and addressed to the Secretary of the Company in care of the Company's Legal Department, 3700 South Stonebridge Drive, McKinney, Texas 75070. Any such notice shall be deemed to have been given when received by the Company. 18. Recoupment. Options awarded hereunder are subject to the Globe Life Inc. Clawback Policy as it may be amended or revised (the "Clawback Policy"). Any Options awarded hereunder may be cancelled or forfeited and any shares of Stock issued upon exercise of the Option shall be subject to forfeiture and recoupment by the Company based on a later determination that recoupment is required under the Clawback Policy. Any such determination by the Committee (in its sole discretion) shall be deemed a failure by the Participant to meet conditions precedent to payment of the Award and render the payment subject to recoupment. 19. Governing Law/Venue. All questions pertaining to the construction, regulation, validity and effect of the provisions of this Agreement shall be determined in accordance with the laws of the State of Texas. In addition, Participant and Company agree that any disputes or claims concerning or relating to the terms and provisions of this Agreement shall be filed in Collin County, State of Texas or the United States District Court for the Eastern District of Texas.

------

![](a10422026employee7-yrsoa006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 Company Name Globe Life Inc. Plan Participant Id Participant Name Participant Address Grant/Award Type Grant Amount Grant/Exercise Price Grant/Award Date VESTING SCHEDULE Vesting Date [No. of Shares] Percent

------

## Exhibit 10.43

![](a10432026employeersuagmn001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GLOBE LIFE INC. RESTRICTED STOCK UNIT AWARD AGREEMENT Globe Life Inc. (the "Company") grants to the Grantee Restricted Stock Units in the amount specified below (the "RSUs") representing the right to earn, on a one-for-one basis, shares of the Company's Common Stock, $1.00 par value ("Stock"), pursuant to and subject to the provisions of the Globe Life Inc. 2018 Incentive Plan (the "Plan") and to the terms and conditions set forth in this Agreement. By accepting the RSUs, Grantee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. TERMS AND CONDITIONS 1. Defined Terms. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. 2. Vesting of RSUs. The RSUs have been credited to a bookkeeping account on behalf of Grantee and do not represent actual shares of Stock. The RSUs are being awarded to the Grantee in return for Grantee's promises contained herein. RSUs will vest and become non-forfeitable on the earliest to occur of the following (the "Vesting Date"): (a) the Vesting Date specified below, provided Grantee has continued in the employment of the Company or its Affiliates through such date, or (b) the termination of Grantee's employment due to death or Disability, or (c) in the event of the termination of Grantee's employment due to Retirement (as such term is defined in this Agreement) after the six month anniversary of the Grant Date, the RSUs shall vest ratably based upon the number of full months of Continuous Service since the Grant Date divided by 36, or (d) a Change in Control of the Company in which the RSUs are not assumed by the Surviving Entity or otherwise equitably converted or substituted in connection with the Change in Control in a manner approved by the Committee or the Board, or (e) upon the occurrence of (i) a Change in Control of the Company in which the RSUs are assumed by the Surviving Entity or otherwise equitably converted or substituted in connection with the Change in Control and (ii) if within three years after the effective date of the Change in Control, Grantee's employment is terminated without Cause or Grantee resigns for Good Reason. In the event Grantee's employment terminates for any reason other than as described above at any time prior to the applicable Vesting Date, all of Grantee's RSUs will immediately be forfeited to the Company without further consideration or any act or action by Grantee unless the Committee approves of vesting within its sole and absolute discretion as described under the terms of the Plan. For purposes of this Agreement, "Retirement" means termination of employment if the Grantee has satisfied one of the following criteria on the date of Retirement: (1) age 65 or (2) age and years of Continuous Service with the Company equal or exceed 65 and the Grantee is at least 55 and has at least five (5) years of Continuous Service. 3. Termination with Cause. If Grantee's employment with Company, any Subsidiary and/or any Affiliate is terminated for Cause or the Committee determines that the Grantee has engaged in conduct that would be grounds for termination with Cause, the RSUs shall immediately be forfeited and any shares of Stock issued hereunder shall be subject to recoupment by the Company based upon a determination by the

------

![](a10432026employeersuagmn002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committee that recoupment is necessary to recover the economic loss associated with the termination with Cause. Any such determination shall be made by the Committee in its sole and absolute discretion. 4. Settlement in Stock. Any vested RSUs will be settled by the Company by issuing shares of Stock (one share per vested RSU) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. Any RSUs that fail to vest in accordance with the terms of this Agreement will be forfeited. 5. Dividend Equivalents. If and when dividends or other distributions are paid with respect to the Stock while the RSUs are outstanding, the dollar amount or fair market value of such dividends or distributions with respect to the number of shares of Stock then underlying the RSUs shall be converted into additional RSUs in Grantee's name based upon the Fair Market Value of the Stock as of the date such dividends or distributions were payable. The additional RSUs will vest on the Vesting Date. To the extent any RSUs are vested and payable to the Grantee as a result of dividend equivalents, such RSUs will be settled in cash or Stock at the discretion of the Committee. If settled in Stock, the Company will issue shares of Stock (one share per vested RSU) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. 6. Restrictions on Transfer and Pledge. No right or interest of Grantee in the RSUs may be pledged, encumbered, or hypothecated or be made subject to any lien, obligation, or liability of Grantee to any other party other than the Company or an Affiliate. The RSUs may not be sold, assigned, transferred or otherwise disposed of by Grantee other than by will or the laws of descent and distribution. 7. Restrictions on Issuance of Stock. If at any time the Committee shall determine, in its discretion, that registration, listing or qualification of the Stock underlying the RSUs upon any securities exchange or similar self-regulatory organization or under any foreign, federal, or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition to the settlement of the RSUs, stock units will not be converted to Stock in whole or in part unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Committee. 8. Limitation of Rights. The RSUs do not confer to Grantee or Grantee's beneficiary, executors or administrators any voting rights, rights to receive dividends or any other rights of a shareholder of the Company unless and until shares of Stock are in fact issued to such person in connection with the units. Nothing in this Agreement shall interfere with or limit in any way the right of the Company or any Affiliate to terminate Grantee's employment at any time, nor confer upon Grantee any right to continue in employment of the Company or any Affiliate. 9. No Entitlement to Future Awards. The grant of the RSUs does not entitle Grantee to the grant of any additional units or other awards under the Plan in the future. Future grants, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the number of units, and vesting provisions. 10. Payment of Taxes. The Company or any Affiliate employing Grantee has the authority and the right to deduct or withhold, or require Grantee to remit to the employer, an amount sufficient to satisfy federal, state, and local taxes (including Grantee's FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the vesting or settlement of the RSUs. With respect to withholding required upon any taxable event arising as a result of the Award, the employer may satisfy the tax withholding requirement by withholding shares of Stock having a Fair Market Value, as of the date that the amount of tax to be withheld is to be determined, as nearly equal as possible to (but no more than) the total minimum statutory tax required to be withheld. The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company, and, where

------

![](a10432026employeersuagmn003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;applicable, its Affiliates will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to Grantee. 11. Recoupment. RSUs awarded hereunder are subject to the Globe Life Inc. Clawback Policy as it may be amended or revised (the "Clawback Policy"). Any RSUs awarded hereunder may be cancelled or forfeited and any shares of Stock issued hereunder shall be subject to forfeiture and recoupment by the Company based on a later determination that recoupment is required under the Clawback Policy. Any such determination by the Committee (in its sole discretion) shall be deemed a failure by the Participant to meet conditions precedent to payment of the Award and render the payment subject to recoupment. 12. Amendment. Subject to the terms of the Plan, the Committee may amend, modify or terminate this Agreement without approval of Grantee; provided, however, that such amendment, modification or termination shall not, without Grantee's consent, reduce or diminish the value of this award determined as if it had been fully vested (i.e., as if all restrictions on the RSUs hereunder had expired) on the date of such amendment or termination. Notwithstanding the foregoing, Grantee hereby expressly agrees to any amendment to the Plan and this Agreement to the extent necessary to comply with applicable law or changes to applicable law (including, but not limited to, Code Section 409A) and related regulations or other guidance and federal securities laws. 13. Plan Controls. The terms contained in the Plan shall be and are hereby incorporated into and made a part of this Agreement and this Agreement shall be governed by and construed in accordance with the Plan. Without limiting the foregoing, the terms and conditions of the RSUs, including the number of shares and the class or series of capital stock which may be delivered upon settlement of the RSUs, are subject to adjustment as provided in Article 15 of the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative. Any conflict between this Agreement and the terms of a written employment with Grantee that has been approved, ratified or confirmed by the Committee shall be decided in favor of the provisions of such employment agreement. 14. Governing Law/Venue. Except as noted below, this Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, United States of America, regardless of the law that might be applied under principles of conflict of laws. In addition, Grantee and the Company agree that any disputes or claims concerning or relating to the terms and provisions of this Agreement shall be filed in Collin County, State of Texas or the United States District Court for the Eastern District of Texas. 15. Severability. If any one or more of the provisions contained in this Agreement is deemed to be invalid, illegal or unenforceable, the other provisions of this Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included. 16. Relationship to Other Benefits. The RSUs shall not affect the calculation of benefits under any other compensation plan or program of the Company, except to the extent specially provided in such other plan or program. 17. Notice. Notices and communications hereunder must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to Globe Life Inc., 3700 South Stonebridge Drive, McKinney, Texas 75070, Attn: Corporate Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by Grantee in a written notice to the Company. 18. Section 409A. The RSUs awarded hereunder are intended to be exempt from Code Section 409A as a short-term deferral. In the event the RSUs are determined not to be exempt, it is intended to comply with Code Section 409A and any ambiguous provision will be construed in a manner that is compliant

------

![](a10432026employeersuagmn004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with or exempt from the application of Section 409A. Any reference to Grantee's termination of employment shall mean a cessation of the employment relationship between the Grantee and the Company which constitutes a "separation from service" as determined in accordance with Code Section 409A and related regulations. Notwithstanding any provision to the contrary in this Agreement, if the Grantee is deemed on the date of termination to be a "specified employee" within the meaning of that term under Section 409A(a)(2)(B) of the Code, then the payments under this Agreement that are subject to Section 409A and paid by reason of a termination of employment shall be made or provided on the later of (a) the payment date set forth in this Agreement, or (b) the date that is the earliest of (i) the expiration of the six-month period measured from the date of Grantee's termination of employment or (ii) the date of the Grantee's death, if applicable (the "Delay Period"). Payments subject to the Delay Period shall be paid to the Grantee without interest for such delay in payment.

------

![](a10432026employeersuagmn005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company Name Globe Life Inc. Plan Participant Id Participant Name Participant Address Grant/Award Type Grant Amount Grant/Exercise Price Grant/Award Date VESTING SCHEDULE Vesting Date [No. of Shares] Percent

------

## Exhibit 10.44

![](a10442026employeersuagmn001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 GLOBE LIFE INC. RESTRICTED STOCK UNIT AWARD AGREEMENT Globe Life Inc. (the "Company") grants to the Grantee Restricted Stock Units (the "RSUs") in the number specified below representing the right to earn, on a one-for-one basis, shares of the Company's Common Stock, $1.00 par value ("Stock") pursuant to and subject to the provisions of the Globe Life Inc. 2018 Incentive Plan, (the "Plan") and to the terms and conditions set forth in this Agreement. By accepting the RSUs, Grantee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. TERMS AND CONDITIONS 1. Defined Terms. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. 2. Vesting of RSUs. The RSUs have been credited to a bookkeeping account on behalf of Grantee and do not represent actual shares of Stock. The RSUs are being awarded to the Grantee in return for Grantee's promises contained herein. RSUs will vest and become non-forfeitable on the earliest to occur of the following (the "Vesting Date"): (a) the Vesting Date specified below, provided Grantee has continued in the employment of the Company or its Affiliates through such date, or (b) the termination of Grantee's employment due to death or Disability, or (c) in the event of the termination of Grantee's employment due to Retirement (as such term is defined in this Agreement) after the six month anniversary of the Grant Date, the RSUs shall vest ratably based upon the number of full months of Continuous Service since the Grant Date divided by 36, or (d) the termination of Grantee's employment by the Company due to a "Qualifying Termination" under the Globe Life Inc. Executive Severance Plan, as such term is defined therein, to the extent Grantee has been designated by the Company as an "Eligible Executive" participating in said plan; provided that the portion vested will depend upon the length of Grantee's employment with the Company or one of its affiliates following the Grant Date, with 33.33% of the RSUs eligible for vesting upon such termination after the first anniversary of the Grant Date and 66.67% of the RSUs eligible for vesting after the second anniversary of the Grant Date, or (e) a Change in Control of the Company in which the RSUs are not assumed by the Surviving Entity or otherwise equitably converted or substituted in connection with the Change in Control in a manner approved by the Committee or the Board, or (f) upon the occurrence of (i) a Change in Control of the Company in which the RSUs are assumed by the Surviving Entity or otherwise equitably converted or substituted in connection with the Change in Control and (ii) if within two years after the effective date of the Change in Control, Grantee's employment is terminated without Cause or Grantee resigns for Good Reason. In the event Grantee's employment terminates for any reason other than as described above at any time prior to the applicable Vesting Date, all of Grantee's RSUs will immediately be forfeited to the Company without further consideration or any act or action by Grantee unless the Committee approves of vesting within its sole and absolute discretion as described under the terms of the Plan. For purposes of this Agreement, "Retirement" means termination of employment if the Grantee has satisfied one of the following criteria on the date of Retirement: (1) age 65 or (2) age and years of Continuous Service with the Company equal or exceed 65 and the Grantee is at least 55 and has at least five (5) years of Continuous Service.

------

![](a10442026employeersuagmn002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 3. Termination with Cause. If Grantee's employment with Company, any Subsidiary and/or any Affiliate is terminated for Cause or the Committee determines that the Grantee has engaged in conduct that would be grounds for termination with Cause, the RSUs shall immediately be forfeited and any shares of Stock issued hereunder shall be subject to recoupment by the Company based upon a determination by the Committee that recoupment is necessary to recover the economic loss associated with the termination with Cause. Any such determination shall be made by the Committee in its sole and absolute discretion. 4. Settlement in Stock. Any vested RSUs will be settled by the Company by issuing shares of Stock (one share per vested RSU) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. Any RSUs that fail to vest in accordance with the terms of this Agreement will be forfeited. 5. Dividend Equivalents. If and when dividends or other distributions are paid with respect to the Stock while the RSUs are outstanding, the dollar amount or fair market value of such dividends or distributions with respect to the number of shares of Stock then underlying the RSUs shall be converted into additional RSUs in Grantee's name based upon the Fair Market Value of the Stock as of the date such dividends or distributions were payable. The additional RSUs will vest on the Vesting Date. To the extent any RSUs are vested and payable to the Grantee as a result of dividend equivalents, such RSUs will be settled in cash or Stock at the discretion of the Committee. If settled in Stock, the Company will issue shares of Stock (one share per vested RSU) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. 6. Restrictions on Transfer and Pledge. No right or interest of Grantee in the RSUs may be pledged, encumbered, or hypothecated or be made subject to any lien, obligation, or liability of Grantee to any other party other than the Company or an Affiliate. The RSUs may not be sold, assigned, transferred or otherwise disposed of by Grantee other than by will or the laws of descent and distribution. 7. Restrictions on Issuance of Stock. If at any time the Committee shall determine, in its discretion, that registration, listing or qualification of the Stock underlying the RSUs upon any securities exchange or similar self-regulatory organization or under any foreign, federal, or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition to the settlement of the RSUs, stock units will not be converted to Stock in whole or in part unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Committee. 8. Noncompetition/Confidentiality/Nonsolicitation. Upon Grantee's separation from employment from the Company for any reason for a period of two (2) years from the date of such separation (the "Restriction Period"), Grantee agrees not to engage or participate, directly or indirectly, including but not limited to as an employee, consultant, advisor, contractor, partner, owner or otherwise, in a competing business, which is one that provides the same or substantially similar products or services as the Business with which Grantee was involved. "Business" is defined as product development, marketing, sales and servicing of life insurance, health insurance and annuity products through captive agents, independent agents and direct response marketing channels. Life insurance includes individual life or group life, with or without return-of-premium benefit. Health insurance includes accidental death or supplemental health insurance products, with or without return-of premium benefits, including cancer, critical illness, hospital indemnity, or Medicare supplement. Annuity includes deferred annuities or single premium immediate annuities. (All of the foregoing are referred to collectively as the "Business"). Grantee further agrees that he will not serve as a Board member for any company that provides the same or similar products or services as the Business. Grantee also agrees and understands that this noncompetition agreement extends to competition in any state in which Grantee worked or directed work for the Company (referred to as the "Restricted Area"). Grantee acknowledges that the Restricted Area, scope of prohibited activities, and the Restriction Period are reasonable and are no broader than are necessary to protect Company's legitimate business interests. Grantee also acknowledges that the Company would not be providing the benefits set forth in

------

![](a10442026employeersuagmn003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 this Agreement but for Grantee's covenants and promises contained in this Section. Grantee further agrees that during the non-competition term, Grantee shall immediately notify the Company in writing of any employment, work, or business he undertakes with or on behalf of any person (including himself) or entity other than the Company and acknowledges and agrees that the Company may place Grantee's future employer on notice of the Grantee's post-employment obligations. Grantee further expressly agrees and understands that the Company has disclosed confidential, proprietary and/or trade secret information to Grantee. Grantee agrees that he will not utilize nor disclose to any third party any of the Company's confidential, proprietary or trade secret information at any time in the future. In consideration of the Company disclosing such information to Grantee and/or for the consideration provided to Grantee by the Company in this Agreement, which Grantee acknowledges is sufficient and reasonable consideration, Grantee has agreed to the non-competition provisions set forth herein. In addition, due to the type of information to which Grantee has been given access, there are some types of future employment in which Grantee would inevitably use and disclose confidential and proprietary information in violation of Grantee's promises. Therefore, Grantee acknowledges as part of this agreement the potential for such unauthorized inevitable disclosure and agrees that the non- competition provisions set forth herein are necessary and reasonable. Notwithstanding any other provision of this Agreement, nothing herein shall prohibit Grantee from reporting possible violations of federal law or regulation to any governmental agency or entity or making other disclosures that are protected pursuant to federal law or regulation. Prior authorization from the Company is not required in order to make any such reports or disclosures and Grantee is not required to notify the Company that such reports or disclosures have been made. IMMUNITY NOTICE. Pursuant to the Defend Trade Secrets Act of 2016, Grantee may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and solely for the purpose of reporting or investigating a suspected violation of the law; or is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Should any provision in this Agreement conflict with this provision, this provision shall control. Grantee also agrees that during the Restriction Period he will not solicit the clients or customers of the Company in order to request or advise such clients or customers to end, change or curtail their business relationship with the Company. In addition, Grantee agrees that during the Restriction Period he will not solicit any employee of the Company in order to request or advise any such employee to end, change or curtail their employment relationship with the Company. If for any reason any court of competent jurisdiction finds any provision of this Section to be unreasonable in duration or scope or otherwise, Company and Grantee agree that the Court shall reform the restrictions and prohibitions contained in this Section so that they shall be effective to the fullest extent allowed under applicable law. Each covenant set forth in this Section shall survive the termination of this Agreement and Grantee's employment for any reason and shall be construed as an agreement independent of any other provision of this Agreement. Grantee acknowledges and agrees that the covenants, obligations and agreements of Grantee contained in this Section concern special, unique and extraordinary matters and that a violation of any of the terms of these covenants, obligations or agreements will cause Company irreparable injury for which adequate remedies at law are not available. Therefore, Grantee agrees that Company will be entitled to an injunction, restraining order, or any other equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate to restrain Grantee from committing any violation of the covenants, obligations or agreements referred to in this Agreement. These injunctive remedies are cumulative and in addition to any other rights and remedies Company may have against Grantee.

------

![](a10442026employeersuagmn004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 In addition, Grantee agrees that if the terms of this Section are violated or if the terms of this Section are determined to be unenforceable by any court of competent jurisdiction, Grantee shall forfeit and not be entitled to receive the RSUs granted herein. If Grantee has already received the RSUs, Grantee agrees to repay the Company the value of the RSUs on the date it was received by Grantee upon five (5) days written notice. 9. Limitation of Rights. The RSUs do not confer to Grantee or Grantee's beneficiary, executors or administrators any voting rights, rights to receive dividends or any other rights of a shareholder of the Company unless and until shares of Stock are in fact issued to such person in connection with the units. Nothing in this Agreement shall interfere with or limit in any way the right of the Company or any Affiliate to terminate Grantee's employment at any time, nor confer upon Grantee any right to continue in employment of the Company or any Affiliate. 10. No Entitlement to Future Awards. The grant of the RSUs does not entitle Grantee to the grant of any additional units or other awards under the Plan in the future. Future grants, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the number of units, and vesting provisions. 11. Payment of Taxes. The Company or any Affiliate employing Grantee has the authority and the right to deduct or withhold, or require Grantee to remit to the employer, an amount sufficient to satisfy federal, state, and local taxes (including Grantee's FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the vesting or settlement of the RSUs. With respect to withholding required upon any taxable event arising as a result of the Award, the employer may satisfy the tax withholding requirement by withholding shares of Stock having a Fair Market Value, as of the date that the amount of tax to be withheld is to be determined, as nearly equal as possible to (but no more than) the total minimum statutory tax required to be withheld. The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company, and, where applicable, its Affiliates will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to Grantee. 12. Recoupment. RSUs awarded hereunder are subject to the Globe Life Inc. Clawback Policy as it may be amended or revised (the "Clawback Policy"). Any RSUs awarded hereunder may be cancelled or forfeited and any shares of Stock issued hereunder shall be subject to forfeiture and recoupment by the Company based on a later determination that recoupment is required under the Clawback Policy. Any such determination by the Committee (in its sole discretion) shall be deemed a failure by the Participant to meet conditions precedent to payment of the Award and render the payment subject to recoupment. 13. Amendment. Subject to the terms of the Plan, the Committee may amend, modify or terminate this Agreement without approval of Grantee; provided, however, that such amendment, modification or termination shall not, without Grantee's consent, reduce or diminish the value of this award determined as if it had been fully vested (i.e., as if all restrictions on the RSUs hereunder had expired) on the date of such amendment or termination. Notwithstanding the foregoing, Grantee hereby expressly agrees to any amendment to the Plan and this Agreement to the extent necessary to comply with applicable law or changes to applicable law (including, but not limited to, Code Section 409A) and related regulations or other guidance and federal securities laws. 14. Plan Controls. The terms contained in the Plan shall be and are hereby incorporated into and made a part of this Agreement and this Agreement shall be governed by and construed in accordance with the Plan. Without limiting the foregoing, the terms and conditions of the RSUs, including the number of shares and the class or series of capital stock which may be delivered upon settlement of the RSUs, are subject to adjustment as provided in Article 15 of the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative. Any conflict between this Agreement and the terms of a written employment with Grantee that has been approved, ratified or confirmed by the Committee shall be decided in favor of the provisions of such employment agreement.

------

![](a10442026employeersuagmn005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 15. Governing Law/Venue. Except as noted below, this Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, United States of America, regardless of the law that might be applied under principles of conflict of laws. However, the terms and provisions set forth in Section 6 shall be governed by the laws of the State of Texas. In addition, Grantee and the Company agree that any disputes or claims concerning or relating to the terms and provisions of this Agreement (including Section 6) shall be filed in Collin County, State of Texas or the United States District Court for the Eastern District of Texas. 16. Severability. If any one or more of the provisions contained in this Agreement is deemed to be invalid, illegal or unenforceable, the other provisions of this Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included. 17. Relationship to Other Benefits. The RSUs shall not affect the calculation of benefits under any other compensation plan or program of the Company, except to the extent specially provided in such other plan or program. 18. Notice. Notices and communications hereunder must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to Globe Life Inc., 3700 South Stonebridge Drive, McKinney, Texas 75070, Attn: Corporate Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by Grantee in a written notice to the Company. 19. Section 409A. The RSUs awarded hereunder are intended to be exempt from Code Section 409A as a short-term deferral. In the event the RSUs are determined not to be exempt, it is intended to comply with Code Section 409A and any ambiguous provision will be construed in a manner that is compliant with or exempt from the application of Section 409A. Any reference to Grantee's termination of employment shall mean a cessation of the employment relationship between the Grantee and the Company which constitutes a "separation from service" as determined in accordance with Code Section 409A and related regulations. Notwithstanding any provision to the contrary in this Agreement, if the Grantee is deemed on the date of termination to be a "specified employee" within the meaning of that term under Section 409A(a)(2)(B) of the Code, then the payments under this Agreement that are subject to Section 409A and paid by reason of a termination of employment shall be made or provided on the later of (a) the payment date set forth in this Agreement, or (b) the date that is the earliest of (i) the expiration of the six-month period measured from the date of Grantee's termination of employment or (ii) the date of the Grantee's death, if applicable (the "Delay Period"). Payments subject to the Delay Period shall be paid to the Grantee without interest for such delay in payment.

------

![](a10442026employeersuagmn006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 Company Name Globe Life Inc. Plan Participant Id Participant Name Participant Address Grant/Award Type Grant Amount Grant/Exercise Price Grant/Award Date VESTING SCHEDULE Vesting Date [No. of Shares] Percent

------

## Exhibit 10.45

![](a10452026employeepsaward001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;GLOBE LIFE INC. PERFORMANCE SHARE AWARD AGREEMENT Globe Life Inc. (the "Company") grants effective _____, 2026 (the "Grant Date") to __________ (the "Grantee") Performance Shares (the "Performance Shares") representing the right to earn, on a one-for-one basis, shares of the Company's Common Stock, $1.00 par value ("Stock"), pursuant to and subject to the provisions of the Globe Life Inc. 2018 Incentive Plan (the "Plan") and to the terms and conditions set forth on the following pages of this award agreement (this "Agreement"). The target number of Performance Shares subject to this award is ________ (the "Target Award"). Depending on the Company's level of attainment of specified targets for the metrics specified in Exhibit A for the period commencing January 1, 2026 and ending on December 31, 2028 (the "Performance Period"). Grantee may earn 0% to 200% of the Target Award, in accordance with the matrices attached hereto in Exhibit A and the terms of this Agreement. By accepting this Award, Grantee shall be deemed to have agreed to the terms and conditions of this Agreement and the Plan. GLOBE LIFE INC. Grant Date: By: Accepted by Grantee: Its: Authorized Officer TERMS AND CONDITIONS 1. Defined Terms. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. In addition, for purposes of this Agreement: (i) "Confirmation Date" the date of the Committee's certification of achievement of the Performance Objectives and determination of the Performance Multiplier following the end of the Performance Period. (ii) "Retirement" means resignation or termination of employment without Cause from the Company six (6) months after providing notice to the Company, unless notice has been waived by the Committee, and the Grantee has satisfied one of the following criteria on the date of Retirement: (1) age 65 or (2) age and years of Continuous Service with the Company equal or exceed 65 and the Grantee is at least 55 and has at least five (5) years of Continuous Service. (iii) "Performance Multiplier" means the percentage, from 0% to 200%, that will be applied to the Target Award to determine the number of Performance Shares that will convert to shares of Stock on the Confirmation Date, as more fully described in Exhibit A hereto.

------

![](a10452026employeepsaward002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 (iv) "Performance Objectives" are the performance objectives relating to Book Value per Diluted Shares Outstanding and Net Operating Income as a Return on Equity set forth on Exhibit A that must be achieved in order for Performance Shares to be earned by Grantee pursuant to this Award. (v) "Vesting Date" is defined in Section 2 of this Agreement. 2. Earning and Vesting of Performance Shares. The Performance Shares have been credited to a bookkeeping account on behalf of Grantee and do not represent actual shares of Stock. The Performance Shares are being awarded to the Grantee in return for Grantee's promises contained herein including the terms and provisions of Section 8. The Performance Shares represent the right to earn up to 200% of the Target Award, based on (i) the Company's attainment of the Performance Objectives and (ii) the application of the Performance Multiplier to the Target Award in accordance with Exhibit A. Notwithstanding the foregoing, in the event of the Grantee's death during the Performance Period, Grantee shall be deemed to have earned 100% of the Target Award upon such event (without application of any Performance Multiplier). In the event of termination of Grantee's employment due to Disability or Retirement during the Performance Period, the Performance Shares shall represent the right to earn an award of 0% to 200% of the Target Award based on (i) the Company's attainment of the Performance Objectives (to the extent certified by the Committee), and (ii) application of the Performance Multiplier (as may be determined by the Committee) to the Target Award in accordance with Exhibit A. Upon a Change in Control of the Company, the vesting and payment of Performance Shares shall be determined in accordance with Section 13.7 of the Plan. Notwithstanding the foregoing, in the event Grantee has been designated an Eligible Executive under the Globe Life Inc. Executive Severance Plan (the "Severance Plan") and Grantee's employment is terminated due to a "Qualifying Termination" (as such term is defined in the Severance Plan) during the performance period, the Performance Shares shall represent the right to earn a prorated award of 0% to 200% of the Target Award based on (i) the Company's attainment of the Performance Objectives (to the extent certified by the Committee), and (ii) application of the Performance Multiplier (as may be determined by the Committee) to the Target Award in accordance with Exhibit A. The calculation of the prorated award shall be determined based upon the proportional number of full months of Grantee's Continuous Service with the Company or one of its affiliates during the Performance Period as of the date of termination. Any earned Performance Shares will vest and become non-forfeitable on the earliest to occur of the following (the "Vesting Date"): (a) the Confirmation Date, provided either (i) Grantee has continued in the employment of the Company or its Affiliates through such date, or (ii) Grantee's employment with the Company has terminated due to Grantee's Retirement , or (iii) Grantee has been designated an Eligible Executive under the Severance Plan and Grantee's employment has terminated due to a Qualifying Termination during the Performance Period, or (b) the termination of Grantee's employment due to death or Disability, or (c) a Change in Control of the Company.

------

![](a10452026employeepsaward003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 In the event Grantee's employment terminates for any reason other than as described above at any time prior to the applicable Vesting Date, all of Grantee's Performance Shares will immediately be forfeited to the Company without further consideration or any act or action by Grantee. 3. Termination with Cause. If Grantee's employment with the Company, any Subsidiary and/or any Affiliate is terminated for Cause or the Committee determines that the Grantee has engaged in conduct that would be grounds for termination with Cause, the Performance Shares shall be immediately forfeited and any shares of Stock issued hereunder shall be subject to recoupment by the Company based upon a determination by the Committee that recoupment is necessary to recover the economic loss associated with the termination with Cause. Any such determination shall be made by the Committee in its sole and absolute discretion. 4. Settlement in Stock. Any earned and vested Performance Shares will be settled by the Company by issuing shares of Stock (one share per vested Performance Share) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. Any Performance Shares that fail to vest in accordance with the terms of this Agreement will be forfeited and reconveyed to the Company without further consideration or any act or action by Grantee. 5. Dividend Equivalents. If and when dividends or other distributions are paid with respect to the Stock while the Performance Shares are outstanding, the dollar amount or fair market value of such dividends or distributions with respect to the number of shares of Stock then underlying the Performance Shares shall be converted into additional Performance Shares in Grantee's name based upon the Fair Market Value of the Stock as of the date such dividends or distributions were payable. The additional Performance Shares will vest on the Vesting Date. To the extent any Performance Shares are vested and payable to the Grantee as a result of dividend equivalents, such Performance Shares will be settled in cash or Stock at the discretion of the Committee. If settled in Stock, the Company will issue shares of Stock (one share per vested Performance Share) within thirty (30) days following the Vesting Date by book-entry registration or by issuance of shares in Grantee's name. 6. Restrictions on Transfer and Pledge. No right or interest of Grantee in the Performance Shares may be pledged, encumbered, or hypothecated or be made subject to any lien, obligation, or liability of Grantee to any other party other than the Company or an Affiliate. The Performance Shares may not be sold, assigned, transferred or otherwise disposed of by Grantee other than by will or the laws of descent and distribution. 7. Restrictions on Issuance of Stock. If at any time the Committee shall determine, in its discretion, that registration, listing or qualification of the Stock underlying the Performance Shares upon any securities exchange or similar self-regulatory organization or under any foreign, federal, or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition to the settlement of the Performance Shares, stock units will not be converted to Stock in whole or in part unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Committee.

------

![](a10452026employeepsaward004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 8. Noncompetition/Confidentiality/Nonsolicitation. Upon Grantee's separation from employment from the Company for any reason for a period of three (3) years from the date of such separation or in the event of termination due to Retirement , during the remaining vesting period prior to the Confirmation Date, whichever is longer (the "Restriction Period"), Grantee agrees not to engage or participate, directly or indirectly, including but not limited to as an employee, consultant, advisor, contractor, partner, owner or otherwise, in a competing business, which is one that provides the same or substantially similar products or services as the Business with which Grantee was involved. "Business" is defined as product development, marketing, sales and servicing of life insurance, health insurance and annuity products through captive agents, independent agents and direct response marketing channels. Life insurance includes individual life or group life, with or without return-of-premium benefit. Health insurance includes accidental death or supplemental health insurance products, with or without return-of premium benefits, including cancer, critical illness, hospital indemnity, Medicare supplement. Annuity includes deferred annuities or single premium immediate annuities. (All of the foregoing are referred to collectively as the "Business"). Grantee further agrees that he will not serve as a Board member for any company that provides the same or similar products or services as the Business. Grantee also agrees and understands that this noncompetition agreement extends to competition in any state in which Grantee worked or directed work for the Company (referred to as the "Restricted Area"). Grantee acknowledges that the Restricted Area, scope of prohibited activities, and the Restriction Period are reasonable and are no broader than are necessary to protect Company's legitimate business interests. Grantee also acknowledges that the Company would not be providing the benefits set forth in this Agreement but for Grantee's covenants and promises contained in this Section. Grantee further agrees that during the non-competition term, Grantee shall immediately notify the Company in writing of any employment, work, or business he undertakes with or on behalf of any person (including himself) or entity other than the Company and acknowledges and agrees that the Company may place Grantee's future employer on notice of the Grantee's post- employment obligations. Grantee further expressly agrees and understands that the Company has disclosed confidential, proprietary and/or trade secret information to Grantee. Grantee agrees that he will not utilize nor disclose to any third party any of the Company's confidential, proprietary or trade secret information at any time in the future. In consideration of the Company disclosing such information to Grantee and/or for the consideration provided to Grantee by the Company in this Agreement, which Grantee acknowledges is sufficient and reasonable consideration, Grantee has agreed to the non-competition provisions set forth herein. In addition, due to the type of information to which Grantee has been given access, there are some types of future employment in which Grantee would inevitably use and disclose confidential and proprietary information in violation of Grantee's promises. Therefore, Grantee acknowledges as part of this agreement the potential for such unauthorized inevitable disclosure and agrees that the non-competition provisions set forth herein are necessary and reasonable. Notwithstanding any other provision of this Agreement, nothing herein shall prohibit Grantee from reporting possible violations of federal law or regulation to any governmental agency or entity or making other disclosures that are protected pursuant to federal law or regulation. Prior authorization from the Company is not required in order to make any such reports or disclosures and Grantee is not required to notify the Company that such reports or disclosures have been made.

------

![](a10452026employeepsaward005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 IMMUNITY NOTICE. Pursuant to the Defend Trade Secrets Act of 2016, Grantee may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and solely for the purpose of reporting or investigating a suspected violation of the law; or is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Should any provision in this Agreement conflict with this provision, this provision shall control. Grantee also agrees that during the Restriction Period he will not solicit the clients or customers of the Company in order to request or advise such clients or customers to end, change or curtail their business relationship with the Company. In addition, Grantee agrees that during the Restriction Period he will not solicit any employee of the Company in order to request or advise any such employee to end, change or curtail their employment relationship with the Company. If for any reason any court of competent jurisdiction finds any provision of this Section to be unreasonable in duration or scope or otherwise, Company and Grantee agree that the court shall reform the restrictions and prohibitions contained in this Section so that they shall be effective to the fullest extent allowed under applicable law. Each covenant set forth in this Section shall survive the termination of this Agreement and Grantee's employment for any reason and shall be construed as an agreement independent of any other provision of this Agreement. Grantee acknowledges and agrees that the covenants, obligations and agreements of Grantee contained in this Section concern special, unique and extraordinary matters and that a violation of any of the terms of these covenants, obligations or agreements will cause Company irreparable injury for which adequate remedies at law are not available. Therefore, Grantee agrees that Company will be entitled to an injunction, restraining order, or any other equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate to restrain Grantee from committing any violation of the covenants, obligations or agreements referred to in this Agreement. These injunctive remedies are cumulative and in addition to any other rights and remedies Company may have against Grantee. In addition, Grantee agrees that if the terms of this Section are violated or if the terms of this Section are determined to be unenforceable by any court of competent jurisdiction, Grantee shall forfeit and not be entitled to receive the Performance Shares granted herein. If Grantee has already received the Performance Shares, Grantee agrees to repay the Company the value of the Performance Shares on the date it was received by Grantee upon five (5) days written notice. 9. Limitation of Rights. The Performance Shares do not confer to Grantee or Grantee's beneficiary, executors or administrators any voting rights, rights to receive dividends or any other rights of a shareholder of the Company unless and until shares of Stock are in fact issued to such person in connection with the units. Nothing in this Agreement shall interfere with or limit in any way the right of the Company or any Affiliate to terminate Grantee's employment at any time, nor confer upon Grantee any right to continue in employment of the Company or any Affiliate.

------

![](a10452026employeepsaward006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 10. No Entitlement to Future Awards. The grant of the Performance Shares does not entitle Grantee to the grant of any additional units or other awards under the Plan in the future. Future grants, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the number of units, and vesting provisions. 11. Payment of Taxes. The Company or any Affiliate employing Grantee has the authority and the right to deduct or withhold, or require Grantee to remit to the employer, an amount sufficient to satisfy federal, state, and local taxes (including Grantee's FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the vesting or settlement of the Performance Shares. With respect to withholding required upon any taxable event arising as a result of the Performance Awards, the employer may satisfy the tax withholding requirement by withholding shares of Stock having a Fair Market Value, as of the date that the amount of tax to be withheld is to be determined, as nearly equal as possible to (but no more than) the total minimum statutory tax required to be withheld. The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company, and, where applicable, its Affiliates will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to Grantee. 12. Recoupment. Performance Shares awarded hereunder are subject to the Globe Life Inc. Clawback Policy as it may be amended or revised (the "Clawback Policy"). Any Performance Shares awarded hereunder or any shares of Stock issued hereunder shall be subject to forfeiture and recoupment by the Company based on a later determination that recoupment is required under the Clawback Policy. Any such determination by the Committee (in its sole discretion) shall be deemed a failure by Grantee to meet conditions precedent to payment of the Award and render the payment subject to recoupment. 13. Amendment. Subject to the terms of the Plan, the Committee may amend, modify or terminate this Agreement without approval of Grantee; provided, however, that such amendment, modification or termination shall not, without Grantee's consent, reduce or diminish the value of this award determined as if it had been fully vested and subject to application of the Performance Multiplier (i.e., as if all restrictions on the Performance Shares hereunder had expired) on the date of such amendment or termination. Notwithstanding the foregoing, Grantee hereby expressly agrees to any amendment to the Plan and this Agreement to the extent necessary to comply with applicable law or changes to applicable law (including, but not limited to, Code Section 409A) and related regulations or other guidance and federal securities laws. 14. Plan Controls. The terms contained in the Plan shall be and are hereby incorporated into and made a part of this Agreement and this Agreement shall be governed by and construed in accordance with the Plan. Without limiting the foregoing, the terms and conditions of the Performance Shares, including the number of shares and the class or series of capital stock which may be delivered upon settlement of the Performance Shares, are subject to adjustment as provided in Article 15 of the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative. Any conflict between this Agreement and the terms of a written employment with Grantee that has been approved, ratified or confirmed by the Committee shall be decided in favor of the provisions of such employment agreement.

------

![](a10452026employeepsaward007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 15. Governing Law/Venue. Except as noted below, this Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, United States of America, regardless of the law that might be applied under principles of conflict of laws. However, the terms and provisions set forth in Section 7 shall be governed by the laws of the State of Texas. In addition, Grantee and the Company agree that any disputes or claims concerning or relating to the terms and provisions of this Agreement (including Section 6) shall be filed in Collin County, State of Texas or the United States District Court for the Eastern District of Texas. 16. Severability. If any one or more of the provisions contained in this Agreement is deemed to be invalid, illegal or unenforceable, the other provisions of this Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included. 17. Relationship to Other Benefits. The Performance Shares shall not affect the calculation of benefits under any other compensation plan or program of the Company, except to the extent specially provided in such other plan or program. 18. Notice. Notices and communications hereunder must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to Globe Life Inc., 3700 South Stonebridge Drive, McKinney, Texas 75070, Attn: Corporate Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by Grantee in a written notice to the Company. 19. Section 409A. The Performance Shares awarded hereunder are intended to be exempt from Code Section 409A as a short-term deferral. In the event the Performance Shares are determined not to be exempt, it is intended to comply with Code Section 409A and any ambiguous provision will be construed in a manner that is compliant with or exempt from the application of Section 409A. Any reference to Grantee's termination of employment shall mean a cessation of the employment relationship between the Grantee and the Company which constitutes a "separation from service" as determined in accordance with Code Section 409A and related regulations. Notwithstanding any provision to the contrary in this Agreement, if the Grantee is deemed on the date of termination to be a "specified employee" within the meaning of that term under Section 409A(a)(2)(B) of the Code, then the payments under this Agreement that are subject to Section 409A and paid by reason of a termination of employment shall be made or provided on the later of (a) the payment date set forth in this Agreement, or (b) the date that is the earliest of (i) the expiration of the six-month period measured from the date of Grantee's termination of employment or (ii) the date of the Grantee's death, if applicable (the "Delay Period"). Payments subject to the Delay Period shall be paid to the Grantee without interest for such delay in payment.

------

![](a10452026employeepsaward008.jpg)

EXHIBIT A The Performance Shares will be earned, in whole or in part, based on the Company's achievement of Performance Objectives relating to Book Value per Diluted Shares Outstanding and Net Operating Income as a Return on Equity (each as defined below). Determination of all Performance Measures will be based on existing Federal corporate tax rates as of the commencement of the Performance Period and excludes any impact from the Corporate Alternative Minimum Tax. Performance Goals / Percent Earned Actual Performance Performance Multiplier Earned 1 Weighted Performance Multiplier Earned 2 Performance Measure Weighting Threshold 50% Target 100% Maximum 200% Book Value per Diluted Shares Outstanding 3 50% $$$ Net Operating Income as a Return on Equity 4 50% % % % Performance Multiplier 5 1 Performance below the Threshold level results in 0% earned. All other percentages earned are determined by pro-ration between the appropriate Performance Goals. 2 Performance Multiplier for the Performance Measure multiplied by the Weighting assigned to that Performance Measure 3 "Book Value per Diluted Shares Outstanding" means the book value per diluted shares outstanding as of the end of the Performance Period. The numerator will equal ending Shareholder's Equity plus accumulated common shareholders' dividends during the Performance Period. Shareholders' Equity shall exclude the effect of Accumulated Other Comprehensive Income and any changes in Federal corporate tax rates or GAAP accounting standards. Diluted Shares Outstanding is the diluted shares outstanding as of December 31, 2028, adjusted to reflect share repurchases under Globe Life's Share Repurchase Program in each calendar year at average share repurchase prices of $______ for 2026, $______ for 2027, $______ for 2028 and a share price of $______ as of the end of the Performance Period. 4 "Net Operating Income as a Return on Equity" (NOI ROE) means average return on equity earned for the three-year Performance Period (calculated to two decimal places) using "Net Operating Income" per the Company's Operating Summary, excluding any changes in Federal corporate tax rates or GAAP accounting standards. Average Shareholder's Equity in the denominator shall exclude the effect of Accumulated Other Comprehensive Income and any changes in Federal corporate tax rates or GAAP accounting standards. The average diluted shares outstanding is the weighted average of common and diluted shares outstanding over the course of the respective fiscal year. Thus, if the NOI ROE earned for each year of the Performance Period were 14%, 15% and 16% respectively, average NOI ROE would be 15%. 5 Total of the Weighted Performance Multiplier Earned.

------

## Exhibit 10.47

![](a1047executivelong-termd001.jpg)

Exhibit 10.47 EXECUTIVE LONG-TERM DISABILITY BENEFITS SUMMARY Executive Long-Term Disability Insurance – Globe Life Inc. (the "Company") provides access to long-term disability insurance for Company Senior Vice Presidents and above through The Guardian Life Insurance Company of America ("Guardian"). Executive officers are responsible for paying their own premiums. Coverage is 60% of the executive officer's earnings up to a $15,000 maximum monthly benefit. Executive Individual Disability Insurance – In addition, the Company provides individual disability insurance to Company Senior Vice Presidents and above. The Company pays the policy premiums. Coverage is 60% of the executive officer's earnings up to a $20,000 maximum monthly benefit.

------

## Ex-21

<u>Exhibit 21</u>

*<u>Subsidiaries of the Registrant:</u>* The following table lists subsidiaries of the registrant which meet the definition of "significant subsidiary" according to Regulation S-X:

---

| | | |
|:---|:---|:---|
| **Name Under Which Company Does Business** | **State of<br>Incorporation** | **Distribution Channel (Division)** |
| Globe Life And Accident<br>Insurance Company | Nebraska | Direct to Consumer |
| American Income Life<br>Insurance Company | Indiana | American Income Life Division |
| Liberty National Life<br>Insurance Company | Nebraska | Liberty National Division |
| Family Heritage Life <br>Insurance Company of America | Ohio | Family Heritage Division |

---

While United American Insurance Company (Nebraska) does not qualify as a significant subsidiary in accordance with Regulation S-X, management views this subsidiary as significant to our operations.

All other exhibits required by Regulation S-K are listed as to location in the "Index of documents filed as a part of this report" in this report. Exhibits not referred to have been omitted as inapplicable or not required.

## Ex-23

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-227501, 333-256848, 333-280641 on Form S-3 and Registration Statement Nos. 2-76378, 333-175185, 333-195314, 333-208999, 333-225417, 333-225992, 333-273422 on Form S-8 of our reports dated February 25, 2026, relating to the financial statements of Globe Life Inc. and subsidiaries and the effectiveness of Globe Life Inc. and subsidiaries' internal control over financial reporting appearing in this Annual Report on Form 10-K of Globe Life Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Dallas, Texas

February 25, 2026

&nbsp;&nbsp;&nbsp;&nbsp;

## Ex-24

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ Matthew J. Adams</u> 

Matthew J. Adams, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, her lawful attorneys and agents, for her and in her name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms her signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below her name.

<u>/s/ Linda L. Addison</u> 

Linda L. Addison, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, her lawful attorneys and agents, for her and in her name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms her signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below her name.

<u>/s/ Marilyn A. Alexander</u> 

Marilyn A. Alexander, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, her lawful attorneys and agents, for her and in her name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms her signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below her name.

<u>/s/ Cheryl D. Alston</u> 

Cheryl D. Alston, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ Mark A. Blinn</u> 

Mark A. Blinn, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ James P. Brannen</u> 

James P. Brannen, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Officer and Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, her lawful attorneys and agents, for her and in her name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms her signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below her name.

<u>/s/ Alice S. Cho</u> 

Alice S. Cho, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Officer and Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ J. Matthew Darden</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J. Matthew Darden

Co-Chairman and Chief Executive Officer and Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ Philip M. Jacobs</u> 

Philip M. Jacobs, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ David A. Rodriguez</u> 

David A. Rodriguez, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Officer and Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>Frank M. Svoboda</u> 

Frank M. Svoboda

Co-Chairman and Chief Executive Officer and Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Director of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, her lawful attorneys and agents, for her and in her name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms her signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below her name.

<u>/s/ Mary E. Thigpen</u> 

Mary E. Thigpen, Director

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Officer of Globe Life Inc. does hereby constitute and appoint R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ Thomas P. Kalmbach</u> 

Thomas P. Kalmbach, Executive Vice

President and Chief Financial Officer

Date: <u>February 25, 2026</u> 

------

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

That the undersigned Officer of Globe Life Inc. does hereby constitute and appoint Thomas P. Kalmbach, R. Brian Mitchell and Chris T. Moore, and each of them severally, his lawful attorneys and agents, for him and in his name and in the capacity indicated below, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary, advisable, or required to enable the said Corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations, or requirements of the Securities and Exchange Commission in connection with the Form 10-K for the fiscal year ended December 31, 2025. Without limiting the generality of the foregoing, the powers granted include the power and authority to execute and file the Form 10-K, any and all amendments to the Form 10-K and any and all instruments or documents submitted as a part of or in conjunction with the Form 10-K. The undersigned hereby ratifies and confirms his signature as it may be signed by said attorneys and all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date indicated below his name.

<u>/s/ M. Shane Henrie</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M. Shane Henrie, Corporate Senior Vice

President and Chief Accounting Officer

Date: <u>February 25, 2026</u> 

## Exhibit 31.1

Exhibit 31.1

<u>CERTIFICATIONS</u>

I, J. Matthew Darden, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this annual report on Form 10-K of Globe Life Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 25, 2026  | /s/ J. Matthew Darden |
| | | J. Matthew Darden<br>Co-Chairman and Chief Executive Officer |

---

## Exhibit 31.2

Exhibit 31.2

<u>CERTIFICATIONS</u>

I, Frank M. Svoboda, certify that:

1. I have reviewed this annual report on Form 10-K of Globe Life Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 25, 2026  | /s/ Frank M. Svoboda |
| | | Frank M. Svoboda<br>Co-Chairman and Chief Executive Officer |

---

## Exhibit 31.3

Exhibit 31.3

<u>CERTIFICATIONS</u>

I, Thomas P. Kalmbach, certify that:

1. I have reviewed this annual report on Form 10-K of Globe Life Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 25, 2026  | /s/ Thomas P. Kalmbach |
| | | Thomas P. Kalmbach<br>Executive Vice President and Chief Financial Officer |

---

## Exhibit 32.1

Exhibit 32.1

<u>CERTIFICATION OF PERIODIC REPORT</u>

We, J. Matthew Darden, Co-Chairman and Chief Executive Officer, Frank M. Svoboda, Co-Chairman and Chief Executive Officer, and Thomas P. Kalmbach, Executive Vice President and Chief Financial Officer of Globe Life Inc., certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of our knowledge:

(1)&nbsp;&nbsp;&nbsp;&nbsp;the Annual Report on Form 10-K of the Company for the period ended December 31, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | February 25, 2026 | /s/ J. Matthew Darden |
|  |  | J. Matthew Darden<br>Co-Chairman and Chief Executive Officer |
|  |  | /s/ Frank M. Svoboda |
|  |  | Frank M. Svoboda&nbsp;&nbsp;&nbsp;&nbsp;<br>Co-Chairman and Chief Executive Officer |
|  |  | /s/ Thomas P. Kalmbach |
|  |  | Thomas P. Kalmbach<br>Executive Vice President and<br>Chief Financial Officer |

---

<br>